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ABSTRACT 
Obesity is a worldwide health issue that has reached epidemic proportions, and is 
defined as increased white adipose tissue mass.  This increase in adiposity is caused by 
either hypertrophy of existing mature adipocytes, or hyperplasia of pre-adipocytes, 
leading to increased adipocyte numbers.  The current study used the murine 3T3-L1 
pre-adipocyte cell line to explore in vitro the differentiation process from pre-
adipocytes to mature adipocytes, termed adipogenesis. Lipidomic analyses 
demonstrated a shift in the predominant lipid species present; from phospholipids in 
the pre-adipocytes, to triglycerides in the mature adipocytes. This was expected from 
the morphological changes known to occur in this cell line, from fibroblastic pre-
adipocytes, to spherical lipid-loaded mature adipocytes. The production of various 
eicosanoids was also investigated, and their concentration was greatest during the pre-
adipocyte stage. This profile was also seen with arachidonic acid, a precursor in 
eicosanoid synthesis.  These changes in lipid metabolism and eicosanoid production 
appeared to be linked, allowing the differentiation process and lipid accumulation to 
continue.   
 
The obese state is also associated with a chronic low-grade inflammation, and so the 
effects of TNF-α and IL-6 intervention on adipocyte metabolism were investigated.  
Differences in lipid mobilisation caused by these pro-inflammatory agents were 
suggested due to increases or decreases observed in the concentrations of various 
triglyceride and fatty acid species.  Increases were observed in the concentration of 
various detected eicosanoid species from the arachidonic acid cascade, mainly 
prostanoid species.   
 
 
Effects of the anti-inflammatory agent dexamethasone were also investigated in 
mature 3T3-L1 adipocytes. It was associated with increases in the concentration of both 
triglyceride and fatty acid species, suggesting possible increase in lipogenesis and/or 
decrease in lipolysis.  Increases in the production of various eicosanoid species from the 
arachidonic acid pathway were also observed.  The majority of these species are pro-
inflammatory; however, PGE2 is known to have both pro-and anti-inflammatory effects, 
and this may help to explain these findings.   
 
 
In conclusion, the work presented in this thesis has revealed how adipocyte 
metabolism changes in the naturally occurring stages of adipogenesis, as well as in 
response to pro- and anti-inflammatory intervention.  Associations were observed 
between adipokine gene expression, lipid metabolism and eicosanoid production; 
however, further work is required to confirm these links by identifying the underlying 
mechanisms involved.  
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GENERAL INTRODUCTION 
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1.1. OBESITY  
Obesity is a medical condition defined by the World Health Organisation (WHO) as being 
associated with the accumulation of excess body fat to the extent of causing adverse health 
effects (WHO, 2000).  The disorder is thought to involve a genetic predisposition to weight 
gain, with twin and adoption studies showing that body mass index (BMI) is under strong 
genetic control.  The estimated heritability of BMI ranges between 64 and 84% (Stunkard et 
al., 1986).  A study involving pairs of monozygous twins born in Sweden between 1886 and 
1958 and raised separately, calculated an intrapair correlation for these twins as 0.70 and 
0.66 for men and women, respectively (Stunkard et al., 1990).  A similar figure was calculated 
in a cohort of twins from the UK, with a heritability of 0.61 being noted (Price and Gottesman, 
1991).  Along with the high heritability of obesity in humans, several major genes are known 
to contribute to the variation in obesity related phenotypes.  The current obesity epidemic is 
unlikely to have been caused by genetic changes alone due the relatively short time frame in 
which it has occurred.  
 
1.1.1. Cause and prevalence of obesity 
The increased fat mass, also termed adiposity, associated with obesity is precisely regulated 
in the process of energy homeostasis, in which food intake is matched to energy expenditure 
and the size of the body’s energy stores (Kennedy, 1953).  When excessive food intake is 
coupled with low levels of energy expenditure, an expansion of adipose tissue mass occurs in 
the body, leading to increased body weight.  In periods of energy deficit, the negative energy 
balance would cause weight loss. 
Obesity is a major worldwide health issue that has reached epidemic proportions (WHO, 
2003).  Even with increased knowledge of diet and exercise and growing medical awareness, 
the prevalence of obesity has increased by more than 75% since 1980 (Flegal et al., 1998).  In 
the UK, the latest Health Survey for England (HSE) indicated that 62.8% of adults are either 
overweight or obese.  An increase in childhood obesity was also observed, with 30.3% of girls 
and boys aged 2-15 being overweight or obese (HSE, 2010).  If current trends continue, it is 
predicted that 60% of men, 50% of women and 25% of children in Britain will be obese by 
2050 (Foresight Report, 2007).  
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1.1.2. Measurements of obesity 
The WHO report published in 2000 was concerned with the health hazards associated with 
being overweight or obese, prevention of excessive weight gain and the treatment of the 
different degrees of obesity (WHO, 2000).  One simple method to assess the weight status of 
an individual is the use of body mass index (BMI) which is calculated by dividing the weight in 
kilograms by the square of the height in metres (kg/m2).  The healthy range of BMI values was 
suggested as being between 18.5 and 24.9 kg/m2, with an age-related increase in the upper 
limits (WHO, 2000).  A study in the early 1990’s highlighted that the prevalence of obesity 
was dependant on the shift in the distribution of the whole population, thereby concluding 
that total population strategies should be the focus of obesity prevention schemes. A mean 
population of BMI < 23 kg/m2 would be necessary if the prevalence of obesity (BMI ≥ 30 
kg/m2) was to be minimised (Rose, 1991).   
 
An alternative classification system for Asian populations was proposed due to their greater 
incidences of hypertension and diabetes (WHO, 2000).  A BMI of 25 kg/m2 was proposed to 
signify obesity, with an upper normal limit of 22.9 kg/m2.  The recommended BMI cut-off 
points for Caucasian populations are shown in Table 1.1.  
 
 
 
 Table 1.1. Recommended BMI Cut-Off Points for Caucasians 
 
BMI RANGE (kg/m2) CONDITION 
Less than 18.5 
18.5-24.9 
25-25.9 
30-40 
Greater than 40 
Underweight 
Normal / Ideal 
Overweight 
Obese 
Morbidly obese 
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BMI provides a measure of overall adiposity; however, increased abdominal adiposity is a 
greater risk factor many obesity related diseases.  A 13-year follow-up study of middle-aged 
men demonstrated that abdominal obesity was associated with an increased risk of stroke, 
myocardial infarction and premature death, and this association did not occur with measures 
of general obesity, such as BMI (Larsson et al., 1984).  Due to this fact, other obesity 
measures are commonly used alongside BMI to signify body fat distribution, including the 
waist-to-hip ratio measurement (WHR) to indicate body shape, and also the waist 
circumference (WC), which is a simple predictor of abdominal adiposity (Lemieux et al., 1996; 
Han et al., 1997). The WHO report in 2000 provided WC cut-off points to predict obesity 
within an individual, and also their susceptibility to lipid disorders.  Values of WC for the 
diagnosis of abdominal obesity were originally based on white Caucasians, and were 94cm for 
men, and 80cm for women at a BMI of 25kg/m2, or 102cm for men and 88cm for women at a 
BMI of 30kg/m2 (Lean et al., 1995).   As with BMI, lower cut-off values for WC were 
implemented for non-European populations. The current waist circumference cut-off points 
for different ethnic groups proposed by the International Diabetes Federation (IDF) are 
presented in Table 1.2. 
 
 
Table 1.2.  Ethnic Specific Cut-Off Points for Waist Circumference 
 
ETHNIC GROUP SEX WAIST CIRCUMFERENCE  (CM) 
Europids / Sub-Saharan Africans / 
Middle East (Arab) and Eastern  
Mediterranean populations 
 
Male 
Female 
 
≥ 94  
≥ 80 
 
USA 
(ATP III values) 
 
Male 
Female 
 
≥ 102 
≥ 88 
 
South Asians / Ethnic South and 
Central Americans 
 
Male 
Female 
 
≥ 90 
≥ 80  
 
Chinese Male 
Female 
 
≥ 90 
≥ 80  
 
Japanese Male 
Female 
 
≥ 85  
≥ 90  
 
 
Table adapted from (IDF, 2005).  ATP III (Adult Treatment Panel III). 
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1.1.3. Obesity as a medical condition  
Excess weight is associated with an increased incidence of many co-morbidities including type 
2 diabetes mellitus (T2DM), coronary heart disease, dyslipidaemia (Mokdad et al., 2001) and 
various cancers (Calle et al., 2003).  Life-insurance studies have found that mortality rates 
steadily increase with rising degrees of obesity (Lew, 1985).  In confirmation of this, weight 
loss in obese patients can improve many of the obesity related comorbidities including insulin 
resistance, T2DM, dyslipidaemia and hypertension (Sjostrom et al., 1999).   
 
T2DM is characterised by a decline in pancreatic β-cell function and target tissue resistance to 
insulin (DeFronzo, 1988; Kudva and Butler, 1997; Yach et al., 2006), and the risk of developing 
diabetes directly correlates with BMI (Ayata et al., 2000).  General obesity has also been 
identified as an independent risk factor for cardiovascular disease (CVD; Poirier and Eckel, 
2002); however, central adiposity is more closely linked to the disease (Yusuf et al., 2005). 
Visceral adipose tissue is functionally and morphologically different from subcutaneous 
adipose tissue, possibly explaining the elevated risk for CVD (Peiris et al., 1989; Hayashi et al., 
2004).  Adipocytes found in the visceral region are less responsive to the anti-lipolytic effects 
of insulin and have a higher rate of fatty acid (FA) turnover when compared to subcutaneous 
adipocytes (Wajchenberg, 2003). 
 
1.1.3.1. The metabolic syndrome 
Obesity is connected with a number of metabolic abnormalities that are known risk factors 
for T2DM and CVD. A common clustering of these factors, including: insulin resistance, 
hyperglycaemia, hypertension, low high density lipoprotein (HDL)-cholesterol, and raised very 
low density lipoprotein (VLDL)-triglycerides was termed the metabolic syndrome (Reaven, 
1988).  A later study highlighted the need to add obesity, especially visceral obesity, as 
another risk factor involved in the syndrome (Lemieux et al., 2000).    A number of expert 
groups have attempted to provide a definition of the metabolic syndrome.  Three such 
definitions were provided by WHO in 1999, The European Group for study of Insulin 
Resistance (EGIR; Beck-Nielsen, 1999), and finally, The National Cholesterol Education 
Program – Third Adult Treatment Panel (NCEP ATP III) in 2001.  The most recent definition for 
the syndrome was provided by the International Diabetes Federation (IDF) and is described in 
Table 1.3.  The definition requires visceral adiposity with the ethnic specific WC cut-off points 
seen in Table 1.1, plus two additional risk factors. 
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 Table 1.3. The 2005 IDF definition of the metabolic syndrome  
 
 
CRITERIA SET VALUES 
Serum triglyceride level (mg/dL) >150 or specific treatment  
Serum high density lipoprotein cholesterol, 
mg/dL 
< 40 (male), <50 (female) or specific 
treatment  
Blood pressure, mmHg ≥130/85 
Fasting plasma glucose, mg/dL ≥100 
Albuminuria, mg/g albumin-to-creatinine ratio ≥30  
 
 
Table adapted from IDF (2005).   
 
 
 
1.1.4. Treatment of obesity 
The purpose of obesity treatment is to not only decrease weight, but to reduce the risk 
factors of the comorbidities associated with the disease.  Currently the main approach in the 
treatment of obesity is to combine a calorie restricted diet with increased physical activity.  
Many studies have demonstrated that weight loss achieved by exercise only is less effective 
than that attained by diet alone (Bertram et al., 1990; Anderssen et al., 1995).  The use of 
behavioural therapy alongside the diet and exercise treatment has been shown to improve 
short-term weight loss and be more effective at maintaining weight (Avenell et al., 2004).   
 
Pharmacotherapy has become involved in obesity management; however, the history of anti-
obesity drugs has not been successful, due to their health risks outweighing possible weight 
loss benefits.  One example is rimonabant, a cannabinoid receptor Type 1 blocker (Rinaldi-
Carmona et al., 1994) discovered and manufactured by Sanofi-Aventis.  Treatment with this 
drug causes weight loss, reduction in WC, and an improvement in various metabolic factors, 
although adverse psychiatric events were observed at daily doses of 20mg compared to a 
placebo (Christensen et al., 2007).  These findings lead to the removal of this drug by the 
European Medicines Agency, and the Food and Drug Administration (FDA) in the USA to 
refuse the approval of its use.   
 
Another anti-obesity drug to be banned was sibutramine (Knoll Laboratories / Abbott 
Laboratories), a selective inhibitor of the reuptake of serotonin as well as norepinephrine 
(Mun et al., 2001).  It causes a reduction in food intake and also increases thermogenesis in 
humans (Hansen et al., 1998; Seagle et al., 1998).  In one study, patients treated with 
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sibutramine achieved a continued weight loss of up to 15% over one year after an initial diet-
induced weight loss, whereas those treated with a placebo regained the weight (Apfelbaum 
et al., 1999).  In contrast to the weight loss benefits of this drug, the Sibutramine 
Cardiovascular Outcomes (SCOUT) trial in 2010 (James et al., 2010) highlighted increased risk 
of non-fatal myocardial infarction and stroke after long-term sibutramine treatment in 
patients with pre-existing cardiovascular conditions. The findings in this report prompted the 
removal of this drug from worldwide markets.  Previously withdrawn drugs were 
fenfluramine (Pondimin; Wyeth) and dexfenfluramine (Redux; Wyeth) in 1997 due to 
increased risk of cardiac valvulopathy; and more recently, benfluorex in 2009, also due to 
valvulpathy risk.  
 
The removal of sibutramine from the market meant that orlistat was the only approved 
prescription drug remaining for the long-term treatment of obesity.  Orlistat is a lipase 
inhibitor, and has been shown to achieve a weight loss of approximately 10%, compared to 
an average 5% with a placebo drug (Sjostrom et al., 1998; Davidson et al., 1999).  It was 
marketed as Xenical (Roche), and without prescription as Alli (GlaxoSmithKline).  With only 
orlistat left, there was an apparent need for effective, yet safe weight-loss drugs. 
 
Very recently (2012), the FDA has approved two new drugs to be used in conjunction with 
diet and exercise regimes. The first is lorcaserin, trade name Belviq (Arena Pharmaceuticals), 
a selective agonist of the serotonin receptor (FDA briefing, May 2012); and the second is a 
combination of an anorectic agent (phentermine) and the antiepileptic drug topiramate (FDA 
briefing, February 2012).  This second medication has the trade name Qsymia and is 
produced by Vivus.  Both lorcaserin and phentermine/topiramate are appetite suppressants, 
and can induce a negative energy balance.  Both drugs met at least one of the two clinical 
weight loss criteria set by the FDA in a one year placebo controlled clinical trial, and improved 
cardiometabolic and anthropometric measures, such as WC and blood pressure (Colman et 
al., 2012). 
 
A final treatment option is surgery; however, this is often only used as the last resort.  Due to 
the increased risk of morbid obesity with premature death, the NIH consensus panel set the 
guidelines for surgical treatment BMI ≥40 kg/m2 or ≥35 kg/m2 with co-morbidities (Consensus 
Development Conference Panel, 1991). 
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Two groups of bariatric surgical techniques exist, and they are malabsorptive and restrictive 
procedures.  The first type involves shortening the small intestine to induce a negative energy 
balance, and eventually, weight loss.  One of the original procedures was the jejunoileal 
bypass, although it was associated with many long-term complications including liver failure, 
causing this method to no longer be used (Santry et al., 2005).  Other malabsorptive methods 
are currently used, although, long-term health complications are associated with this type of 
surgery, including malnutrition and vitamin deficiencies (Murr et al., 1999). 
 
Restrictive procedures reduce the size of the stomach leading to reduced meal size and 
calorie intake.  One example of this type of surgery is the vertical banded gastroplasty, where 
the stomach is portioned to form a small pouch, thereby limiting the food passage into the 
bulk of the stomach (Mason, 1982).   
 
1.1.5. Obesity as an inflammatory condition 
The obese state is characterised by chronic low-grade systemic inflammation and is linked to 
the increased risk of developing CVD and T2DM in obesity (Yudkin et al., 1999; Festa et al., 
2001).  The circulating concentrations of various inflammatory markers and pro-inflammatory 
cytokines increase in the obese state (Trayhurn and Wood, 2004).   
 
This inflammatory environment in adipose tissue occurs due to changes in the expression and 
secretion of the inflammatory adipokines, and also the infiltration of macrophages (Weisberg 
et al., 2003; Xu et al., 2003).  The number of macrophages in white adipose tissue (WAT) is 
directly correlated with the size of adipocytes in both humans and mice, thereby possibly 
increasing the secretion of the pro-inflammatory cytokines, and contributing to obesity 
associated diseases (Weisberg et al., 2003; Xu et al., 2003; Curat et al., 2004).  Monocyte 
chemoattractant protein 1 (MCP-1) is a chemokine expressed by adipocytes, and this 
expression is directly correlated with obesity (Christiansen et al., 2005).  Other proteins 
secreted by adipocytes that contribute to the infiltration and retention of macrophages are 
leptin and macrophage migration inhibitory factor (MIF), the expression of which increase in 
obesity (Trayhurn and Wood, 2004; Skurk et al., 2005a). As well as an infiltration of 
macrophages occurring in the obese state, pre-adipocytes are capable of differentiating into 
macrophages (Cousin et al., 2001).   
 
 
9 
 
The inflammatory environment caused by the infiltration of macrophages into adipose tissue 
may contribute to the onset of the obesity-associated comorbidities (Bouloumie et al., 2005).  
The immune response observed in obesity may possibly be triggered by the development of 
hypoxia within the adipose tissue.  As WAT mass expands during the development of obesity, 
adipocytes distanced from the vasculature will become hypoxic, with areas of low oxygen 
tension (Trayhurn and Wood, 2004).  The transcription factor hypoxic inducible factor-1 (HIF-
1) is a heterodimeric protein consisting of α and β sub units expressed within adipocytes 
(Lolmede et al., 2003).  The β sub unit is constitutively expressed, whereas HIF-1α acts as a 
molecular oxygen sensor (Semenza, 2001) and is expressed in response to hypoxia (Jiang et 
al., 1996).  Activation of the HIF-1 complex leads to an increase in the release of several pro-
inflammatory cytokines, chemokines and angiogenic factors with the purpose of stimulating 
angiogenesis and increasing blood flow to the depleted areas (Trayhurn and Wood, 2004). 
 
Endoplasmic reticulum (ER) stress has been suggested as another possible cause for the 
inflammatory state observed in obesity.  A molecular link between ER stress, reduction in 
insulin sensitivity and the development of T2DM has been demonstrated (Ozcan et al., 2004).   
These proposed mechanisms for the inflammatory response are linked, as hypoxia has been 
shown to induce ER stress, and also the generation of ROS (Koumenis et al., 2002; Carriere et 
al., 2004). 
 
1.1.5.1. Treatment of the obesity related inflammatory co-morbidities 
A class of drugs called thiazolidinediones (TZDs) were introduced in the 1990’s to treat T2DM.  
Three of these agents are rosiglitazone (Avandia), pioglitazone (Actos) and troglitazone 
(Rezulin); however, only pioglitazone is still on the market.  These drugs activate the 
peroxisome proliferator-activated receptors (PPARs) which causes decreased insulin 
resistance, modified adipocyte differentiation and altered adipokine profiles; including 
increased adiponectin (Ghanim et al., 2006) and decreased IL-6 (Miles et al., 1997) gene 
expression and protein secretion.  These findings support the anti-inflammatory effects of 
these drugs; however, they also have dangerous side effects.  Rosiglitazone, for example, was 
withdrawn from the European market because it was linked to an increased risk of 
myocardial infarction and stroke. 
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The adrenal cortex produces a family of hormones called glucocorticoids, and they have been 
used historically to treat a variety of inflammatory conditions, such as asthma (Barnes, 1985).  
Dexamethasone is a synthetic glucocorticoid and has potent anti-inflammatory properties, as 
seen by its ability to inhibit the gene expression and protein secretion of the inflammatory 
cytokines IL-6 and IL-8 (Fain et al., 2005).  Therefore, this agent could be of clinical interest.  
However, chronic dexamethasone treatment is associated with a number of side effects, 
including reduction of the anti-inflammatory adipokine adiponectin, and also an impairment 
of insulin-induced glucose uptake (Sakoda et al., 2000; Bazuine et al., 2004).  Also, excessive 
glucocorticoid excess is the main cause of Cushing’s disease, which is associated with 
increased visceral adiposity, glucose intolerance and hypertension (Cushing, 1912).    Due to 
these findings, dexamethasone tends to only be used for acute treatments on inflammatory 
conditions in the clinical setting. 
 
1.2. ADIPOSE TISSUE 
The adipose organ of mammals consists of two different types of adipose tissue; brown 
adipose tissue (BAT) and WAT, and cells from both types can be found together in specific 
sites; especially the subcutaneous and visceral depots (Frontini and Cinti, 2010).  Suggestions 
that trans-differentiation can occur between the two cell types in response to environmental 
changes have been put forward (Himms-Hagen et al., 2000; Granneman et al., 2005; 
Barbatelli et al., 2010).  The location of WAT varies between species; however, mammals and 
birds have both visceral and subcutaneous WAT.  In humans, WAT is found at both visceral 
and subcutaneous depots (Gesta et al., 2007).  As mentioned, BAT often coexists with white 
adipose tissue, although it is mainly found in mammal foetuses and newborns in axillary, 
cervical, perirenal, and periadrenal regions (Cannon and Nedergaard, 2004), and in the past 
was believed to be completely lost by adulthood (Lean, 1989). 
 
1.2.1. Brown adipose tissue 
Brown adipocytes are densely packed with mictochondria, which, along with the rich vascular 
supply of BAT, account for the brown colouration of the tissue.  Lipid is stored in multiple 
droplets within the brown adipocyte, and they have a centrally located nucleus (Avram et al., 
2005). In humans, BAT is found in the neonate and newborn in the interscapular region, 
pancreas, adrenal glands, kidneys and also perivascularly (Ricquier and Bouillaud, 2000).   
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1.2.1.1. Function of BAT 
BAT has also been referred to as the ‘hibernation gland’ due to its original discovery in 
hibernating mammals (Cannon and Nedergaard, 2004). Its main function is to enable heat 
production by non-shivering thermogenesis from the metabolism of triglycerides (Au-Yong et 
al., 2009).  BAT is activated in cold conditions by the sympathetic nervous system (SNS; 
Cannon and Nedergaard, 2004), and can generate 300 times more heat than any other tissue 
(Power, 1989).  Brown adipocytes exclusively express uncoupling protein (UCP)-1 (Dulloo and 
Samec, 2000), a 32kDa protein found in the inner mitochondrial membrane. This protein 
uncouples mitochondrial oxidative phosphorylation to dissipate the electrochemical gradient 
as heat, rather than adenosine-5'-triphosphate (ATP) synthesis (Cannon and Nedergaard, 
2004).  The process of UCP-1 expression is regulated by the SNS basal tone, in response to 
cold, diet and photoperiod (Dulloo and Samec, 2000). Increased sympathetic activity results 
in hypertrophic and hyperplastic expansion of BAT, as well as increased blood flow and 
utilisation of lipid and carbohydrate substrates for oxidative metabolism (Avram et al., 2005). 
 
BAT thermogenesis is activated after excess dietary energy intake (Klaus, 2001a), possibly 
acting to limit weight gain and obesity.  This tissue may therefore also have a role in obesity, 
with a previous study suggesting an inverse correlation between BMI and BAT activity (Cypess 
et al., 2009).  A study of knockout mice without BAT resulted in diet-induced obesity and 
T2DM (Lowell et al., 1993).  Increased age- and diet-induced obesity has also been observed 
in UCP-1 deficient mice (Kontani et al., 2005).  The activity of BAT decreases with age, which 
may correlate with age-related obesity (Saito et al, 2009).   
 
1.2.2. White adipose tissue 
In humans, the majority of WAT is found in major abdominal depots around the omentum, 
intestines, and perirenal areas, and also in subcutaneous depots in the buttocks, thighs, and 
abdomen (Gesta et al., 2007).  Body fat distribution is a sexual characteristic, with woman 
tending to gain weight in the gluteo-femoral depot, and men in the abdominal region.  The 
male and female type obesity are termed android and gynoid, and it has been observed that 
both men and women can vary between the two, with android-type obesity being a greater 
risk factor for obesity-related metabolic diseases (Vague, 1956). A later study demonstrated 
that with increasing weight gain, females under the age of 60 stored the excess fat in 
subcutaneous sites, whereas males of all ages and women over the age of 60 stored fat in 
visceral depots (Enzi et al., 1986). 
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1.2.2.1. Morphology and function of WAT 
Mature adipocytes account for approximately 50% of WAT in adults, with the remaining 
tissue mass consisting of other cell types, including fibroblasts, pre-adipocytes and 
macrophages (Hausman, 1985). Developing white adipocytes contain multiple lipid droplets 
before these finally coalesce into a single droplet (Napolitano, 1963).   
 
The fat storage mechanisms present in WAT lead to the view that the tissue acts as a long-
term fuel reserve, with the storage and release of FAs being its main function (Trayhurn and 
Beattie, 2001).  The discovery of leptin in 1994 changed this view, and established WAT as an 
endocrine organ (Zhang et al., 1994), supporting a wide range of roles for adipose tissue. 
 
1.2.2.2. Energy balance 
In obesity, WAT mass increases due to both hyperplasia and hypertrophy of white adipocytes 
(Johnson et al., 1971; Faust et al., 1978; Johnson et al., 1978; Lowell et al. 1993).  This can 
only occur if energy intake is greater than energy expenditure, with the changes in the fat 
stores acting as a buffer for any imbalance (Trayhurn, 2005).   Energy homeostasis may be 
more adept at preventing weight loss than weight gain, as seen by the obesity epidemic 
(Ahima et al., 1996 and 1999).  Two pathways involved in energy homeostasis are termed 
anabolic and catabolic.  Anabolic-effector pathways stimulate food intake and weight gain, 
whereas catabolic-effector pathways lead to weight loss.  Both pathways are regulated such 
that an increase in one accompanies decreases in the other to maintain stability in the energy 
balance equation (Schwartz et al., 2000).  Previous studies have demonstrated that weight 
loss caused by calorie restriction leads to an increase in food intake (Levitsky, 1970), and vice 
versa, with energy intake being suppressed by over-feeding and weight gain (Cohn and 
Joseph, 1962). The majority of adult mammals maintain stable body weight by closely 
matching their intake and expenditure (Frayn, 2003).  
 
1.2.2.3. Energy intake 
Regulation of adipose tissue stores by the brain was suggested by the ‘set-point theory’ in the 
1950s, a negative-feedback system based around an individual’s target ‘set-point’.  Any 
deviations from this set point would result in food intake adjustments (Kennedy, 1953).  The 
brain is an important site of appetite regulation, especially the hypothalamic arcuate (ARC) 
nucleus, which has two opposing neuronal pathways, either the appetite stimulating anabolic 
pathway, or the appetite inhibiting catabolic pathway (Schwartz et al., 2000; Gale et al., 
2004).  Subsets of neurons in the ARC nucleus express two peptides within the anabolic 
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pathway.  These are neuropeptide Y (NPY) and agouti-related protein (AgRP), and both 
stimulate food intake (Broberger et al., 1998; Hahn et al., 1998) either directly or indirectly.  
NPY directly signals to the paraventricular nucleus (PVN) to promote energy intake, whereas 
AgRP blocks the appetite-inhibiting receptors melanocortin type 3 and 4 (MC3R and MC4R) 
and acts indirectly to counteract the effects of α-melanocyte stimulating hormone (α-MSH), 
which is anorexigenic (Stanley et al., 2005).  NPY is expressed and secreted by human 
adipocytes, and reduces leptin secretion which effects central appetite control (Kos et al., 
2007).  The catabolic pathway synthesises precursor prepro-opiomelanocortin (POMC) 
derived α-MSH, and also expresses cocaine-amphetamine–regulated transcript (CART), 
which, like α-MSH, also potently reduces food intake (Elmquist et al., 1999). 
 
Both pathways are influenced by peripheral hormonal signals that can cross the blood-brain 
barrier, such as leptin, insulin, ghrelin and peptide YY (Gale et al., 2004).  ARC NPY/AgRP 
neurons are inhibited by leptin and insulin, whereas the reverse is true for the POMC/CART 
neurons (Schwartz et al., 1997; Thornton et al., 1997; Mizuno et al., 1998; Benoit et al., 
2002).  Leptin and insulin are involved in long-term regulation of food intake, lesser 
circulating concentrations of both cause an increase energy intake, and decrease energy 
expenditure (Mizuno et al., 1999; Benoit et al., 2002).  Both leptin and insulin stimulate α-
MSH and suppress NPY and AgRP expression in the hypothalamus, therefore activating the 
catabolic pathway, and inhibiting the anabolic pathway (Gale et al., 2004).  However, direct 
administration of both leptin and insulin into the central nervous system (CNS) has been 
shown to reduce food intake and body weight in a dose-dependent manner (Chavez et al., 
1995). 
 
Short-term control of food intake involves neural and humoral signals from the 
gastrointestinal tract and liver generated in response to nutrient intake (McMinn et al., 
2000).  One hormone involved is ghrelin, a peptide secreted from the stomach and upper 
intestine to stimulate food intake (Kamegai et al., 2000; Tschop et al., 2000).  Central 
administration of ghrelin stimulates endogenous growth hormone (GH) release by binding to 
hypothalamic and pituitary growth hormone secretagogue receptor, which is a G-protein 
coupled receptor.  In humans, ghrelin is involved in initiation of food consumption; a peak in 
plasma ghrelin concentration is observed before a meal, and decreases afterwards 
(Cummings et al., 2002; Espelund et al., 2005).   
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Other hormones involved in short-term regulation of food intake are peptide YY (PYY) and 
cholecystokinin (CCK).  Both are released from the intestinal tract after ingestion of food to 
enhance satiety.  PYY inhibits NPY- and AgRP-expressing neurons to decrease food intake 
(Batterham et al., 2002).  Administration of PYY significantly decreases energy intake over a 
24 hour period in both lean and obese subjects (Batterham et al., 2003).  The same study also 
found that the obese subjects had lower endogenous concentrations of PYY in comparison to 
their lean counterparts, suggesting a possible role for PYY deficiency in the pathogenesis of 
obesity (Batterham et al., 2003).  The hormone CCK acts both locally on CCK-A receptors, and 
centrally within the hypothalamus CCK-B receptors to enhance satiety (Wilding, 2002). 
  
1.2.2.4. Energy expenditure  
Energy is expended continuously over a daily period, with the majority being accounted for 
by the basal metabolic rate (BMR).  Changes in BMR have a major impact on total energy 
expenditure (TEE), and a reduced rate of energy expenditure is a known risk factor for weight 
gain (Ravussin et al., 1988). Ravussin and colleagues discovered that energy expenditure over 
a 24 hour period (24EE) varied between subjects according to their body size. Obese subjects 
had higher 24EE, and the effects of exercise were even greater on energy expenditure when 
compared with lean subjects.  This is due to a greater tissue mass which is metabolically 
active, and a greater energy demand of physical activity (Ravussin et al., 1988).   Variance in 
BMR can be explained by body mass (including free fat mass), age and sex (Boothby et al, 
1936; Halliday et al., 1979; Bogardus et al., 1986).  A genetic link has also been suggested 
with a study of twins finding that the heritability of BMR accounts for approximately 40% of 
the variation seen (Bouchard et al., 1989). 
 
Other factors contributing to energy expenditure include physical activity and skeletal muscle 
metabolism.  A previous study has reported an inverse relationship between slow muscle 
fiber types and body fatness, and suggested that muscle fiber type may be a possible cause of 
obesity (Wade et al., 1990).  A final process requiring energy is thermogenesis, as described in 
Section 1.2.1.1.  
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1.2.2.5. Lipid metabolism 
The major energy reserve in WAT of higher eukaryotes is in the form of triglyceride (TG).  Two 
major processes keep this lipid pool in a constant state of flux, and they are lipogenesis and 
lipolysis (Figure 1.1).  Lipogenesis is the synthesis of lipid whereas lipolysis refers to the 
breakdown of lipid, and a balance between the two determines fat accumulation.  
Lipogenesis acts to synthesis FAs, whereas during lipolysis TGs are hydrolysed to generate FAs 
and glycerol. 
 
1.2.2.6. Lipogenesis 
Lipogenesis converts excess carbohydrates into lipids for storage, and the process starts with 
de novo FA synthesis from simple sugars and this occurs in the cytoplasm of the cell.  The FAs 
produced are then esterified with glycerol to form TGs, which are either stored in the 
adipocyte, or incorporated into complex structures such as lipoproteins.  Lipoprotein lipase 
(LPL) is involved in the regulation of lipogenesis, and is the rate-limiting enzyme for importing 
triglyceride-derived fatty acids into adipocyte storage (Weinstock et al., 1997).  A summary of 
this process is shown in Figure 1.2. 
 
Two enzymes are important during the lipogenesis process and these are acetyl-CoA 
carboxylase and fatty acid synthase (FAS).  Both use acetyl-CoA and malonyl-CoA derived 
from carbon precursors such as glucose to generate palmitate, and various lipid species can 
then be produced due to modification of palmitate by endogenous elongase and desaturase 
enzymes.  The process of de novo lipogenesis (DNL) can produce lipid species with 
bioactivities distinct from those of lipids derived predominantly from the diet (Cao et al., 
2008).  DNL in liver causes increased serum TGs and intrahepatic lipid (steatosis), leading to 
non-alcoholic fatty liver disease and steatohepatitis (Postic and Girard et al., 2008).  Increased 
liver DNL is associated with insulin resistance (Hudgins et al., 2011); however, the opposite is 
true for adipocyte DNL, with a previous study in humans finding that increased expression of 
lipogenic enzymes lead to enhanced insulin sensitivity, irrespective of obesity (Roberts et al., 
2009).   
 
Lipogenesis is very responsive to changes in diet.  Polyunsaturated fatty acids (PUFA) have 
been shown to decrease lipogenesis by suppressing gene expression of many of the 
necessary enzymes, including fatty acid synthase (Jump et al., 1994).  Carbohydrates 
stimulate lipolysis in both liver cells and adipocytes, leading to increased postprandial plasma 
TG concentration. During chronic energy deprivation, adipose tissue lipogenesis is reduced, 
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and this is combined with an increase in lipolysis, causing a loss of TGs from adipocytes, and 
eventually weight loss (Kersten, 2001).  Glucose is a substrate for lipogenesis, and stimulates 
FA synthesis by being converted into acetyl-CoA.  It can also induce the expression of the 
lipogenic genes, and, stimulate the release of insulin whilst inhibiting the release of glucagon 
from the pancreas (Kersten, 2001).   
 
Insulin is an important hormonal factor which influences lipogenesis.  It binds to its receptor 
on the cell surface and activates its tyrosine kinase activity, thereby inducing many effects via 
tyrosine phosphorylation (Lane et al., 1990; Nakae and Accili, 1999).  Some of the effects of 
insulin include increased glucose uptake into the adipocyte via recruitment of glucose 
transporters to the plasma membrane, and also activating lipogenic and glycotic enzymes 
(Kersten, 2001).  Leptin is also involved, as it stimulates FA oxidation and inhibits lipogenesis 
(Bai et al., 1996; Wang et al., 1999) to increase the release of glycerol from adipocytes 
(Siegrist-Kaiser et al., 1997).  Another important hormonal factor is GH which reduces 
lipogenesis in adipose tissue (Goodman, 1963). 
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Figure 1.1. Lipid metabolism in adipocytes 
The lipid pool within mature adipocytes is in a constant state of flux due to two processes; 
lipogenesis and lipolysis.  Lipogenesis is the synthesis fatty acids which can be incorporated 
into TG structures, whereas lipolysis involves the hydrolysis of TG species into FAs and 
glycerol.  Abbreviations used: FA, fatty acid; TG, triglyceride. 
Triglycerides 
Lipogenesis 
Lipolysis 
Glucose Fatty acids 
Fatty acids Glycerol 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Schematic representation of lipogenesis 
The process of lipogenesis begins with the synthesis of fatty acids, which are then esterified with glycerol to form TG.  The enzymes involved in the process 
are shown in red.  Abbreviations used: CoA, Coenzyme A; TG, triglyceride. 
  
1
8
 
Glucose Acetyl-CoA Malonyl-CoA Fatty acids Fatty acyl-CoA TG 
Acetyl-CoA 
carboxylase 
Citrate 
lysate 
Fatty acid 
synthase 
Glycerol-P 
Acyl-
transferase 
19 
 
1.2.2.7. Lipolysis 
Obesity is associated with disturbances in lipolysis; an increase in the basal rate has been 
shown to contribute to the development of insulin resistance and also impaired 
responsiveness to stimulated lipolysis (Reynisdottir et al., 1995; Large et al., 1999).  This is 
due to fact that obese individuals have a greater relative abundance of larger adipocytes, 
and the size of adipocytes has been directly correlated to lipolysis (Large et al., 1999).  
Lipolysis is the process by which TGs are hydrolysed to form a diglyceride (DG), and then a 
monoglyceride (MG), with a FA being released at each stage.  This process is dependent 
on specific hydrolases, termed lipases (Lass et al., 2006; Figure 1.3).  Finally, MG is 
hydrolysed to liberate the final FA along with glycerol.   
 
During energy deprivation, net rates of lipolysis initially increase, leading to a greater 
generation of FAs and glycerol through hydrolysis of TG.  These FAs are released into the 
vasculature and utilised as energy substrates by other organs. Longer-term fasting; 
however, results in the rates of lipolysis returning to baseline after initial stimulation of 
the process (Weber and Reidy, 2012).  During periods of increased energy demand, 
lipolysis in adipocytes is mediated by hormone-sensitive lipase (HSL).  This process is 
activated by the catecholamine family of hormones interacting with G protein-coupled 
receptors. Resistance to catecholamine-induced lipolysis occurs in the subcutaneous 
depot of obese adults and children (Jensen et al., 1989; Bougneres et al., 1997).  
 
There are two types of catecholamine-binding adrenergic receptors (adrenoreceptors),   α 
and β, both of which are expressed in white adipocytes, with the β-receptors being able to 
mediate lipolysis in both rats and mice (Arch et al., 1984) and thermogenesis in BAT (Arch 
et al., 1989). The binding of an agonist to a β subtype results in activation of cyclic 
adenosine 3’, 5’-monophosphate (cAMP)-dependent protein kinase A (PKA) as well as an 
increase in adenylate cyclase activity and cAMP. Phosphorylation of HSL by PKA then 
occurs at several serine residues and by extracellular signal-regulated kinase (Holm et al., 
2000).  This phosphorylated HSL is then translocated from the cytoplasm of the adipocyte 
to the surface of the lipid droplet (Egan et al., 1992), where it binds to a docking protein, 
lipotransin (Syu and Saltiel, 1999), and to fatty acid-binding protein (Shen et al., 1999).  
PKA also phosphorylates a protein found on the surface of the lipid droplet called perilipin 
A, and this action changes its conformation, exposing the stored TGs to HSL action 
(Greenberg et al., 1991).  This protein moves to the cytoplasm in response to lipolytic 
stimulation (Brasaemle et al., 2000). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic representation of lipolysis 
Lipolysis is the process by which triglycerides are hydrolysed in a multistep process.  The TG is firstly hydrolysed to a diglyceride, and then a monoglyceride, 
with a fatty acid being released at each stage.  The enzymes involved in the process are shown in red.  Abbreviations used: ATGL, adipose triglyceride lipase; 
DG; diglyceride; FA, fatty acid; HSL, hormone sensitive lipase; MG, monoglyceride; MGL, monoglyceride lipase; TG, triglyceride. 
 
2
0
 
TG DG MG Glycerol 
ATGL 
HSL 
HSL MGL 
FA FA FA 
21 
 
HSL was originally thought to be the only factor involved in lipolysis within adipocytes 
(Holm et al., 2000); however, studies with HSL-deficient mice have suggested otherwise 
(Osuga et al., 2000; Wang et al., 2001; Haemmerle et al., 2002).  These mice showed a 
reduction in both subcutaneous and abdominal adipose depots when compared to normal 
littermates.  Adipocytes isolated from these mice had a lack of catecholamine-induced 
lipolysis, although basal lipolytic activity was similar to that of normal cells, suggesting that 
non-HSL mediated pathways of adipocyte lipolysis exist. 
 
A triglyceride lipase called adipose triglyceride lipase (ATGL) has recently been identified 
and also plays a role in lipolysis (Jenkins et al., 2004; Villena et al., 2004; Zimmermann et 
al., 2004).  The study by Zimmermann and colleagues used antibodies against ATGL in the 
HSL-deficient mice and found that this lipase is involved during lipolysis.  A low DG-
hydrolase activity was observed with ATGL treatment by an approximate 20-fold increase 
in DG accumulation, in contrast to the lack of DG accumulation with HSL.  It was calculated 
that almost 90% of the FAs released from ATGL treated cells came from the hydrolysis of 
TG in the first ester bond.  In contrast, the FA release in the HSL treated cells was seen 
from all three ester bonds (Zimmermann et al., 2004).  These findings suggest that both 
HSL and ATGL may coordinate in the breakdown of TGs.   
 
 A lipase called monoglyceride lipase (MGL) has been identified as specific to the 
hydrolysation of MG but not TG or DG (Tornqvist and Belfrage, 1976).  Other lipases 
possibly involved in lipolytic activities in adipocytes include four members of the PNPLA 
family which have high sequence homology to ATGL, and are referred to as  PNPLA 1, 3, 4 
and 5 (Lake et al., 2005).  PNPLA 3 is the closest to ATGL, although its TG hydrolase activity 
is much smaller (Jenkins et al., 2004).  Two proteins from the carboxylesterase family are 
also involved; carboxylesterase 3, also called triglyceride hydrolase (TGH-1) and 
carboxylesterase ML1, also called TGH-2.  TGH-1 was originally purified from mouse WAT 
(Soni et al., 2004).  Both TGH-1 and TGH-2 are weak hydrolases for long chain fatty acid 
TGs, preferring short chain esters.  They move to the ER rather than lipid droplet and this 
may imply that these proteins are involved in the hydrolysis of the microsomal TG pool, 
rather than the TG within the lipid droplet (Gilham et al., 2005; Okazaki et al., 2006).   
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1.2.3. Adipocyte differentiation and development 
The increase in adiposity associated with obesity is due to either hypertrophy of existing 
white adipocytes, or hyperplasia of pre-adipocytes leading to an increased number of 
mature adipocytes (Johnson et al., 1971; Faust et al., 1978; Johnson et al., 1978; Lowell et 
al. 1993).  In periods of excess energy intake, adipocytes increase up to a maximal size, 
and once reached, hyperplasia is triggered (Faust et al., 1978).   
 
The adipocyte lineage is thought to be derived from an embryonic stem cell precursor 
with the capacity to differentiate into the mesodermal cell types of adipocytes, 
chondrocytes, osteoblasts, and myocytes (Konieczny and Emerson, 1984).   The complex 
adipocyte differentiation process is called adipogenesis, and starts with the pre-adipocytes 
undergoing mitosis and growth arrest 24 hours after induction (Bernlohr et al., 1985).  
After a further 24 hours, the cells complete post-confluent mitosis, and undergo another 
period of growth arrest, after which they are destined to become mature adipocytes 
(Scott et al., 1982a and 1982b).  Late markers of differentiation begin to be expressed at 
day 3 post-differentiation, and are responsible for the mature adipocyte phenotype.  The 
cells become terminally differentiated adipocytes between days 5 and 7, with 
characteristic spherical morphology, and accumulation of lipid droplets (Ntambi and Kim, 
2000). 
 
Each stage of adipogenesis is characterised by the involvement of many factors, as well as 
the presence of specific markers, and these are summarised in Table 1.4.  The induction of 
differentiation is triggered by two families of transcription factors; the first are the 
CAAT/enhancer binding proteins- (C/EBP-) α, β and δ; and these are expressed at specific 
times during adipogenesis (Cao et al., 1991).  The second is the peroxisome proliferator-
activated receptor (PPAR) family, made up of α, γ and δ subunits (Dreyer et al., 1992; 
Kliewer et al., 1994; Tontonoz et al., 1994).   PPARγ exists as two isoforms, γ1 and γ2, 
formed by alternative splicing (Zhu et al., 1995), and N-terminal differences (Tontonoz et 
al., 1994).  The γ2 isoform is greatly expressed in adipose tissue (Tontonoz et al., 1994). 
 
In the early stages of adipocyte differentiation, C/EBP-β and –δ are stimulated (Lane et al., 
1999), and induce the expression of PPARγ.  This transcription factor then induces C/EBP-α 
expression, which is necessary for terminal differentiation due to its proliferation 
inhibition effect (Tang et al., 2005; Wang et al., 2006).   
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Another factor involved in the differentiation process is adipocyte determination- and 
differentiation-dependent factor-1/sterol regulatory element-binding protein-1 (ADD-
1/SREBP-1), and it is induced early on during adipogenesis to stimulate the expression of 
genes required for the synthesis of FAs (Kim and Spiegelman, 1996; Ericsson et al., 1997).  
This protein also induces the expression of PPARγ along with C/EBP-β and –δ.  A final 
factor is steroid receptor coactivator-3 (SRC-3) which acts with C/EBP to control the gene 
expression of PPARγ and therefore has an impact on the formation of adipocytes (Louet et 
al., 2006).  
 
Many markers are associated with each stage of the differentiation process; one example 
is LPL which is abundant in adipose tissue, and catalyses the hydrolysis of TGs. Its 
expression is considered as an early marker of adipocyte differentiation (MacDougald and 
Lane, 1995).  Pre-adipocyte factor-1 (pref-1) is also an important differentiation marker, 
and its expression decreases during the process (Smas and Sul, 1993).  Intermediate 
markers of differentiation include aP2, a fatty acid binding protein specific to adipocytes 
(Spiegelman and Ginty, 1983; Bernlohr et al., 1984).  It has a role in intracellular 
metabolism and transport of FAs.  Finally, adipocytes also express and secrete adipsin, 
angiotensinogen II and leptin, and all three are described as late markers of adipocyte 
differentiation (Jones et al., 1997).  The activation of many of these genes, including aP2 
and leptin is coordinated by both PPARγ and C/EBP-α (Spiegelman et al., 1993; Hollenberg 
et al., 1997). 
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Table 1.4. Stages of adipocyte differentiation 
EVENT CELL TYPE REGULATORY 
GENES 
MARKERS 
 Mesenchymal / pleuripotent 
Multipotential, can differentiate into 
many cell types 
  
Determination Adipoblasts  
Unipotential, can only differentiate 
into adipocytes 
 LPL 
Pref-1 
Commitment Pre-adipocytes C/EBP-β and –δ  
ADD-1/SREBP-1 
SRC-3 
aP2 
Terminal 
differentiation 
Adipocytes 
(lipid accumulation) 
PPARγ  
C/EBP-α  
adipsin 
angiotensinogen II 
leptin 
 
Citations present in text (Section 1.2.3). 
1.2.3.1. Adipocyte and adipose tissue studies 
The use of clonal cell lines has facilitated adipocyte biology research in vitro, with the 
murine 3T3-L1 and 3T3-F442A cells being the most commonly used.  When pre-adipocytes 
from both cell lines are injected into mice, they differentiate and form fat pads that are 
indistinguishable from normal adipose tissue (Green and Kehinde, 1979).  This finding has 
led to the development of both lines into well-established models for studying the 
conversion of pre-adipocytes into adipocytes.  Both cell types can also spontaneously 
arrest growth at confluence and can be induced to differentiate after treatment with 
adipogenic compounds (Spiegelman et al., 1993).  The 3T3-L1 cell line is a derivative of the 
3T3 mouse fibroblast cell line, developed by Green and colleagues (Green and Meuth, 
1974; Green and Kehinde, 1974).  It has been extensively characterised, and mimics the 
differentiation process seen in vivo (MacDougald and Lane, 1995).  Like other established 
cell lines, 3T3-L1 adipocytes may be propagated indefinitely; however, they remain in a 
resting state for long periods once a confluent monolayer has formed (Todaro and Green, 
1963).  This period of growth arrest is essential for successful differentiation, and is 
achieved through contact inhibition (Chang and Polakis, 1978).    
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Other advantages of clonal cell-lines are that they are homogeneous, and at the same 
stage of differentiation, which allows a consistent response to external stimuli.  They are 
also relatively straightforward to set up and maintain in culture.   A final advantage of 
clonal cell-lines is that they are immortal as long as they are passaged and stored 
correctly; however, it is known that the ability of 3T3-L1 pre-adipocytes to differentiate 
into adipocytes declines with increasing passage number (Poulos et al., 2010).   
 
A limitation of clonal cell-lines is that genetic modifications have occurred to ensure the 
immortality of these cell-lines and this is disadvantageous as the properties of these cells 
may be to be different from adipocytes isolated from primary sources.  Another 
disadvantage is that they do not allow assessment of depot-specific differences.  The 
metabolic behaviour of adipocytes differs between depots; pre-adipocytes isolated from 
different areas have different adipogenic potential (Djian et al., 1985; Adams et al., 1997). 
 
Only recently has the use of a human clonal cell-line been documented.  The increase in 
adipose tissue mass in obesity depends on the self-renewal capacity of adipocyte 
progenitors, and these are present during adult life (Hauner et al., 1989; Spalding et al., 
2008). These adipocyte progenitors are found in the stromal vascular fraction (SVF) of 
adipose tissue, along with a heterogeneous mixture of other cell types.  It has been 
reported that subpopulations of adipocyte progenitors show stem cell properties in the 
SVF of human adipose tissue, and so could be an alternative source of mesenchymal stem 
cells (Zuk et al., 2002).  Since then, a mesenchymal stem cell population, called human 
Multipotent Adipose tissue-Derived Stem cells (hMADs cells) has been isolated from 
human infant adipose tissue. These cells exhibit stem cell properties such as self-renewal 
and multipotency (Rodriguez et al., 2005).  The multipotency of these hMADs cells was 
proved when previous studies found that they could differentiate into adipocytes and 
osteocytes; and that the differentiation into both was temporally regulated by the 
expression of transcription factors specific to the two lineages (Rodriguez et al., 2004; 
Elabd et al., 2007).  Once fully differentiated, these cells display many of the features of 
human adipocytes in vivo (Rodriguez et al., 2004).   
 
Before the discovery of this cell line, the SGBS human pre-adipocyte cell strain was, and 
still is, commonly used.  These cells derive from the subcutaneous WAT of a human infant 
with Simpson-Golabi-Behmel syndrome, characterised by generalised tissue overgrowth 
(Wabitsch et al., 2001).  These cells have a high capacity for adipocyte differentiation and 
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the mature adipocytes are functionally indistinguishable from those differentiated in 
primary culture (Wabitsch et al., 2001).  Therefore, these cells provide an almost unlimited 
supply of identical human pre-adipocytes, but their lack of immortality means that they 
cannot be called a cell-line. 
 
Other methods used for in vitro study of adipocyte metabolism include primary culture 
and mature adipocytes.  During primary culture pre-adipocytes are removed from adipose 
tissue and induced to differentiate into mature adipocytes, and these cells can survive in 
culture for between two and four weeks (Hauner et al., 2001).  A disadvantage to this 
method includes the requirement of large volumes of material due to only a small fraction 
of WAT being made up of pre-adipocytes.  Approximately 50% of WAT is composed of 
mature adipocytes; the reminder of the tissue consists of numerous other cell types, 
including pre-adipocytes (Hausman, 1985).  Finally, mature adipocytes are isolated from 
WAT and these cells may give the closed representation of the in vivo system due to the 
limited intervention.  However mature adipocytes are fragile and can only be maintained 
in culture for up to 48h (Fain et al., 2003). 
 
The use of both primary culture and clonal cell-lines require a differentiation step, and in 
vitro differentiation has been shown to activate the majority of the genes present in 
adipose tissue in vivo (Spiegelman et al., 1993).  In culture, the pre-confluent cells 
resemble fibroblasts, both morphologically and biochemically (Green and Meuth, 1974; 
Green and Kehinde, 1975).  Once confluence has been reached, the cells can be 
differentiated by an adipogenic cocktail.  Maximal differentiation is achieved with a 
combination of insulin-like growth factor-1 (IGF-1), a glucocorticoid, an intracellular cAMP 
elevator and bovine serum (Student et al., 1980).  IGF-1 can be substituted for insulin in 
the adipogenic mixture (Smith et al., 1988).  Both IGF-I and insulin have been shown to 
stimulate differentiation of pre-adipocytes through their own receptors, although greater 
numbers of IGF-I receptors are present on pre-adipocytes (Christoffersen et al., 1998).  
IGF-I is more potent than insulin in stimulating proliferation of pre-adipocytes, whereas 
insulin is more potent in promoting differentiation (Deslex et al., 1987; Vierck et al., 1996; 
Rajkumar et al., 1999).  A commonly used glucocorticoid is dexamethasone, which is used 
to stimulate the glucocorticoid receptor pathway, and 3-isobutyl-1-methylxanthine (IBMX) 
increases intracellular cAMP levels by stimulating the cAMP-dependent protein kinase 
pathway (Rosen and Spiegelman, 2000).  Dexamethasone is a powerful inductor of 
adipogenesis at the early stages of differentiation, but is antiadipogenic if added at later 
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stages of adipocyte maturation, implying that its effects are time dependent (Caprio et al., 
2007).  Bovine serum contains a variety of proteins and growth factors, and these are 
essential for the maintenance of cell culture systems (Student et al., 1980). 
 
The in vitro studies are advantageous in that they can be used to identify a specific cause 
and effect relationship.  Disadvantages include a lack of a paracrine interaction between 
the cultured cells and other cell types that would be present in whole adipose tissue.  
Also, endocrine and neural signals would be interacting with the adipocytes in a whole 
body system.  These problems are solved with the use of in vivo studies, which are able to 
investigate the full physiological response to a stimulus.   
 
1.3. ENDOCRINE FUNCTION OF WAT 
Until recently, WAT was just regarded as an inactive energy store; however, it is now 
recognised as a major secretory organ which releases fatty acids during fasting, as well as 
other lipid moieties such as cholesterol, retinol, steroid hormones and prostaglandins 
(Trayhurn and Beattie, 2001).  The discovery of leptin by the identification and sequencing 
of the mouse obese (ob) gene in 1994 (Zhang et al., 1994) firmly established WAT as an 
endocrine organ.  Since this discovery, a wide range of hormones and proteins secreted by 
WAT have been identified, and these act at the autocrine, paracrine and endocrine level 
and collectively named ‘adipokines’ (Kershaw and Flier, 2004).  This term is restricted to 
proteins secreted by adipocytes alone, as whole WAT contains other cell types than can 
also secrete proteins (Trayhurn and Wood, 2004). Therefore, WAT is now known to 
communicate with the brain and peripheral tissues via secretion of these adipokines 
(Trayhurn and Beattie, 2001; Ronti et al., 2006).  Increased adipocyte size in humans is 
related to dysregulated adipokine expression and secretion (Skurk et al., 2007).   
 
The endocrine role of WAT is summarised in Figure 1.4 and its secretory products will be 
discussed in more detail in later sections. 
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Figure 1.4. Proteins secreted from white adipocytes 
This figure is a schematic representation of factors secreted by white adipocytes, although 
it is not a complete list.  TNF-α, tumour necrosis factor-α; IL, interleukin; MCP-1, monocyte 
chemoattractant protein-1; MIF, monocyte chemoattractant protein 1; NGF, nerve growth 
factor; VEGF, vascular endothelial factor; FAs, fatty acids.  Adapted from (Trayhurn and 
Wood, 2004; Romijn and Fliers, 2005).  
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1.3.1. Leptin 
The discovery of leptin by the identification and sequencing of the mouse obese (ob) gene 
in 1994 (Zhang et al., 1994) contributed to the understanding that WAT is an active 
endocrine organ.  Leptin (Greek leptos, meaning thin or small) encodes an 18-kDa protein 
containing a signal sequence which is cleaved to produce the mature 16-kDa hormone.  It 
was originally identified as a satiety factor secreted by WAT in genetically obese (ob/ob) 
mice using positional cloning (Zhang et al., 1994).  Both leptin gene expression and protein 
secretion are exclusive to adipocytes within WAT, although leptin is also produced in 
additional sites including BAT (Moinat et al., 1995), placenta (Hoggard et al., 1997a), 
skeletal muscle (Wang et al., 1998), oestoblasts (Reseland et al., 2001) and also stomach, 
mammary gland, ovarian follicles, heart, bone and possibly the brain (Trayhurn et al., 
1999).  Even though leptin synthesis occurs in multiple sites, WAT is the main source of 
the circulating concentrations of the hormone (Considine et al., 1996). 
 
1.3.1.1. Regulation of leptin expression and secretion 
Leptin is expressed and secreted from all WAT depots; however, there are variations 
between the sites.   In humans, gene expression and secretion is greater in subcutaneous 
adipocytes than visceral cells (Russell et al., 1998; Van Harmelen et al., 1998). The 
opposite is true in rodents, with the lowest leptin gene expression occurring in 
subcutaneous tissue, with the epididymal and perirenal depots showing greater leptin 
concentration (Trayhurn et al., 1995).   
 
Serum leptin displays a diurnal rhythm, with an increase during the night shortly after 
initiation of feeding, and a decrease during the day in both rodents (Saladin et al., 1995) 
and humans (Sinha et al., 1996).  This diurnal rhythm of leptin is strongly associated with 
meal pattern (Schoeller et al., 1997), although plasma leptin concentration is also 
pulsatile, with approximately 30 pulses in a 24h period (Licinio et al., 1997; Sinha et al., 
1996).  Leptin gene expression responds to nutritional status, with a decrease seen during 
short-term starvation of rodents (Becker et al., 1995; Saladin et al., 1995) and humans 
(Boden et al., 1996; Considine et al., 1996) which returned to normal after re-feeding.  
Plasma leptin concentration declines gradually during 24-36h of fasting in both lean and 
obese subjects, with little or no loss of fat mass observed (Boden et al., 1996; Kolaczynski 
et al., 1996).  Leptin acts as a signal of the size of WAT stores, and the two are directly 
correlated, meaning that its gene expression increases with weight gain (Maffei et al., 
1995; Kolaczynski et al., 1996; Rosenbaum et al. 1997) and decreases with weight loss 
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(Maffei et al. 1995).  A diet high in carbohydrates produces greater leptin peaks during the 
night when compared to a high-fat diet, without affected leptin concentration in the 
morning (Havel et al., 1999).  The effect of acute cold exposure on leptin production is 
similar to that of short-term fasting, with reduced expression and secretion being 
observed; however, this can be reversed by re-warming (Trayhurn et al., 1995; Hardie et 
al., 1996). 
 
Leptin gene expression and protein secretion is also controlled by a number of hormones.  
Therefore, it has been proposed that the SNS regulates the production of leptin via a 
negative feedback loop (Trayhurn et al., 1998). This is suggested because leptin gene 
expression is inhibited by administration of the catecholamines noradrenaline and 
adrenaline (Trayhurn et al., 1995).  Furthermore, inhibition of noradrenaline synthesis in 
rodents leads to increases in both gene expression and secretion of leptin (Rayner et al., 
1998).  The effects of SNS on leptin are mediated through β3-adrenoceptors in rodents 
(Gettys et al., 1996; Trayhurn et al., 1996) and β1 and β2 adenoreceptors in humans 
(Rayner and Trayhurn, 2001).    
 
A class of drugs called thiazolidinediones (TZDs) are used to treat T2DM and have been 
shown to suppress both gene expression and protein secretion of leptin via activation of 
PPARγ (Mantzoros et al., 1996; Trayhurn et al., 1996).  Numerous studies have suggested 
that glucocorticoids increase plasma leptin concentration as well as gene expression in 
vivo.  In humans, the synthetic glucocorticoid dexamethasone increases plasma leptin 
concentration (Larsson and Ahren, 1996) from 9h onwards (Miell et al., 1996), and leptin 
gene expression in subcutaneous tissue after 2h (Kolaczynski et al., 1997).  These findings 
were not related to insulin sensitivity; however, glucocorticoids have been shown to 
induce insulin resistance and hyperinsulinemia (Larsson and Ahren, 1996; Papaspyrou-Rao 
et al., 1997).  A direct role of insulin in leptin regulation was demonstrated in vitro, with 
24h of insulin treatment in human subcutaneous white adipocytes causing a 50% increase 
in leptin secretion, although there was no effect on its gene expression (Russell et al., 
1998).  Also, insulin is crucial for maintenance of leptin gene expression and secretion over 
24h in human adipocyte culture (Wabitsch et al., 1996).  Finally, leptin concentration 
increases in response to inflammatory cytokines, with an increase in leptin gene 
expression seen after treatment with tumour necrosis factor (TNF)-α and 
lipopolysaccharide (LPS); and to a lesser extent IL-6 (Sarraf et al., 1997). 
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1.3.1.2. Function of leptin 
Leptin is a satiety signal and is part of a feedback loop to modulate the size of WAT mass.  
A direct relationship is seen between leptin concentration and body fat mass in the fed 
state. With the onset of starvation, a reduction in leptin concentration is observed which 
is disproportional to changes in adipose tissue mass (Ahima et al., 1996). This decrease in 
leptin production signals for the initiation of the adaptive response to starvation. Energy 
homeostasis consists of a balance between energy intake and expenditure.  Leptin 
administration either centrally or peripherally decreases food intake and body weight, and 
also a mutation in the leptin gene or receptor is associated with obesity in both humans 
and rodents (Friedman and Halaas, 1998).  As well as inhibition of food intake, leptin also 
influences energy expenditure.  Previous studies in ob/ob mice found that leptin 
administration increased body temperature and physical activity (Pelleymounter et al., 
1995).  Another study demonstrated that body weight reduction in chronic leptin-treated 
animals was too great for decreased food intake alone (Levin et al., 1996).  Therefore 
leptin appears to play a role in both sides of the energy balance equation (Campfield et al., 
1995).   
 
Another important role of leptin is the regulation of insulin sensitivity, as demonstrated by 
the significant reduction of insulin-mediated glucose uptake in isolated mature human 
omental and subcutaneous adipocytes (Zhang et al., 1999).  Also, insulin sensitivity was 
improved in a mouse model of diabetes with localised adipose tissue loss when leptin was 
over-expressed (Ebihara et al., 2001).  
 
Leptin-deficient (ob/ob) and leptin-receptor-deficient (db/db) mice are characterised by 
obesity, as well as abnormal reproductive function, hormonal imbalances, and alterations 
in the hematopoietic and immune system, with similar dysfunctions being described in 
leptin-deficient humans (Ozata et al., 1999). Therefore, leptin is also involved in the 
reproductive system as demonstrated by causing a restoration of fertility in infertile ob/ob 
mice (Chehab et al., 1996).  Finally, leptin appears to be a significant modulator of both 
immune and inflammatory responses, including in the activation of neutrophils, 
macrophages and natural killer cells and lymphocyte proliferation (Otero et al., 2005).  It 
also modulates cytokine production from monocytes/macrophages; an increase in LPS-
induced production of TNF-a, IL-6, and IL-12 has been reported in both murine peritoneal 
macrophages and human monocytes (Loffreda et al., 1998; Santos-Alvarez et al., 1999).   
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1.3.1.3. Leptin receptor 
The leptin receptor (Ob-R) is a product of the Lepr gene (Tartaglia et al., 1995) and due to 
alternative splicing, six isoforms exist in mice, and these are: Ob-Ra, c, d and f (short 
form); Ob-Rb (long form) and Ob-Re, a soluble form (Lee et al., 1996).   Four isoforms of 
the human leptin receptor exist and are known as Ob-R5, -15, -67, and -274 (Barr et al., 
1999).  The splice variants have identical extracellular ligand binding domains, but 
different intracellular domains (Ahima and Osei, 2004; Koerner et al., 2005).  The long 
form of the receptor is found in various tissues, including the kidney, adrenal medulla, 
pancreatic β-cells and adipose tissue (Emilsson et al., 1997; Guan et al., 1997; Hoggard et 
al., 1997b). It is highly expressed in the hypothalamic arcuate nucleus (ARC), dorsomedial 
nucleus (DMH), paraventricular nucleus (PVN), ventromedial nucleus (VMH) and lateral 
hypothalamic area (LHA) of the central nervous system (Ahima et al., 2000).  The 
hypothalamus is involved in the regulation of energy homeostasis (Trayhurn et al., 1999), 
and the presence of the Ob-Rb protein supports the idea that this part of the brain is a 
target for leptin (Hakansson et al., 1998).  The Ob-Rb receptor regulates gene transcription 
via janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins 
(Vaisse et al., 1996). Leptin also induces STAT-3 translocation and phosphorylation of both 
phosphoinositide 3-kinase (PI3K) and phosphodiesterase 3B (PDE3B), and this reduces 
cAMP levels in the hypothalamus.   
 
The short form of the leptin receptor Ob-Ra is highly expressed in the choroid plexus and 
facilitates leptin transport across the blood-brain-barrier (McClain, 1998).  Once in the 
CNS, leptin interacts with the Ob-Rb receptor, causing the expression of the appetite 
stimulants NPY, melanocortin concentrating hormone (MCH), AgRP and orexin-A, which 
are inhibited by leptin.  NPY has been classified as an adipokine, as it is expressed and 
secreted by human adipocytes (Kos et al., 2007).  This adipokine decreases leptin secretion 
and therefore may play a role in the central control of appetite (Kos et al., 2007). 
Alternatively, appetite suppressants such as α-MSH derived from POMC, CART and 
corticotrophin releasing factor (CRF) show an increased response caused by leptin 
(McMinn et al., 2000). 
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1.3.2. Adiponectin 
The production of adiponectin is exclusive to adipocytes (Ouchi et al., 1999) and it has the 
greatest circulating plasma concentration of all the adipokines (Diez and Iglesias, 2003). 
The circulating plasma concentration of adiponectin is significantly greater in women than 
in men (Arita et al., 1999; Nishizawa et al., 2002).  This protein is also known as AdipoQ, 
AcrP30, apM1 or gelatine binding protein- (GBP)-28 and was first described as a collagen-
like molecule (Maeda et al., 1996); however, it is now known that adiponectin is 
composed of a globular and a collagenous domain.  Once synthesised, adiponectin forms 
trimers, and these then oligomerise to form polymers consisting of between four and six 
trimers.  Adiponectin is present in the circulation of both humans and mice in three forms; 
trimer, low molecular weight (LMW) hexamer and a high molecular weight (HMW) 
oligomer.  These are also commonly termed full length adiponectin (fAd) and globular 
adiponectin (gAd).  
 
1.3.2.1. Regulation of adiponectin gene expression and secretion 
As opposed to leptin, plasma concentrations of adiponectin decrease in a number of 
dysfunctional metabolic states, including obesity (Arita et al., 1999), dyslipidemia 
(Matsubara et al., 2002), T2DM, and coronary artery disease (Hotta et al., 2000). Many 
factors are able to regulate adiponectin gene expression and secretion, with one being 
diet.  Weight loss in both obese and insulin resistant individuals increased circulating 
adiponectin concentrations (Hotta et al., 2000; Yang et al., 2001).  Gene expression of 
adiponectin also increases with weight loss, with a previous study demonstrating that this 
increased in subcutaneous WAT biopsies in humans after diet induced weight loss, and 
this was also coupled with increased plasma concentrations.  The same reversal effect has 
been documented after treatment with insulin sensitising TZDs (Maeda et al., 2001; 
Combs et al., 2002). 
 
Circulating concentrations of adiponectin are inversely correlated with insulin sensitivity, 
suggesting a role for insulin in adiponectin regulation.  A previous in vitro study of 3T3-L1 
adipocytes found that insulin acted as a negative regulator of adiponectin gene expression 
(Fasshauer et al., 2002).  Certain cytokines are also suggested regulators of adiponectin 
production; TNF-α has been shown to decrease adiponectin gene expression and secretion 
in both human pre-adipocytes (Kappes et al., 2000) and 3T3-L1 adipocytes (Fasshauer et 
al., 2002).  A reduction in both is also seen in human adipocytes after IL-6 treatment 
(Bruun et al., 2003a).  Administration of anti-inflammatory drugs, such as the TDZs, is 
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known to increase the concentration of serum adiponectin.  These drugs are therefore 
used to treat T2DM in humans (Ghanim et al., 2006). Testosterone therapy also reduces 
plasma adiponectin concentrations, which may explain the differences between men and 
women (Nishizawa et al., 2002).  Other proposed regulators of adiponectin production 
include glucocorticoids (Halleux et al., 2001) and beta-adrenergic agonists (Delporte et al., 
2002; Zhang et al., 2002). 
 
1.3.2.2. Function of adiponectin 
Adiponectin acts to modulate a number of metabolic processes, and has anti-atherogenic 
(Ouchi et al., 1999 and 2000) and anti-inflammatory (Yokota et al., 2000) properties.  As 
mentioned above, gene expression and protein secretion of this protein decreases in the 
obese state (Arita et al., 1999), as well as in CVD with increasing severity (Matsuzawa et 
al., 2004), insulin resistance and T2DM (Hotta et al., 2000) and finally dyslipidaemia 
(Matsubara et al., 2002).   Adiponectin reduces the TG content of adipose tissue by 
increasing FA oxidation, and is therefore known as an insulin sensitiser (Yamauchi et al., 
2001).  The concentration of adiponectin increases when insulin sensitivity improves, such 
as after weight loss or insulin-sensitising drug treatment (Yang et al., 2001; Matsazawa et 
al., 2004), leading to the suggestion that adiponectin plays a part in the onset of the 
metabolic syndrome (Matsazawa et al., 2004).  Adiponectin also plays a role in obesity, as 
seen in obese mice, as it enhanced energy expenditure and prevented adipocyte 
differentiation (Bauche et al., 2006). 
 
Adiponectin is thought to be involved in the inflammatory response, as shown by the fact 
that it down-regulates the production of TNF-α (Masaki et al., 2004), whereas TNF-α is 
also known to reduce adiponectin production (Kappes et al., 2000).  Other anti-
inflammatory effects of adiponectin include inhibition of IL-6 gene expression and 
secretion, and an induction of the anti-inflammatory cytokines IL-1 and IL-10 receptor 
antagonist (Kumada et al., 2004; Wolf et al., 2004; Wulster-Radcliffe et al., 2004).   
 
The protein also may have an effect on vascular structure and function.  Studies in 
adiponectin knockout mice demonstrate vascular alterations, including thickening of the 
intima layer and increased production of vascular smooth muscle cells in mechanically 
injured arteries (Kubota et al., 2002), and so, adiponectin may be part of a link between 
atherosclerosis and obesity (Ouchi et al., 1999).  These effects may be caused by 
adiponectin inhibiting intercellular adhesion molecule- (ICAM) -1 and vascular cell 
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adhesion molecule- (VCAM) -1 by either TNF-α or resistin (Ouchi et al., 1999; Kawanami et 
al., 2004).  Also, over expression in vivo of adiponectin in apolipoprotein E-deficient mice 
suppresses atherosclerosis by reducing production of adhesion molecules (Okamoto et al., 
2002).  Over expression of adiponectin RNA in vitro resulted in greater cell proliferation 
and differentiation as well as increases in the expression of adipogenic genes, lipid 
content, and improved insulin sensitivity (Fu et al., 2005). 
 
1.3.2.3. Adiponectin receptor 
Two receptor forms have been cloned for adiponectin, and both are unique in distribution 
and affinity for the molecular forms of the protein.  The two forms are AdipoR1 which has 
a high affinity receptor for gAd but low affinity for fAd, and AdipoR2, which shows similar 
affinity for both forms of adiponectin (Yamauchi et al., 2003).  AdipoR1 is mainly 
expressed in skeletal muscle, whereas AdipoR2 is predominantly expressed in the liver. 
Therefore, both gAd and fAd have metabolic effects in skeletal muscle, and fAd alone has 
a greater effect on hepatic metabolic signalling (Tomas et al., 2002; Yamauchi et al., 2002 
and 2003).   Adiponectin mediates its insulin sensitising effects by binding to both 
receptors and activating 5’-AMP-activated protein kinase (AMPK), an enzyme involved in 
FA oxidation, and glucose metabolism in both the liver and skeletal muscle (Yamauchi et 
al., 2002).  The expression of both receptors decreases in the obese state (Kadowaki and 
Yamauchi, 2005), and both are expressed in human adipose tissue and isolated 
adipocytes, although the expression of AdipoR1 is greater than AdipoR2. T2DM and insulin 
treatment decreases AdipoR1 expression, but maintains that of AdipoR2 (Inukai et al., 
2005).  This may suggest that AdipoR1 expression plays a role in  insulin sensitivity and 
secretion, as previously demonstrated in mice (Staiger et al., 2004) and humans 
(Civitarese et al., 2004).  
 
1.3.3. Adipsin  
Adipsin is a differentiation dependent serine protease, and was originally called protein 
28K (Hunt et al., 1986).  Initially this hormone was thought to be primarily expressed in 
adipose tissue (Cook et al., 1985), and mainly by adipocytes in mice and humans (White et 
al., 1992).  This protein is associated with metabolic and genetic obesity in rodent models, 
and acts as a feed-back signal for food intake regulation (Cleary et al., 1980; Flier et al., 
1987).  The concentration of adipsin is reduced in obese mice models (Flier et al., 1987), 
but either increased (Napolitano et al., 1994), or constant in humans.  Roles for adipsin in 
the regulation of lipolysis and lipogenesis have also been suggested (Flier et al., 1987). 
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1.3.4. Recent adipokine discoveries 
Since the turn of the century, a number of new adipokines have been identified, and a few 
are mentioned here.  The first is resistin, discovered in 2001, and originally found to 
induce insulin resistance in mice, where it was primarily expressed by adipocytes (Steppan 
et al., 2001). In humans; however, macrophages are the greatest source of resistin (Rea 
and Donnelly, 2004).  Resistin is a member of the FIZZ (found in inflammatory zone) family 
of molecules, which are involved in the regulation of inflammation.  Original studies 
demonstrated that insulin resistance was induced by resistin (FIZZ3) administration in 
mice (Steppan et al., 2001), indicating a possible link between obesity and insulin 
resistance.  Later studies; however, have shown a decrease or no change in resistin 
concentration in obese mice, meaning that its true role is yet to be established (Way et al., 
2001).   
 
Four new adipokines were all identified around the same time, and these are visterin, 
visceral adipose tissue–derived serpin (vaspin), omentin 1 and retinol-binding protein 4 
(RBP4).  Visfatin is expressed mainly by visceral WAT, and mimics insulin action both in 
vivo and in vitro by binding to the insulin receptor (Fukuhara et al., 2005).  Unlike insulin, 
concentration of visfatin is not affected by either fasting or feeding (Fukuhara et al., 2005).  
Visfatin gene expression appears to be mediated by many factors; it increases in response 
to dexamethasone, and decreases after treatment with growth hormone and TNF-α in 
3T3-L1 adipocytes (Kralisch et al., 2005). 
 
Vaspin is a member of the serine protease inhibitor family, and was identified in the 
visceral adipose tissue of Otsuka Long-Evans Tokushima fatty (OLETF) rats (Hida et al., 
2005).  This rat model shares common signs of human T2DM such as abdominal obesity, 
insulin resistance, hypertension, and dyslipidemia (Kawano et al., 1992). Administration of 
vaspin to obese mice improves glucose tolerance and insulin sensitivity (Hida et al., 2005).  
In humans, vaspin gene expression is detected more frequently in visceral as opposed to 
subcutaneous adipose tissue (Kloting et al., 2006).    
 
 
Greater gene expression of omentin 1 is found in visceral adipose tissue in relation to 
subcutaneous adipose tissue. This protein was originally identified as being secreted by 
visceral stromal vascular cells (Kralisch et al., 2005; Schaffler et al., 2005; Yang et al., 
2006).  Omentin 1 is also found in other cell types, albeit at a lesser expression, and these 
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include intestinal Paneth cells (Komiya et al., 1998), endothelial cells and visceral adipose 
stromal-vascular cells (Yang et al., 2006).  In isolated human adipocytes, omentin 1 
activates the protein kinase Akt/protein kinase B to increase insulin signal transduction, 
and also enhances insulin-stimulated glucose transport (Yang et al., 2006).  The secretion 
of this adipokine is decreased in cultured human adipocytes by D-glucose and insulin (de 
Souza Batista et al., 2007; Tan et al., 2008).  Human plasma concentrations and gene 
expression of omentin 1 in versceral tissue are decreased in obesity (de Souza Batista et 
al., 2007). 
 
Finally, RBP4 is a protein secreted by both adipocytes and the liver, and may be involved in 
systemic insulin resistance (Yang et al., 2005).  Increased concentrations of the protein are 
associated with T2DM (Basualdo et al., 1997; Abahusain et al., 1999), and administration 
of RBP4 into mice impairs insulin signaling in muscle (Yang et al., 2005).  Serum 
concentrations of RBP4 correlate with CVD risk factors along with insulin resistance as part 
of the metabolic syndrome (Reaven, 2005).   
 
1.3.5. Cytokines 
Cytokines have been described as a wide range of low molecular weight, 
pharmacologically active proteins that are secreted by a cell and have either an autocrine 
or paracrine effects (McDermott, 2001).  Over 200 cytokine ligands have been identified; 
however, only a few of these have been studied in adipose tissue, particularly the 
interleukins (IL) and TNF-α.   
 
1.3.5.1. TNF-α 
TNF-α is a well-studied cytokine and was originally identified in the WAT of rodents, and 
the majority of its gene expression is found within the adipocytes (Hotamisligil et al., 1993; 
Kern et al., 1995; Montague et al., 1998).  The gene expression of TNF-α is less than that of 
other proteins in WAT (Montague et al., 1998), and minimal secretion occurs from normal 
tissue (Crawford et al., 1997).  In obese subjects; however, secretion of TNF-α is increased 
(Hotamisligil et al. 1997).   Gene expression of TNF-α has been found to be increased in 
human subcutaneous WAT when compared to visceral tissue (Fain et al., 2004). TNF-α is 
also expressed by the stromovascular cells of WAT and pre-adipocytes, although its gene 
expression increases with the degree of differentiation (Hube and Hauner, 1999).  The 
protein is synthesised as a 26-kDa transmembrane pro-hormone and is cleaved into a 17-
kDa biologically active molecule.  Both forms of TNF-α mediate its biological effects. 
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1.3.5.1.1. Function of TNF-α 
TNF-α is also known as cachectin due to its original characterisation as a cachexia inducing 
factor (Oliff et al., 1987; Siegel et al., 1995). This condition, also known as ‘wasting 
syndrome’ is caused by a negative energy balance and is therefore on the other side of the 
energy equation to obesity; however, both are inflammatory conditions.  TNF-α has been 
well documented as being an important mediator of obesity-related insulin resistance 
(Hotamisligil et al., 1993, 1994 and 1995).  It has been shown to induce serine 
phosphorylation of the insulin receptor, thereby inhibiting insulin signalling.  Weight loss is 
associated with decreased production of TNF-α, and improved insulin sensitivity 
(Hotamisligil et al., 1995).  Insulin-sensitising drugs such as TZDs decrease TNF-α gene 
expression in vivo (Miles et al., 1997).   
 
The cytokine also down-regulates glucose transporter type 4 (GLUT4) in adipocytes, which 
causes a decrease in insulin-stimulated intracellular glucose transport (Stephens and 
Pekala, 1991; Stephens et al., 1997).  This reduction by TNF-α is coupled with an increase 
in HSL gene expression, therefore leading to an increase in lipolysis (Sumida et al., 1997).  
TNF-α has also been shown to inhibit the activity and gene expression of LPL (Kawakami et 
al., 1982; Semb et al., 1987; Fried and Zechner, 1989; Feingold et al., 1992), causing an 
induction of insulin resistance and mobilisation of lipids (Ogawa et al., 1989; Hauner et al., 
1995) from within the adipocytes.  TNF-α mediates these effects by suppression of C/EBPs 
(Stephens and Pekala, 1991) and PPARγ (Zhang et al., 1996), possibly down-regulating 
certain adipocyte-specific proteins involved in lipogenesis (Doerrler et al., 1994).  These 
include fatty acid-binding protein, fatty acid synthase, acetyl-CoA carboxylase, glucose-6-
phosphate dehydrogenase, LPL and GLUT4 (Hube and Hauner, 1999).  TNF-α is also able to 
decrease the gene expression of β3-adrenoceptors in both white and brown adipocytes  
(Berkowitz et al., 1998; Nisoli et al., 2000), and these receptors are involved in 
sympathetically-mediated lipolysis and thermogenesis in WAT and BAT respectively 
(Zaasma and Nahorski, 1990; Langin et al., 1991; Lonnqvist et al., 1993).  TNF-α deficient 
mice exhibit lower concentrations of circulating free fatty acids (FFAs) and TGs than their 
wild-type littermates (Uysal et al., 1997), possibly implying that mediation of insulin 
resistance by TNF-α may occur due to increased lipolysis. 
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The down-regulation of the transcription factors C/EBP and PPARγ by TNF-α as mentioned 
above (Stephens and Pekala, 1991; Zhang et al., 1996) may also be involved in the 
inhibition of adipocyte differentiation caused by the cytokine.  TNF-α also suppresses the 
expression of adipocyte-specific genes in fully differentiated adipocytes (Ruan et al., 
2002).  Many of these genes, such as GLUT 4 and aP2 have binding sites for PPARγ and/or 
C/EBPα in their promoters, which may explain why their gene expression decreases after 
TNF-α treatment.  TNF-α may also regulate cell size; as the cells grow, gene expression and 
secretion of TNF-α increases, acting to limit adipocyte size or to induce apoptosis 
(Hotamisligil et al., 1995).  An induction of apoptosis by TNF-α has been seen in both pre-
adipocytes and mature adipocytes (Prins et al., 1997).  Treatment with the adipogenic and 
anti-inflammatory agent, dexamethasone, reverses the anti-adipogenic and apoptotic 
(Zhang et al., 2001) effect of TNF-α.   
 
Finally, TNF-α is a regulator of adipokine gene expression, especially inflammatory 
mediators.  It has been shown to upregulate gene expression and secretion of leptin 
(Grunfeld et al., 1996; Kirschgessner et al., 1997; Berkowitz et al., 1998), as well as gene 
expression of IL-6, MCP-1, nerve growth factor (NGF), vascular endothelial growth factor 
(VEGF) among others  in adipocytes in vitro (Wang et al., 2005).   
 
1.3.5.1.2. TNF-α receptors 
TNF-α interacts with many receptors; however, the major TNF receptors active in adipose 
tissue are TNF-R1 and TNF-R2.  Studies with knockout models have found that TNF-R1 is 
involved in the stimulation of lipolysis (Sethi et al., 2000).  TNF-R2 is thought to be 
involved in insulin resistance (Hube and Hauner, 1999).  Both receptors can be released 
from the cell membrane and exist in a soluble form.  Membrane-bound TNF-α binds to 
both receptors, whereas soluble TNF-α preferably interacts with TNF-R1 (Hube and 
Hauner, 1999).  The circulating concentration of both receptors increases in obesity 
(Hotamisligil et al., 1997) and therefore may alter the activity of TNF-α (Sethi and 
Hotamisligil, 1999). 
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1.3.5.2. Interleukins 
The interleukins (IL) are a group of cytokines who got their name from the originally 
identified members which were both produced by, and acted on leukocytes.  The first to 
be discovered was IL-1, derived from macrophages (Smith et al., 1980).  It triggers the T-
helper cell to produce IL-2 along with mitogen or antigen (Farrar et al., 1980; Smith et al., 
1980). IL-2 maintains the proliferative capacity of activated cells (Smith et al., 1983), 
influences antibody responses to T-dependent antigens (Leibson et al., 1981) and also 
causes maturation of cytotoxic precursor cells into effectors (Shaw et al., 1978; Wagner et 
al., 1980).  Many interleukins have since been identified, and are known to be expressed 
and secreted by other cell types, including white adipocytes (Trayhurn and Wood, 2004). 
 
IL-6 is the most extensively characterised member of the IL family.  Both IL-6 and its 
receptor IL-6R are expressed in adipocytes and adipose tissue, with approximately a third 
of circulating IL-6 originating from adipose tissue (Fernandez-Real and Ricart, 2003).  IL-6 
circulates in various glycosylated forms of different sizes, while the receptor exists as 
either a membrane-bound form, or a soluble form (Fain et al., 2004).  Depot differences in 
IL-6 gene expression and secretion occur, with the greatest observed in the omental depot 
when compared to subcutaneous tissue (Fain et al., 2004).  Production of IL-6 is positively 
correlated with adiposity in humans (Fried et al., 1998); an increase in plasma 
concentration is observed in obese and insulin resistant states (Mohamed-Ali et al., 1997; 
Bastard et al., 2000; Vozarova et al., 2001), whereas weight loss leads to a decrease in 
circulating concentrations of IL-6 (Ziccardi et al., 2002; Esposito et al., 2003).  
Furthermore, increased IL-6 concentration is predictive of the development of T2DM 
(Pradhan et al., 2001) and is therefore thought to be involved in insulin resistance, as it 
suppresses insulin-stimulated metabolic actions in hepatocytes via the induction of 
suppressor of cytokine signalling- (sOCs) -3 gene expression (Senn et al., 2003).  This has 
been demonstrated by the inability of insulin to suppress glucose production in the liver 
after IL-6 administration in mice (Kim et al., 2004).  On the other hand, IL-6 deficiency in 
high-calorie fed mice causes increased hepatic insulin resistance (Matthews et al., 2010).  
However, reduced IL-6 activity in adipose tissue inhibits insulin resistance via regulation of 
sOCs3 expression in the liver (Sabio et al., 2008).  Other functions of IL-6 include inhibition 
of adipogenesis and the stimulation of lipolysis (Path et al., 2001).  Gene expression of IL-6 
is stimulated by TNF-α (Wang et al., 2005) and like TNF-α it has implications in the WAT 
wasting as seen in cancer cachexia (Greenberg et al., 1992).   
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Other interleukins expressed by WAT include IL-1β, IL-18 and IL-10 (Fain et al., 2004; Juge-
Aubry et al., 2005).  IL-1β binds to the IL-1 receptor and activates the NFκB signalling 
pathway.  It stimulates leptin secretion from human adipocytes (Flower et al., 2003) and 
also promotes leptin production in response to inflammatory stimuli in mice (Faggioni et 
al., 1998).  Concentration of IL-1β increases with obesity (Um et al., 2004), and this 
increase is a risk factor to both T2DM and the metabolic syndrome when combined with 
an increase in IL-6 production (Spranger et al., 2003). Chronic IL-1β treatment causes 
insulin resistance in both human and rodent adipocytes (Lagathu et al., 2006), due to 
decreased IRS-1 expression (Jager et al., 2007). IL-18 is also a pro-inflammatory cytokine, 
and is expressed in both human adipose tissue and adipocytes.  IL-18 gene expression is 
induced by LPS, TNF-α and IL-1β in these sites (Juge-Aubry et al., 2005; Skurk et al., 
2005b), whilst dexamethasone has been shown to inhibit IL-18 gene expression (Bruun et 
al., 2001).   The plasma concentration of IL-18 has also been shown to increase with 
obesity, and decrease after weight loss (Esposito et al., 2002).  However, mice deficient in 
IL-18 or its receptor exhibit hyperphagia, insulin resistance, hyperglycaemia and obesity 
(Netea et al., 2006).  Finally, IL-10 is secreted from human adipocytes and also the stromal 
vascular fraction of human WAT (Fain et al., 2004).  It differs from most cytokines due to 
its anti-inflammatory nature.  An expansion in WAT mass in both humans and mice causes 
increased gene expression of IL-10 (Esposito et al., 2003; Juge-Aubry et al., 2005).  
 
1.3.6. Chemokines 
Chemokines are low molecular weight proteins structurally similar to cytokines.  Their 
main functions include regulation of cell trafficking and also leukocyte migration into 
damaged tissues.  Chemokines were first discovered with the purification of secreted 
platelet factor- (PF) -4 (Wu et al., 1977).  Since then, more than 50 human chemokines and 
20 chemokine receptors have been identified (Zlotnik et al., 1999).  As previously 
mentioned, infiltration of macrophages is associated with obesity, causing an increase in 
the expression of several macrophage-specific genes (Weisberg et al., 2003; Xu et al., 
2003).  The gene expression of MCP-1, MIF and IL-8 from adipocytes is particularly 
important in macrophage infiltration (Gerhardt et al., 2001).  MCP-1 is mainly produced by 
macrophages and endothelial cells, and is a potent chemotactic factor for monocytes.  
Many previous studies have demonstrated that MCP-1 gene expression is increased with 
obesity.  MCP-1 is also present in human adipose tissue, with increased gene expression 
and secretion found in the visceral depot, compared to subcutaneous WAT (Bruun et al., 
2005).  The expression of an MCP-1 transgene under the control of the aP2 gene promoter 
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in adipose tissue has been found to induce macrophage infiltration into adipose tissue, 
insulin resistance, and increased hepatic triglyceride content in mice.  The same study also 
found that acute disruption of MCP-1 lead to improved insulin resistance and hepatic 
steatosis in obese mice, and suggested that the increased MCP-1 gene expression in 
adipose tissue during obesity is important in the pathogenesis of insulin resistance, 
macrophage infiltration into adipose tissue, and hepatic steatosis (Kanda et al., 2006).  
This possible role in insulin resistance is also supported by the fact that TNF-α (known to 
induce insulin resistance), increases MCP-1 gene expression and secretion in human 
adipocytes in vitro (Wang et al., 2005).  Another function of MCP-1 within adipose tissue 
includes a reduction in the gene expression of adipogenic genes, leading to an inhibition of 
adipocyte growth and differentiation (Sartipy and Loskutoff, 2003). 
 
MIF is also involved in macrophage infiltration into WAT, and has been demonstrated to 
be positively correlated with BMI in humans (Skurk et al., 2005a); circulating 
concentration of MIF is increased in the obese state (Dandona et al., 2004; Ghanim et al., 
2004) and decreased after weight loss (Church et al., 2005).  The chemokine is also 
expressed by pancreatic β-cells and in the presence of raised plasma concentrations of 
glucose, increased gene expression of MIF may be used as a marker for β-cell dysfunction 
(Church et al., 2005). 
 
A member of the interleukin family, IL-8, is expressed and secreted from human 
adipocytes in vitro and in vivo.  Like the other chemokines, circulating concentrations of IL-
8 correlate with adiposity, and so may be involved in obesity related comorbidities (Bruun 
et al., 2003b). 
 
A more recently discovered chemokine is chemerin (Wittamer et al., 2003), and it is 
expressed in both the liver and WAT (Bozaoglu et al., 2007; Goralski et al., 2007).  It 
modulates chemotaxis, and activates dendritic cells and macrophages through G protein-
coupled receptors (Cash et al., 2008; Zabel et al., 2008).  Macrophage derived cysteine 
proteases cleave chemerin to generate potent anti-inflammatory products that inhibit the 
production of pro-inflammatory mediators such as TNF-α, IL-1β, and IL-6, whilst increasing 
the gene expression of anti-inflammatory cytokines (Cash et al., 2008).  Chemerin is also 
associated with the metabolic syndrome (Bozaoglu et al., 2007). 
 
 
43 
 
1.3.7. Other factors 
WAT also expresses and secretes a wide range of other factors.  These include 
haemostatic and haemodynamic factors, acute phase proteins and growth factors.  
Haemostatic and haemodynamic factors include the renin-angiotensin aldosterone system 
(RAAS) and Plasminogen-activator inhibitor 1 (PAI-1).  RAAS is a regulator of systemic 
blood pressure and renal electrolyte homeostasis (Engeli et al., 2000).  Many of the RAAS 
proteins are secreted by WAT including renin, angiotensinogen (AGT), angiotensin I and II, 
angiotensin receptors type I (AT1) and II (AT2), and angiotensin-converting enzyme (ACE).  
RAS gene expression is positively correlated with adiposity in humans, and is therefore 
possibly involved in obesity-associated hypertension (Harte et al., 2005).  PAI-1 is a serine 
protein inhibitor, and increased concentrations are a risk factor for thrombosis (Fay, 
2004).  It its concentration increases with visceral obesity (Kershaw and Flier, 2004).  PAI-1 
deficient mice have smaller adipocytes and lower tissue triglyceride concentration than 
wild-type mice in response to a high-fat diet (Schafer et al., 2001; Ma et al., 2004), 
suggesting a role for this protein in WAT development. 
 
Acute phase proteins are mainly secreted by the liver; however, several are expressed in 
and secreted from WAT.  These are therefore classed as adipokines, and their circulation 
concentration increases in the obese state (Trayhurn and Wood, 2004).  One such protein 
is serum amyloid A (SAA), an amyloid A precursor.  It is an independent risk factor for 
coronary artery disease and AA amyloidosis, with its serum concentration being correlated 
with BMI and adiposity (Poitou et al., 2005).  Haptoglobin is another acute phase protein 
and its gene expression is known to increase during the differentiation process in both 
humans and mice (do Nascimento et al., 2004).  It binds haemoglobin to prevent kidney 
damage during haemolysis, and has also been demonstrated to stimulate endothelial cell 
differentiation and vascularisation (Cid et al., 1993).  Another acute phase protein is 
metallothionein (MT), which is expressed in BAT, where it has a suggested antioxidant role 
(Beattie et al., 2000).  This antioxidant role has also been suggested in WAT by protecting 
fatty acids from oxidative damage (Trayhurn et al., 2000).  The gene expression of MT 
occurs in all WAT depots, and is adipocyte specific (Trayhurn et al., 2000). 
 
WAT expresses and secretes various growth factors including; transforming growth factor-
(TGF) -β, IGF-1, vascular endothelial factor (VEGF) and nerve growth factor (NGF). TGF-β is 
expressed in WAT, and mice obesity models demonstrate an increase in its gene 
expression (Samad et al., 1997).  It is involved in many processes, including tissue 
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remodelling, wound repair, cell adhesion and migration, extracellular matrix production 
(Sporn et al., 1987), and so regulates differentiation of many cell types.  IGF-1 is secreted 
from WAT and stimulates pre-adipocyte differentiation (Hausman et al., 2001).  VEGF is 
mainly secreted by visceral WAT, and db/db mice have an increased plasma concentration 
of this growth factor (Miyazawa-Hoshimoto et al., 2005).  NGF is a target-derived 
neurotrophin, and these proteins are involved in the development of the nervous system 
(Hennigan et al., 2007).  The SNS is involved in many aspects of WAT function, including 
lipolysis (Hales et al., 1978; Bartness and Bamshad, 1998) and adipokine production 
(Trayhurn et al., 1995; Rayner and Trayhurn, 2001).  Therefore, neurotrophins are involved 
in the regulation and maintainance of sensory neurons (Vega et al., 2003).  NGF has been 
shown to be expressed in mice and human WAT in vivo (Peeraully et al., 2004), and is also 
secreted in vitro by mice and human adipocytes (Peeraully et al., 2004). 
 
1.4. EICOSANOIDS 
Eicosanoids are local hormones that have specific effects on nearby target cells. They are 
produced by multiple cell types, and therefore have many functions.  Their main role is as 
mediators of inflammation, giving the view that these signalling lipids are pro-
inflammatory; however, some have anti-inflammatory roles, such as the lipoxins (Gewirtz 
et al., 2002; Serhan et al., 2003).  Others, such as prostaglandin (PG) E2, have both pro- 
and anti-inflammatory effects.  This eicosanoid is an inhibitor of certain pro-inflammatory 
cytokines, including TNF-α and IL-1, as seen in monocytes and macrophages (Miles et al., 
2002).  In contrast, PGE2 induces the formation of anti-inflammatory lipoxins (Levy et al., 
2001; Vachier et al., 2002).   
 
Production of eicosanoid species occurs via  the oxidation of C20 polyunsaturated fatty 
acids, primarily 5,8,11,14-eicosatetraenoic acid, also known as arachidonic acid (AA); but 
also 5,8,11,14,17-eicosatrienoic acid, commonly named eicosapentaenoic acid (EPA), and 
all-cis-docosa-4,7,10,13,16,19-hexa-enoic acid; docosahexaenoic acid (DHA; Levin et al., 
2002; Wada et al., 2007).  AA is a member of the omega-6 family, whereas both EPA and 
DHA are omega-3 fatty acids.  The eicosanoid species produced by these pathways include 
PGs, leukotrienes (LT) and lipoxins (LX), as summarised in Figure 1.5.   
 
The eicosanoid species investigated in this thesis are all derived from AA, and so, this 
pathway will be discussed in greater detail in Sections 1.4.1 to 1.5. 
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1.4.1. The arachidonic acid cascade 
The classic eicosanoid family is comprised of three groups, produced via three pathways, 
as summarised in Figure 1.6.  These are the cyclooxygenase (COX) pathway, whose 
products include PGs and thromboxanes (Tx); the lipoxygense (LOX) pathway which forms 
LTs and certain mono-, di- and tri-hydroxy acids; and finally epoxides are synthesised by 
the epoxygenase pathway.  These pathways are often referred to as cascades, and they all 
need a critical oxygenase to produce a reactive intermediate, which occurs by integrating 
molecular oxygen into the arachidonic acid structure.  These intermediates are then 
processed by secondary enzymes to form the biologically active eicosanoid species. All 
three oxygenase cascades will be discussed in more detail. 
 
1.4.1.1. The cyclooxygenase cascade 
Prostanoids are produced via the COX pathway, and are synthesised in response to cell 
specific stimuli.  The intermediate involved in this cascade is PGH2, and this is then 
converted into the biologically active eicosanoids, such as PGE2 which utilises PGE2 
synthase (Helliwell et al., 2004).  Before the conversion of PGH2 into PGE2, AA is released 
via hydrolysation of phospholipids present in the cell membrane by the enzyme 
phospholipase A2 (PLA2).  After its release, AA is converted into PGG2, the prostanoid 
precursor, and this is subsequently peroxidised to PGH2. Both of these reactions are 
catalysed by COX.  There are two COX isoforms, COX-1 located in the ER and COX-2 which 
acts near the nuclear envelope (Morita et al., 1995).  COX-1 is constitutively expressed 
(O’Neill et al., 1994) and is involved in physiological functions such as platelet aggregation 
(Funk et al., 1991).  The inflammatory functions of prostanoids are due to expression of 
COX-2 (Maier et al., 1990; Lee et al., 1992; Xie et al., 1992).  The biologically active 
prostanoids are considered as PGD2, PGE2, PGF2α, PGI2 (possibly PGH2) and TxA2 (Straus 
and Glass, 2001; Hata and Breyer, 2004).  These are synthesised from the conversion 
enzyme substrate, PGH2.  These enzymes are PGD2, PGE2, PGF2α, prostacyclin and 
thromboxane synthase.  Some of the biologically active prostanoids can be further 
converted into other products, for example, PGE2 can form PGA2, PGB2 and PGC2, while 
PGI2 can be converted into 6-keto-PGF1α (Straus and Glass, 2001).  This more detailed COX 
pathway is presented in Figure 1.7. 
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1.4.1.2. Prostanoid structure and function 
The prostanoids all share a similar structure; they are all oxygenated fatty acids composed 
of 20 carbon atoms and contain a cyclic ring, a trans-double bond between C-13 and C-14, 
and a hydroxyl group at C-15.  The prostanoid group contains PG species, all of which 
contain a cyclopentane ring, and classified into types A to I due to modifications of this 
ring.  PG types D to I exist naturally, with PGG2 and PGH2 being unstable intermediates 
(Hamberg and Samuelsson, 1973).  Types A to C are produced in extraction procedures, 
but are prone to artefacts (Schneider et al., 1966).  A final PG to be discovered was PGI2, 
also called prostacyclin (Moncada et al., 1976), whose structure differs from the remaining 
PGs due to an oxygen bridge between carbons six and nine.  The prostanoid group also 
consists of two Tx sub-groups, A (Hamberg et al., 1975) and B (Hamberg and Samuelsson, 
1974), and both contain a cyclohexane ring.  Individual prostanoids species structures are 
shown in Figure 1.8. 
 
The prostanoids play a major role in the inflammatory response, especially the 2-series 
members derived from AA.  The symptoms of acute inflammation include local reddening, 
heat, swelling and pain.  Studies using prostanoid receptor knockout mice identified that 
prostanoids and their receptors mediated these symptoms.  Mice deficient in IP receptor 
displayed a reduction in carrageenin-induced paw swelling when compared to wild-type 
mice (Murata et al., 1997).  This reduction was also seen in the non-steroidal anti-
inflammatory drugs (NSAIDs) treated wild-type mice.  These drugs act in a similar way to 
aspirin by inhibiting PG biosynthesis (Vane, 1971).  Therefore it was predicted that 
prostanoids are mediators of acute inflammation.   
  
 
 
 
 
 
 
 
  
 
 
Figure 1.5. Eicosanoid synthesis pathways 
Summary of the eicosanoid synthesis pathways including enzymes (bold) and products (red).  The AA pathway is presented in more detail in future sections.  
The abbreviations used are: AA, arachidonic acid; EPA, eicosapentaenoic acid, DHA; docosahexaenoic acid; COX, cyclooxygenase; LOX, lipoxygenase; PG, 
prostaglandin; Tx, thromboxane; LT, leukotrienes.  The series number relates to the number of double bonds.  
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Other studies using knockout mice have discovered that IP, EP1, EP3, and EP4 prostanoid 
receptors are involved in perphipheral hyperalgesia, with EP2 being shown to inhibit 
glycinergic inhibitory neurotransmission in the spinal cord, thus causing this effect 
(Ahmadi et al., 2002).  The formation of both PGE2 and PGI2 via activation of both EP2 and 
IP respectively has been shown to increase vascular permeability and leukocyte infiltration 
(Hirata et al., 1991).  A lack of fever generations has also been observed in EP3-deficient 
mice after administration of bacterial endotoxin (LPS) and IL-1 (Ushikubi et al., 1998).  An 
induction of COX-2 is evident in inflammatory cells and tissue; however, both COX 
isoforms have an inflammatory role (Kennedy et al., 1982).   
 
COX inhibitors (such as aspirin) are known to have physiological implications.  A study in 
COX-2 knockout mice found that these animals developed severe nephropathy (Morham 
et al., 1995).  However, another study has demonstrated a decrease in the size and 
number of polyps in COX-2 knockout mice with adenomatous polyposis (Oshima et al., 
1996).  Opposing effects have been noted between some of the prostanoids species, for 
example, PGI2 is mainly synthesised by vascular endothelium and is a potent vasodilator 
and inhibits platelet aggregation (Moncada et al., 1976; Tatesson et al., 1977), whereas 
TxA2 is a vasoconstrictor and aggregator of platelets (Needleman et al., 1976; Ellis et al., 
1977).   
 
As well as the pro-inflammatory functions described above, some of the 2-series 
prostanoids also have anti-inflammatory properties.  One example is PGD2 and its 
derivatives, as they have been shown to be involved in the resolution of inflammation in 
rat pleurisy (Gilroy et al., 1999 and 2003).  More commonly associated with anti-
inflammatory actions are the 1-series prostanoids derived from dihomo-c-linolenic acid 
(DGLA).  Examples include PGA1, an inductor of the anti-inflammatory cytokine IL-10 in 
activated monocytes and macrophages (Kim et al., 2008); and PGE1 which improved 
inflammation in murine models for arthritis (Zurier and Quagliata, 1971). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. The arachidonic acid cascade 
Summary of the eicosanoid generated pathways including enzymes (bold) and products (red).  These pathways are presented in more detail in future 
sections.  The abbreviations used are: COX, cyclo-oxygenase; PG, prostaglandin; TX, thromboxane; LOX, lipoxygenase; HPETEs, hydroperoxyeicosatetraenoic 
acids; HETEs, hydroxyeicosatetraenoic acids; LTs, leukotrienes; Cytochrome P450, Cytochrome P450 epoxygenase; EETs, epoxyeicosatrienoic acids. 
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Figure 1.7. The cyclooxygenase cascade 
This schematic representation illustrates the COX cascade, which leads to the production 
of various prostanoid species.  The enzymes (bold) involved and the final products 
synthesised (red) are included in the diagram.  The abbreviations used are: COX, 
cyclooxygenase; PG, prostaglandin; TX, thromboxane; NE, non-enzymatic. 
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1.4.1.3. Prostanoid function in WAT 
Adipocytes have been identified as a source of prostanoid synthesis (Shillabeer et al., 
1998).  Secretion of PGE2, PGD2, PGF2α and 6-keto-PGF1α occurs from 3T3-L1 adipocytes 
(Borglum et al., 1999).  In isolated human adipocytes, the secretion of PGI2 and PGE2 has 
been observed, although greater gene expression of these prostanoids is found in the 
stromal vascular fraction (Fain et al., 2002).  The prostanoids have various roles within 
WAT, with both pre-adipocytes and mature adipocytes synthesising them to regulate their 
own cellular functions (Lu et al., 2003).  This study by Lu and colleagues confirmed PGD2 
formation by arachidonic acid during the maturation phase of the adipocyte 
differentiation process, whereas the opposite was true for the production of PGE2, which 
was more efficient in the pre-adipocyte stage in 3T3-L1 adipocytes.  It was suggested that 
these findings reflect a switch in prostanoid generation depending on the stage of the 
adipocyte life cycle (Lu et al., 2003).  Also, the greater gene expression of PGE2 in pre-
adipocytes may cause inhibition of adipocyte differentiation (Vassaux et al., 1992a and 
1992b).  PGD2 is effective in the stimulation of triglyceride accumulation, and PGE2 
promotes the storage of lipids. A previous study with rat isolated adipocytes 
demonstrated that PGE2 interacted with G-protein-linked EP3 receptors to inhibit lipolysis 
(Strong et al., 1992), possibly causing the increased accumulation of triglycerides.  Another 
action of PGE2 is the stimulation of leptin release by WAT (Fain et al., 2000).  These 
multiple actions of PGE2 may be due to the fact that it can bind to four EP subtypes 
(Negishi et al., 1995).   
 
A final prostanoid found in WAT is PGF2α, and this has an antiadipogenic effect (Lepak and 
Serrero, 1993).  Therefore, the major roles of prostanoids in WAT are during adipogenesis, 
with the differing actions depending on specific prostanoids, and also the stage of 
adipocyte differentiation. 
 
52 
 
Prostanoid:    Structure: 
TxA2 
 
 
 
 
 
PGD2 
 
 
 
 
PGE2 
 
 
 
 
 
PGF2α 
 
 
 
 
 
PGI2 
 
 
 
 
 
 
 
Figure 1.8. Chemical structures of members of the prostanoid family 
Chemical structure of the primary prostanoids. 
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1.4.1.4. Prostanoid receptors 
The first prostanoid receptor to be cloned was the human TxA2 receptor (Hirata et al., 
1991).  Since then, eight types and subtypes of prostanoid receptors were identified in 
various species.  The receptors are a family of rhodopsinlike seven transmembrane 
spanning G-protein-coupled prostanoid receptors (GPCRs).  These identified receptors are 
all present in humans and mice, and a few have also been found in other species.  They 
include DP, a PGD receptor; PGF receptor FP; PGI receptor IP; and TP which is the TxA 
receptor (Hata and Breyer, 2004).  The final receptors are those for PGE, and they 
compose a complete receptor family, consisting of four receptors, EP1 to EP4 (Narumiya et 
al., 1999).  Each prostanoid has its highest binding affinity to its corresponding receptor; 
however, cross-reactivity between the prostanoids and receptors has been observed 
(Breyer et al., 2001).  Ligand-receptor interactions are responsible for the roles of the 
prostanoid receptors, and these interactions depend on many factors including ligand 
affinity, receptor expression profile and differential coupling to signal transduction 
pathways (Hata and Breyer, 2004).  The expression of the prostanoid receptors also differs 
with tissue distribution.  The EP1 receptor is mainly found in fibroblasts, with EP2 and EP4 
predominately observed in smooth muscle cells.  The FP receptor is found in kidney cells 
and astrocytes, TP receptor in platelets and DP receptors in the ileum, lung, stomach, and 
uterus (Bos et al., 2004).  The prostanoids may also act through intracellular targets, for 
example, PGI2 has been suggested as a ligand for PPARα and PPARδ (Kubis and Levy, 2004; 
Pola et al., 2004). 
 
1.4.2. The lipoxygenase cascade 
The three lipoxygenases present in mammals aid the incorporation of molecular oxygen 
into AA.  The name of each of the three enzymes indicates the position at which molecular 
oxygen is inserted, and so these are 5-, 12- or 15-lipoxygenase (LO). The first product 
produced from AA via these enzymes is a hydroperoxyeicosatetraenoic acid (5-, 12-, or 15-
HPETE).  This is then reduced to the corresponding hydroxyeicosatetraenoic acid, either 5-
, 12- or 15-HETE, (Smith, 1989).  The 5-LOX pathway is involved in leukotriene (LT) 
formation; 5-HETE is converted into LTA4 due to the removal of water.  This is turn can be 
converted into LTB4 via LTA4 hydrolase and the addition of water (Funk et al., 1987; 
Minami et al., 1987), or into LTC4 by the addition of a glutahionyl group via glutathione S-
transferase action (Hammarstrom et al., 1985).  LTC4 can then produce LTD4 via cleavage 
by γ-glutamyltranspeptidase, and LTD4 can be further metabolised by dipeptidase to form 
LTE2 (Hammarstrom et al., 1985).  The 15-LOX pathway also forms additional products.  As 
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well as 15-HETE, 15-HPETE can be converted into epoxytetraene, and then lead to 
lipopoxin formation (LX) of which there are two types; LXA4 and LXB4.  The 15-HETE 
product of 15-HPETE can also be further metabolised into 15-oxo-ETE.  The LOX cascade is 
summarised in Figure 1.9, and the structures of the LOX products are shown in Figure 
1.10. 
 
1.4.2.1. Functions of LOX cascade products  
The lipoxygenases catalyse the LOX cascade reactions, and are also involved in other 
processes.  They are classified based on the position of molecular insertion in the 
arachidonate substrate.  The LOXs have been identified in various sites; 12-LO has been 
characterised in mice and human platelets, 15-LO in human monocytes, 5-LO in human 
neutophils and 12/15-LO in murine peritoneal macrophages (Hammond and O’Donnell, 
2012).  The expression and secretion of 12-LO is upregulated by hyperglycemia (Kang et 
al., 2001; Chakrabarti et al., 2002; Laybutt et al., 2002) in pancreatic β-cells and mesangial 
cells and also by inflammatory cytokines in pancreatic β-cells (Chakrabarti et al., 2002) and 
human islets (Ma et al., 2010).  It has a role in the development of atherosclerosis 
(Natarajan and Nadler, 2004; Reilly et al., 2004), as does 5-LO and 5-LO-activating protein 
(5-FLAP) which are involved in the inflammatory pathways leading to this disorder 
(Radmark, 2003; Osher et al., 2006; Back et al., 2007; Ferguson et al., 2007; Gubitosi-Klug 
et al., 2008).  The formation of LTB4 is enhanced by 5-FLAP, a fatty acid transport protein 
that specifically binds to arachidonic acid.  LTB4 has been shown to increase MCP-1 gene 
expression in human monocytes (Huang et al., 2004). 
 
1.4.2.2. Functions of LOX cascade products in WAT 
The LOXs also have functions within WAT.  Inflammation within adipose tissue, and also 
insulin resistance has been shown to be implicated by 12-LO in response to a high-fat diet 
(Nunemaker et al., 2008; Sears et al., 2009). The gene expression and secretion of 12-LO is 
increased in 3T3-L1 adipocytes by free fatty acids (Bullo et al., 2003).  Addition of 12-LO 
products has been shown to increase the gene expression of several cytokines in 3T3-L1 
adipocytes, suggesting a possible role for 12-LO in the inflammatory pathways present 
within adipocytes (Chakrabarti et al., 2009).  Both 5-LO and 5-FLAP have also been found 
to have roles in obesity and insulin resistance (Ferguson et al., 2007; Horrillo et al., 2010).   
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Figure 1.9. The lipoxygenase cascade 
This schematic representation illustrates the LOX cascade, which leads to the production 
of HETEs, LTs and lipoxins.  The enzymes (bold) and the final products (red) involved in the 
cascacde are included in the diagram.  The abbreviations used are: LO, lipoxygenase; 
HPETE, hydroperoxyeicosatetraenoic acid; HETE, hydroxyeicosatetraenoic acid; LTs, 
leukotrienes and LX, lipoxin. 
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LOX product:    Structure: 
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Figure 1.10. Chemical structures of products from the lipoxygenase cascade 
Chemical structure of the primary LOX products 
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As mentioned previously, macrophage infiltration occurs in the obese state, and 12-LOX is 
highly expressed in macrophages.  Its products have been shown to increase IL-6 and 
MCP-1 gene expression of cultured macrophages (Wen et al., 2007).  Similarly, the 
addition of 12/15-LO products to cultured macrophages caused upregulation of TNF-α and 
MCP-1 gene expression in a previous study (Wen et al., 2008).   
 
When directly added to 3T3-L1 adipocytes, the 12/15-LO products also up-regulated the 
gene expression of several cytokines, such as TNF-α, IL-6 and MCP-1, as well as down-
regulating the gene expression of adiponectin (Chakrabarti et al., 2009). The gene 
expression of 5-LO has been shown to be greater in the macrophage containing SVF than 
in adipocytes (Chakrabarti et al., 2009).   
 
As well as a role in inflammation, the 12/15-LO products may also be involved in insulin 
resistance, as 12/15-LO deletion in mice fed on a high-fat diet has been shown to improve 
glucose metabolism (Chakrabarti et al., 2009).  Also, 12-HETE (product of 12-LO) 
administration in 3T3-L1 adipocytes increases JNK-1 activation, which is known to reduce 
insulin signalling (Okamoto et al., 2005). Therefore, 5-, 12- 12/15-LO may all be involved in 
the activation of the inflammatory response, as well as insulin signalling impairment 
within adipocytes. 
 
 
1.4.3. The epoxygenase cascade 
The epoxygenase pathway produces epoxyeicosatrienoic acids (EETs) from AA via   
cytochrome P450 (CYP) epoxygenases.  The epoxygenase inserts molecular oxygen into 
arachidonic acid on a double bond and this double bond reduces as the epoxide forms.  
Epoxidation of arachidonic acid leads to four EET regioisomers which are termed 5,6-; 8,9-; 
11,12- and 14,15-EET by the CYP2C and CYP2J epoxygenase enzymes (Wu et al., 1996). 
The EETs can then be hydrolysed to their corresponding dihydroxyeicosatrienoic acid 
(DHET) metabolites by soluble epoxide hydrolase (sEH), and these are less biologically 
active than EETs (Fang et al., 2001).   
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1.4.3.1. Function of EETs 
One group of products of the epoxygenase cascade are the EETs, and these have effects 
within the vascular and renal systems (Fitzpatrick and Murphy, 1989; McGiff, 1991; Harder 
et al., 1995).  Deletion of sEH has been shown to decrease blood pressure in mice (Sinal et 
al., 2000), and treatment with a sEH inhibitor has also been shown to decrease blood 
pressure in hypertensive rats (Yu et al., 2000).  These EET products also have anti-
inflammatory effects in the endothelium (Node et al., 1999), and can stimulate 
angiogenesis (Munzenmaier and Harder, 2000; Medhora et al., 2003) and prevent arterial 
smooth muscle migration (Sun et al., 2002).  
 
1.4.3.2. Function of EETs in WAT 
The EETs are thought to reduce adipocyte dysfunction (Inceoglu et al., 2007; De Taeye et 
al., 2010) because they can down-regulate the 2-LO and 5-LO pathways, resulting in 
synergism with NSAIDs and aspirin to decrease the concentration of inflammatory 
eicosanoids (Schmelzeret et al., 2006).  These eicosanoids are degraded by sEH into the 
less active DHETs and sEH activity increases during adipocyte maturation (De Taeye et al., 
2010), thereby decreasing the concentration of the anti-inflammatory EETs, leading to 
tissue inflammation.  The concentration of sEH has been shown to be increased by   
PPARα agonists in rodents (Hammock et al., 1983) and PPARγ agonists can induce the 
activity of this enzyme in adipose tissue (De Taeye et al., 2010).  De Taeye and colleagues 
also demonstrated that the gene expression and secretion of sEH did not differ in mice 
when fed either a normal or high-fat diet, although sEH activity was increased in the 
adipose tissue of obese mice (De Taeye et al., 2010).   Therefore sEH appears to be 
involved in inflammation, obesity and its related comorbidities.  In subjects with T2DM, 
single nucleotide polymorphisms in the gene that encodes sEH can lead to a greater risk of 
cardiovascular disease (Lee et al., 2006), insulin resistance (Ohtoshi et al., 2005) and 
hypertension (Burdon et al., 2008).  Anti-inflammatory agents including the NSAIDS and 
aspirin appear to reduce the severity of the metabolic syndrome (van Kerckkhoven et al., 
2000; Yuan et al., 2001; Renna et al., 2009). 
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1.5. LIPIDOMICS 
The major challenge of the post-genomic era has been the global analysis of biomolecules 
such as proteins, lipids and carbohydrates within a cell, tissue or organism.  Various 
strategies have evolved to aid in this research, including transcriptomics approaches to 
study all mRNA species present at a particular time and/or set of conditions, and 
proteomics techniques to monitor changes in protein expression, as well as investigate 
post-translational modifications.  A relatively new tool is the use of metabolomics 
analyses, used to examine low molecular weight metabolites and observe any changes 
occurring in set environmental conditions (Fiehn et al., 2001).  These metabolic profiling 
techniques provide a ‘snapshot’ of the biochemical status of a system at any one time 
(Hellerstein, 2003). Metabolomics has advantages over both transcriptomics and 
proteomics.  The metabolome is further downstream than both the proteome and the 
transcriptome, meaning that it is more closely related to the phenotype of the cell (Barsch 
et al., 2004).  Also, the metabolite profile displays any changes before they are seen in the 
proteome or genome, thereby making it useful in monitoring a biological response to any 
environmental changes (Davis and Hord, 2005).   
 
Lipidomics is a subset of metabolomics, and this term can be used to describe the 
emerging field of systems-level analysis of lipids and factors that interact with them (Han 
and Gross, 2003; Lagarde et al., 2003).  Initial studies in the field of lipidomics involved the 
use of mass spectrometry, and led to the observation of chemical properties common to 
lipid species (Han and Gross, 2003).  Some accepted definitions commonly used in both 
the metabolomics and lipidomic fields are given in Table 1.5; however, variations in these 
definitions exist. 
 
Two main types of lipidomic analyses exist, and they are ‘global’ and ‘targeted’, and both 
allow different areas of the lipidome to be analysed, as shown in Figure 1.11.  Global 
lipidomics maps the entire spectrum of lipids and lipid molecular species in a biological 
system.  Targeted lipidomics, on the other hand, quantifies a single, or multiple selected 
species.  Interest in lipidomics has been driven by the wide and diverse role of lipid species 
in the cell (Roberts et al., 2008), technological advances, and the recent recognition of the 
role of lipids in many metabolic diseases (Gross and Han, 2007).   
 
 
 
60 
 
Table 1.5.  Lipidomic and metabolomic definitions 
 
 
 
1.5.1. Current experimental strategies              
 
The predominant approach for lipidomic analysis is the use of mass spectrometry (MS) 
techniques.  These are advantageous in that they are extremely sensitive and selective, 
and can be used for quantitative analysis if internal standards are added to the sample 
mixture.  The major disadvantages of MS techniques are that the majority of biological 
samples have to undergo extensive preparation prior to analysis, and also if a 
chromatography system is coupled to an MS, analysis times are increased (Dunn et al., 
2005a and 2005b; Scalbert et al., 2009).  Chromatography itself is a lipidomic experimental 
strategy which has been well adapted for the analysis of various lipid classes.  Many 
approaches exist including thin layer chromatography (TLC), liquid chromatography (LC) 
and gas chromatography (GC). Various combinations of chromatography systems coupled 
to mass spectrometers exist, and are used in the field of lipidomics.  In the current study, 
global lipidomic profiling methods were achieved using LC coupled to an orbitrap MS; and 
targeted techniques involved the use of an LC system coupled to a triple quadruple MS.  
Both systems are described in Section 2.9.    
TERM DEFINITION REFERENCE 
Metabolomics The identification and quantification of all 
metabolites in a given biological sample 
Weckwerth and Fiehn, 
2002 
Metabonomics  The time-related multiparametric metabolic 
response of living systems to 
pathophysiological stimuli or genetic 
modification 
 
Nicholson et al., 1999 
 
Metabolome The metabolic composition of a cell; 
analogous to the genome or proteome 
 
Lindon et al., 2003 
Lipidomics The full characterisation of lipid molecular 
species and of their biological roles with 
respect to expression of proteins involved in 
lipid metabolism and function, including 
gene regulation 
 
Spener et al., 2003 
Lipidome The entire spectrum of lipids in a biological 
system 
 
Seppanen-Laakso and 
Oresic, 2009 
 
                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Schematic representation of a lipidomic work flow 
Global analysis allows the whole lipidome to be profiled, although only relative changes can be observed.  Absolute quantification is achieved with targeted 
approaches, in which a selected lipid species is extracted and analysed. Abbreviations used: GC-MS, gas chromatography-mass spectrometry; LC-MS, liquid 
chromatography-mass spectrometry. 
 
6
1
 
Global analysis 
Sample 
collection 
Lipid 
extraction 
Lipidomic analysis 
LC-MS / GC-MS 
Multivariate 
data analysis 
Relative 
lipid changes 
Absolute 
quantification 
Targeted analysis 
62 
 
Many recent lipidomic techniques have evolved, one example involves fluorescently 
tagging lipids to study various functions including trafficking and partitioning into 
specialised sub-cellular compartments and membrane domains (Mukherjee and Maxfield, 
2000), and also the transbilayer movement of lipids (Kol et al., 2004).   
 
1.6. APPLICATIONS OF LIPIDOMIC TECHNIQUES 
The main advantage of lipidomic techniques is that lipid profiles produced from cells, 
tissues or body fluids provide a global snapshot of the lipids present in a sample, meaning 
that effects of environmental changes can be directly investigated.  Therefore, a major 
application for lipidomic techniques is the identification of biomarkers in lipid related 
diseases.  Lipidomic techniques have been previously used in the discovery of potential 
biomarkers in metabolic diseases such as obesity (Yetukuri et al., 2007; Kolak et al., 2007), 
T2DM (Han et al., 2007), cardiovascular disease (Brindle et al., 2002) and various cancers 
(Tung et al., 2008).  Breast cancer is the most frequently diagnosed amongst women, and 
a previous study has suggested that lysophospholipids are potential biomarkers in the 
bloodstream (Murph et al., 2007).  Lipidomic methods have also been applied to rat and 
mouse models, including Kyoto and Wistar rats of fatty liver disease (Griffin et al., 2007), 
APOE*3 Leiden transgenic mice of atherosclerosis and liver inflammation (Kleemann et al., 
2007) and purebred male wild-type C57bl6 mice of starvation-induced hepatic steatosis 
(van Ginneken et al., 2007).  These studies have uncovered a variety of lipid biomarkers by 
comparisons of the lipid profiles between control and diseased animals.  
 
Another application of lipidomic techniques is in the identification of metabolic pathways 
and enzymes.    This involves analysis of paired samples, followed by differential analysis 
(Forrester et al., 2004), including multivariate data analysis, and metabolic control analysis 
(Cascante et al., 2002).  Many genetic disturbances in model animals do not cause the 
expected phenotype, and so inspection of lipid metabolites may help to identify the 
underlying metabolic pathways involved in such cases (Weckwerth et al., 2004). 
 
The identification of new lipid-binding proteins may provide new opportunities in drug 
design and development.  The previous discovery of cannabinoid receptors caused the 
discovery of a potent ligand for the CB1 cannabinoid receptor (Devane et al., 1992).  As 
well as drug development, lipidomics may also aid in drug delivery and response.   
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1.6.1. Lipidomic analyses of adipocytes, adipose tissue, and obesity 
Lipidomics-based analyses have been widely used to investigate many areas of adipocyte 
metabolism.  Due to the fact that obesity is associated with increased adiposity, and that 
this can be caused by either hyperplasia of existing adipocytes, or the differentiation of pre-
adipocytes; the process of adipogenesis has been investigated by various previous studies 
in terms of lipid metabolism.  One such study use lipidomic methodologies to explore the 
lipid metabolism of 3T3-L1 cells during the differentiation process, and demonstrated that 
odd-chain fatty acids including TG and phospholipid species accumulated during 
adipogenesis (Su et al., 2004).  More recently, a more complete study also explored the 
effects of differentiation on lipid metabolism of 3T3-L1 cells.  Changes in metabolite 
concentrations during various stages of the differentiation process were investigated, and 
various mechanisms were demonstrated as implicit to the maturation of these cells, 
including glycolysis, and the oxidation, synthesis, and desaturation of fatty acids, among 
others (Roberts et al., 2009).  
 
Lipidomic analyses of serum samples from human patients and animal models can be useful 
when exploring possible lipid profile changes between control and diseased states.  A 
previous study used monozygotic twins to determine whether acquired obesity is 
associated with changes in serum lipid profiles (Pietilainen et al., 2007). Obesity was found 
to be related to an increase in the concentration of lysophosphatidylcholines, and a 
decrease in that of other phospholipid species known to have antioxidant properties.   
 
A recent development in adipose tissue metabolism investigations was the discovery of a 
‘lipokine’, first used in 2008 to describe FAs that modulate lipid metabolism via a chaperone 
effect (Cao et al., 2008).  This study focused on mice deficient in the adipose tissue 
chaperones aP2 and mal1 (FABP4 and FABP5, respectively).  Deficiency of both affects 
systemic metabolic regulation, and causes the mice to become resistant to all components 
of the metabolic syndrome (Maeda et al., 2005).  Lipidomic analyses of these mice found 
increased de novo lipogenesis, creating adipose tissue resistance to the effects of dietary 
lipid exposure.  The identification of an adipose tissue-derived lipid hormone led to the 
term lipokine, and it was C16:1n7-palmitoleate.  This hormone stimulates insulin action of 
the muscle, and suppresses hepatosteatosis, allowing the authors to conclude that adipose 
tissue uses lipokines to regulate systemic metabolic homeostasis via communication with 
other organs (Cao et al., 2008). 
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1.7. AIMS OF THE THESIS 
WAT is a complex secretory and endocrine organ with extensive roles in regulating 
appetite and energy homeostasis.  Obesity and its associated diseases are linked to 
adipocyte dysfunction, reflected by altered gene expression, and concentrations of 
various lipid species.  The work presented in this thesis focuses on characterising 
adipokine metabolism using the 3T3-L1 pre-adipocyte cell line, in terms of gene 
expression and the lipidome.  The overall purpose was to explore the effects of 
differentiation, as well as the addition of various inflammatory and anti-inflammatory 
agents on gene expression and both global and targeted lipidomic profiles of adipoytes.   
 
The first specific aim of the thesis was to biochemically characterise the course of 
differentiation using the 3T3-L1 cell line from pre-adipocyte to fully mature adipocyte.  A 
change in the gene expression profile was predicted, with the differentiation markers 
leptin and adiponectin only being expressed once the differentiation process had begun.  
It was also predicted that a shift in the abundant lipids present would occur.  As 
adipocytes mature, lipid accumulation is evident, and so it was predicted that the 
abundance of triglyceride species would increase as the adipocytes continue to mature.  
Once gene expression and lipidomic profiles of differentiation were established, these 
baseline data would act as a reference for the future aims. 
 
The second aim was to monitor the response of these baseline cells to the inflammatory 
mediators TNF-α and IL-6.  Obesity is linked to adipocyte dysfunction, and so it was 
predicted that treatment with these agents would cause both the gene expression and 
lipidomic profiles to differ between the control and treated cells.  More specifically, the 
targeted lipid analysis focussed on eicosanoid synthesis, and so it was further predicted 
that members of this lipid species would increase with inflammatory agents, due to their 
role in various inflammatory conditions. 
 
The final aim was to look at the effect of the anti-inflammatory agent dexamethasone on 
the metabolism on baseline adipocytes.  Glucocorticoids have both lipolytic and 
adipogenic actions, as well as being potent anti-inflammatory agents.  It was predicted 
that changes would be observed between the control and treated cells, although specific 
changes were not hypothesised due to the multiple functions of dexamethasone, and so 
this final aim was exploratory. 
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CHAPTER 2: 
Materials and methods 
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2.1. 3T3-L1 ADIPOCYTE CELL CULTURE 
Aseptic technique was essential for the prevention of infection.  All work was carried out 
in a category II biological safety cabinet, which had been cleaned with 1% (w,v) Virkon, 
followed by 70% (v,v) ethanol, and everything placed into the cell culture hood was 
sprayed with 70% (v,v) ethanol.  All media were prepared within this sterile environment 
and filtered through a 0.22μm filter membrane (Helena Biosciences / TPP, Tyne and Wear, 
UK). Excess culture medium was kept for a maximum of one week at 4oC and preheated at 
37oC in a water bath before use.  Both induction and feeding media were freshly made 
before use. 
 
2.1.1. Reagents and suppliers 
3T3-L1 pre-adipocytes, along with 1 x Dulbecco’s Modified Eagle Medium (DMEM) and 
Calf Serum (CS) were all obtained from LGC standards (Middlesex, UK).  Dexamethasone, 
Insulin, 3-Isobutyl-1-methylxanthine (IBMX), TRI Reagent® and 
trypsin/ethylenediaminetetraacetic acid (EDTA) were all purchased from Sigma-Aldrich 
Chemical Company (Dorset, UK).  Isotonic phosphate buffered saline (PBS; pH 7.2) was 
from PAA Laboratories Ltd (Somerset, UK).  Virkon was from Antec International Ltd 
(Suffolk, UK) and the ethanol used to clean the cell culture hood was obtained from Fisher 
Scientific (Leicestershire, UK). 
 
2.1.1.1. Medium components 
Culture medium: 1 x DMEM; 10% (v,v) CS. 
Induction medium:  1 x DMEM; 10% (v,v) CS; 5µg/mL Insulin; 0.25mM dexamethasone; 
0.5mM  IBMX. 
Both dexamethasone and IBMX stock solutions were made in 95% (v,v) ethanol, and 
aliquots stored at -20oC. 
Feeding medium (post-differentiation): 1 x DMEM; 10% (v,v) CS; 5µg/mL Insulin 
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2.1.2. Cell culture and maintenance 
3T3-L1 cells were immediately cultured at 37oC according to the manufacturer’s protocol 
in an incubator with a humidified atmosphere of 5% CO2/95% air.  Extra frozen cell 
aliquots were stored at -150oC.  If cultured from frozen, the vial was removed from -150oC 
storage, and thawed in a water bath set to 37oC.  The defrosting process was helped by 
the addition of 1mL of pre-warmed culture medium, which was gently pipetted up and 
down inside the cell vial.  This thawed aliquot was then added to a 25mL Universal vial 
containing 9mL of culture medium.  The cells were then centrifuged at 125 x g for 5 
minutes (min) using a Heraeus Biofuge Pimo R (Thermo Scientific, Hemel Hempstead, UK).  
The supernatant was removed, and a further 1mL of culture medium was added, and 
pipetted up and down to break up the cell pellet.  The cells were then transferred into a 
25cm3 flask containing 3mL of culture medium, and placed in the incubator.  The medium 
was replaced every 48 hours (h) for as long as necessary, to ensure the survival of the 
cells. 
 
2.1.2.1. Cell passaging 
Greater cell numbers were generated by splitting the original 25cm3 flask into four extra 
flasks when the cells in the original flask were approximately 70% confluent.  The medium 
was removed, and 3mL trypsin/EDTA added to the flask.  The flask was then placed in the 
incubator for between 1 and 2 min, to allow the detachment of cells, confirmed by 
microscopy.  Once the cells had detached from the flask surface, 1mL of CS was added to 
deactivate the trypsin.  The cell suspension was gently pipetted up and down to break up 
any clumps, and then transferred to a 25mL Universal.  Four flasks containing 3mL culture 
medium each received 1mL of cells, and were then placed back into the incubator. 
 
2.1.2.2. Cell plating 
The cells were trypsinised as described in Section 2.1.3.1, and the cell suspension from 
each flask was transferred into a single universal.  The required number of plates were set 
up with 1mL culture medium in each well, and 50µL of cells were added per well. 
 
2.1.2.3. Cell differentiation 
Once the cells had been plated out into 12-well plates, they were left to reach confluence, 
supported by fresh culture medium every 48h.  Two days after confluence had been 
observed by microscopy (Leica DM IL LED inverted microscope, Leica Microsystems Ltd, 
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Bucks, UK), the cells were induced to differentiate by replacing the culture medium with 
1mL of differentiation medium per well.  The cells were kept in this medium for 72h, 
which was then replaced with feeding medium for a further 48h.  From day 5 post-
differentiation up to 24h before the cells were treated and/or harvested, they were fed 
with culture medium which was replaced every 48h.  Differentiation into adipocytes was 
confirmed by the accumulation of lipid droplets. 
 
2.1.2.4. Cell and medium collection for polymerase chain reaction analysis  
The medium from each well was removed and collected into individual sterile 2mL RNase- 
free tubes.  The cells were removed from each well by the addition of 1mL of TRI 
Reagent
®
, which was used to wash the cells to ensure removal of the maximum number 
of cells.  The cells from each well were transferred into individual 2mL sterile RNase tubes.  
Both the cells and medium were stored at -80oC until required.  
 
2.1.2.5. Cell and medium collection for lipidomic analysis 
As described in Section 2.1.2.4, the medium from each well was collected into individual 
sterile 2mL RNase-free tubes.  Each well was then washed three times with PBS, and after 
the final wash, 125µL of sterile water was added to each well.  A cell scraper was used to 
remove the cells from the bottom of each well.  Two wells were combined into a sterile 
0.5mL centrifuge tube, resulting in six tubes per plate, each containing 250µL of the cell 
suspension.  Both cells and media were stored at -80oC until required. 
 
2.2. OIL RED O STAINING 
Oil Red O staining is a technique used for staining neutral lipids (Lillie and Ashburn, 1943).  
The dye stains triglycerides red, and a counter stain of haematoxylin is used to stain the 
nucleus of the cell blue. 
 
2.2.1. Reagents and suppliers 
1 x isotonic PBS (pH 7.2) was purchased from PAA Laboratories Ltd, and 10% Formalin was 
from ReAgent (Cheshire, UK).  Oil Red O and Haematoxylin stains were both obtained 
from Sigma-Aldrich Chemical Company, and were filtered through a 0.22µm filter (Helena 
Biosciences / TPP, Tyne and Wear, UK) prior to use to remove any debris. 
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2.2.2. Method 
After removal of medium, cells were washed twice with 1xPBS and fixed by adding 1mL of 
10% (v,v) formalin solution to each well for 30 min at room temperature.  The washing 
step was then repeated, and 1mL of Oil Red O stain was added per well, which stains the 
lipids.  The cells were incubated on a shaking platform (Orbital shaker SSM1, Stuart, 
Staffordshire, UK) for 1h at room temperature.  Once stained, each well was washed five 
times with cold water, and 1mL of haematoxylin stain was added to stain the nuclei.  The 
plate was returned to the shaking platform for a further 5 min at room temperature, and 
then washed five times with hot water, and 1mL water was added.  Images were captured 
using a Leica DM IL LED inverted microscope (Leica Microsystems). 
 
2.3. TOTAL RNA EXTRACTION FROM 3T3-L1 ADIPOCYTES 
2.3.1. Reagents and suppliers 
Chloroform (HPLC grade) and Isopropanol (LC-MS grade) were obtained from Fisher 
Scientific.  100% molecular biology grade ethanol was from VWR (Poole, UK). 
 
2.3.2. RNA extraction method 
Frozen cell aliquots were thawed, and pipetted up and down inside the tube to break up 
clumps of cells.  Once thawed, 500µL of the cell and TRI Reagent
®
 mixture was removed 
into a separate centrifuge tube.  The cells were pulled through a 23 gauge needle five 
times, and the needle was changed between different groups of cells.  The samples were 
incubated for 5 min at room temperature, before the addition of 100µL of chloroform, 
and were then vigorously shaken for 15 seconds (sec).  The samples were incubated at 
room temperature for 10 min, and then centrifuged at 20,800 x g 10 min at 4oC (Legend 
X1R, Thermo Scientific).  This created three phases, a bottom red phenol phase containing 
protein, a white DNA interphase, and an upper colourless aqueous phase containing RNA.  
The upper RNA phase was transferred to a new centrifuge tube, and 35µL isopropanol 
was added to remove any genomic DNA which may have also been transferred.  The 
samples were vortexed, left to stand at room temperature for 10 min, and then 
centrifuged at 20,800 x g for 10 min at 4oC.  The supernatant was removed into a new 
tube, with the addition of 225µL isopropanol to precipitate out the RNA.  The samples 
were once again vortexed, incubated at room temperature for 10 min, and centrifuged at 
20,800 x g for 10 min at 4oC to produce an RNA pellet.  The supernatant was carefully 
discarded to avoid disturbing the pellet, and 100µL of 75% (v,v) ethanol was added.  The 
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samples were centrifuged at 20,800 x g for 10 min at 4oC for the final time, and the 
supernatant removed.  The pellet was allowed to air dry for 5-10 min, and then dissolved 
in 20µL of autoclaved water.  If the RNA samples were not being used for PCR straight 
away, they were stored at -80oC until required.  
 
2.3.3. RNA quantification  
Nucleic acids have maximal light absorbance at A260, and proteins at A280.  The ratio 
between A260 and A280 gives an indication of the RNA purity in the sample.  The optimal 
ratio is between 1.8 and 2.0, which indicates RNA of high purity.  A ratio of 1.6 or less 
suggests protein contamination (increased absorbance at A280), whereas a ratio above 
2.0 is indicative of genomic DNA contamination.  The RNA concentration per sample was 
calculated automatically by the spectrophotometer using the Beer-Lambert law, 
(Swinehart, 1962; Ricci et al., 1994): 
 
[RNA] μg/µL = A260 x extinction coefficient x dilution factor 
 
The extinction coefficient for RNA is approximately 40, and the samples were tested 
undiluted. Therefore, the equation becomes: [RNA] μg/mL = A260 x 40 
 
The RNA samples were quantified using a NanoDrop Spectrophotometer ND-1000 (Fisher 
Scientific).  The sensor was first cleaned using 1µL distilled water, and then 1µL of sample 
was added.  The RNA-40 programme was selected, and absorbance was measured at 
260nm (A260) and 280nm (A280), with distilled water used as a blank.  The RNA 
concentration was automatically calculated.   
 
2.4. REVERSE TRANSCRIPTION 
The purpose of reverse transcription is to produce single stranded DNA which is 
complimentary to a given mRNA template sequence (complimentary DNA; cDNA).  A 
premix of anchored oligo-dT and random primers were used.  Anchored oligo-dT primers 
are specifically designed to anneal at the mRNA/poly-A junction, to produce higher quality 
cDNA and improve the efficacy of PCR and real-time PCR for genes that are not highly 
expressed.  Standard dT and random primers are less specific as they anneal randomly 
within the poly-(A) tail, or at a random point along the mRNA sequence respectively.  
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2.4.1. Reagents  
Reverse transcription was completed by using an iScript cDNA synthesis kit from Bio-Rad 
Laboratories Ltd (Hemel Hempstead, UK), which contained the following: 
(i) RNase H+ iScript reverse transcriptase 
(ii) Premix of RNase inhibitor and blend of oligo dT and random primers 
(iii) Nuclease-free water 
 
2.4.2. Method 
This procedure was carried out using sterile RNase/DNase–free tubes and filter tips.  All 
incubations were performed using a GeneAmp PCR system 2700 (Applied Biosystems, 
Cheshire, UK) and the manufacturer’s instructions were modified.  For a 10μL reaction, 0.5 
μg of RNA, 2μL of 5xbuffer and 0.5μL of reverse transcriptase were added to a 0.5mL 
tube.  This was made up to 10μL with 7.5µL nuclease-free water and vortexed.  The 
samples were then incubated at 25oC for 5 min to allow the primers to anneal to the RNA.  
This was followed by 30 min incubation at 42oC to synthesise the cDNA and a final stage at 
85oC for 5 min to terminate the reaction.  The samples were then immediately used for 
PCR, or stored at -80oC. 
 
2.5. POLYMERASE CHAIN REACTION   
Polymerase chain reaction (PCR) was discovered by Kary Mullis (Saiki et al., 1985) and 
amplifies the cDNA of interest with the use of gene-specific primers and DNA polymerase.  
The process starts with a denaturation phase by incubating at 94oC, and is followed by 20 
to 40 amplification cycles.  Each cycle doubles the amount of DNA synthesised from the 
previous cycle, and consists of three stages; denaturation, annealing and extension.  
Denaturation reduces the DNA double helix by dissociating the double-stranded DNA 
(dsDNA) into single stranded DNA (ssDNA), making the strands accessible to the primers. 
The annealing step enables the primers to hybridise to their complementary bases on the 
DNA template strand.  The annealing temperature (Ta) is primer specific and depends on 
factors such as primer length.  During the final extension phase, the DNA polymerase 
synthesises a complementary DNA strand in a 5’-3’ direction, starting from the primer 
annealing site. 
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When assessing RNA expression of the gene of interest, it is compared to that of a 
constitutive gene that is transcribed at a constant concentration.  These are termed 
housekeeping genes and are expressed by all cells of an organism (Butte et al., 2001).  
Typical housekeeping genes include β-actin, glyceraldehyde-3-phosphate (GAPDH), 18S 
rRNA and RNA polymerase IIa (RNA pol 2).  In this study, β-actin was used as the 
housekeeping gene for reverse-transcription PCR (RT-PCR); and three housekeeping 
genes, β-actin, GAPDH and RNA pol 2 were used for real time-PCR (qPCR). 
 
2.5.1. Reagents and suppliers 
A ReddyMix PCR Master Mix Kit: 1.1x ReddyMix was obtained from ABgene (Epsom, UK), 
and the sense (s) and anti-sense (as) primer mixes used (10μM) were from Eurogenetec 
(Hampshire, UK). 
 
2.5.2. Method 
This procedure was performed using sterile 0.2mL RNA/DNA-free tubes and filter tips.  A 
master mix was prepared which contained 11.25μL of 1.1x ReddyMix, 0.25μL of primer 
mix and 0.5μL of ultra-pure water per sample.  This master mix was vortexed, and 12μL 
was added to each tube, along with 0.5μL of the cDNA template, to make a final reaction 
volume of 12.5μL.  For non-template controls (NTC), the cDNA template was replaced 
with ultra-pure water.  After addition of all elements, the tubes were vortexed, 
centrifuged and then placed into the GeneAmp PCR system 2700 (Applied Biosystems) 
ready for the PCR reaction.  A denaturation step starts the PCR program by incubating the 
samples at 94oC for 2 min.  This was followed by 20-35 cycles of the following:  
 
1. 94oC for 20 sec (denaturation) 
2. 53-62oC for 30 sec (annealing) 
3. 72oC for 30 sec (extension) 
 
The cycle number and annealing temperature (Ta) is optimised for each primer pair (see 
Table 2.1).  After the final cycle, the samples underwent a final elongation step at 72oC for 
5 min. 
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Table 2.1    Sequences of the RT-PCR primers and PCR conditions 
 
 
GENE PRIMER SEQUENCE 
5’-3’ 
Ta 
(OC) 
CYCLE  
NUMBER 
PRODUCT 
SIZE 
(bp) 
β-actin s 
β-actin as 
TGCTGTCCCTGTATGCCTCT 
AGGTCTTTACGGATGTCAACG 
60 23 463 
Leptin s 
Leptin as 
CTGTCTTATGTTCAAGCAGTGCCTAT 
AAGCCACCACCTCTGTGGAGTA 
62 34 394 
Adiponectin s 
Adiponectin as 
TTAATCCTGCCCAGTCATGCCG 
AGAACTTGCCAGTGCTGCCGTC 
62 34 430 
 
 
Primer sequences taken from (Dutton and Trayhurn, 2008). 
 
2.5.3. Agarose gel electrophoresis 
The PCR products were identified on a 1.5% (w,v) agarose gel stained with ethidium 
bromide (EtBr).  This binds strongly to DNA by intercalating between the bases and is 
fluorescent.   
 
2.5.3.1. Reagents 
The agarose used was obtained from Prepro Tech EC (London, UK), and EtBr at 5mg/mL 
was from Sigma-Aldrich Chemical Company. 1x Tris Borate-EDTA (TBE) buffer and the 
GeneRuler™ 100 bp DNA ladder (Fermentas) were from Fisher Scientific.   
 
2.5.3.2. Method 
An appropriately-sized gel casting tray was prepared by sealing both ends with autoclave 
tape.  The agarose was weighed and placed into a 500mL conical flask containing 1x TBE 
and heated in a microwave, mixing occasionally, until the agarose had completely melted.  
Once cool, the EtBr was added and mixed, and the mixture was poured into the casting 
tray.  The combs were placed in their slots, after being used to push any bubbles to the 
edges and the gel was left to set for at least 30 min.  Once set, the combs and autoclave 
tape were removed and the gel was placed into the electrophoresis tank. The gel was 
completely submerged by adding 1x TBE to the tank, and then loaded with 10μL of PCR 
product and 2μL of the 100bp ladder in separate wells.  The loaded gel was run at 105 V 
for 20-30 min or until the samples were at least halfway down the gel.  Bands were 
74 
 
identified using a UV Transilluminator (2011 MacrovueTM, Ultra-Violet products).  The 
images were captured with a DC120 digital camera (Kodak) and analysed using digital 
Science ID 1 image analysis software (Kodak).  
 
2.6. REAL-TIME POLYMERASE CHAIN REACTION 
The concentration of mRNA within a sample can be quantified using qPCR.  During the 
reaction, fluorescence is emitted, which represents the formation of product during each 
PCR cycle.  The fluorescence signal is directly proportional to the amount of PCR product 
produced, and there is an increase during the exponential phase.  The earlier the 
fluorescence signal begins its exponential rise, the more initial template present in the 
sample.  
 
2.6.1. TaqMan® system 
The qPCR work completed in this thesis was carried out using the TaqMan® system, which 
amplifies the mRNA of interest, and was first reported in 1991 (Holland et al., 1991).  The 
method involves the use of two primers (forward and reverse), and a TaqMan® probe.  
The probe is composed of a short oligodeoxynucleotide which is labelled with two 
different fluorescent dyes.  The 5’ base has the reporter dye (FAM-6- carboxyfluorescein), 
and the 3’ base has the quenching dye (TAMRA – 6 carboxytetrametheyrhodamine).  The 
probe is homologous to a target sequence in the PCR amplicon, and is able to bind to it.  
When the probe is intact, the reporter dye is unable to emit fluorescence due to the 
proximity of the quencher, and energy is transferred between the two, based on the 
fluorescence resonance energy transfer (FRET) principle (Cardullo et al., 1988).  The probe 
cleaves during the extension phase of PCR by 5’ nuclease activity of Taq polymerase.  This 
separates the reporter from the quencher dye, which ends the FRET, and allows the 
reporter dye to emit fluorescence (at 518nm for FAM). The amount of fluorescence 
increases with each cycle of PCR, and is proportional to the rate of probe cleavage.  A 
camera within the qPCR machine measures the fluorescence spectrum and intensity, 
which is caused by exciting each well with a laser light source.  This occurs during each 
PCR cycle, to generate real-time data.  The increase in fluorescence (ΔR) is detected by 
monitoring the accumulation of PCR product (Bustin, 2002; Ayra et al., 2005).  The 
reporter dye signal is normalised to a reference dye (ROX) and plotted as ΔRN.  The 
reference dye is used to correct for differences in reaction mix volumes between wells.  
The principle of the TaqMan® assay is illustrated in Figure 2.1. 
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Figure 2.1 Principle of TaqMan® assay 
This figure illustrates what happens at each TaqMan® cycle.  A specific probe 
oligionucleotide is used which has a reporter dye (FAM) at the 5’ end, and a quenching 
dye (TAMRA) at the 3’ end.  The probe anneals to its target sequence and product is 
amplified 5’ to 3’.  During this polymerisation step, the exonuclease activity of the 
polymerase cleaves the probe, which separates the reporter and quencher dyes, ending 
FRET.  This allows fluorescence emission from the reporter dye to occur.  The amount of 
fluorescence increases with each cycle of PCR, and is proportional to the rate of probe 
cleavage.
  
 
 
 
Fluorescence 
PCR products 
Forward primer Reverse primer 
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2.6.2. Preparation of a 96 well plate for real-time PCR 
2.6.2.1. Reagents 
A qPCR Core Kit was obtained from Eurogentec, which included: 10 x reaction buffer; 
50mM magnesium chloride; 5mM dNTP mix and 5U/μL Hot Goldstar enzyme.  The sense 
and anti-sense primers, as well as the TaqMan® probes used were also from Eurogentec. 
 
2.6.2.2. Method 
A master mix was prepared for each gene of interest, using the following components and 
amounts per well, as follows: 
 
10 x reaction buffer   1.25µL 
50mM magnesium chloride  1.25µL 
5mM dNTP mix    0.5µL 
Sense primer    0.038µL 
Antisense primer   0.038µL 
TaqMan® probe   0.063µL 
5U/µl Hot Goldstar enzyme  0.0625µL 
Ultra-pure water   8.2985µL 
 
Each well of the 96 well plate received 11.5µL of the master mix.  The addition of 1µL of 
the selected cDNA to each well completed the plate which was then sealed with an 
adhesive optical cover.  All samples were run six times and NTCs, in which the cDNA was 
replaced with ultra-pure water, for each primer and probe set were also included.  The 
plate was centrifuged using a plate spinner (BR3.11, Jouan; Thermo Scientific) for 1 min to 
remove bubbles and ensure that the reaction mixture was at the bottom of the well.  The 
sequences and conditions of both the sense and antisense primers used, as well as the 
TaqMan® probes are detailed in Table 2.2. 
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Table 2.2. Sequences and conditions of the primers and TaqMan® probes used 
qPCR analyses 
 
 
 
 
2.6.3. TaqMan® system real-time PCR setup   
All reactions were performed on a StepOnePlus Real-Time PCR system (Applied 
Biosystems, Cheshire, UK).  The plate was inserted into the heat block, and the cover 
locked into position.  The reporter dye was selected as FAM and the reference dye as ROX.  
Amplifications started with a denaturation step by incubating at 95oC for 10 min.  This was 
followed by 40 cycles consisting of: 
 
(i) 95˚C for 15 sec (denaturation)  
(ii) 60˚C for 60 sec (combined primer annealing and extension)  
 
The total run time was approximately 2h.  Data were automatically collected by the 
software and analysed once the run had completed. 
GENE PRIMER SEQUENCE 
5’-3’ 
CONCENTRATION 
(nm) 
PRODUCT SIZE 
(bp) 
β-actin s 
β-actin as 
β-actin p 
ACGGCCAGGTCATCACTATTG 
CAAGAAGGAAGGCTGGAAAAG 
ACGAGCGGTTCCGATGCCCTG 
300 
300 
100 
97 
Leptin s 
Leptin as 
Leptin p 
CATCTGCTGGCCTTCTCCAA 
ATCCAGGCTCTCTGGCTTCTG 
AGCTGCTCCCTGCCTCAGACCAGTG 
300 
300 
100 
76 
Adiponectin s 
Adiponectin as 
Adiponectin p 
GGCTCTGTGCTCCTCCATCT 
AGAGTCGTTGACGTTATCTGCATAG 
CCCATACACCTGGAGCCAGACTTGGT 
300 
300 
100 
97 
IL-6 s 
IL-6 as 
IL-6 p 
ACAACCACGGCCTTCCCTACTT 
CACGATTTCCCAGAGAACATGTG 
TTCACAGAGGATACCACTCCCAACAGAACCT 
300 
300 
100 
76 
TNF-α s 
TNF-α as 
TNF-α p 
CCCAGACCCTCACACTCAGATC 
GCCACTCCAGCTGCTCCTC 
TAGCCCACGTCGTAGCAAACCACCAAG 
300 
300 
100 
78 
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2.6.4. Analysis of real-time PCR data  
The amplification plots were displayed in log scale and the threshold was automatically 
set with the StepOnePlus software (Applied Biosystems).  The CT values were exported as 
a Microsoft Excel file and the gene expression was analysed by relative quantification 
using the 2-ΔΔCT method (Livak and Schmittgen, 2001).  Two or three housekeeping 
genes were used as internal standards for all qPCR experiments.  All samples were 
normalised to either β-actin, GAPDH or RNAPolIIa, and the results were expressed as fold 
changes of CT values relative to controls. 
 
2.6.4.1. Statistical data analysis of qPCR data 
For qPCR data, non-parametric statistical tests have been suggested to be more 
robust than parametric statistical tests, irrespective of normality (Yuan et al., 2006).  
Therefore, non-parametric test were used for the analysis of qPCR data in this study, 
even though the data were normally distributed.   The data were presented as mean ± 
standard deviation (SD) and the specific test used is indicted in the data chapters, for 
a group size of six.  
 
2.7. ENZYME-LINKED IMMUNOSORBENT ASSAY FOR LEPTIN AND ADIPONECTIN PROTEIN 
CONCENTRATION  
The Enzyme-Linked Immunosorbent Assay (ELISA) technique was based on a previous 
method known as radioimmunosorbent techniques (RIST), in which a radioactively 
labelled antigen is coupled to cellulose, along with insolubilised antibodies.  The binding of 
the labelled antigen is competitively inhibited by unlabelled antigen (Wide and Porath, 
1966).  Two research groups were simultaneously involved in the development of the 
ELISA method, both of which labelled the antigen with an enzyme, rather than an isotope.  
The first group (Engvall and Perlmann, 1971) used rabbit IgG as the antigen, and this was 
labelled with alkaline phosphatase.   The ‘immunosorbent’ was formed by the attachment 
of anti-rabbit IgG antibodies to cellulose, and the enzyme-linked antigen and unknown 
antigen would be reacted with it.  The unknown antigen is unlabelled and competes with 
labelled antigen.  Therefore, the enzyme attached to the immunosorbant would reduce as 
more of the unknown antigen was added.  The second group (van Weemen and Schuurs, 
1971) described a similar assay.  These original ELISAs were competitive assays.   
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Sandwich ELISAs were used in this study to quantify the concentration of leptin and 
adiponectin within cell medium samples.  In this method, the surface of the ELISA plate is 
pre-coated with a polyclonal antibody which is specific to the protein of interest.  Samples 
are then added to the desired wells on the plate, and any specific protein present in the 
samples is bound by the antibody.  The plate is washed to remove any unbound antibody-
enzyme reagent, and an enzyme-linked antibody, specific to the primary antibody, is 
added.  The addition of a substrate solution causes a blue colouration, and this is changed 
to yellow after a stop solution is added to the wells.  The intensity of this colour is directly 
related to the concentration of protein within the sample.  A schematic representation of 
the sandwich ELISA principle is illustrated in Figure 2.2. 
 
In the current study, concentrations of mouse leptin and adiponectin were measured in 
the medium using a Mouse Leptin or Adiponectin Immunoassay kit.  The sensitivity of the 
kits were and 22pg/mL and 0.003ng/mL for leptin and adiponectin, respectively.  Any 
concentration less than this this was considered to be non-detectable. 
 
2.7.1. Reagents 
All reagents were prepared according to the manufacturer’s protocol (R&D systems, 
Abingdon, UK) and brought to room temperature before use.  The kit reagents consisted 
of: 
 
(i) Mouse leptin or adiponectin kit control 
- Reconstituted with 1mL distilled water 
 
(ii) Wash buffer 
- For one plate add 25mL to 600mL distilled water 
 
(iii) Substrate solution 
 
(iv) Mouse leptin or adiponectin standard 
- Reconstitute with 2mL calibrator diluent to produce a 4000pg/mL stock 
solution for leptin standard 
- Reconstitute with 5mL calibrator diluent to produce a 10ng/mL stock solution 
for adiponectin standard 
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Figure 2.2. Principle of a sandwich ELISA  
This schematic diagram represents the principle of the sandwich ELISA, which is a 
competitive assay.  The intensity of the final colour is directly proportional to the 
concentration of the antigen in the sample. 
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2.7.2. Method 
The reagents were brought to room temperature and prepared as described above.  A 
two-fold serial dilution of the stock solution was prepared to produce a standard curve 
and give the following concentrations for leptin (ng/mL): 4000, 2000, 1000, 500, 250, 125 
and 62.5.  The final concentrations for the adiponectin kit (pg/mL) were as follows: 10, 5, 
2.5, 1.25, 0.62, 0.31 and 0.16.  Once all reagents, standard curve dilutions and samples 
were prepared, 50µL of Assay Diluent was added to each well, followed by 50µL of 
standard, control or sample and covered with an adhesive strip.  A preliminary 
experiment, with different concentrations of leptin and adiponectin medium, indicated 
that undiluted samples fell within the standard curve range, and so the samples were 
added to the wells undiluted.  Distilled water was used for the blank measurements.  The 
plate was left to incubate for 2h at room temperature.  After the incubation, each well of 
the plate was aspirated and washed, and this process was repeated a further four times to 
give a total of five washes.  Once washed, 100µL of mouse leptin or adiponectin conjugate 
was added to each well.  The plate was covered with another adhesive strip and left to 
incubate at room temperature for a further 2h.  The aspiration and washing step was 
repeated, making sure the plate was washed five times.  After washing, 100µL of 
substrate solution was added to each well and the plate was covered and protected from 
light for 30 min at room temperate.  The addition of 100µL of stop solution to each well 
completed the method, and the plate was gently tapped to ensure thorough mixing.  The 
absorbance was determined immediately using a Varioskan Flash MultiMode Reader 
(Thermo Scientific) at 450nm corrected to 540nm. Data were collected for each 
protein, analysed and a standard curve for each was generated using GraphPad Prism 
5 (GraphPad software). 
 
2.7.3. Statistical analysis of ELISA data 
A Shapiro–Wilk W test was initially used to determine whether the sample data were 
normally distributed.  This test suggested that they were not, and so the non-parametric 
Cuzick’s test for trend (Cuzick, 1985) was used, and the data are presented as median ± 
range for a group size of three.  
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2.8. PROTEIN ASSAY (BRADFORD ASSAY)  
The Bradford assay originated from the observation that Coomassie Brilliant Blue G-250 
exists as either a red or blue colour.  The red form changes to the blue form when the dye 
is bound to protein (Reisner et al., 1975).  This causes an alteration in the light absorbance 
properties of the dye in the acidic environment of the reagent.   The red (unbound form) 
maximally absorbs light with a wavelength of 465nm, and this shifts to a maximum of 
595nm after the addition of protein.  A direct relationship occurs between the protein 
concentration and absorbance of light at 595nm. This protein-dye complex was utilised in 
the development of the Bradford assay (Bradford, 1976), which allows measurement of 
the protein concentration within a sample at a wavelength of 595nm.  The assay is very 
sensitive for the measurement of protein concentration, and is also very efficient because 
the binding of the dye to the protein occurs in approximately 2h.  Finally the dye-protein 
complex remains dispersed in solution for up to 1h, meaning that this assay is easy to use, 
reliable and efficient in the detection of protein. 
 
In this study, the Bradford assay was used to determine the concentration of protein in all 
of the cell samples.  These concentration figures were then used for the normalisation of 
mass spectrometry data. 
 
2.8.1. Reagents and suppliers 
 Bovine Serum Albumin (BSA) was obtained from PAA Laboratories Ltd and Coomassie 
Plus Protein Assay Reagent was from Thermo Scientific, and was brought up to room 
temperature before use. 
 
2.8.2. Method 
Diluted albumin standards were prepared from the BSA stock solution in the following 
manner: 
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Vial  Volume of diluent Volume and source of BSA BSA concentration 
  (µL)   (µL)    (µg/mL) 
A  0   300 from stock   2000 
B  125   375 from stock   1500 
C  325   325 from stock   1000 
D  175   175 from B   750 
E  325   325 from C   500 
F  325   325 from E   250 
G  325   325 from F   125 
 
Once the BSA dilutions had been prepared, 10µL of each standard, blank or unknown 
sample was added to the appropriate wells.  Distilled water was used for the blank 
reading, and the standards, blanks and unknown samples were all assayed undiluted in 
triplicate.    This was followed by the addition of 300µL of Coomassie reagent to each well, 
and the plate was mixed on an Orbital shaker SSM1 (Stuart, Staffordshire, UK) for 30 sec.  
The plate was removed and incubated at room temperature for 10 min away from light.  
After incubation, the absorbance was read at 595nm with a Varioskan Flash Multimode 
Reader (Fisher Scientific).  The average of the blank measurements was removed from 
each individual standard or unknown sample, and a standard curve was created using 
GraphPad Prism 5 (GraphPad software).   
 
2.9. MASS SPECTROMETRY ANALYSIS 
Mass spectrometry (MS) is a powerful analytical tool widely used in lipid analysis.  The 
technique involves detection of charged ionised analytes according to their mass-to-
charge ratio (m/z).  Initially, MS could only be used to analyse small and volatile lipids, 
until two soft ionisation techniques were developed. These techniques were matrix 
assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI), both of 
which allowed generation of ions of intact biomolecules (Karas and Hillenkamp, 1988; 
Fenn et al., 1989).   
 
A typical mass spectrometer is composed of three parts, which include an ion source, a 
mass analyser and a detector, as represented in Figure 2.3.  Most mass spectrometers 
also have a way of automatically injecting the samples, such as an autosampler, and a 
computer to collect the data (de Hoffmann and Stroobant, 1999).  There are several 
commonly used mass analysers in lipid research, including: Paul ion trap, linear 
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quadrupole, time of flight (TOF), Fourier transform ion cyclotron resonance (FT-ICR-MS) 
and Orbitrap.  Many mass spectrometers are coupled to a chromatography system which 
allows the separation of a sample before it enters the mass spectrometer.  Two types 
exist, gas chromatography (GC) and liquid chromatography (LC).  If a lipid extract is 
introduced after chromatographic separation, the process is termed either gas-
chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass 
spectrometry (LC-MS; Houjou et al., 2005), depending on the type of chromatography 
used.  The work presented in this thesis was conducted using LC-MS, and so strategies 
appropriate to this technique will be described in more detail.  
 
2.9.1. Ionisation 
The lipidomic analysis in the current study was performed using LC-MS, and the ionisation 
technique used was electrospray ionisation (ESI).  This is a soft ionisation technique, which 
produces intact ions.  The major principle of ESI is to transfer ions from solution into a 
gaseous phase before they enter the mass spectrometer.   
 
This occurs by infusing a sample into a capillary tube, and a high voltage is applied to the 
tip, which, in the case of positive ion ESI, pulls a positive charge towards the liquid front.  
When electrostatic repulsion becomes greater than surface tension, the surface of the 
emerging liquid becomes charged and is dispersed into a fine spray of charged droplets 
(Fenn et al., 1989; Figure 2.4).  A nebulising gas, such as nitrogen, can be applied to 
enhance a higher flow rate.  The charged droplets present in the spray then pass down a 
pressure and potential gradient, and with the aid of an elevated ESI-source temperature 
and nitrogen, the solvent is evaporated under vacuum to produce analyte ions.   
 
Two theories exist as to how the small droplets produce analyte ions.  The first is called 
the “Charged Residue Model” in which the solvent evaporation continues and causes the 
droplet to continue decreasing in size until only the analyte ion remains (Dole et al., 
1968).   The “Ion Evaporation Mechanism” is the second theory, and it states that when 
the droplets become small enough, the electric field at its surface reaches a critical point 
(Rayleigh limit) causing it to expel a charged analyte ion from the surface of the droplet 
into the surrounding gas (Iribarne and Thomson, 1976).   
 
85 
 
Both positively and negatively charged ions can be produced with ESI.  Polar molecules 
which do not contain an acidic or basic group can be charged through the formation of 
adducts with various ions.  In positive ion mode, many adducts can be formed including 
Na+, K+, and NH4
+.  In negative ion mode, Cl- adducts can be produced.  Therefore various 
ion charge states can be produced, and a few are presented in Table 2.3. 
 
 
 Table 2.3. Adduct formation with ESI-MS 
 
ION MODE ADDUCT ION TYPE 
Positive [M+H]+ 
 [M+Na]+ 
 [M+K]+ 
 [M+NH4]+ 
Negative [M-H]- 
 [M-Cl]- 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic representation of a typical mass spectrometer 
A mass spectrometer consists of three parts, including an ion source, mass analyser and a detector.  A method of introducing samples and a 
computer to collect the data are often present. 
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Figure 2.4. Schematic representation of positive ion ESI 
A high voltage is applied to the capillary tip which charges the surface of the emerging liquid, releasing a fine spray of charged droplets.  The solvent is 
removed, due to evaporation and these ions pass into the mass spectrometer.    
8
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2.9.2. Mass analysers 
Following ionisation, the ions move to an analyser to be detected.  Two mass analysers 
were used in the work presented in this thesis, an orbitrap for global lipidomic analysis, 
and a triple quadrupole mass analyser for a targeted lipidomic approach. 
 
2.9.2.1. Orbitrap 
 
The orbitrap was proposed by Alexander Makarov (Makarov, 2000).  It is a modification of 
the Kingdon ion trap (Kingdon, 1923) which consists of a thin central wire and an outer 
cylindrical electrode. A static applied voltage results in a radial logarithmic potential 
between the electrodes.   A modified outer electrode was later added and it included an 
axial quadrupole which confined the ions on the trap axis (Knight, 1981).  
 
The external part of the orbitrap is barrel shaped and cut into two parts which are 
separated by a small gap, and inside is a central electrode which is spindle shaped.  The 
ions are injected tangentially into the electric field through the space between the two 
parts of the external electrode.  These ions are trapped in an electrostatic field (Makarov, 
2000; Hardman and Makarov, 2003).  This electrostatic attraction towards the central 
electrode is compensated by a centrifugal force, and so the ions are forced to move in 
complex spiral patterns (Figure 2.5).  The frequency of the oscillations is inversely 
proportional to the square root of the m/z, and so the orbitrap can be used as a mass 
analyser to accurately detect the m/z of analyte ions. 
 
The performance of a mass spectrometer is judged on characteristics including resolution 
(the ability to distinguish between two peaks of slightly different m/z), mass accuracy, 
mass range and ion dynamic range (McLuckey and Wells, 2001).  The best quality of the 
orbitrap is the very high resolution obtained.  The orbitrap resolving power is proportional 
to the number of oscillations of the ions, and therefore inversely proportional to the 
square root of m/z.  The orbitrap also has high mass accuracy and dynamic range 
(Makarov et al., 2006).  In the current study, an Orbitrap Exactive mass spectrometer was 
used, and an overiew diagram of this system is shown in Figure 2.6. 
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Figure 2.5. Schematic representation of the orbitrap 
Adapted from de Hoffman and Stroobant, 2006.  A barrel shaped outer electrode is cut 
into two parts separated by a small gap.  The ions spiral around the central electrode 
while oscillating back and forth along the z-axis.   
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Figure 2.6. Schematic representation of the Orbitrap Exactive  
Charged analytes are moved from the ion source to the orbitrap analyser via a series of ion optics which use a combination of direct current (DC) and radio 
frequency (RF) voltages, and a vacuum gradient.  The ions can be held in the analyser for a selected period of time, and the ions are detected by the outer 
electrodes which surround the orbitrap analyser. 
9
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2.9.2.2. Quadrupoles 
The quadrupole analyser uses the stability of the trajectories in oscillating electric fields to 
separate ions according to their m/z (Paul and Steinwedal, 1953).  A quadrupole consists 
of four parallel rods equally spaced around a central area (Figure 2.7).  Opposite rods are 
electronically connected, and an equal but opposite direct current (DC) voltage 
superimposed with a radio frequency (RF) alternating current (AC) voltage is applied to 
the diagonally placed pair of rods.  This causes the ions to move in the z direction with an 
oscillatory motion in the x-y plane.  The amplitude of oscillation can be controlled by 
altering the DC and RF voltages, and has a relationship with the m/z.  The DC and RF 
voltages can be set so that the amplitudes of oscillation for desirable m/z are stable, 
allowing the ions to travel along the z-axis without hitting the quadrupole rods, and 
therefore reaching the detector.  The oscillatory amplitudes of undesirable ions are 
unstable and so hit the metal rods and get neutralised, rather than reach the detector (Ho 
et al., 2003).  Positive and negative fields are generated at perpendicular axes to each 
other by the application of opposing polarities to pairs of rods.  A positive ion entering the 
space between the rods will be attracted towards a negative rod.  If the potential changes 
sign before discharging itself on the rod, the ion will change direction (de Hoffman and 
Stroobant, 1999).   
 
Quadrupole mass analysers are advantageous in that they are robust, economical, 
physically small, and easily interfaced with a wide variety of inlet systems (Ho et al., 2003).  
A series of three quadrupole analysers can be set-up in a linear fashion to form a triple 
quadrupole.   
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Figure 2.7.  Schematic drawing of a quadruple 
Adapted from de Hoffman and Stroobant, 2006.  Four hyperbolic rods are equally spaced 
around a central area.  The electrical potential of the rods are denoted by the + or – 
symbols.  There are three major dimensions of the trajectory of the ions through the 
quadrupole, and these are x, y and z. 
 
 
 
 
 
+ 
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In a typical triple quadrupole system (Figure 2.8), the ions enter the first quadrupole (Q1) 
where specific ions (precursor ions) are mass selected.  By selecting specific m/z, Q1 acts 
as a filter to the other ions present and so can help reduce sample purification before MS 
analysis.  The selected ions then collide with a collision gas in Q2 causing fragmentation of 
the precursor ions, which is a process known as collision induced dissociation (CID).  The 
resulting product ions are then monitored by Q3, and finally move to the detector.  Both 
Q1 and Q3 are operated by DC and RF potentials, whereas Q2 is operated only by the RF 
potential (Dass, 2007).  Different data acquisition modes are commonly used with this 
type of mass analyser and are: 
 
- Product ion scan;  a precursor ion is focussed in Q1, fragmented in Q2 and 
detected by scanning in Q3 
- Precursor ion scan; Q3 is held to measure the occurrence of a selected fragment 
ion and Q1 is scanned, resulting in a spectrum of precursor ions relating to a 
particular product ion 
- Neutral loss scan; both Q1 and Q3 are scanned to produce a spectrum of 
precursor ions that undergo the same neutral loss 
- Multiple reaction monitoring (MRM); both Q1 and Q3 are static for a pre-
determined precursor and product ion pair 
 
These scanning modes have many applications, for example, previous studies have used 
precursor ion and neutral loss scanning to detect sub-sets of lipids containing a specific 
functional group such as phospholipids (Ekroos et al., 2002; Han et al., 2005; Han et al., 
2006a and 2006b).  These scanning acquisitions are a major advantage of a triple 
quadrupole mass spectrometer; however, they also have several disadvantages including 
low resolution, medium mass accuracy and a low duty cycle for the scanning modes 
(excluding MRM).  Hybrid instruments now exist in which Q3 is replaced with a different 
analyser to try and improve the problems.  When Q3 is replaced with a TOF analyser, 
named QTOF (Ekroos et al., 2002; Rainville et al., 2007), a good mass accuracy and 
resolving power can be provided for product ion, but they cannot perform precursor and 
neutral loss scans.  Another hybrid instrument called QQ-LIT or Qtrap replaces Q3 with a 
linear ion trap (LIT), and this can perform precursor and neutral loss scans (Hopfgartner et 
al., 2004; Hou et al., 2008).     
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Schematic representation of a triple quadrupole mass spectrometer 
A triple quadrupole mass spectrometer consists of three quadrupoles.  The ions enter the first quadrupole (Q1) where specific ions (precursor ions) 
are mass selected. These then pass into Q2 where they collide with a collision gas which causes fragmentation of the precursor ions.  The resulting 
product ions are then monitored in Q3 and detected by the detector.  
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2.9.3. Detectors 
Once ions have passed through the analyser, they reach the detector, used to measure 
and record their m/z.  Electron multipliers are the most common detector type used in 
mass spectrometry.  This type of detector operates by a process called secondary electron 
emission.  When an ion strikes the surface it causes the ions in the outermost area of the 
atom (secondary electrons) to be released from atoms in the surface layer.  The number 
of these secondary electrons released depends on the type of primary particle, the angle 
it strikes the surface, and the energy and characteristic of the incident surface.                 
There are two basic forms of electron multipliers: the discrete-dynode electron multiplier, 
and the continuous-dynode electron multiplier.  The discrete-dynode electron multiplier is 
made up of 12 to 20 dynodes that have good secondary emission properties.  These 
dynodes are held at decreasing negative potentials by a chain of resistors.  When 
secondary electrons from the conversion dynode strike the first dynode surface, 
secondary electrons are emitted, and these are then accelerated towards the next 
dynode.  These electrons therefore strike the secondary dynode, causing the emission of 
even more electrons.  This continues until an electric current is produced at the end of the 
electron multiplier (de Hoffmann and Stroobant, 1999).            
A continuous-dynode electron multiplier exists in a curved tube shape and has good 
secondary emission properties.  The walls of the tube have a standardised electric 
resistance.  Therefore when a voltage is applied at either end of the tube, a continuous 
accelerating field is produced.  The secondary particles emitted from the conversion 
dynode collide with the curved inner wall of the tube, thus producing secondary 
electrons.  These are then accelerated towards the exit of the tube, all the while striking 
the wall and releasing more secondary electrons.  Therefore a cascade of electrons is 
created until eventually a metal anode collects this stream of secondary electrons at the 
detector exit, allowing the current to be measured (de Hoffmann and Stroobant, 1999).              
Other types of detector exist, including Faraday cups and ion-to-photon detectors.  In the 
case of the orbitrap, the detector consists of two metal surfaces in which the ions only 
pass as they oscillate.  This means that only a weak AC current is produced in a circuit 
between the electrodes.                                                                                                                    
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2.9.4. Chromatography systems 
The term chromatography refers to any technique which separates compounds based on 
their partition coefficient between a stationary and a mobile phase (Purnell, 1962).  In 
terms of lipid analysis, three chromatography techniques are commonly used, and each 
has its own advantages. Gases and volatile substances can be separated by gas 
chromatography (GC), involatile chemicals and high molecular weight molecules by liquid 
chromatography (LC) and finally, inexpensive separations can be performed using thin 
layer chromatography (TLC).  Both GC and LC are performed in a column which has been 
pre-treated with a stationary phase.  Specific properties of the stationary phase, as well as 
the applied compounds determine how they interact with each other.  These interactions 
vary between the different compounds, which affects the speed at which a compound 
passes through the column, thereby separating them.  The mobile phase (gas or liquid) 
passes through under pressure to elute the sample from the column.  The method of TLC 
is much simpler; the stationary phase is coated onto a glass plate, and a liquid mobile 
phase travels up the plate to elute the sample.  The sample is present in the mobile phase 
and each solute is retained, with weaker held solutes eluting first, and the more strongly 
held eluting later to allow separation of the sample.  TLC is mainly used analytically to 
measure the proportions of analytes present in the sample.  Both GC and LC can be used 
alone for analytical chemistry, or be coupled to a mass spectrometer as a preparation 
measure to separate a sample before analysis by mass spectrometry.     
 
The chromatography system used for the current study was LC, which can be used to 
separate and detect a wide range of compounds. During LC-MS analysis, the stationary 
phase is packed into a column, and the mobile phase is a liquid, often a mixture of 
solvents and water.  This solvent gradient is altered over time and causes disassociation of 
the compounds with the stationary phase.  Modern LC-MS systems allow for up to four 
mobile phases to be mixed together at once; however, two phases are most commonly 
used.  This binary solvent system consists of an aqueous solvent (often referred to a 
solvent A) and an organic solvent (solvent B).  The aqueous phase is often HPLC grade 
water with 0.1% acid.  Many solvents are commonly used for B, including acetonitrile 
(ACN), methanol (MeOH) and isopropanol (IPA).  These solvents may also be mixed 
together, along with the addition of an acid, which is added to improve chromatography, 
and also to provide a source of protons.  Commonly used acids are formic and acetic.   
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Two main types of liquid chromatography are used in lipidomic LC-MS analyses, and they 
are normal-phase, and reverse phase.  Normal phase chromatography separates analytes 
based on their affinity for a polar stationary phase.  The column is equilibrated with a non 
polar solvent, and so aids the separation of analytes soluble in these non-polar solvents.  
The analytes associate with the polar stationary phase, and the strength of adsorption 
depends on the polarity of the analyte.  Therefore, the analytes with the lowest polarity 
elute off first, while more polar compounds are retained on the column for longer 
(Willoughby et al., 2002).  As the solvents in the mobile phase become more polar, the 
retention time (RT) of the analytes will decrease, and vice versa.  The opposite is true for 
reverse-phase chromatography.  The column has a non-polar stationary phase, and is 
equilibrated with polar solvents.  Therefore, polar analytes elute readily, whilst less polar 
molecules have longer retention times.        
 
2.10. LIPIDOMIC ANALYSES USED IN THE CURRENT STUDY 
Three lipidomic analysis techniques were utilised in the current study to investigate lipid 
species present in 3T3-L1 adipocytes from both the cells themselves, and also lipids which 
may have been secreted by these cells into the medium.  Global lipidomic approaches 
were used to investigate the lipidome of the 3T3-L1 cells, and a targeted approach 
allowed detection of various eicosanoid species which had been secreted into the cell 
medium.  A summary of the lipidomic analyses used is shown in Figure 2.9. 
 
 
 
 
 
 
 
 
 
                                                                                                                        
 
 
 
 
 
 
 
 
 
Figure 2.9. Summary of lipidomic analyses used in the current study  
Global lipidomic analyses were used to study the lipidome of 3T3-L1 cells, and a targeted lipidomic technique was used to investigate eicosanoid secretion from the 3T3-L1 cells 
into the medium.  Abbreviations used: DI-MS, direct infusion-mass spectrometry; LC-MS, liquid chromatography-mass spectrometry; LC-MS/MS; liquid chromatography-
tandem mass spectrometry. 
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2.10.1. Global lipidomics 
Lipidomics is the comprehensive understanding of the influence of all lipids, and factors 
that interact with them, and the term was first defined through the analysis of lipid 
molecular species by mass spectrometry (Han and Gross, 2003).  Global lipidomics 
theoretically allows the identification and analysis of all lipid species present in a sample. 
 
Two global lipidomic techniques were used in the current study.  The first involved 
infusing the samples directly into the mass spectrometer (direct-infusion mass 
spectrometry), and this method has been termed ‘shotgun lipidomics’ (Han et al., 2005; 
Schwudke et al., 2006).  Direct infusion-mass spectrometry (DI-MS) avoids any prior 
chromatographic steps, allowing a high throughput, and therefore rapid analysis of many 
samples.  This method also provides high sensitivity and mass accuracy, as well as being 
simple to use (Han et al, 2005).  There are limitations to this lipidomic analysis method, 
especially added difficulty in assigning identifications to lipid species due to only having 
the m/z to search against. 
 
2.10.2. Cell preparation  
There were three replicates for each sample group, and quality control (QC) samples were 
also prepared.  Lipids were extracted from cell samples using the Folch extraction method 
(Folch et al., 1957).  A 200µL aliquot of the cells collected in distilled water (described in 
Section 2.1.2.5) from each sample was spiked with 1 nmol of a phosphatidylcholine 
internal standard, 1,2-didodecanoyl-sn-glycero-3-phosphocholine; PC (12:0/12:0) and 1 
nmol of a triacylglycerol internal standard, 1,2,3-trioctadecanoyl-sn-glycerol; TG 
(18:0/18:0/18:0).  The internal standards were added to account for any error or 
variations that may occur during the sample preparation.  The internal standard would 
undergo the same errors, and so the ratio between analyte and internal standard would 
remain unchanged.  By adding a known volume of a known concentration, the internal 
standard can also be used to quantify the lipid species within the sample. 
 
After the addition of the internal standards, the sample mixture was added to 4mL 
chloroform/methanol (2/1, v/v) and left to stand for 1h at room temperature.  The 
samples were centrifuged at 1500 x g for 10 min (Legend X1R) and the supernatant was 
removed to a clean test-tube.  The samples were then partitioned with 0.8mL of 0.1M KCl 
and centrifuged again at 1500 x g for 10 min.  The upper aqueous phase was removed and 
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discarded.  The lower chloroform phase was dried down under a gentle stream of 
nitrogen gas, and reconstituted in 600µL chloroform/methanol (2/1, v/v) and stored at -
80oC until required.  Before directly infusing into the mass spectrometer, 10mM 
ammonium formate (NH4HCO2) was added to each sample.  
 
2.10.3. Calibration method  
Prior to any global lipidomic analysis, an external calibration routine was employed to 
reduce any instrumental drift, and to obtain accurate masses.  This involved directly 
infusing a positive and negative calibration mixture into an Orbitrap Exactive mass 
spectrometer (Thermo Scientific); with a methanol wash in-between each mixture.   
 
The positive calibration mixture consisted of caffeine; L-methionyl-arginyl-phenylalanyl-
alanine acetate x water (MRFA) and UltramarkTM 1621, which is a commercially available 
mixture of fluorinated phosphazines, in an acetonitrile (ACN): MeOH: Water (H2O) 
solution in the following percentages (%v); 50:25:25.  The mixture was finalised with the 
addition of 1% (v) acetic acid.  Stock solutions of caffeine; MRFA and UltramarkTM 1621 
were made up firstly, to the volumes and concentrations stated below: 
 
Caffeine:  1mL of 1mg/mL in distilled water 
MRFA:  1.5mL of 166.7pmol/µL in 50:50 (%v) MeOH: H2O 
UltramarkTM 1621:  10mL of 0.1% (%v) UltramarkTM 1621 in ACN 
 
The positive calibration mixture was then prepared to 10mL by firstly adding 200µL of the 
caffeine stock solution to a 10mL volumetric flask.  To this, 100µL of the MRFA and 
UltramarkTM stock solutions were added to the flask, along with 100µL of glacial acetic acid 
and 5mL of ACN.  The remaining volume was made up with 50:50 (%v) MeOH: H2O.  The 
negative calibration mixture was made up of the same solvent system used for the 
positive mixture and UltramarkTM 1621, as well as sodium dodecyl sulphate (SDS) and 
sodium taurocholate.  The stock solutions were prepared to the following volumes and 
concentrations: 
 
 
SDS: 10mL of 1nmol/µL SDS in 50:50 (%v) MeOH: H2O 
Sodium taurocholate: 10mL of 1nmol/µL sodium taurocholate in 50:50 (%v) MeOH: H2O 
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Preparation of the negative ion calibration mixture began with the addition of 100µL of 
the SDS, sodium taurocholate and UltramarkTM 1621 stock solutions into a 10mL 
volumetric flask, along with 100µL of glacial acetic acid.  As with the positive mixture, 5mL 
of ACN was then added and the mixture was brought up to 10mL with 50:50 (%v) MeOH: 
H2O.   
  
2.10.3.1. Mass spectrometry parameters 
Both the positive and negative calibration mixtures were directly infused into the Orbitrap 
Exactive at a flow rate of 5µL/min.  The intensity signal was left to stabilise for 2 min 
before the start of the automatic calibration, and MeOH was washed through between 
the mixtures for 5 min, or until the calibration mixture ions had reduced to background.  
Some of the settings were the same for both ionisation modes:  the sheath gas was set to 
5 (arbitrary units), and the vaporiser and capillary temperatures were held at 40oC and 
275oC, respectively.  The spray voltage differed between the two ionisation modes, and 
was set at 3kV for positive, and 2.5kV for negative.  In both ionisation modes the 
resolution was set at 60,000 with a 2Hz scan speed.  The maximum injection time was 100 
milli sec (msec) and the AGC target was set at ultimate mass accuracy.  The scan range 
analysed was between m/z 100 and 2000Da.   Example spectra generated from the 
positive and negative calibration mixtures are shown in Figure 2.10. 
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Figure 2.10. Representative spectra of the calibration mixtures 
Representative spectra of the positive (A) and negative (B) calibration mixtures, with a 
mass-to-charge (m/z) range between 100 and 2000Da. 
 
 
 
(A) 
(B) 
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2.10.4. DI-MS method 
Prepared 3T3-L1 adipocytes and QCs were directly infused into the Orbitrap Exactive at a 
flow rate of 5µL/min.  A 2 min stabilisation period was employed for each sample before 
data were acquired for 450 scans.  The samples were infused in both positive and negative 
ion mode, and all the settings were the same as those described in Section 2.10.3.1, with 
the exception of the scan range which set for m/z between 100 and 1000.   
 
2.10.5. Data analysis of DI-MS global lipid profiles 
 A selection of abundant peaks from each experiment was selected, and quantified using 
the intensity of the appropriate internal standard, therefore, all TGs used TG 
(18:0/18:0/18:0) and all other lipid species used PC (12:0/12:0).  This value was then 
normalised to the protein concentration of the cell lysate. The peaks were identified using 
their m/z with the following databases: the Human Metabolome Database (HMDB; 
www.hmdb.ca), LIPID Metabolites and Pathways Strategy (LIPID MAPS; 
www.lipidmaps.org), and the Metabolite and Tandem MS Database (METLIN; 
http://metlin.scripps.edu).  Identifications were confident if the mass accuracy between 
the observed mass and the theoretical mass was less than 5 parts per million (ppm).  This 
is calculated by the following formula: 
 
ppm = observed mass – theoretical mass x 1,000,000 
  theoretical mass 
 
The concentrations of the selected lipid species from each study were presented as 
median ± range for a group size of three.  Appropriate non-parametric tests were applied, 
and the specific test used is indicated in the data chapters.  
 
2.10.6. Global lipidomics, LC-MS analysis 
Another global lipidomic approach is the use of LC-MS.  Advantages of this method 
include a better sensitivity than DI-MS, and the ability to detect and identify lipids based 
on RT and accurate mass.  The major advantage of LC-MS over DI-MS; however, is that 
lipids in complex samples can be separated.  Disadvantages include longer analysis times, 
and problems with sample carry over between runs, and coelution of lipids may exist 
(Nygren et al., 2011). 
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2.10.6.1. Cell preparation 
The cell lysate samples were prepared as described in Section 2.10.2, without the addition 
of 10nM ammonium formate (AF).   
 
2.10.6.2. Chromatography conditions 
Lipid extracts from the cell samples and QCs were separated on a Hypersil Gold C18 
1.9µm; 50mm x 2.1mm column (Thermo Scientific, Hemel Hempstead, UK).  The LC 
conditions were adapted from a previous method (Nygren et al., 2011) and were the same 
for both positive and negative ion mode analyses.  A binary solvent system was used in 
which mobile phase A consisted of H2O + 1% ammonium formate (AF) + 0.1% formic acid 
and mobile phase B of ACN/ IPA  (1:1, v,v) + 1% AF + 0.1% formic acid.  Analyses were 
performed over an 18 min gradient with a flow rate of 400µL/min.  The sample tray and 
column were held at 4oC and 50oC respectively.  The mobile phase gradient was as shown 
in Table 2.4. 
 
 
Table 2.4. Mobile phase compositions for global LC-MS analysis 
 
Time  % mobile phase A  % mobile phase B 
0  65    35 
2  20    80 
7  0    100 
14  0    100 
18  65    35 
 
  
2.10.6.3. Mass spectrometry conditions 
An Accela ultra high performance liquid chromatography (UHPLC) system was coupled to 
an Orbitrap Exactive, which was equipped with a heated electrospray ionisation (HESI) 
probe.  The heated capillary and HESI probe were held at 250oC and 300oC, respectively.  
The sheath gas flow was set at 50 (arbitrary units) and the auxiliary gas at 20 (arbitrary 
units).  These conditions were constant for both positive and negative ion mode 
acquisitions.  The spray voltage was set at 4.5kV in positive ion mode, and 2.5kV in 
negative ion mode.  A lock mass of m/z 413.26623 was selected in positive ion mode only.  
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A lock mass is a compound of known mass which compensates instrumental drift.  The 
instrument underwent a complete calibration (as described in Section 2.8.1.3) to reduce / 
remove instrumental drift, and improve the mass accuracy of the instrument.  After 
calibration of the mass spectrometer, 1µM of a lyso-phosphatidylcholine standard (LPC 
14:0) was directly infused in both positive and negative ion mode before every acquisition 
to check the chromatography conditions. 
 
The mass spectrometer was run in high resolution mode which corresponds to a 60,000 
resolution and 2 Hz scan speed.  The AGC target was set at ultimate mass accuracy and 
the maximum injection time was 100 msec.  These conditions were the same for positive 
and negative ion mode for a scan range between m/z 100 and 1000.  Each sample set had 
three biological replicates which were injected once in a randomised order, with blanks 
and QCs being dispersed throughout the sequence run.  The sample sequence was run 
separately in positive and negative ion modes. 
 
2.10.7. Analysis of global LC-MS data 
All LC-MS raw files in the current study were analysed using SIEVE v1.3 (Thermo 
Scientific), which is an automated label-free differential software package.  It can be used 
for the analysis of protein, peptide and small molecule datasets.  Therefore, the SIEVE 
experiments in this study were set up for non-differential analysis of small molecules.  The 
workflow of these experiments consists of three stages: alignment, framing and 
identification.  The alignment method used is called ‘adaptive chromatographic alignment’ 
and can only be applied to full datasets.  This method involves pairs of full scan data being 
compared and separated into ‘bins’ of equal size.  Correlations between two spectra can 
then be calculated, and used to construct a matrix tile.  An optimal path is found in the 
matrix, and subsequent tiles overlap the original one.  This overlapping of tiles continues 
until the full plane is covered, and a final alignment score can then calculated. 
 
The next process in the SIEVE workflow is framing, which involves ordering all of the peaks 
above a set threshold by their intensities.  Each peak relates to a frame, with the most 
intense peak becoming the first frame, and this continues until all of the selected peaks 
have been framed.    The final process in the workflow is identification, and ChemSpider is 
the internal identification algorithm used for small molecules.  
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2.10.8. Multivariate Data Analysis 
A large volume of data is produced from mass spectrometry techniques, and so the use of 
standard statistical techniques is not suitable.  Multivariate data analysis (MVDA) allows 
the analysis of data relating to more than two variables from each sample.  These 
techniques treat the data set as a group to allow the identification of values which vary 
from other data points.   
 
Two main approaches are used in MVDA and they are either supervised, or unsupervised.  
Of the unsupervised techniques, principle component analysis (PCA) is commonly used as 
a tool for exploratory data analysis and for making predictive models.  PCA was invented 
by Karl Pearson in 1901 (Pearson, 1901) and is mathematically defined as an orthogonal 
linear transformation.  The aim of PCA is to convert data into information by analysing a 
dataset in an ‘n’ dimensional space.   The data is transformed into new variables which are 
linear combinations of the original ones and referred to as principal components.  The 
greatest variance of the data comes to lie on the first coordinate (called the first principal 
component), the second greatest variance on the second coordinate, and so on.  The total 
number of principle components are less than or equal to the number of original 
variables.  These new variables are uncorrelated, and so each principal component 
explains a different part of the information.  PCA can generate a scores plot and a loadings 
plot.  A scores plot of the first two principle components allows any clustering within a 
dataset to be displayed.  The loadings plot provides information on any variables which 
contribute to the groupings of the first two principal components.  
 
Supervised approaches, such as partial least square (PLS) analysis (Holmes and Antti, 
2002; Lindon et al., 2003) are used to maximise separation between unknown samples 
after a relationship between metabolic profile and phenotype has been established.  PLS 
projects the predicted and observed variables into a new space.  Both the x (measure 
data) and Y (response data) are projected into a new space, and when the Y is binary, the 
process is called partial least squares-discriminant analysis (PLS-DA).  PLS maximises the 
variation between X and Y by deriving latent variables.  The algorithm is then applied to a 
dummy matrix Y which consists of an orthogonal vector unit for each class.  Therefore, a 
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supervised technique uses an existing model from other datasets, and compares an 
individual dataset to it, whereas this model does not exist in unsupervised approaches.  
Both supervised and unsupervised models can be improved with the correct use of 
scaling.  Three scaling types include unit variance (UV), centering with no scaling (Ctr) and 
Pareto scaling (Par).  The UV scaling should be used where the variables in the data are 
different.  It gives each variable a weighting of one, and therefore an equal chance of 
being expressed in the model.  In terms of mass spectrometry data, spectral regions 
containing large changes in signal amplitude will be compressed, whilst magnifying 
regions with less variation.  A commonly used scaling type with spectral data is Ctr, in 
which the influence of a variable is related to its signal, and so regions of low amplitude 
will have little influence.  A compromise between unit variance UV and Ctr scaling is Par 
scaling.  This option allows regions of low amplitude the chance of influencing the model, 
but only if they show variation.  This scaling type is commonly used for mass spectrometry 
data (Eriksson et al., 1999). 
 
The fit of a model is estimated by the R2 value, and the Q2 value estimates the goodness 
of prediction.  An R2 and Q2 value of 0.5 or greater indicates a good model, and is typical 
for metabolomic and lipidomic analyses.  
 
 
2.10.9. Data processing and MVDA in the current study 
After LC-MS analysis (positive and negative ion mode), the raw data files were processed 
using SIEVE v1.3 to produce m/z and RT pairs, along with their associated intensities.  The 
m/z window was set at either 1 min, 30 sec or 15 sec, and the parameters used for the 
framing process were: 
 
m/z minimum: 100 
m/z maximum: 1000 
frame time width(min): 0.25 
frame m/z width (min): 0.020 
RT start (min): 0  
RT stop (min): 18 
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Lipid species were searched using the three databases mentioned in Section 2.10.5: 
HMDB, LIPID MAPS and METLIN, and the following adducts were included in the searches: 
[M+H]+; [M+K]+; [M+Na]+ and [M+NH4]
+ for positive ion, and [M-H]- for negative ion. The 
mass tolerance was set at 1 ppm.   
 
After SIEVE analysis, the m/z and RT pairs, along with their intensities were manually 
normalised to the total ion current (TIC).  Both the non-normalised and the TIC-
normalised data were imported into SIMCA-P (v12, Umetrics) for MVDA by PCA and PLS.  
PLS was chosen due to the number of samples analysed, and also the fact that the y-
variable data were continuous.  Both model types were Pareto scaled and their 
robustness was measured using R2 and Q2 values.  The corresponding loadings plots 
allowed identification of causes of variance within the pattern recognition models. 
 
2.11. TARGETED EICOSANOID ANALYSIS 
The alternative to global lipidomics is a targeted approach.  Rather than all lipids present 
in the sample being analysed, a selected lipid class is investigated.  All cell preparation and 
mass spectrometry conditions are designed specifically for the analysis of the chosen lipid 
class.  In the current thesis, a targeted lipidomic analysis method was used to identify and 
quantify eicosanoid species secreted from 3T3-L1 adipocytes.   
 
2.11.1. Medium sample preparation 
Media samples (1mL) removed from the 3T3-L1 cells were prepared by the addition of 
2mL ice cold methanol and were then stored at -20oC for 30 min.  Three internal standards 
were added at 1ng/mL concentration per sample and they consisted of a mono-, di- and 
tri-hydroxy eicosanoid species. These were the deuterated forms of 15-
hydroxyeicosatetraenoic acid (15(S)-HETE-d8), leukotriene B4 (LTB4-d4) and prostaglandin 
E2 (PGE2-d4), respectively (Cayman Chemical, Cambridge, UK).  The samples were then 
centrifuged at 670 x g for 10 min at 4oC (Legend X1R, Thermo Scientific) to aid the 
precipitation of any protein, and the supernatant was added to 18mL distilled water.  
Finally, the samples were acidified to pH 3.5 with 2M HCl.  
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2.11.2. Solid phase extraction chromatography 
Solid phase extraction (SPE) chromatography involves the removal of analytes from a 
flowing liquid sample due to retention on a solid sorbent.  This is followed by the recovery 
of selected analytes by elution from the sorbent.  This method has been greatly aided by 
disposable cartridges containing the solid sorbent, and the first sorbent used was bonded-
phase silica.  The use of SPE chromatography on commercially available bonded phase 
silica was first described in the clean-up of histamines from wine (Subden et al., 1978).  
The process consists of four stages (Figure 2.11).  In the first, the sorbent is conditioned 
with solvent, to improve analyte retention and also to reduce solvent impurities passing 
through during elution.  The solvent that is present in the sample is then passed through 
the conditioned column, followed by the sample itself.  A number of washing steps follow, 
to remove any undesired sample components from the column, whilst still retaining the 
analytes of interest.   Finally, these analytes are eluted from the column, and collected, 
using a suitable solvent. 
 
2.11.2.1. Solid phase extraction chromatography method 
Eicosanoid lipids were extracted from medium samples harvested from the 3T3-L1 cell 
culture, by SPE chromatography using C18 6cc Sep-Pak cartridges (Waters, Manchester, 
UK).  Each cartridge was initially conditioned with 6mL methanol. This was repeated with 
a further 6mL of methanol, and then twice with 6mL distilled water.  Once the cartridge 
had been conditioned, the extracted medium sample (Section 2.11.1) was applied, and 
allowed to run through into waste.  The sample tubes were washed with 10mL distilled 
water, and this was also applied to the cartridge.  Final drops from the cartridges were 
checked for a neutral pH, and the previous step was repeated if necessary until a neutral 
pH was achieved.  The cartridge was then washed twice with 5mL hexane, and the 
eicosanoids eluted off with two washes of 3mL methanol into glass tubes.  The eluted 
samples were dried down under nitrogen, and reconstituted into 100µL methanol: water 
(1:1; v,v).  They were then stored at -80oC until analysis. 
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Figure 2.11. Principles of SPE chromatography 
Schematic representation of the four stages of SPE chromatography.  The first step involves 
conditioning the sorbent with solvent, after which, the sample is loaded onto the cartridge.  
This is followed by a number of washing steps to remove any undesired sample components 
(interferences).  Finally, the analytes are eluted from the sorbent, and collected, using a 
suitable solvent. 
Wash Condition 
 
Elute Load 
Analyte 
 
Interferences  
 
Collect 
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 2.11.3. LC-MS conditions 
The extracted eicosanoid samples were analysed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). They were analysed on a TSQ Quantum Ultra triple quadrupole 
mass spectrometer interfaced with a Thermo Accela UHPLC system (Thermo Scientific). The 
analyses were performed by Dr Benjamin Maskrey (Lipidomics Research Facility, University of 
the Highlands and Islands).  A standard mix was run in triplicate alongside unknown samples 
at the following concentrations to produce a standard curve: 25, 50, 100, 200, 400 and 800 
pg/mL.  The standards in the mix are presented in Table 2.6. 
 
2.11.3.1. Chromatography conditions 
The eicosanoids were separated using a Hypersil Gold C18 3µm; 50mm x 2.1mm column 
(Thermo Scientific).  The solvent gradient utilised two mobile phases with A being H2O + 10% 
MeOH + 0.02% Acetic acid, and B consisting of MeOH + 0.02% Acetic acid.  Separations were 
completed over 25 min, with a flow rate of 300µL/min.  The sample tray and column were 
held at 4oC and 30oC respectively.  The mobile phase gradient is shown in Table 2.5: 
 
 
Table 2.5. Mobile phase gradient for targeted eicosanoid analysis by LC-MS/MS 
 
Time  % A  % B 
0  55  45 
10  40  60 
18  0  100 
21  0  100 
21.1  55  45 
25  55  45    
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2.11.3.2. MS conditions 
The LC-MS/MS run occurred in negative ion mode, with a voltage of 2.5kV.   The capillary and 
vaporiser temperatures were set at 250oC and 350oC, respectively.  The sheath gas was held 
at 60 (arbitrary units) and the auxiliary gas at 10 (arbitrary units).  A divert valve was set to go 
to waste for the first 90 sec, and the last 7 min, and was switched to go to the detector 
between these times.  The collision gas used in Q2 was argon, at a pressure of 1.5mTorr.  
Individual eicosanoids were monitored in the multiple reaction monitoring (MRM) mode 
using specific precursor to product ion m/z transitions.  The collision energies were optimised 
for each individual eicosanoid by direct infusion.  The MRM transitions and respective 
collision energies used for eicosanoid identification are presented in Table 2.6. 
 
Each sample set had three biological replicates which were injected once in a randomised 
order, with blanks and QCs being dispersed throughout the sequence run.   
 
2.11.4. Quantitative data analysis of eicosanoid profiles 
LCQuan v2.6 (Xcalibur, Thermo Scientific) was used to produce a standard curve for each 
eicosanoid present in the standard mix.  These standard curves were used to automatically 
calculate the quantity of the eicosanoids in the unknown samples.  Any concentration below 
the lowest standard curve point (25pg/mL) was considered to be non-detectable.  An 
example standard curve is shown in Figure 2.12. 
 
 The intensities of the eicosanoid species present in the samples were related to the intensity 
of the appropriate internal standard.  This was then normalised to the protein concentration 
of the cell.   
 
2.11.5. Statistical analysis of targeted lipidomic data 
A Shapiro-Wilk W test was first used to determine the normality of the data, and all targeted 
eicosanoid data were not normally distributed.  Therefore, non-parametric tests were used, 
and the results presented as median ± range for a group size of three.  The specific non-
parametric test utilised for each experiment is indicated in the data chapters. 
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Table 2.6 MRM transitions and CE used for eicosanoid identification  
 
 
Compound   Precursor  Product  CE 
Internal standards: 
15(S)-HETE-d8   327.2   226.2   16  
LTB4-d4    339.2   197.2   17 
PGE2-d4    355.2   193.2   21 
 
Mono-hydroxy: 
5-OxoETE   317.2   203.2   23 
15(S)-HETE   319.2   175.3   17 
5-HETE    319.2   115.2   18 
12(S)-HETE   319.2   179.3   16 
20-HETE   319.2   245.2   17 
5, 6 EET    319.2   191.3   15 
8, 9 EET    319.2   151.2   15 
14, 15 EET   319.2   175.3   17 
14, 15 dHET   337.2   207.2   19 
 
Di-hydroxy: 
LTB4    335.2   195.1   18 
 
Tri-hydroxy: 
6-keto PGF1α   369.2   245.1   28  
Thromboxane B2  369.2   169.2   20 
20-OH LTB4   351.2   195.2   20 
11β-PGF2α   353.2   193.2   27 
PGF2α    353.2   193.2   27 
PGD2    351.2   233.2   16 
PGE2    351.2   189.2   22 
 
 
 
 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Eicosanoid standard curve 
This figure illustrates a typical standard curve generated by the dilution of each eicosanoid 
present in the standard mix.  The software produced a standard curve of the concentration of 
the eicosanoid compared to the area of the peak.  A line of best was automatically plotted 
and used to calculate the eicosanoid concentration in each sample based on its peak area.  
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CHAPTER 3 
Validation of a model of adipogenesis: Application of 
lipidomic analyses to this model  
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3.1. INTRODUCTION 
A major role of white adipose tissue (WAT) is the storage of triglycerides (TG).  An increase in 
TG storage is caused by a positive energy balance, which if left to continue would lead to 
increased adiposity, and eventually obesity. The increase in WAT mass is due to hypertrophy 
of mature white adipocytes, and/or hyperplasia, with hypertrophy often occurring first 
(Johnson et al., 1971; Faust et al., 1978; Johnson et al., 1978).  Hypertrophy is a complex 
process which increases the number of mature adipocytes by the differentiation of pre-
adipocytes, and is also termed adipogenesis.  A detailed account of adipogenesis is outlined 
in Section 1.2.3, and a summary of the factors involved, and differentiation markers 
expressed are presented in Table 1.3. 
 
Research into adipocyte development has been facilitated by the use of clonal cell lines, 
including two commonly used murine cell lines, 3T3-L1 and 3T3-F442A.  The work described 
in this thesis has been completed using the 3T3-L1 cell line, which is a derivative of the 3T3 
mouse fibroblast cell line, developed by Green and colleagues (Green and Meuth, 1974; 
Green and Kehinde, 1975).  This cell line was chosen because it has been extensively 
characterised.   
 
The process of adipogenesis is complex, involving many factors and the expression of 
differentiation markers.  Two late markers of differentiation are the adipokines leptin and 
adiponectin, and the gene expression and secretion of both has been thoroughly 
documented.  As described in Section 1.3.1, leptin is primarily expressed in and secreted by 
adipocytes, and plasma concentrations of this protein are positively correlated with adiposity 
in both humans, and rats (Maffei et al., 1995; Considine et al., 1996).  In terms of adipocyte 
differentiation, a previous study has demonstrated that leptin gene expression was present in 
differentiated 3T3-L1 adipocytes from day three onwards, and this gene expression increased 
as the adipocytes became fully mature.  Leptin gene expression; however, was not present in 
the pre-adipocyte stage (MacDougald et al., 1995).  The study also found that the leptin gene 
expression in adipocytes was much less than that present in WAT, suggesting that WAT may 
have access to factors which upregulate the gene expression of leptin. 
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Adiponectin is exclusively produced by mature adipocytes (Ouchi et al., 1999) and, like leptin, 
not during the pre-adipocyte stage.  However, unlike leptin, circulating concentrations of 
adiponectin are decreased in obesity (Arita et al., 1999).  A previous study found adiponectin 
to be involved in pre-adipocyte proliferation and differentiation, as well as lipid accumulation 
in mature adipocytes, with over-expression of the protein augmenting these processes (Fu et 
al., 2005).  The gene expression of various markers of differentiation were measured in 
response to an over-expression of adiponectin, and during differentiation, a prolonged gene 
expression of both PPARγ and C/EBPα occurred (Fu et al., 2005).  The ADD1/SREBP1c gene 
also appears to have a role in adipocyte differentiation, with a previous study demonstrating 
that the expression of this gene increases as cultured pre-adipocytes begin differentiation 
(Kim and Spiegelman, 1996).  Over-expression of adiponectin in 3T3-L1 cells lead to an 
increase in the gene expression of ADD1/SREBP1c (Fu et al., 2005), indicating a role for 
adiponectin in adipogenesis. 
 
The major process involved in adipogenesis is TG accumulation, and shortly after the 
development of the 3T3-L1 murine pre-adipocyte cell line, these cells were used to monitor 
lipid accumulation during differentiation (Mackall et al., 1976).  TG accumulation was 
detected from as early as three days after confluence and, by day 14, over 80% of the cells 
had lipid droplets, seen by Oil Red O staining.  Six days after confluence de novo lipogenesis 
(DNL) also increased, leading to the conclusion that the increase in TG accumulation was 
associated with increased DNL (Mackall et al., 1976).  Lipogenesis involves the processes of 
FA synthesis, and their esterification with glycerol to form TGs.    Before the formation of TGs, 
elongation or desaturation of FAs is necessary, and both of these events induce lipogenesis in 
mice (Sampath et al., 2007).   
 
Another metabolic pathway involved in adipogenesis is that of eicosanoid production 
(Madsen et al., 2003).  A previous study has found that the certain products of the 
cyclooxygenase (COX) pathway play a role in adipocyte differentiation.  Prostaglandin (PG)D2 
was shown to be formed during the maturation phase, as was PGE2, although greater 
formation of this eicosanoid occurred in pre-adipocytes.  Finally, PGF2α had an opposing 
effect; it was seen to inhibit differentiation by reducing triglyceride accumulation (Lu et al., 
2003). 
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3.1.2. Aims of the current study 
The work described in this chapter aimed to investigate lipid metabolism processes occurring 
within the 3T3-L1 cell-line and monitor any changes over the course of differentiation.   The 
first specific aim was to validate the 3T3-L1 cell-line as a model of adipogenesis.  A wealth of 
previous work has demonstrated both morphological changes (Green and Kehinde, 1974) and 
also differences in the gene expression of the adipokines leptin and adiponectin (MacDougald 
et al., 1995; Ouchi et al., 1999) occurring during the differentiation process.  It was predicted 
that similar findings would be observed in the current study, thereby acting as a validation for 
the correct behaviour of these cells. 
 
Once validated, the second part of the current study focussed on using lipidomic analyses to 
investigate lipid metabolism during adipogenesis.  The second specific aim was to determine 
whether the differentiation process caused altered global lipidomic profiles of 3T3-L1 
adipocytes, particularly in terms of identifying individual lipid species present at each stage, 
and monitoring any changes in their concentration.   
 
The final specific aim of the current study was to examine whether 3T3-L1 cells produced 
arachidonic acid (AA)-derived eicosanoid species, and if so, observe whether the 
concentrations of these eicosanoids changed over the course of differentiation. 
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3.2 MATERIALS AND METHODS 
3.2.1. Cell culture 
3T3-L1 cells were cultured at 37oC in a humidified atmosphere of 5%CO2 / 95% air, as 
previously described in Section 2.1.3.  The compositions of all media are outlined in Section 
2.1.2.  The cells were harvested as described in Section 2.1.3 on the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  In the current study, the time-course of 
differentiation was extended until day 25, with the aim to determine whether these cells just 
continue to mature and accumulate lipid, or adopt a different phenotype.  The cells were 
synchronised by starving of CS for 24 hours (h) before collection and therefore feeding with 
DMEM alone.  Both the cells and medium were collected and stored at -80oC until needed.                         
                                                                                                                                                                            
3.2.2. Oil Red O and haematoxylin staining 
One well per plate was stained with Oil Red O and haematoxylin, as described in Section 
2.2.2, and images of the different time points were captured.    
 
 
3.2.3 Reverse transcription PCR and Real-time PCR  
Total RNA was extracted from harvested cells using TRI Reagent®
 
as described in Section 
2.4.2. The genes investigated in this study were leptin and adiponectin, with a group size of 
six.  
 
 
3.2.4. Enzyme-linked Immunosorbent Assay  
Leptin and adiponectin protein concentrations were analysed in the harvested cell culture 
medium using an Enzyme-linked Immunosorbent Assay (ELISA) kit specific to each, as 
described in Section 2.7.2.  The standards were assayed in duplicate, and each time point had 
a group size of three.  The optical density was read at 450nm. 
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3.2.5. Global lipidomics  
3.2.5.1. Cell preparation  
Lipids were extracted from cell samples using the Folch extraction method (Folch et al., 1957) 
as described in Section 2.10.2, and the lower chloroform phase was dried down under 
nitrogen, and reconstituted in 600µL chloroform / methanol (2/1, v/v).  Three biological 
replicates were prepared for each sample, and 10mM of ammonium formate was added to 
each sample before direct infusion-mass spectrometry (DI-MS) analysis, but not liquid 
chromatography-mass spectrometry (LC-MS) analysis.  
 
3.2.5.2. DI-MS method  
The lipid extracts were directly infused into an Orbitrap Exactive mass spectrometer in both 
positive and negative ion mode as described in Section 2.10.4.  One technical replicate of 
each sample, along with quality control (QC) samples were analysed.  Selected lipid peaks 
were quantified using an appropriate internal standard, either: 1,2-didodecanoyl-sn-glycero-
3-phosphocholine, PC (12:0/12:0); or, 1,2,3-trioctadecanoyl-sn-glycerol, TG (18:0/18:0/18:0), 
both of which were added at 1nmol concentration.  These had a mass-to-charge ratio (m/z) 
of 622.4436 and 908.8629, respectively in positive ion mode.  These values were then 
normalised to the protein concentration of the cell samples.  Various databases were used to 
identify lipid species, including the Human Metabolome Database (HMDB; www.hmdb.ca), 
LIPID Metabolites and Pathways Strategy (LIPID MAPS; www.lipidmaps.org), and the 
Metabolite and Tandem MS Database (METLIN; http://metlin.scripps.edu).  Confident 
identifications were assumed when the mass error was within 5 parts per million (ppm), and 
all mentioned identifications are within this error, unless stated. 
 
3.2.5.3. LC-MS method 
Lipid extracts were analysed by liquid chromatography-mass spectrometry (LC-MS) as 
described in Sections 2.10.6.2 and 2.10.6.3.  Three biological replicates were analysed per 
time point, with one technical replicate each, along with three quality control (QC) samples.     
 
3.2.5.4. LC-MS data processing and multivariate data analysis 
All LC-MS raw files were processed using SIEVE v1.3 to produce m/z, retention time (RT) and 
intensity values.  Three different RT windows were investigated, 1 minute (min), 30 seconds 
(sec) and 15 sec.  Lipids were identified using the databases mentioned above in either 
positive or negative ion mode, with the parameter for confident identifications being 5ppm.   
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The RT and m/z pairs, along with their associated intensities, were manually normalised to 
the total ion current (TIC) intensity.  Both the non- and TIC-normalised datasets were then 
imported into SIMCA-P v12 for multivariate data analysis, including the unsupervised 
principal component analysis (PCA), and supervised partial least squares (PLS).  PLS was 
chosen due to the number of samples, and the fact that the y-variables are continuous.  All 
models were Pareto scaled and both the scores and loadings plot were analysed. 
 
3.2.6. Targeted eicosanoid analysis  
Solid phase extraction chromatography was used to extract eicosanoid lipids from the 3T3-L1 
medium samples (Section 2.9.3.1).  The extracted eicosanoid samples were then analysed by 
LC-MS/MS as outlined in Sections 2.11.1 and 2.11.2.1.  Individual eicosanoids were identified 
using specific precursor-to-product ion m/z transitions, as detailed in Table 2.3 (Chapter 2).   
 
3.2.7. Statistical analysis 
A Shapiro-Wilk W test was used to determine whether the samples were normally 
distributed.  All mass spectrometry data (direct infusion and eicosanoid) were not normally 
distributed.  For qPCR analyses, even though the data were normally distributed, a non-
parametric test was used.  It has been suggested that qPCR statistical analyses should be 
undertaken using non-parametric tests (Yuan et al., 2006).  Therefore, all data in this study 
were analysed using the non-parametric Cuzick’s test for trend (Cuzick, 1985).  The data were 
presented as mean values ± SD for the normally distributed qPCR data, and as median ± range 
for non-normally distributed mass spectrometry data.  The group size is mentioned in the 
figure captions, and a P-value of < 0.05 was considered statistically significant. 
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3.3. RESULTS – PART A; VALIDATION OF THE 3T3-L1 PRE-ADIPOCYTE CELL LINE ADIPOGENESIS MODEL 
3.3.1. Morphological changes during adipocyte differentiation 
The most obvious change that occurred during the differentiation process from pre-adipocyte 
to adipocyte was morphological.  At induction, the cells had a fibroblast-like appearance and 
as differentiation continued, they began to accumulate lipid droplets.  By terminal 
differentiation, the cells had taken on the characteristic spherical appearance of a mature 
adipocyte.  Oil Red O stained images of 3T3-L1 cells across a full time course from day 0 to 
day 25 post-differentiation are presented in Figure 3.1.  Lipid droplets were noticeable at day 
5 post-differentiation, and continued to be accumulated until day 25.   
 
3.3.2. Gene expression and secretion of leptin and adiponectin during adipogenesis 
The presence or absence of leptin and adiponectin gene expression was determined by 
reverse transcription-PCR (RT-PCR; Figure 3.2).  Both were compared to β-actin (A), which 
was expressed throughout the course of differentiation, as would be expected of a 
housekeeping gene.  Leptin was detected from day 4, and adiponectin from day 1 post-
differentiation (B and C, respectively).  The PCR cycle numbers were 25, 32 and 26 for β-actin, 
leptin and adiponectin, respectively. 
 
The gene expression of both leptin and adiponectin was then quantified by real-time PCR 
(qPCR) as illustrated in Figures 3.3 and 3.4, respectively.  Three housekeeping (HK) genes 
were used: β-actin, GAPDH and RNApol2 and the gene expression of leptin with all three is 
represented in Figure 3.3.  Both β-actin and GAPDH (A and B, respectively) produced similar 
profiles, although the relative fold changes were greater with GAPDH.  A very different profile 
was associated with RNApol2 (C); however, some similarities existed.  A trend of leptin gene 
expression was observed with all HK genes (P<0.0001 for all; 2 sided); as the day post-
differentiation increased, so did leptin gene expression.  This was true until the end of the 
time course where a decrease in leptin gene expression was observed with all HK genes, 
especially at day 25 post-differentiation.  The fold changes associated with the use of 
RNApol2 as the HK genes were approximately three, and 25 times greater than GAPDH and β-
actin, respectively.   
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Figure 3.1 Morphological changes during adipogenesis of 3T3-L1 cells 
Representative images of Oil Red O stained 3T3-L1 cells during the course of differentiation.  The 
images represent cells induced to differentiate at day 0, and cultured at the following times post-
differentiation; (A) 0 (B) 5 (C) 10 (D) 15 (E) 20 and (F) 25.  A clear change is seen from a fibroblast pre-
adipocyte at day 0, to spherical, lipid loaded mature adipocytes from day 10 onwards, with lipid 
accumulation continuing until day 25. The scale bars represent 100μm. 
 
(A) 
(C) (D) 
(E) (F) 
(B) 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.2. Gene expression of leptin and adiponectin in 3T3-L1 cells during adipogenesis 
Representative RT-PCR gels of 3T3-L1 adipocytes collected at various time points after the induction of 
differentiation into adipocytes (days 0-8, 10, 15, 20, 25).  Total RNA was extracted and gene expression 
of β-actin (A), leptin (B) and adiponectin (C) was determined using mouse specific primers.  A negative 
control was run alongside the samples, which contained only the PCR mix (labelled as –tive).  The gene 
expression of β-actin was seen throughout the whole time course, whereas that of leptin and 
adiponectin only occurred from day 4 and day 1 post-differentiation onwards, respectively. 
Amplification cycle numbers were: β-actin, 25; leptin, 32 and adiponectin, 26. 
(A) 
-tive 4 5 6 7 8 10 15 20 25 0 1 2 3 
(B) 
 
 
 
4 5 6 7 8 10 15 20 25 -tive Days 0-3 -tive 
(C) 
1 2 3 4 5 6 7 8 10 15 20 25 0 -tive -tive 
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Adiponectin gene expression profiles are shown in Figure 3.4 and they appeared to vary 
depending on the HK gene was used.  As with leptin gene expression, the use of RNApol2 
(C) greatly altered the profile of adiponectin gene expression over the time course, and 
produced the greatest fold changes, with an approximate 9 fold, and 7 fold increase when 
compared to the profiles of β-actin and GAPDH (A and B, respectively).  All HK genes; 
however, also produced a trend in adiponectin gene expression (P<0.0001 for all; 2 sided). 
 
The secretion of both leptin and adiponectin was detected in cell culture medium from 
the differentiated adipocytes using an ELISA kit specific to each protein.  The evolution of 
their secretion by 3T3-L1 cells is shown in Figure 3.5 (A and B for leptin and adiponectin, 
respectively).  As expected from the qPCR data, a trend was also observed in the secretion 
of both proteins (P<0.001 for both; 2 sided), in that they were only secreted once the 
adipocytes had begun the terminal differentiation process and, after an initial increase, 
their secretion declined as the cells continued to mature.  Adiponectin was secreted at 
much greater concentrations, roughly 1000 times that of leptin at their peak (units of 
measurement in ng/mL vs. pg/mL). 
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Figure 3.3. Gene expression of leptin in 3T3-L1 cells during adipogenesis 
3T3-L1 adipocytes were collected on the following days post differentiation: 0-10, 12, 15, 18, 20, 22, 
and 25.  For all, total RNA was extracted, and leptin expression investigated and normalised to day 0 by 
qPCR, using (A) β-actin, (B) GAPDH, and (C) RNApol2 as the housekeeping gene.  For each time point, 
n=6, with results represented as mean ± SD. An increase in leptin gene expression was seen from 
approximately day 8 post-differentiation with the use of both β-actin and GAPDH as the housekeeping 
gene.  The leptin gene expression profile was different when RNApol2 was used as the housekeeping 
gene, with an increase in leptin gene expression occurring from day 1. A 2-sided Cuzick’s test for trend 
was applied, and a trend in leptin gene expression was observed with all three housekeeping genes 
(P<0.0001 for all).  
(B) 
(C) 
(A) 
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Figure 3.4. Gene expression of adiponectin in 3T3-L1 cells during adipogenesis 
3T3-L1 adipocytes were collected on the following days post differentiation: 0-10, 12, 15, 18, 20, 22, 
and 25.  For all, total RNA was extracted, and adiponectin expression investigated and normalised to 
day 0 by qPCR, using (A) β-actin, (B) GAPDH, and (C) RNApol2 as the housekeeping gene.  For each time 
point, n=6, with results represented as mean ± SD. An increase in adiponectin gene expression was 
seen from approximately day 4 post-differentiation with the use of all three housekeeping genes. A 2-
sided Cuzick’s test for trend was applied, and a trend in adiponectin gene expression was observed 
with all three housekeeping genes (P<0.0001 for all).  
(A) 
(B) 
(C) 
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Figure 3.5. Protein secretion of leptin and adiponectin from 3T3-L1 cells during adipogenesis 
The protein levels of both leptin (A in pg/mL) adiponectin (B in ng/mL) over the course of 
differentiation were determined using a mouse ELISA kit specific for each.  The results show actual 
concentrations present in the medium at each time point.  Results are represented as medium ± range 
for a group size of three at each time point.  Secretion of leptin was detected from day 9 post-
differentiation, whereas this occurred at the earlier time point of day 5 for adiponectin secretion. A 
decrease in protein secretion was seen from day 12 post-differentiation until the end of the time 
course for both leptin and adiponectin.  A 2-sided Cuzick’s test for trend found a trend for both 
proteins (P< 0.0001 for both). 
(A) 
(B) 
Undetected 
Undetected 
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3.4. RESULTS – PART B; LIPIDOMIC ANALYSIS OF THE 3T3-L1 MODEL OF ADIPOGENESIS  
3.4.1. DI-MS analysis 
The time course of the global lipid profiles of 3T3-L1 adipocytes from the day of induction 
(day 0) to day 25 post-differentiation were analysed by DI-MS in both positive (Figure 3.6) 
and negative (Figure 3.7) ion modes.  Both figures show representative spectra of days 0, 
5, 10, 15 and 25 post-differentiation.   
 
3.4.1.1. Positive ion DI-MS analysis 
In positive ion mode, an obvious change in the lipid profile of the 3T3-L1 cells was seen 
over the course of differentiation.  At day 0, only a few lipid species were present, and the 
most abundant had m/z between 700 and 850.  These lipids were identified as either 
phospholipid or sphingomyelin (SM) species.  From day 5 post-differentiation until the 
end of the time course, there was an increase in the number of lipid species present.  The 
most abundant were seen with m/z between 500 and 600, and also 750-900Da.  The 
majority of these lipid species were identified as either phospholipids or TGs.   
 
Identifications of lipid species based on their m/z in positive ion mode are presented in 
Table 3.1.  The top ten abundant lipid species at day 0 (A), and day 25 (B) are shown.  At 
day 0, these were all phosphatidylcholine (PC) species, including: PC (32:0), (34:2), (34:1), 
(36:4), (36:3), (36:2), (38:4), with the one exception being SM (34:1).  The two internal 
standards, PC (12:0/12:0) and TG (18:0/18:0/18:0) were also present.  By day 25, the most 
abundant lipid species present were all TG species, and they were: TG (46:1), (47:2), 
(47:1), (48:2), (48:1), (49:2), (49:1), (50:3), (50:2).  One diglyceride (DG) identification was 
also suggested, which was DG (31:3); however, its mass accuracy (ppm=65.487) fell 
outside of the set parameter of 5ppm, and so this was not certain.   
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Figure 3.6. Positive ion DI-MS analysis of 3T3-L1 cells during adipogenesis 
Representative spectra of 3T3-L1 adipocytes were induced at day 0, and harvested at the following 
time points post-differentiation: 0 (A); 5 (B); 10 (C); 15 (D) and 25 (E). Lipids were extracted from the 
cell samples using a Folch extraction. The lower phase was dried down under nitrogen and 
reconstituted in 600µL chloroform/methanol (2/1, v/v). A 150µL aliquot was removed and had 10mM 
ammonium formate added to it. The samples were then directly infused into an Orbitrap Exactive mass 
spectrometer at a flow rate of 5µL/min for 90 sec (450 scans) in positive ion mode. The m/z range 
analysed was between 100 and 1000Da, and the current figure represents m/z between 450 and 
950Da. A clear shift in the global lipid profiles was seen, with a few peaks with m/z between 700 and 
850Da being observed at day 0. In the remaining time points, more peaks were present, and these 
were mainly seen at m/z 400-500 and 750-900Da. 
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Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification  
 
(A) Day 0  
622.4436       622.4442  -0.964    [M+H]
+  
       C32H64NO8P               PC (24:0) 
703.5744       703.5748  0.569    [M+H]
+  
       C39H79N2O6P               SM (34:1) 
734.5685       734.5694  1.225    [M+H]
+  
       C40H80NO8P               PC (32:0) 
758.5686       758.5694  1.055    [M+H]
+
           C42H80NO8P               PC (34:2) 
760.5843       760.5850  0.920    [M+H]
+
           C42H82NO8P               PC (34:1) 
782. 5683       782.5694  1.406    [M+H]
+
         C44H80NO8P               PC (36:4) 
784. 5826       784.5851  -3.186    [M+H]
+
         C44H82NO8P               PC (36:3) 
786.5997       786.6007  1.271    [M+H]
+
         C44H84NO8P               PC (36:2) 
810.5991       810.6007  1.974    [M+H]
+ 
      C46H84NO8P               PC (38:4) 
908.8629  908.8641  -1.320    [M+NH4]
+
 C57H110O6   TG (54:0) 
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(B) Day 25  
549.4872       549.4513  65.487    [M+NH4]
+ 
      C34H60O5                DG (31:3) 
794.7225       794.7232  -0.881    [M+NH4]
+ 
      C49H92O6                TG (46:1) 
806.7233       806.7232  0.124    [M+NH4]
+ 
      C50H92O6                TG (47:2) 
808.7378       808.7388  1.484    [M+NH4]
+ 
      C50H94O6                TG (47:1) 
820.7379       820.7389  1.097    [M+NH4]
+ 
      C51H94O6                TG (48:2) 
822.7532       822.7545  1.580    [M+NH4]
+
       C51H96O6                TG (48:1) 
834.7583       834.7545  4.552    [M+NH4]
+
       C52H96O6                TG (49:2) 
836.7682       836.7702  1.767    [M+NH4]
+
       C52H98O6                TG (49:1) 
846.7536       846.7545  1.063    [M+NH4]
+
       C53H96O6                TG (50:3) 
848.7686       848.7701  -1.767    [M+NH4]
+
       C53H98O6                TG (50:2) 
 
Table 3.1. Identifications of selected positive ions from 3T3-L1 cells at day 0 and 25 post-differentiation 
Abbreviations used: DG, diglyceride; PC, phosphatidylcholine; SM, sphingomyelin; TG, triglyceride  
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These identified lipid species from Table 3.1 were quantified using the relevant internal 
standard, either PC (12:0/12:0) with m/z 622.4436 or TG (18:0/18:0/18:0) at m/z 
908.8629, and then normalised to the protein content of the sample.  The top two 
concentrated species from day 0 and the top three from day 25 post-differentiation were 
chosen, and presented graphically in Figure 3.7.  The two selected from day 0 had m/z 
760.5843 and 782.5683, and were identified as PC (34:1) and PC (36:4), respectively.  Their 
concentration was greatest between days 0 and 2 post-differentiation.  By day 3, their 
concentration decreased and remained at a lesser concentration in the rest of the time 
points (P<0.01 for both; 2-sided).  At day 7, three TG species (48:2, 49:2 and 50:2) were 
the most concentrated in the samples, and their concentration continued to increase 
throughout the remainder of the time course (P<0.0001 for all; 2 sided). 
 
3.4.1.2. Negative ion DI-MS analysis 
The number of lipid species detected in negative ion mode (Figure 3.8) was less than that 
in positive ion mode, and fewer changes were observed across the course of 
differentiation.  At day 0, the most abundant lipid species present had m/z between 250 
and 350Da, in particular 311.17, 325.18 and 339.19.  These peaks were thought to relate 
to linear alkylbenzenesulfonates (Andreu and Pico, 2004), which are commonly used as 
surfactants in detergents, and therefore contaminants.  Due to this, these ions were 
excluded from all data analysis.   
 
The profiles for days 5, 10 and 15 post-differentiation were all the same in regards to the 
m/z of the top three most abundant species, which were: 253.2175, 281.2488 and 
303.2331.  These were identified as the fatty acids C16:1, C18:1 and C20:4, respectively.  
At day 25, these three lipids were still present, along with another species with m/z 
301.2176, which was the most concentrated at this time point, and identified as C20:5.  
  
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Concentration of individual lipid species during adipogenesis of 3T3-L1 cells from positive ion DI-MS analysis 
3T3-L1 cells were induced to differentiate at day 0, and harvested at the following time points:  0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted from the cell samples 
using a Folch extraction.  The lower phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 150µL aliquot was removed and 
had 10mM ammonium formate added to it.  The samples were then directly infused into an Orbitrap Exactive mass spectrometer at a flow rate of 5µL/min for 90 sec (450 
scans) in positive ion mode. 
 
The selected phospholipid species were quantified using the PC internal standard, PC (12:0/12:0) with m/z 622.4443; and TG species using TG (18:0/18:0/18:0) at m/z 
908.86.  The selected lipids are shown in the key, and for each time point, n=3, with results represented as median ± range.  The concentration of the two phospholipid 
species was the greatest in the pre-adipocytes (days 0-6 post-differentiation).  By day 7, the three triglycerides were the most concentrated.  A Cuzick’s 2-sided trend test 
was applied to each lipid species over the time course, and P=0.0009 and 0.0024 for PC (34:1) and PC (36:4), respectively.  For the TG species, P<0.0001 for all.
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Figure 3.8. Negative ion DI-MS  analysis of 3T3-L1 cells during adipogenesis  
Representative spectra of 3T3-L1 adipocytes were induced at day 0, and harvested at the following 
time points post-differentiation:  0 (A), 7 (B), 15 (C) and 25 (D). Lipids were extracted from the cell 
samples using a Folch extraction. The lower phase was dried down under nitrogen and reconstituted in 
600µL chloroform/methanol (2/1, v/v). A 150µL aliquot was removed and had 10mM ammonium 
formate added to it. The samples were then directly infused into an Orbitrap Exactive mass 
spectrometer at a flow rate of 5µL/min for 90 sec (450 scans) in negative ion mode. The m/z range 
analysed was from 100-1000Da, and the current figure represents 200 to 900Da. The most abundant 
ions present in all spectra (not including the contaminant peaks) had m/z 281.2488 and 303.2331. 
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The identifications of these and other lipid species are presented in Table 3.2.  As with 
positive ion mode, the top ten abundant peaks from day 0 (A) and day 25 (B) post-
differentiation are presented.  At day 0, the lipids present were mainly phospholipids, 
including phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol, 
phosphatidylinositol (PI) and phosphatidylserine (PS) species.  At day 25, the majority were 
fatty acids, with one PS species and four of the species present in the top 10 at day 0 were 
also seen in this final time point.  
 
These species were quantified using the internal standard PC (12:0/12:0) with m/z 666.4443, 
and then normalised to the protein content of the sample.  Five of the most concentrated 
lipid species present in all time points were selected, and presented graphically in Figure 3.9.  
These chosen lipid species had m/z 281.2488, 303.2331, 747.5673, 804.5769 and 885.5515, 
and were identified as C18:1, C20:4, phosphatidylglycerol (O-35:1)/(P-35:0), PC (38:6) and PI 
(38:4), respectively. All were confident identifications, with the exception of 
phosphatidylglycerol (O-35:1)/(P-35:0) and PC (38:6) due to their mass accuracy being outside 
the set parameter (ppm=16.989 and 27.344, respectively).   The concentration of the fatty 
acids C18:1 and C20:4 fluctuated throughout the time course, whereas that of 
phosphatidylglycerol (O-35:1)/ (P-35:0), PC (38:6) and PI (38:4) decreased from day 3 post-
differentiation until the end of the time course, with this trend being significant in the last 
two (P<0.001 for both). 
 
 
Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification 
(A) Day 0 
281.2488       281.2486  0.711    [M-H]
-         
    C18H34O2    C18:1 
303.2331       303.2330  0.330    [M-H]
-
          C20H32O2    C20:4 
 
722.5145       722.5130  2.076    [M-H]
- 
         C41H74NO7P   PC (P-36:4) 
                PC (O-36:5) 
747.5673       747.5546  16.989    [M-H]
-
          C41H81O9P   phosphatidylglycerol (O-35:1) 
                phosphatidylglycerol (P-35:0) 
748.5313       748.5287  3.473    [M-H]
-
          C43H76NO7P   PE (P-38:5) 
                PE (O-37:6) 
750.5442       750.5079  48.367    [M-H]
-
          C4H74NO8P   PC (34:5) 
802.5618       802.5392  28.161    [M-H]
-
          C46H78NO8P   PC (38:7) 
804.5769       804.5549  27.344    [M-H]
-
          C46H80NO8P   PC (38:6) 
830.5933       830.5917  1.926    [M-H]
-
          C45HNO10P   PS (39:1) 
885.5515       885.5499  1.807    [M-H]
-
          C47H83O13P   PI (38:4) 
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(A) Day 25 
253.2175       253.2173  0.790    [M-H]
- 
         C16H30O2    C16:1 
255.2332       255.2330  0.783    [M-H]
- 
         C16H32O2    C16:0 
267.2330       267.2330  1.123    [M-H]
- 
         C17H32O2    C17:1 
279.2330       279.2330  0    [M-H]
- 
         C18H32O2    C18:2 
301.2176       301.2173  0.996    [M-H]
-
          C20H30O2   C20:5 
 776.5477       776.5447  3.863    [M-H]
-
          C41H80NO10P   PS (35:0) 
 
 
Table 3.2. Identifications of selected negative ions from 3T3-L1 cells at day 0 and 25 post-differentiation 
Abbreviations used: DG, diglyceride; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phoshatidylserine; ppm, parts per million 
Underlined species are present in both day 0 and 25. 
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Figure 3.9. Concentration of individual lipid species during adipogenesis of 3T3-L1 cells from negative ion DI-MS analysis  
3T3-L1 cells were induced to differentiate at day 0, and harvested at the following time points:  0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted from the cell samples 
using a Folch extraction.  The lower phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 150µL aliquot was removed and 
had 10mM ammonium formate added to it.  The samples were then directly infused into an Orbitrap Exactive  mass spectrometer at a flow rate of 5µL/min for 90 sec (450 
scans) in negative ion mode. 
 
The selected species were quantified using the internal standard, PC (12:0/12:0) with m/z 666.4443; and then to the protein concentration of the cell sample.  The selected 
lipids are shown in the key.  The fatty acids C18:1 and C20:4 were the most concentrated species present at each time point, and this fluctuated over the course of 
differentiation.  The concentration of the remaining lipids decreased from day 3 post-differentiation onwards.  A Cuzick’s 2-sided trend test was applied to each lipid 
species, and the trend seen in PC (38:6) and PI (38:4) was significant (P<0.001 for both).  For this figure only, PG represents phosphatidylglycerol. 
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3.4.2. Positive ion LC-MS analysis 
Representative chromatograms of days 0, 5, 10 and 25 post-differentiation are shown in 
Figure 3.10.  A few peaks were identified on the day 0 chromatogram, and these all had a 
retention time (RT) between 5 and 8 min.  The lipid profiles in the chromatograms from day 5 
post-differentiation onwards were all similar, with a greater number of peaks being observed.  
All of these peaks were in the RT region between 5 and 9.5 min.  At day 25 post-
differentiation, the relative abundance of peaks with RT between 4.5 and 6.5 min decreased.  
The most abundant ions associated with these chromatographic peaks are identified in Table 
3.3.  The majority had a mass accuracy that was much greater than 5ppm, and so were not 
confident identifications.  
 
Multivariate data analysis (MVDA) was used to analyse the positive ion LC-MS data, starting 
with principal component analysis (PCA).  The PCA scores plots of principal component 1 vs. 
principal component 2 for the raw data (not normalised) and that which had been normalised 
to the TIC are presented in Figure 3.11.  Three RT windows were investigated, as indicated in 
the figure.  The sample data were interpreted as being split into three main groups with all RT 
windows, and these were: days 0-2, 3-12 and 15-25.  In all PCA plots, the QCs were located 
either on, or outside of the ellipse, which is based on Hotelling’s T2 95% tolerance, and 
observations outside of this ellipse are considered to be outliers.  Tighter clustering of the 
data points was observed with all RT windows when the data were normalised to the TIC 
before MVDA.  When the RT window was set at 1 min, the R2 and Q2 of the models were: 
0.773 and 0.635 for the non-normalised data; and 0.778 and 0.64, for the TIC-normalised 
data, respectively.  With the 30 sec RT window, the R2 and Q2 were: 0.767 and 0.604; and 
0.738 and 0.582 for the non- and TIC-normalised data, respectively.  Finally, when the RT 
window was narrowed to 15 sec, these values were: 0.694 and 0.527 for the non-normalised 
data, and for the TIC-normalised data they were 0.677 and 0.503, respectively.   
 
Loadings plots were also produced for all of the PCA plots, and were labelled by m/z, as seen 
in Figure 3.12.  The plots were all similar, and various points were possible causes of variance 
between the chromatograms due to their distance from the origin.  Out of these points, those 
that could be identified were all located on the left hand side (LHS) of the origin, and were all 
PC species, with one SM.  The individual identifications are presented in Table 3.4.  When 
these points underwent trend analysis; the abundance of all species increased until between 
day 5 and 7 post-differentiation, where it then either plateaued, or gradually decreased until 
the end of the time course.   
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Figure 3.10. Positive ion LC-MS analysis of 3T3-L1 cells during adipogenesis 
Representative chromatograms of 3T3-L1 adipocytes, which had been  induced at day 0 and harvested 
at the following time points post-differentiation:  0 (A); 5 (B); 10 (C); 15(D) and 25 (E).  Lipids were 
extracted from the cell samples using a Folch extraction.  The lower phase was dried down under 
nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  The samples were analysed by 
LC-MS in positive ion mode over 18 min for a scan range of 100 – 1000 m/z.  The presented 
chromatograms show RT between 2 and 10 min.  An increase in the abundance of lipids with RT 
between 7 and 8.5 min was seen at the following time points: 10, 15 and 25. 
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(D) 
RT: 1.98 - 10.05
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Day 0 
Day 25 
Day 10 
Day 5 
Retention time (min) Ion mass Theoretical mass  Δ Mass accuracy (ppm) Ion  Empirical composition  Identification 
Day 0 
5.36   703.5745 703.5748  -0.426   [M+H]
+
  C39H79N2O2P   SM (34:1) 
5.43   758.5694 758.5694  0   [M+H]
+
  C42H80NO8P   PC (34:2) 
5.61   610.1841 610.1681  26.222   [M+H]
+
  C31H29O13 
5.80   760.5843 760.5850  -0.920   [M+H]
+
           C42H82NO8P               PC (34:1) 
 6.02   684.2031 684.2134  -15.054   [M+H]+  C30H38NO17  
6.49   758.2222 758.2264  -5.539   [M+H]
+ 
 C33H41O20 
6.91   832.2401 832.2420  -2.283   [M+H]
+ 
 C39H43O20 
7.28   906.2610 
7.64   980.2786 
9.94   908.8651 908.8640  1.210   [M+NH4]
+
 C57H110O6   TG (54:0) 
 
Day 25 
5.32   610.1833 610.1681  24.911   [M+H]
+
  C31H29O13 
5.70   684.2025 684.2134  -15.931   [M+H]+  C30H38NO17 
6.12   758.225  758.2264  -5.144   [M+H]
+ 
 C33H41O20 
6.52   832.2403 832.2420  -2.043   [M+H]
+ 
 C39H43O20 
6.88   906.2597  
1
4
2
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7.05   776.6769 776.6768  0.129   [M+NH4]+ C48H86O6    TG (45:3) 
7.21   790.6920 790.6919  0.126   [M+NH4]+ C49H88O6    TG (46:3) 
7.36   778.6920 778.6919  0.128   [M+NH4]+ C48H88O6    TG (45:2) 
7.49   792.7076 792.7076  0   [M+NH4]+ C49H90O6    TG (46:2) 
7.63   806.7228 806.7232  -0.496   [M+NH4]+ C50H92O6    TG (47:2) 
7.76   820.7385  820.7389  -0.487    [M+NH4]
+ 
      C51H98O6                TG (48:2) 
7.88   834.7541 834.7545  -0.479    [M+NH4]
+
       C52H96O6                TG (49:2) 
 8.00   848.7694 848.7701  -0.825    [M+NH4]
+
       C53H98O6                TG (50:2) 
8.12   862.7851 862.7858  -0.811   [M+NH4]
+
       C54H100O6                TG (51:2) 
8.25   876.8011 876.8014  -0.342   [M+NH4]
+
       C55H102O6                TG (52:2) 
8.35   890.8167 890.8171  -0.449   [M+NH4]
+
       C56H104O6                TG (53:2) 
8.50   904.8323 904.8327  -0.442   [M+NH4]
+
       C57H106O6                TG (54:2) 
9.08   908.8654 908.8640     [M+NH4]
+
 C57H110O6   TG (54:0) 
 
Table 3.3.  Retention times and associated abundant ion mass of each major chromatographic peak from positive ion LC-MS analysis of 3T3-L1 cells during adipogenesis 
Red highlight indicates internal standard
1
4
3
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Figure 3.11. PCA scores plots representing positive ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis 
3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase was analysed by LC-MS in positive ion mode, and the data was processed using SIEVE.  The 
data represented here have been Pareto scaled, and the RT window was set at either 1min, 30sec or 
15sec.  Either the raw data or data which were normalised to the total ion current were analysed.  
Each time point consisted of three biological replicates.  The panels represent: 1min RT window, no-
norm (A); 1min RT window, TIC norm (B); 30sec RT window, no-norm (C); 30sec RT window, TIC-norm 
(D); 15sec RT window, no-norm  (E) and 15sec RT window, TIC-norm (F).  
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Figure 3.12. PCA loadings plots representing positive ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis  
3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase was analysed by LC-MS in positive ion mode. Before multivariate data analysis, the data 
was processed using SIEVE.  The data represented here have been Pareto scaled, and the RT window 
was set at either 1min, 30sec or 15sec.  Either the raw data or data which were normalised to the total 
ion current were analysed.  Each time point consisted of three biological replicates.  The panels 
represent: 1min RT window, no-norm (A); 1min RT window, TIC-norm (B); 30sec RT window, no-norm 
(C); 30sec RT window, TIC-norm (D); 15sec RT window, no-norm (E) and 15sec RT window, TIC-norm. 
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SIMCA-P+ 12.0.1 - 2012-06-20 00:04:54 (UTC+0) 
(E) (E) 
Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification  
703.5750       703.5748  0.284    [M+H]
+  
       C39H79N2O6P               SM (34:1) 
718.5390       718.5381  1.253    [M+H]
+  
       C39H76NO8P               PC (31:1) 
720.5650       720.5538  15.544    [M+H]
+  
       C39H78NO8P               PC (31:0) 
732.5550     732.5538  1.638    [M+H]
+
           C40H78NO8P               PC (32:1) 
744.5530       744.5538  -1.074    [M+H]
+
           C41H78NO8P               PC (33:2) 
746.5700       746.5694  0.804    [M+H]
+
           C41H80NO8P               PC (33:1) 
760.5850       760.5850  0    [M+H]
+
           C42H82NO8P               PC (34:1) 
756. 5540       756.5538  0.264    [M+H]
+
         C42H78NO8P               PC (34:4) 
786.6000       786.6007  -0.890    [M+H]
+
         C44H84NO8P               PC (36:2) 
786.5997       786.6007  -1.271    [M+H]
+
         C44H84NO8P               PC (36:2) 
 
Table 3.4. Lipid species identified as causes of variance from positive ion PCA and PLS loadings plots 
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4
6
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The next step involved a supervised technique called partial least squares (PLS).  The 
scores plots of the models for all three RT windows are presented in Figure 3.13.  As with 
the PCA data in Figure 3.11, all PLS plots were seen to have three major groupings of data 
points.  These groupings were much clearer than those in the PCA models, especially with 
the 15 sec RT window, as the data points were clustered tightly within the groups, and 
gaps were seen on the plot between the three groups.  The QCs were still situated outside 
of the 95% tolerance region for all plots in the figure.  For the 1 min RT window, the R2X, 
R2Y and Q2 values were: 0.502, 0.925 and 0.849 for the non-normalised data, and 0.529, 
0.912 and 0.85 for the TIC-normalised data, respectively. 
 
At the 30sec RT window, the TIC-normalised model (D) had one point situated outside of 
the 95% tolerance region, and so may be considered an outlier.  This point related to one 
of the day 22 post-differentiation samples.  The R2X, R2Y and Q2 for the 30sec RT window 
data were: 0.578, 0.982 and 0.9 for the non-normalised data, and for the TIC-normalised 
data these were: 0.498, 0.963 and 0.897.  For the 15 sec RT window dataset, these values 
were: 0.471, 0.968 and 0.833 for the non-normalised data, and 0.498, 0.963 and 0.897 for 
the TIC-normalised data, respectively. 
 
The loadings plots for the positive ion PLS models are shown in Figure 3.14.  The points of 
interest were comparable between the different RT windows, and normalisation 
conditions, and were also similar to those seen in the PCA loadings plots.  The individual 
identifications of the points of interest are, therefore, also found in Table 3.4 and, as 
mentioned above, were all phospholipid species.  Although they were located in different 
areas of the loadings plots for each model, trend analysis showed that the relative 
abundance of these species behaved in a similar manner to those seen with PCA analysis.  
An increase was observed from at least day 12 post-differentiation which, after a 
continued increase for a few time points in some species, either plateaued or slightly 
decreased towards the end of the time course.   
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Figure 3.13. PLS scores plots representing positive ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis  
 3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase was analysed by LC-MS in positive ion mode. Before multivariate data analysis, the data 
was processed using SIEVE.  The data represented here have been Pareto scaled, and the RT window 
was set at either 1min, 30sec or 15sec.  Either the raw data or that normalised to the total ion current 
were analysed.  Each time point consisted of three biological replicates.  The panels represent: 1min RT 
window, no-norm (A); 1min RT window, TIC norm (B); 30sec RT window, no-norm (C); 30sec RT 
window, TIC-norm (D); 15sec RT window, no-norm  (E) and 15sec RT window, TIC-norm. 
-12000
-10000
-8000
-6000
-4000
-2000
0
2000
4000
6000
8000
10000
12000
14000
16000
-12000 -10000 -8000 -6000 -4000 -2000 0 2000 4000 6000 8000 10000 12000
t[
2
]
t[1]
R2X[1] = 0.161276            R2X[2] = 0.112653            
Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2012-10-08 22:51:32 (UTC+0) 
-18000
-16000
-14000
-12000
-10000
-8000
-6000
-4000
-2000
0
2000
4000
6000
8000
10000
12000
-14000 -12000 -10000 -8000 -6000 -4000 -2000 0 2000 4000 6000 8000 10000 12000 14000
t[
2
]
t[1]
R2X[1] = 0.174014            R2X[2] = 0.172334            
Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2012-10-08 22:33:11 (UTC+0) 
(F) (E) 
-18000
-16000
-14000
-12000
-10000
-8000
-6000
-4000
-2000
0
2000
4000
6000
8000
10000
12000
-14000 -12000 -10000 -8000 -6000 -4000 -2000 0 2000 4000 6000 8000 10000 12000 14000
t[
2
]
t[1]
R2X[1] = 0.21091             R2X[2] = 0.183902            
Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2012-12-07 12:14:35 (UTC+0) 
(C) 
-80
-70
-60
-50
-40
-30
-20
-10
0
10
20
30
40
50
-70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70
t[
2
]
t[1]
R2X[1] = 0.193888            R2X[2] = 0.114212            Ellipse: Hotelling T2 (0.95) 
SIMCA-P+ 12.0.1 - 2012-12-07 12:54:15 (UTC+0) 
(D) 
-20000
-18000
-16000
-14000
-12000
-10000
-8000
-6000
-4000
-2000
0
2000
4000
6000
8000
10000
12000
-12000 -10000 -8000 -6000 -4000 -2000 0 2000 4000 6000 8000 10000 12000
t[
2
]
t[1]
R2X[1] = 0.214389            R2X[2] = 0.212302            
Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2012-12-07 11:45:29 (UTC+0) 
-20000
-18000
-16000
-14000
-12000
-10000
-8000
-6000
-4000
-2000
0
2000
4000
6000
8000
10000
12000
14000
-14000 -12000 -10000 -8000 -6000 -4000 -2000 0 2000 4000 6000 8000 10000 12000 14000
t[
2
]
t[1]
R2X[1] = 0.229699            R2X[2] = 0.215785            
Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2012-12-07 11:57:25 (UTC+0) 
(A) (B) 
Key: (day post-differentiation) 
0-2 
QC 
15-18 
3-12 
149 
 
-0.18
-0.16
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
-0.00
0.02
0.04
0.06
0.08
0.10
-0.15 -0.14 -0.13 -0.12 -0.11 -0.10 -0.09 -0.08 -0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10 0.11
w
*
c
[
2
]
w *c[1]
R2X[1] = 0.229699 R2X[2] = 0.215785 
X
Y
684.203
758.222
685.204
536.165
622.445
759.223
906.26
980.279
686.202
981.279
832.241907.26
82.277
760.221
908.258
610.185
833. 42
760.586
730.539
834.24
537.166
758.57
908.864
718.539
908.865
786.6
983.277
780.553
732.554
538.163
746.571
703.576
611.185
766.539
909.258
744.553
782.569
810.601
756.554
909.868
761.22
687.201
902.817
623.448
909.868
168.123
908.865
784.585
835.239
612.183
908.865
654.567
864.802
761.589
862.786
806.569
496.339
759.573
874.787
731.542
668.583
984.275
734.571
818.724
788.616
151.097
719.542
787.604
640.552
834.755874.786
904.834
439.339
876.802
890.817
903.82
808.586
781.557
704.523
778.6 3
902.818
846.755
909.868
878.818
910.256
720.555
680.583
792.709
173.079876.802
304.3
811.604
750.661776.676
783.573
806.724
767.542
706.539
804. 08
747.574
909.868
666.567
772.586
733.557
682.598
742.539
848.772
524.371
704.579
757.557
745.557
834.754
626.215
862.786
865.805
850.786
836.77
863.789
5. 9
478.41
816.708
626.536652.551
848.771
768.554
790.693
762.218
376.176
785.589
764.677
820.74
836.237
834.756
875.789
905.836878.818
877.805
819.728
807.572
812.654
891.82
903.821
537.396
768.554
794.57
2. 1
835.758
808.739
539.163
842.724
89.56
774.601
860. 7
224.186
772.274698.256688.199
47.75
694.5999. 21
808.739
864.802
910.871
832.739
838.787
778.693
655.57
806.724
750.544859.252
740.64
359.1
877.805
498.4
696.615
789.62
933.269
790.692
95.124
754.538
930 49528.411
434.384
659.522
552.197
736.646
804.708
809.589
10.871
06
792.554
669.58
613.182
645.507
793.712
519.139
779.696
525 2.426
830.7 4863.788
849.775
985.275
36 71
735.574
72. 37
777.679
807.727
522 43680 11
722.63
627.216
31.491
482.324
33
675.544
851.79
700.235
701.56
934.269
773.274
641.555
835.758
189.053
20 39
656.583
802.692
708. 14
837.7 4
872.77
860 52
766.574
522.3
751.664
849.7 5
817.712
586.4534 4. 84
813.65983. 65
858.755
780.708
642.568
8 8
371.101
791.696
46 4
716.522
748.645
6 8.5 1
207.159
311.294
721.557
628.195
6 . 56
2 . 43
705.526
673.538
773.589
832.739
850.786
846.755
879.822
888.801
788.617
93 .268
461.384
866.723
835.7598 1.773
820.74
0 .
8 1.251 616.463
743.542
770.57
18
657.506
724.646
683.602860.77
843.727
464.358
774.272785.232
778.538
644.427
911.256
902.576
381.132
822. 55
411.3 6
788.677
60. 71
724.529
765.68
667.5711.5 5
846.29
809.742
671.522
814. 92
707.542
638.234449 366 8.214
769.557
49 6
794.605
497.343
63. 4
748. 29
94.324
118.086
17. 57
762.592
900. 02
782.568
291.25
7630. 79
833.742
554.175
900. 02
740.521
9 . 4
839.79
624.451
731.606
930.848
809.742
722.513 795.573
904.833
760.576
371. 01
764.523
7
6 .693
5 . 74
653.55
746.571
22. 56
792.708
627.539
807.72
748.585
701.2 5
700.254
779.696
752.67
796.584
848.77
847.294305. 69
6
805 711
503.108
710.629
17
91.696
7 .
68 . 37
82 .708
769.557
916.833
692.523
775.604
60. 9
4 0.342
837.7 3
7 .708
831.727
437.32
3553.19
788.606
874.787
4 0. 58
840.707
752.52
81 .724
7 .
687.553
751.547
4 .739
910.871
913.81
8 .802
408. 09
90 .592
720.544
74 .643
6. 7
56.739
786.232 695.602
836.61
906.849
878.818
6 9
821.742
859.7 8
788.676
62
510.355
701.569
793.557
808.582
813.682
690.56350. 79559.13 750.50774.505
70.755
812.607
7. 1
847.758
73 .649
5 .
7 4.724
670.598
824.771
866.808
738.661
05.59
47 7
889.804
1105.042
335.28848. 92
742.538
614. 6525.374810.7
349.2 5
766.538
612. 2
844.74
867.726
901.804
803.695
485.112 2 1
794.57
2 . 56
7 .664
892.833
8 1.7
78
714.507
913.82
851.789
734.629702.2336 9. 9
764.558
861.774
678.506
781.711
936.267
479.413837.236 27 378
85 .5683 . 42
520.139
723.633
813.685
6 0.52901.805
931.851
70 .6 6
341.109 64 .51782.723
688. 92
906. 39
784.575
70.3 9
746.606
746.559
8 .74
23 .15
633.506
640.551
79 . 24
767.578
. 166 42 74 .648301.141904.823
70. 5
823.759
802.535
763.217
905.836
755.61
9
716.523
94.72
38 .277
782. 232
787.23
734.56
7 .
73 .50
05.303
531.408
8 3.6
02.563
8
171.149
725.649
672.185 781.6 1
5 8.399
1 .
748.575
832.582
47.523
632. 94
752.559
39 293
47.131
932.86
718.539
758.559
228 667 .639.235
. 46
89.68
7 3.647
815.695
8 8.69
706.598
907.772
167.013
804.551
824.771
9 . 36
789.62
12. 53 678.
396.332
554.195
86 .25
913.82
86 .7 9
67.742
283.2 2
903.579
18.849
2
823.759
8 0.824
129. 0
657.586
795.608
624.519
566.462
680 481
56 . 1 7 111
889.805
231. 84
779.542
520.418
661.538
676.547
63 54
49 74
804.554
7 2.6
643.571
986.2 808.212.15
817.61
8 4.792
674.541
752.67
2 6.952
879.742
839.71
717. 91
780.552
29.554
610.2
51 1
395. 13
97.664
5 . 53
7.475
771.573
732.544
775. 2
560.502
9 .755
914.823
629.475
5 .
689.197
829. 11
99.554
630.1 3
852. 08
1 67 75. 9
8. 2
151.096
7
25.532
792.591
.28
619.4 15 5
2 4
717. 26
67.616
879.741
749.532
553.39
1.264
907.852
79. 21
904.8
79 .712
845. 43
79 .648
701.5 9841. 11
778.535
6 2.583638.535
8 8.69809 63
102. 28
3 2. 95 3.79
70 4967. 969 .4
58.88
8 8.808 82 . 93
. 4
785
8 4. 23
2.3 67 4
666.567
6. 2.453
377.18
19. 6
904.824
.4
1 .
7 . 6
1 758
720.614
90.623
494. 05
2.72
83.571
725.557
23
614.18
672.52
11
765.526
9
769.6 3
.
914.823
864.79
540.159 7 61
3 3
9 .5 8
5 .3 6 795.628
848.761
742.575
845. 43
8 .79
74 .6017
898. 86
821.663
5 . 5
37.619
727.5 537 101 1 1 8
3 1. 58
53. 7 4.661 69.248 664.58 4
3 491
8 3
828.55
723.516
299.18367 0
397.106
732.554
.632
43 .38
6 . 42
907.773
741.524
2 7.1 5
612.52
749.589
8 6.792
3 2
3 1 298
789.68
7 . 6795.6
747.573
1.036 36
226.952
69. 57
686.5 1
820.73
900.803
838.77
521.136
0
905.596
98 .911
9081 558
722.63
.8 2 815.698
603.467 5. 27
.6 2
8 0.755
0 .254
880.825
730.538
1
523.35
811 75
83.648
754.536
429.0
226. 52
8 .663
233.915
2 . 59
32.44
690.507
386. 02
2
560.
906.848
151.096
3 .7 9
6 .573
5 . 119 67
54 .34
2 1
645.42
173.079
. 4
675.496
563.164
629. 1 . 98
809.585
61 .1
786.591
881.757
4 69
768.59
852.802227.07
5 . 5
504.10
53 .
173.079
847. 79
920. 12 09.788
67 . 60
890.818
73
810.59
8 .7583 7.29
3 .7
4 .0 9
229.141
71. 58
25 695
911.874
79 . 4
7 6.5 2
13 .05. 27
9. 91
53.524
2 9.159
84 . 255 924 8
78 .559
6.771
83. 27
463. 3
360.153
8 9.741
739.66
53.72
919.852
669. 04 0.30
702 7 8. 57
485 8
840. 08
9.
7 6.577
515.414
911.874
93 2
84.77
9 3.868
753.60.2
914.823
39. 11
3 81. 49
32 .3 8912.2 4
04.10
95. 73
8 22
1
173.079
767.541
7 3.727
5. 5
73.7 3. 53
960.89608.776 .15
813.62
720.497
755.61
5 3
98. 04
9 1.31
151.097
5. 28
895.757
800.67
3 6 13
62 87
66 .481
853.727
4.68
3 .21 . 07
5 7
1 . 1
3 .9136. 6
71. 1
880.591
29 278
8. 02
806.567
855.742 87.667
8 . 3 . 3
868.745
173.079
52. 58
79
9.08
830.568
80
814.688
173.079
813.694
9 7. 67
750.543
809.6 3
7 4.492
837.694
6 . 1
445.12
1 .1
864.802
9 6.818
9 4.8
542.324
811.6 9
1 3.05586.785
7 6.5 4
0
8 5 708.496
743.542
783 2
22 . 52
2 . 481 99
959. 83
5
173.079
8 9. 92
668.619
76 .561
744.59
814. 32
8 .1 9
3. 63
.3 . 5
8 0
853.711
45 . 9
6 .
706.594
173.079
. 2
2 . 7 8 8. 13
7 4.52381 .694
7 2. 5922.311 4
51.096
1 12
6. 16.2
.
647.4
6 6
15.51
8 4 7
226. 52
. 371 3.079
607.566
508.34
811.679
790.575
480. 94 .405 3 3
6 803. 38
8. 65
7 .59
2 5 1
3. 6
756.62
7
86. 8
173.079
702.508
38. 44
69. 7
173.079
638. 08
9
788.23
2 .952
40.713
0 8
0.606
8. 4 .32
26.
6 5.519
.52
607.56
9 802
.
173.079
81 . 4
7
790.538
100.112
80.7 6
303.105
.609
932.865
173.079
8 77
58 .402
09.6 7600. 2.
173.079
788.617
880. 44
0 .7
173.079
69 .65
8 .914
898.786
810.598
372 10
94.715
. 2
766.6 4
42 76
2 4. 3 15.5
793.63
48.
41. 6
34.602
753.56
16 . 9
79 .739
8 . 1
52.
5. 471.67
876.791 840.7936 .7
173.079
173.079
2 . 9
812.682
173.079
8 5.554
9 6 81871 .527
226.952
01 05
0
702.544
689.51
641. 55
71 .58549 . 2
744.545
489.14
1 6.044
796.631
642.5 7
798.601
626.535
92. 3
173.079
151.097
66.
752.667
70 3
759.638
12 2
734 4
6 6
4. 15
7 .51
8 . 07. 48
729. 01
88 . 4
4 0.3 9
2 6.952
736.49185 63 866.818
. 4
26.952
4. 4
2.
800. 16
.649
798.668
1
6 .745
1
805.557
9
133.0
15.128
9
838.778
5 7
18.
928.83
698.63
2 07. 01
60 44
173.079
19. 8
7 .6
173.079
2
7 3.5 4
371. 01
4. 5568 .4 6
703.528
329
627 535
2 . 3
37
706.528
7
1.484
84 .
3 .2 8
76 . 0
1 .1 2
5.6 4
2 6.
801.683
687.49
226.952
3 .
34 88
4.
63 .51
5.503
173.079
6 .309
892.823
760.586
86 .24
50 .10 648.
2 .505
7 .
22. 4
753.68
79 6517.669
822.66
20.3
786.6
. 9 768.619
679. 1
818.71
2 .12
719.541
664. 5
958.88
69 846 9
. 36
799.66
08.545
907.852
61
215. 25
8.
7 4.601
783.7 7
. 9
382.1 5
961.89
891.82
6 6.64
7 5. 47
5
151.097
28 59
5
854.723
76 .5 3
5 .4
0
7 6
9.668
70 .
91 .791
0 05.4 5
93 .848
929. 93
226.952
7. 2981.279
73.48
5 5 4
7
980.278
151.097
49.2 3
7
0.57
8 2.76
2. 0890.806 7 .5
173.079
71
79.5
1 2.
9 7 4
770.5 979 64
8. 9
0 .1 2
20 .159
5
505.1 4
792. 9
6.6
6. 3
3. 4
87 56
2 3.
. 9
57 . 0
6 2.542
7 2. 041
573
4 0. 8 . 4
440 .1 7
253.1 8
211.
8 5. 79
69 .53
.
129.102
.
.
4 .2
151. 97 59 7
986.911
793. 3
30 454.6
882. 6
430 2 911. 59
87 56
4 .
874.776
68
812. 6
9 . 7
151.097
64 . 1
81 . 2
.
781.556
9 5.80
550. 29. 9
510.355
2. 8 3.774
838. 3
946.885 .
4 2.14 7
702. 72
39 8
. 1
72 5
728.522
.122 11
4 .682 932.8 4
878.808685. 36
1
28
.
5 . 06
927 821 625.523
288.29
.2 5
151. 97
6 7.57
748.585
838.632
2
721.616749
779. 38
15 .097
693.5
960. 6
4 . 8
0.6
.5 5630.4 8
.66
66 570
8 0 67
4.620.494
70 .5 132. 2
8 3.6 4
90 .8 9
8.
26.6 9 324.84
866. 23
8 1 7 1
1
5. 8
829.
29 4. 9
5 28 35 3 30. 82 8
0 1
7 8 3
.
4 2 5
9 . 95
702.507
7
68.123
167.013
76 . 67
9 . 6
. 3
865.805
714. 72
. 525.333
173. 79
73. 79
612.1 2
716. 59
8.47 . 2
522.5 7
.505
.65
854. 3
6 0.5
766 3
00
909.78 84
6
5.5
151.097
44.
918.849
. 68
.745 9 44.8 4
173.079
. 3
173. 79
771.59
812.61
2.739
17 .07
9 .7 9
151.09
893 7 1
7.084 7
23 6
55.
98 .277
3 .6
.
553.3
6 4.23
2 .
64 . 95
8.5
3. 26
63.
838.6
67 .492
6 .
23.75
6 39
0.
. .850.
5.741
151.097
4. 11. 427 .645
.
0 .582
6 2
7.468 . .
733.557
90 . 5
1
734.
763.6 4
9.6 7
6 55
719
8 28 8
8 5.5 3
6 8 29
8.9 7
8 .
79 3 . 82
43 . 3
4 010 13
707 52
75 . 5
89 . 1
82. 4
86
151.097
8. 51
769.593 1 594
924. 02
81 .6 9
9 .
9
718.5 4
28 .
5.
.55 6 .
7 .
.
64.6
.
38. 1
6 1
959. 82
4
8 6. 8 9 6.9 2
2 3. 9
151.097
1 8.9 4
3 7
9 1.874
8 4.6 8
7 .54
758.57
86 87
565 7
931. 51
9 . 03
81 .6 2
5.66
9. 4
8 4. 84 .1 1
3.
391. 85
5
702.567
.8
.
1 3.
63. 96
91.56
2 8.04
9.41
729.591
8.72862. 7
22.444
9. 0
151.097
904.5 2
7 .08 7.65
731.542
56 1 5
5 8
.4 1
. 0
704.5
151.097
7 1. 48
9 3. 1
8 .725
24
792.5547 0.994. 3
5 4
1.579
7
807.57
789.609
1647555 93 3 98
0 4
.741 .127
. 5
2
0. 07
8
915.8 6
6 .694
6
58
1 572
756.544
8439
3 . 26
5
8 0.7 6
677 51
7 14
5 04
604 463
808 65
6 6
5. 1 64
51.097
1 59 63
867.
756.
70 .5 2
.489
29
4 7.
750.6 1
9 .606
815.635
49 .0
1 .543
59 .14 . 0
1 9
797.588
151.097
7 4.63
. 5
95. 16
6.
66134 9
.576
0
6 .5
9
246. 0
151.0536.166
9 . 5
3 2 848
7 .5 4
96 6
7 .5 1
76.
610.185
5 6
.
692.582
1.5
. 2
1.609
. 7
7 .6 6
811.6 1
09.5
383 3
8 0.824
.731.
75 .5 4
947.883
0
72.68
51.097
7 .
811
587.5 9
755
3 3
. 1
6 .36
745. 4 8 5 7 6
6 4 .
4.074
4 6
.638 7. 63
8 . 6
7 .
625.4
149 0
32.585
3. 5
8.
6 3.
41.
7
96.611
64
7.513
987
79 .
8 .552
0 97
. 5
.90 .7 74
475.
.
5. 04
7.6 5
.1
430. 1
9 88.66 . 7
6 . 5
167.0 3 .
. 8
.
7 .
133
10.5
45.1
9.605
9 . 79
6
196.1
29. 98 . 65
.915
8 . 12
3 1
4 .48
2 .7
35. 0
151.097
15.
9
6 53
9 .88
.
89
9 1.80
9 . 29
.
790.623
930. 7
2
6 2.5
2 4.274
5 38
7 .
7 694
2.48
. 7
99 5
73 4
151.097
734.571
9 .899
0 1 7.
9 .
784.586
400.3 98 .
8 .
00 0
3 9
29. 6
9 . 6.2 . 99
409.331
9 4
227.071
6
932.864
. 1
6 2
.155
. 57 . 67
54
703.571
789.62
.
45.8
7.
41 . 2
9 6 . 7
03.51
7. 6
6 .
6 9.6 2
1. 41
7 .56
3 . 34
81 8
9.611
772.575
56 . 52
1
619. 9
7 6.528
.
.6
. 8
0
26.8 .
5
9167. 13
3 1
23.0 4
0 . 9
9 9.8 2
8. 5 .
1 7.0 3 5.
.
0. 04
3
54 . 3
167.013
786.6 1
5
9. 1
1. 48
36 .1 667
1 3.107
5.
50. 99
.7
6 47
92 .79
603.
. 0 0
537.535
9 . 33
.
0.
8 4
.1
770. 59
. 83
11. 22
167.013
0. 35
913.
983.277
0 . .7
.6
9 .822 .939
.679
05. 6
2 .1
1
9 25 3
.
6 . 5
3 .
00
. 5
8 6
31. 73
429 08
9 .
6 .
88
7 . 29
0 .163
761.589
787.604
5 4 9.
9 3
0
1.2. 3 581 11
806.714
785.579
787.6 9
9 . 9
8 8. 5
.
7 2.621
.. 4
.493.
5
7 16 .
2 71
1.
3
9. 215 5.
. 49
69.
7
1. 4
. 91
28 .
. 1
71 .529
1 .7
.
71 41
1 .1
5
. 08
. 8
06 59 94.28.5
08. 9
2 .4
842.713. 3
. 4
5. 41
70.74
9 17. 17 2
20.5 5
. 1.
61 . 78 59.
906. 5
39 . 5
3
75.497
2 .
5 .
. 29
5. 0
4
2 .635. 48
2 5
1 9
8 .5. 4
0 5
151.09
7
844 7 9
0.
719. 8
1
.55
3 .9
9 .895
184.073
798.
8 9.5 9
09
4
7 .
4 .3 5
1
768.544
355 0 6 .4
9 54
7
76 .5 7
752.521
9 .
72 35
3
3.6 4
9 5
7.63
0 0861
. 5
0. 5
0
4 . 6
1 69 . 411 .6617
0
.9
759.563
7 . 70. 54
. 0 5
0 6789.
8 2 7 8
3 0 .
7. 2
40 5
721.547
8 4
16 .
2 3. 58
9 2. 8
4 .88
8 . 07
.
42 .2 1
. 1
0
. 8
.4 9
6 3. 2
. 12 6
754.6
47
2. 2
5 0 .7
67.0
1 5.
2
9 2.80
446 1
.80
5
.2
40.
846.
8 9. 0906.76
. 45
7 8.59
82. 24
839.6 5
9 6. 64
77 04
. 5
1 .
30.7
8
3. 9
0
.
8
8 3 2
4 . 8
0.651
0 .58
6
4 0
8
91 8 3
98 . 11
.698
5
2
.4 .4 2.
963.
. .
8 8.
4.
8
8 .
730. 716 0 9 . 4
3 2. 47
7 .
5 . 8
8
5.11
99.
.6
.61 7 .5 38 74
.
74 . 2
59 5
81
7 . 7 .5 2
.
6 .16
.
6.
.9
1 .
7 . 4
. 6
.4 9
892.833
49 4
32. 13
. 2
.
7.0 3
7 .
7
3.
. 9
6 4
8.7
.
1. 0
7. 94
2
5 .
5
7 0
82.
.6
.
. 3
6 .
4 .9
6 .2
3 4
56 . 1
0
2 .5
90 . 12
8 .80
5 3
9 .62
4 .
814.682
.9 4
49. 79
94
5
49 146
.
. 66.
7 92
3 .
05.5 .6 9
768.57 .
62 .2
67.01
51
.
7
33 54
947.8831
. 6 3 . 433 . 8
0. 9
. 15
43
.
.
13
5.8
.
5 .
.8 . 0 3
.
44.73
2
342 0
5
86.044
. 7
23
9
1 . 4
82 .
100.0 6
717.56
1.
.8 2
3
5 .
8
.
7 . 1
. 4
61. 4
1 .1
222
9
8 09
3
0
.
54 7
0
4
4 8
. 6
96. 0.
99 251 5
9 . 3
81 . 4
37.
. 4 . 4
6. 44
.
0.0
0 3
8 8. 23
907.852
2.
294. 9
9
158.964
5
36.537
6 .
.
. 27
5 60.3
.
.. 390
. 59
4.
03.7 .1 9.
6.
2 . 1
0
415.12
.22 .0
65 4
9 .
.37
2
8 5. 3
5
. 9
227.07
415. 2 26. 9
14
5 . 9
5 .
0. 44921 6
3
.
95 15
2 4. 3
7 9.572
3
7 . 5
49 33
.
30
2 07123 .91
. 5
6.54
16.5
816 4
27 04
7 . .5 9
6
.6
6
207 5
9.4
.
.
33.867
01. 59
281.1
. 3
.
1. .
24
.
7.
.512
..
1 1.14
20.86
7
5
.0 6
5.
.
7 . 2
740.523
. 8
1 .44.
03
575 0
.
25
48 . 4 6
8 2.63
7 8. 76
7 5 5
6 3
4
2 7
69
5.685
1 .146
195 23
226 5
0 1
8
3 8. 59. 3
8 6
9 3.8 8229.14
49 .
49. 8
7 0.5 4
9
. 9
707.2 . 1 79 3
. 2
.
7 0
28
.
4 5
2 2
7 . 0
610.184 0.5
.5
69
9 23
8 8
. 6
731.602
7 8
1 0
9
. 9 .558
. 86
7 2
876.5
8
144.9 2
73 .6 5
. 38 6 9
. 6
80. 38.
1.
6 4
. 1
2
.
7.
2
. 9
4 7
611.185
95 .8
61 .
6
84
4
0. 8
.
5. 0
. 0
2.7
4 .2
. 2
1
1 .43 4
95 .8
. 4
7 22
2 . 04
MZ
SIMCA-P+ 12.0.1 - 2012-10-08 16:55:44 (UTC+0) 
-0.16
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
-0.00
0.02
0.04
0.06
0.08
0.10
-0.12 -0.11 -0.10 -0.09 -0.08 -0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 -0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10 0.11 0.12 0.13
w
*
c
[
2
]
w *c[1]
R2X[1] = 0.21091  R2X[2] = 0.183902 
X
Y
684.203
758.222
685.204
536.165
622.445
759.223906.26
980.279
686.202
981.279
832.241
907.26
982.277
760.221908.258
610.185
833.242
760.586
730.539
834.24
537.166
758.57
908.864
718.539
908.865
786.6
983.277
780.553
786.599
908.864
732.554
538.163
746.571
908.865703.576
611.185
766.539
909.258
744.553
782.569
810.601
756.554
909.868
760.584
761.22
687.201
780.554
902.817
623.448
909.868
168.123
908.865
810.601
784.585
835.239
612.183
756.553
654.567
864.802
761.589
862.786
806.569
496.339
759.573
909.868
874.787
731.542
668.583
984.275
734.571
909.868
818.724
788.616
151.097
719.542
787.604
640.552834.755
874.786
904.834
439.339
876.802
744.554
908.865
890.817
3. 2
808.586
781.557
806.569
704.523
778.693902.81846. 55
902.817
787.603
909.868878.818
910.256
718.539
720.555
680.583
792.70973. 79
876.802
304.3
811.604
750.661
776.676
783.573
806.724 767.542
706.539
804.708
788.616
747.574
750.6 1
666.567
772.586
733.557
6 2.598
742.539
848.772
524.371
704.579
904.833
757.557
745.557
834.754626.215
862.786
865.805
850.786
761.5 8
836.77
811.604
863. 89
781.557
875.79
478.41
816.708
626.53
776.676
652.551
734.57848.771
768.554
790.693
86 . 02
762.218
376.176
785.589 764.677
20. 4
173.078
836.237
834 756 909.869875. 8981 .723
905.836
790.692
878.818
87 .805
819.728
807.572
812.654
806.72
891.82
764.677903.82
903. 21
768.554
537.396
730.538
794.57
762.661
835.758
757.556
808.739
539.163
842.724
689.56
890. 18
774.601
60. 7
224.186
772.274698.256 846.755
792.708
688.199
84 .758
694.599
21
8. 39 864. 02
910.871
32.739
838.7
77 .693
655.57
8 6.724
750.544
859.252
740.64
359.15
877.805 49 .4
696.615
8 6.802
789.62
933. 69
195.124
754.538
30 49
74.601
528.411 434.384 659.522
552.197
736.646
905.835804.708
809.589910.871
6. 5
792.554
6 . 86
613.182
832.739
78.
792.708
762.661
45.507
793 712
519.139
779.6 6
778.693
5 2. 26
830.724
812.655
807.573
3 8
849.7985.275 20. 1
8 6. 71
735.574
72. 37
7 .679
80 .727
745.557
522 4305.711
722.63
627.216
31.4 1
482.324
930.849
33
675.544
851.79
700.235
701.56
736.646
934.269
773.274
641.555151.096
8 5.758
189.053
20 39
736.64
656.583
802.692
708. 1
7. 74
6 06
872.77
860.252
782.57
66.5 4
75 . 1
22.355
1 4
751.6
6 .66184 .775
817.712
586.4534 4. 84
813.659
483.365
85 .755780.708
642.568
908.865
7 9.62
8 86
536.165
371.101
7 1.696
846. 54
716.522
748.645
628.551207. 9
311 294
721.557
719.543
76. 779 0.871
6 19599.256
21. 43
705.526
673.538
773.589891.821
32 739850.786
879.822
7.
888.801
935. 68
61. 84
819.726
866.723
835. 5961. 73
910.871
808.739
861.251
61 . 63
743.542
770.57
6 7.506
724.646
683.602
860.77
843.727
4 4.3
791.696
774.272
785.232
778.538
644.427
911.256
902.576
381.132
822.755 41 .306
788.677
6 . 7
47.75807. 26
744.554
724.5297 5.68
816.708
667.571
1 5
846.293 09.742
760.585
8 2. 2
671.522
81 . 92
707.542
63 .234628.214
769.557
4 9 36
794.605
780. 8
906.848
497.343
877.805
656.5 3
830.723
818. 23
784.585
763.664
765.681
748.529
494.324
812.655
118.0 17. 57
762.592
900. 0
782.568
36 771
91 2 3630 79
696.614
814.692
.742
786.601
554.17 9 .
740.521
722. 39
788.616
839.79
708.613
624.451
35.573
731.606
788.677
930.848
804.709
79 . 119. 42
722.513
689.559
79.8 1 795.573
04.833
37 .101
764.523
9 . 3
766.69345 . 7
653. 55
931.852
746.571
22. 6
792 8
627.53907 727
748.585
769.557
7 8.645
01. 35
682.598
700.254
842.722
876.803
62. 86
779 696
.52.
796.584
4 .
84 .29430 .269
768.554
732.545
. 11
503.108
710.62
9 848
3 437 4 6
685. 37
2 . 08
916376.176
692.523
775.604
6 .4
80.582
4 0.3 2
866.723
83 .773
80
83 . 2
4 7.3243 6
553.197
793. 11
2 . 4
788.606
874.787
2. 99
4 0.358
810.601
40. 07
752.52
18 24
3. 73 687.553
1. 476 . 67
844.7 9
913.819
782.559
763.664
7 4.6 6
8 .802
408.309
904.592
720.544654.567
. 43
79. 6
56. 39
6 8.583
8 0.78
786.232
95.602
836.61
731.541
8 8 8 8
76 921. 4
09. 68
902.81
9 8
510.355
701.569
793.557
808.58
44. 39
813.682
690.563
371. 1
4 37
559 13
750.507
.5 7 8.606
.755
812.607
697.617
.6 4
3 .649
755.541
4.598
4. 24
670.598
732.555
746.57
2 771
866.808
73 .661
705.59
4
89.8
8 8. 0 1 05.042
335.28848.292
742.538
0.551 614.536525.374810.49.295 766.5387 . 4
748.585
906.849
612.1
44. 4
867.726
9 1.804
803.695
485.1 270 .21
737.648
794.5
22 756850.786
5 6
892.833
861.7 3
7
714.507
59.15
913.82
5 89
734.629
70 .2339.195
783.574
764.558
7
692.5 3
58.
813.683
678.506
86 .792
752.677
18. 3981.711
93 . 7
73 84 9.413
38.661
837.236
2 . 7
8 2.56
833 2
520.139
723.6 3
907. 1 6 0.52
9 . 0
812.616
904.834
709.616
341.109
840.708
876 793
646.51
2.723
688.492
910.872
84. 75
0 3 9
746.606
931.851
746.559
9 2
. 5 633.504. 4
7.
769.558
. 1 86 42
749. 48
301.141
. 55
823.
17.711
710.629
0 .535
754.535
836.616
763.217
05.8
9 . 2
0 . 15 .
716.523
1 26
4.
383
766.692
758.56
19. 27
78
81 . 07
1 3. 2195.123
787.23
734.56
774.2 3
738.506
3 5. 31.40823.68
02.5 3
17 . 9
725.649
7 . 85
762. 9
781.631
538.399
514 9 7 8. 75
3 .5 2
647.523
55.616
906.839
632. 94
752.5 9
. 37
4 .5069
347.131
932.865
2 8.196670 2. 35
913.82
4
. 8
820.731
758.57
8 7. 06
83 47 . 2
3 74815.695
838.69
0 55
706.5 8167.01304.551
4. 1
. 36
815.695
2. 53
36 6 678. 67
2. 1
904.59
6
554 5862.25
843.725
.7 1
537.166 8. 39
86 .74
2 .2 2
903.579
31. 9
8 3.7 9
8 3. 9
. 0.
29.102 65 58
795.608 624.519
5 6.462
6 0.481
5 4
. 3
5 1371 101
9.805
08
7 .542
67 2
4.692
808.576
903. 21 661.538
05. 1
676.547
6 3.454
4
80 .5 4
762.6
643.571
986.2 4 8. 8
2
918. 4
8 7.6
752.523
1 3
6 4.5 1
52.677
226.952
6 . 3 .7 2
9
717.591
789. 8
629.554
1
3 9. 251.71
745.558
9 319 . 4 6.3 3 7 47
7 .57
775.27 5 . 0
894. 55914. 23
629.4755 5. 7
7 8.536
6 .197
2 .711
6 9.5 4
.1 3
52.708
81 .6 9
75.
. 2
5.532
7 2.59
890.818
788. 6
718. 1
701. 9
8 2
619. 91
904.824
6 .54
71 .526
785.58814.691
767.616
.633. 4 . 32
749.532
960.895
5 3.3 .2 9. 21
720.554
793 1
832.582
4 7
30. 2
795. 48
41. 11
692.583638. 35
8 6.6
703.575
913.82
789.62
02..2 5
82.324
8 5. 42
70 .491
.
761.589
.
958.8
75 . 82 . 93
8 47
787.604
. 92
13366.3 .4 3
3 7.18
19
43 9
151.096
85 . 03
14 2
87 .56
71.
758.559
720.614
7 . 8
790.6 3
9
767.616
51. 9
3
783.571
725.557
8 6
29 .
614.18
672.52
7.
8 7
65 26
34. 56
9.2 . 4
.63
3. 14
914. 23
4.7 . 3
540.159
3 . 1
797.588
3 2. 0
795.628
848.761
90 .853
3. 8
742.575
43
852.793
741.601
54
8
21 663
7
83 .619
727.585
3 2. 0
171. 38
769.632
91.158
753
802.535
74 6
661. 38.1
9. 48
664.55
25 4
8
643.426 . 4
893.83
828.5
723.516
299.183
8 . 54 31.605
.
0
74 .6
397.1 732.554
.53
711.632
435.3
. 20
741.524
9. 58217.105
70. 5
612. 2
905.836
749.589
6. 392
51. 9
738.507
3 .29
.56
683.6019
7 .5 3
714.506
3
26. 52
69 50 .708
811.604
686.5 16
900.803
610.184 3 .7 721 36
905.596
1 6
9 . 11
690. 63
0 6. 5
768.544
33. 7
92 .832
603.46
14. 23
7 388 0.75
01. 54
381. 2
167.013
880. 25
63
808. 52 .358
725.649
1.
7 3
852.7
1.
4 89
226.952
14.663
233. 5
3 59
532.44
6 .50
3 6. 02
864.802
4 1
4 3456 .1
906.848151.096
56.5
734.57
1.5 19 7
717.591
2 .9 2
8 1. 1
544. 4
6
645 2
774.601
4. 4 675.496
563.164
8
9. 4
809.5
687 55.1
9 7
6 1. 8
8 75 4.
730.539
768.5
809 588
22 .07
50. 87
946. 8
04.10
8.5
173.079
47.67
920.312
909.788
.
6 . 44
762.601
7 2. 67
810.59
3 602
746.56
.
9.7.0.
5825. 95
9 7
7 6. 4
756.552
132.0
95. 749
53.524
.159
1
914.824
52
704.523
. 83.327.1
3 0.153
7
8 9.741
7 9.664
5 .
6 9.502
0 08
78.817
0 72 8.557
778.5 5
38 0
73 .577
1 1.0 6
750.542
515.4 4
9 1.
93 52
84 7 .6
0 9 6.
0
706.538
1 9
3 88 .
912.254
780.551
79 2104.107
7 .573
. 21 8
173.079
767.541
.
538.162
1 3.075 9
.
752.559
5.59
75 .68
766
60.896
0 .63 .15
813.62
720.49
. 29 7
17
3 598. 04
638.535
21.
1 1.097
747.574
79 28
9 9.852
9 57
800. 6
. 3 1
746.60
8 1. 815 .
2 .3 2 5.1 0 2
5 .
772.585
68 2
5 8. 21
3 .913
71. 1
643.49
5
. 0
808.57696 . 9
826.693
.7 2
787.667
75 . 3
.
73 .39
173.079
9 9
3 .568
.
78 .
90 1
1 3.079
49. 88 958.88
733.558
4. 1
1 .
93 . 6
750.543
6.
0 .
4 6
3
78 .648
72 4937 46
6 .7
445.12
1
8 .892 .81
91 2
54 .324
151.09
811.66
3.055
886. 5
796.584
24.65
708.496
934.88
3. 42. 4
2 07
173 0 9
76 .69
78
226.9 2
173.079
8 3. 3
2
. 4
8.6 3
3 19
.
91 .82
959.8 3
173.079
764 522
39.6927 4
6 8. 9
7 5.561
.
744.59
2 6.
814. 32
. 10 . 92
3.563
9
9
4
1. 5
52 9 2.8650
445.1
5 .711
4 .6
0 . 4
95
173.079
8 .7
818.6 3
704.523
. 4
82 63
173.079
64 . 52 . 1 .6 . 1
415. 2
7 . 29
815.6 7
64 . 5
.
15.5
227.071
93 49
8
56 49. 37
.173.079
891.8217.5 6 508.34
1 .6
790.575
18.80 3
803.538
8. 5
7 4.59
722.561
83 .5
7 7.6
808.585
6 8 5
173.079
02.508
738.5 4
01. 59
4.
.
80
1
8.608
9
788.23
26.952
13
770.606
7
6.952
711.632
625. 9
9
72 .522
5 6
2
86 .
7 6.6 9
.
.
.
90. 38
9 8
1
80 71
30 .10
747.609
72 545
173.079
90 . 2
5. 9
0 .52
151.096
1 3
788.617
880.744
6
173.079
9 5
14
89 78
905.594
81 .5 8
3. 8
.102
.
64
61 .3
173.079
5 9
7 2.537
8
41. 2
834.602
53.
173.079
1
693.526 .5
279 3
913.82
26.9 2
44.864
. 13
6 0 89
1 3.079
92.
67 .5
8
871.67
8
840 793
5
173.079. 8173.079
827.
8 .682
34 .
173. 79
1 4
. 80 5 4
75 .538
18
.527
26.952
706. 9
01
7 44
.
689.512
94.
828.5 1
622.444
58
495.327
44. 45
9. 6
059.75 . 431 6 044
173.079
796.63
7 8.601
684.203
2.739
17 .079
6
151.097
37 2
7 9.63
85 .806
12 298
173.079
7 7.6
3 . 4
794.606
8 82
0 . 9
.
739.51
2
807.648
729.60
88 . 4
9 . 75
43 . 89
26.952
3 . 9
78 . 63
866. 1
173.079
226.952
3
4
80 .61
173.078
4.667
48.178
.
173.079
173.079
8. 4
0 . 57
8 . 8 10.871
. 1
892 8
415.12
59.572
.38.
173.079
2
26.952
.
53.526
755 53
1
4 707. 01
1. 3
760.
.
.
. 98
6 2. 88
7
3.59
0.676
5. 5
.
3 .1 1
6
68 .4 6
. 703.528
2 .5 5 7 9.6 7
1
1. 48 . 29
.
32. 8
763. 4
3 . 0
6 . 9
2 .
25.69 2.8 53 .58
906.8
.
801. 83
7.
6.95
. 9 9 .88
. 8 6 4.51
57 03
68. 02.823
.
760.586
863
947. 8
. 0
4 . 6
72 . 05
.
822. 4
5. 8 7 2. 7
.
173.079
822.6 7
. 654.567
.
768.6
0.6 4
679.511
24.1 8
6 .
8 1.7 60.
6 . . 8
6
799.6
0 .545
752. 59
0 .
.
5
933.8
173.0 9
2 .
17
173.079
813.619
83.7 5 95 4
53
799.66
. 3
8 .7 2
.
865 806
61.89
8
6 . 4
7 5.664
.
5 . 97
72 . 9
78 .
4.
2.5 3
728. 1
6 . 7
5 70
98.7
0 . 6
90. 8
91 .7 1
93. 32
. 1
1
.567
6 . 2
05. 793 .
.
. 30 .56
226.952
226.952
26
2
3.4
795.629
3 . 5
932.854
81 . 4
51.097
813.685
22 2
.
0. 7
82 6 6 . 0
611.185
8 .679
11 55
8.
79
. 11
1
9 9. 94
77 6
7 .
9
7 9
2 61
0 . 02
9.883
3
0 . 04
9
76.606
. 83
3. 42
0 566
93 86
. 5
877.56
6
. 82
8 2.792
4 28. 1
1 .5
74 .60
66 .5 3
7 .6
0 27
4
1 1.0
253 0
1
836. 1
. 5
7.538
. 3
129 102
. 82.
7 6.5
4. 07 9. 28
6.911
4
.2 9
03.539
511. 5
7 .584
87
8 . 94
874.
663.454
09 0 12
70 .4 6
.
7 51
1 .097
21
16.55
29
9.53980.279
5. 3 0. 9
794.569
.3902
721.557
2 6
38.235
.3
46 . 6 5
. 22 .5 4
704.578
728. 8
758.222
2 .
956.8644 .6
6 5.43
. 1592 . 3 .92 .82 .523
288.29
.
684.61
740.521
51.0
7
838.6 2
226.952
21. 1
0
731.606
2.604
151.097
93.58
60.896
933. 8743.578
906.259
788.606
90.57
63 478 8 . 6
1 3.0 9
3 2 .
811.6 8
51. 9
8 0.60 64. 4
151.097
20. 70 .51
1.
81 .
90 .839
5
0 .5
7 9 69 6
70 . 4
. 46
3 852
.
151.09
829.5 4
.
7 0.6 8
. 7
. 91
8 5
3 . 63
770.561
5 3 4
.8
796.586
5
. 5
0 .
64.6
4 . 3
9. 1
800.676
7 .
. 5 3
173.07
6 . 6
.
71 .
981.279
. 96. 8
1 . 1315 .097
522.5 7
1 3.07
1 5
. 5
6 0.
6.7 .
7
9
45 323.
9 . .5
709.617
4. 93
. 43
716.52
56. 6 9
173.079
7. 6
1 3 07
75 1
748.585
7 .0
9 53
76 .6 4
1 2
1 3 7
99. 9 720.5 4
4 .8 6
5. 9
0.
5.
893.741
9
19 .081
7 7
3 .
.
1 6.0 4
. 8
5 .3
4. 9
77 .5
151.097
173.0
5 3.
3 594
.
1 3.0
6. 92
64 21
. 7.
226.951
39
813.
. 9
. 91 . 7
7
51.09
9 .62
6 .
7 . 4
. 45
8
7 4 2
48. 984 . 0 3 . 7
51.5 6
1
2 . 160 06
51.
5 .8 .7190.7
3.
3 .53
744.59
48.
1
80
2
9 8
98 .278
07 5
43 .193 75
710.513
07
7 5 6
537.394
83.774
.
2
7
51.0 7
8.65769.5 3 . 9
24. 2
151.0 7
7 6
8
60.89
9 . 4. 9
3 9
151.097
79 4
5 97
718.5 4
0.
2 1 2
8 3
.2 . 1
4 .
4 .
4
9 . 8
6
.912. 1233.0
5
8.544
151.0978.9 4
907.26
8 4
43 1
58. 7
565. 775.604
9 6076
51.097
8 8.8
6
7 . 2
. 8
14. 9
4 1
9 ..8
892.
.
6 .4970 .
6 1. 6
08. 4 73. 9
2 .0 2415 6 9 .60
729.591
8.7 8
735.573
62
2.444
75 6
86. 6
.
9 4. 2
90 . 02
9.6
56
5 9
041
781. 5
890. 0
704 6
151.097
.3 .9.
1 1
7 51
79 . 4
99 .3
946.88812.617
65. 26
78 60
4
8
5 . 4.
904.824
. 72 .
9 .89
24
415.1
.
2 .6
. 3
6 .50
6 69 5
1 26.9 2
2 1. 72
66
50 4
756.544
3
362.
.
42
7.
87.91459 04
3
9 57
3. 63
44. 29
6 4.
808. 1
6 .5 1
5.
18.594
2
51.097
3. 23
8.1
8 2
8.51290
0 6 1
815. 35
4 . 6
832.241
151.09
0
717.549 9
907.853
74 .61 707.5417 .682
81 . 0
79 .5
151.097
. 1.5
3 4
81 .
920.312
3 .10
7
.
691.5
4 1
90 538
51.0536.166
3 4 2
3. 91
5 7
54.538
610.185
98 .278
0 .
.5
68 . 5
77 . 09
.
24.63
43
768.589
1. 0
5
908.258
4.
7 6
13 2
8 . 2
6
.71
5 74
.
15 .097
981.278 2 681
1 1
8.88
6 99
5 9
929. 4792.698
7 9 13
759.223
20
9
705.52
8 .
79.53
9 . 38
745.5
5
6 9
.82 6
6
685.204
742.538
4
. 4
885
0 . 98
7 4
.4
0 3
5
. 3 83
8 . 6
612.1 2
.
2
33.86
6
7
8 .
9 5
700 7
8 27
6. 2
0
2
5
15 .096
4
7 6
4
4 09
4 5
35. 04
0.91
9 .
4 .6 8
151.097
6 . 5
7 . 20
.
. 22
4
16 .1
5
99.60
5
35. 7
.
2. . 8
.013
921.313
.7
33. 1
81
. 20.8 4
26. 07
9.482
5
151.097
5. 2
1.
9 .6 3
5 652
.6
3 . 8
16. 9
9 0
9 .
3
6
61 3
1
9 3. 7
2 .27
208.04
0 .
7
. 4
99. 99
.
5 0
1
766.536
3 . 71
9 .6
.
1.899
51.097
5
9 8
0 3 93
29.52
1 8 9
9. 1.8
0 82
.
227. 1
.
.0
7 1
15 . 64
3 . 1
. 3.
. 5
8 .564
0 1
7 .572
7 .571
9.621.
.
4 864
129. 2
.
9 .7
0
. 7
03.5
7.0 3
2.8
5 4
9 2
9
791.541
80 .
9.
3 . 3.2
15 .964
.6
2 5
5 2
7 9 1
736.52
.
.
4
5 .
9 .
813.62
5 . 8
.
795.609
9 .842
3
801.
3
. 5
.
9 8 84
8. 1 .016 0 3
8 . 5
.
11 05
7 0 0
3
7 . 74
. 41
5
167.013
0 5
9 . 73 . 3
6 6
115 .097
.
2 .56
702. 0
.8
. 9 9.7 4
537 5
92 .7 3
16 0 3
. 6 8.
55 4
15 .
8
61. 9
5
. 3.0
0.5 5
91 .
2
8 8. 22
.6
6
718.574
. 37 ..
922.31 4 . 8.55
.
6. 08
9 2
8 9
7 8.523
. 3
7
3 8
3. 44
2
288.29
6
0 .
6 . 5
1.
29 0
4
2
761.589
94
.
7
7 .52
2 1 6
60 4
84.5
36.6 6
8
8 3 8
785.57 87.6
. 22
246. 0
. 5
02. 62
8 75
15 .0 7
23
772. 2
.
91 .8
7. 5
.
90 .
7
3 .647
9 0 2
6.
52
. 24 0 8
. . 4
63
7 3. 4
2 .913
. 2
20.59
4
.6
98
718.529
7 3 2
.
760.22
.4 5
14 783.563
9
2
.
.
.
0 5.
3 .9 6
3
9 53
0.8
6
70. 44
7
3. 5
0.
.7 2.7
615.1
65 4
7
3 2 5
.07
. 9
8
7 6.57
610.184
..
0
72
82
3 .8
0
1 .0
92
6 . 9
.
.
7 . 5
2
51 9
8 072
4
8 8 3
.
8. 67
8 9 79
9. 4
8 . 5. 4 3
3 . 6 4 7
7
2
.
.
72 5 5
.5
.2 5
5
932.8
0 .
8 0.
6 . 44
.
59.5
.
10 51. 2 8
.
8
90. 24
..
0
7 7. 89
770.55
577. 2 4 . 889
0
7 .
. 9
6.88
5.4 1
812. 72
4 . 2
0 69 5. 6
8 .7 5 173. 8
5.7 69
0 47.8 3
2
60 7 8
3
38.7 7
90 . 0
9. 0
46. 75.
069 6 . .
.
83 .63 0
.5 95
0 3.. 3. 7
7
.
686.201
770.606
.6 .
. 97
.
9
43
9 .85
.
8 84
86 9
81. 4
. 3
.
.5 5. 72
8 5.
9 8
2
4
8
3
.
1
5 5
. 51
3.5
19
.
33. 140.
1
4 .
1
74 . 62
. 49
.
5
0 2
9
795.572
.
04. 51
. 5
51 . 7 1 8. 4
.
4
8 2. 5.. 3
892.833
3
. 22
519.139
.
29 . 4
7.
94 .88
.
6 7.
.
1.7 9. 1 .805
1 964
7
29.5 2
5
.
.8
3 12
752.667
.
8
983.277
7.01
7 . 43
0.91
9
91 7
7 .864 5
3 . 63 34. 6
907.53
5
96. 22
5 . 2
814. 82
5 .
. 2
0
48
30 7 7
1 .0.
7
794.568
4
6 .
50 97 8
6
8
30. 1
4 .525
65
05 5
1. 9
76 . 9
23 2
55 .
1 .6 91 75
64.559
7 . 2
2 . 1
.
2 .2 7 8
8. 4
36. 0
1
2 . 52
. 68
.8 5
0
91
.
9
2
2
.
6
.96
696.613
9 . 9
2. 4
82 .
.
9 8
9 .
.
2. 7
623.447
3 . 02 .14
7
6.044
.1 32 . 4
.
.
. 4
.
. 749.5. 6
9 3
1
.
25
.705
760.57
2.
6
.
.64
6 23
5
12
9
9
03
.
. 6
8 2.60
.
8
7 595
73 .61
9
399.251
5. 2
.
869
4
.
.
5.5
0 5 3
6
. 4
2 1
8 3 . 3
. 26294. 3
. 6
.
. 1
. 93 7
813. 4
.
94 9
.
57 0.
53.
.
08
4
. 114
4. 1
.
2 7.0
4 6
6
9 1 7.
2. 01
. 18 .
6 . 26
5 .56
74 . 7
71
15 2 .
8 4. 3
4.
. 0
6 93 6
2 2
. 04
782.568
.3
22 .
0
9
.88
7 9 23
4 5
3
9
84. 8
82 4
.54
1 .85
816.
816. 47
66
8
.
. 9
2 9
.
.
1 . 3
227.07
9.
3. 1 .964. 5
3. 742
5 9
0 7 4
0 . .
3 .
.
.
0 1
5 16
9 0.8 5
.01 .
2
6 . 26
.5 3
. 41
. 9
9
7 4
. 4
.
4
03
0 .
.6
4 4
.
2.63
6
.073
7 52
744.62
.
.
6 3
908 865
.
03
3
983.277
. 02
9 .831 . 1. 4
85 80
4 4.5 6.
04
1 5
9 9.5 6
0
604.
3 .
.
0
9 .5
64
. 1.
4 0
2.
. 5
3
61 .18
3 . 8
. 3
9 0 .7 .591
6 7
. 5
5
1 8.
833.242
7
7 . 2
. 9 .
16.698
.
3
6
41
7 17
2
. 71
9 .882 .
8 .
68
4. 16
8 0.833
3 58.964
2 54
.
92933 .0
5
288.29
.. 4
.
6
.1
22.4 4
61 .185
768.544
4 0.
.
. 3 .5 2
7
37. 2
3
7 . 4
2
.
4
.
909.257
.
1
7
7 .62
MZ
SIMCA-P+ 12.0.1 - 2012-10-08 21:54:42 (UTC+0) 
-0.05
-0.04
-0.03
-0.02
-0.01
0.00
0.01
0.02
0.03
0.04
-0.030 -0.025 -0.020 -0.015 -0.010 -0.005 -0.000 0.005 0.010 0.015 0.020 0.025 0.030 0.035 0.040
w
*
c
[
2
]
w *c[1]
R2X[1] = 0.193888 R2X[2] = 0.114212 
X
Y
684.203
758.222
5. 4
536.165
622.445
9. 3906.26
980.279 6. 21
832.241
7.
2 7
60 18 58
610.185
3. 2
760.586
730.539
4.
7. 6
758.57
908.864
718.539
908.865
786.6
3
780.553
786.599
908.864
732.554
538.163
746.571
908.865
703.576
1.
766.539
909.2
744.553
782.569
810.601
756.554
90 . 6
760.584
1.
687.201
780.554
902.817
3. 8
9. 8
168.123
908.865
810.601
784.585
835.239
612.183
756.553
654.567
864.802
761.589
862.786
806.569
496.339759.573
909.868
874.787
1. 42
668.583
4 5
734.571
9 8
818.724
788.616
151.097
9. 42
787.604
640.552
834.755
874.786
904.834
439.339
876.802
744.554
908.865
890.817
903.82
808.586
1 7
806.569
704.523
778.693
902.818 846.755
902.817
787.603909.868
878.818
910.256
718.539
720.555
680.583
792.709
173.079
876.802
304.3
811.604
750.661
776.676783.573
806.724
7. 42
706.539
804.708
788.616
747.574
750.661
666.567
772.586
733.557
682.59
742.539
848.772
524.371
704.579
4 33
7. 7 5. 7
834.754
626. 15
862.786
5 5850.786
761.588
836.77
811.604
3. 9
1. 7
875.79
78.41
816.708
626.536
776.676
652.551
734.5
848.771
768.554
790.69386 02
2 18
376.176
785.589
764.677
820.7
173.078
83 . 37
834.756
909.86
875.789
18. 23
905.836
790.692
878.818
877.805
819.728
807.572
812.654
806.724
1 2
764.6773 2
3. 21
768.554
537.396
730.538
794.57
762.661
8
7. 6
808.739
9.
842.724
689.56
90 8
774.601
860.7 224.186
772.274
698.256
846.755
92.70
8.199
7.
694.599879.821
8. 39
864.802
91 .871
832.739
838.787
7 . 93
655.57
8 6.7 4
750.544
859.252 740.64
359.15
877.805
498.4
96. 15
76
9. 2
933.269
195.124
754.538
930.849
774.601
528.411
4 84
659.522
55 .197
736.646
5 5
804.708
809.589
10. 71
906.85
792.554
9. 6
3. 2
832.739
878.818
792.708
762.661
64 .507
793. 12519.139
9. 6
778.693
852.802
2.426
830.724
812.655
807.573
3. 8
9. 5
5
82 .7 1
8 6.771
735.574
572.437
777.679
7 7
5. 7
522
5. 11
722.63
7.2 6
631.491
482.324
930.849
904.833
675.544
851.79
700 23
701.56
736.646
4.
3.
1
151.096
835.758
189.053
820.739
736.645
656.583
802.692
708.614
837.774
6
872. 7
60.
782.57
766.574
750.661
522.355
751.664
751.664
762.661
849.7 5
817.712
586.453
484.384
813. 59
483.3 5
858. 5
780.708
642.568
908.865
789.62
1. 6
536.165
371.101
1. 6
846.754
716.522
48. 45
628.551
207.159
311 29
1 7
9. 43
776.677
910.871
8 19
69 .256
1. 43
705.526
673.538
3. 9
1 1832.739
850.786
9. 22
77.68888.801
5 8
69 6
866.723
8 5.759
. 3
91 .871
8.7 9
1 1
616.463
3. 42
770.57
657.506
724.646
683.602
60.
3. 7
464.358
1. 6
774.272
785.232
778.538
644.427
1.
902.576
381.132
22. 5
411.306
788.6 7
860.771
7. 8807.726
744.554
724.529
5. 8
816.708
667.571
931.852
865.805
846.293
09 42
760.585
802.692
671.522
814.692
707.542638.234
62 .214
769.557
49. 6
794.605
780.708
906.848
497.343
7
656.583
830.723
818.723
784.585
3. 4
5 6 1
748.529
494.324
812.655
118. 86
57
762.592
900.802
782.568
836.771
291.253
630.4 9
96.614
814.692
3 42
786.601
554.175
900.802
740.521
722.63
892.834 788.616
839.79
708.613
4. 51
735.573
731.606
788.677
930.848
804.709
. 119 42
722.513
689.559
879.821
5. 3
904.833
371.10
764.523
892.833
910.872
766.693
454.374
3. 5
1 52
746.571
822.756
92.708
627.5 9
807.727
748.585
769.557
748.645
701.2 5
682.598
700.254
842.722
76.803
2 6
779.696
813.659
752.677
796.584
4
7 4
305.269
768.554
2. 45805.711
50 .108
710.629
918.848
890.817
33. 3
. 6 685.537
828.708
916.833
376.176
692.523
775.604
60 9
680.582
40 42
866.723
. 3
780. 08
831.727
437.324853.806
3.
793.711
1.
788.606
8
682.599
44 .358
810.601840.707
752.52
18. 2
873.773 687.553
751.547
666.567
844.739
913.819
782.559
763.664
724.646
8.802
08. 09
904.5 2
720.544
654.567
1. 3
779.696
856.739
668.583
850.7 7
6.
5 602
836.616
1. 41
878.818
476.394
821.742
909.868
02.818
859.758
510.355
701.569
3 7
808.582
44.739
813.682
690.563371.101
450.379
5 9.13
750.507
674. 05
788.606
870.755
812.607
6 7.6 7
775.604
7. 9
5. 41
694.598
794. 24
670.598
732.555
746.57
2 866.808
738.661
705.59
847.757
9. 4
828.707 919.851
105.042
3 5.28
848.292
742.53
640.551
614.536
525.374
8 0.755
3 . 95
766.538
763.664
748.585
906.849
612.182
44 4
7 6
901. 04
803.695
485.112
702.214
737.648
794.57
55
751.664
892.833
8 1.773
838.786
714.507
359.15
913.82
51.789
734.629
2 33
9.
783.5 4
764.558861.774
692.523
858.755
813.683
678.506
4 9
752.677
718.539
1 11
936.267
737. 83
738.661
7.2 6
. 78
852.56
833.742
20.
723.633907.851
60.
901.8 5
812.616
904.834
709. 6
341.109
840.708
8 .7
646. 1
782.723
68 .492
910.872
784.575
470.369
746.606
931.851
746.559
9 4
239.15
633.50
794.7 4
7.578
769.5 8
704.51
777.6
26 2
49. 48
301.141
870.755
8 3.759
817.711
710.629
802.535
754.535
836.616
3. 7
905.8 6
904.824
708.614
755.616
716.523
831.726
79 . 25
383.277
766.692
758.56
819.727
7
812.607
872.7 1
913.82
195.123
787.23
734.56
774.253
738.506
5. 03
531.408
823.68
702.563
893.83
17 .149
725.649
672.185
762.59
781.63
538.399
14.395
748.575
803.695
832.582
647.523
755.616
906.839
. 4
752.559 893.83
645.506
397.293
347.131
932.865
228.1 6
670.223639.235
913.82
724.646
789.68
82 . 31
932.865
758.57
877.80
783.647
671.522
7 4
8 5.695
838.69
1
919.851
706.598
907.77
167.013
804.551824.771
917.836
815.695
712. 53
.
678.567
652.551
904.59
396.3 2
4 5
2
843.7 5
7 1.711
397.293
7. 6
868.739
867.742
283.262
903.579
891.82
631.491
3 9
823.759
684.202
880.824
129. 2 7. 6
795.608
62 . 19
66
680.481
564.21
26.536
275.111
371.101
9. 5
31.084
779.542
867.726
52 .418
66 69
808.576
903.821
661.538
805.712
6 7
663.454
8 . 4
804.554
762.6
3. 71
6 4
878.808
212.15
918.849
817.61
752.523
4. 41
52.677
226.952
868 7 8
87 . 42
83 .71
717.591
789.68
629 5 4
610.22
913.82 659.522
851.71
745.558
95.
797. 64
546.353
17.475
771.573
775.272
560.502
894.755
866.8 8
4 23
629.475
5. 6
778.536
689.19
2 .711
699.554
6 .19
347.131
852.708
811.6 9
9
558.422
4 0.347
725.532
792.591
890.818
788.676
7 8. 31
701.569
08.
61 .491
904.824
8. 1
6 2. 44
7. 6
5. 9
814.691
767.616
723.633
879.741
81.632
749.532
960.895
5 3.3
321.264
879.821
720.554
3 7 2
832.5
5 43
830.723
79 .648
841.711
692.583638.535
828.692
817.61
09.663
703.575
913.82
9 2
102.128
2. 9
482.324
8 5. 42
707.491
7 .696
1. 9
499.403
958.88
758.222
82 69
857.742
7 5. 7
854.723
7. 4
78.692
38 .313 4
66 21
634.453
377.18
19. 26
9
151.096
852.803
876.56
871. 58
58.559
720.614
749. 48
790.62
94. 05
767.616
851.79
2. 23
783.571
725.557
874.78
.617
4.
2 5
872. 7
657.506
. 11
765.526
834.756
829.71
9 4
769.633
3.
914.823
4 92 34.63
4 5
732.6133. 52
79 .588
352.306
95.62
84 . 61
907.853
3 678
742.575
5. 3
852.793
741.601
775 2 4
89 .78
821.663
7. 6
837.619
72 .585
372. 01
171.138
769.632
391.158
753.68
02. 3
774.66
661.538
6 4.143
269.248 664.55
4
657.5 6 643.491
269.248 893.837
828.
723.516
299.183
58. 4
731.605
7 .479
06. 1
741.6
397.106
732.554
685. 37
711.632
86 .7 2907.773
741.5
859.758
217.105
870.7 4
612.52
905.836
749.589
436.363
876.792
738.507
730.227
381.298
713.569
3 601
79 .6 7
747.57
714. 06
231.084
4 6. 63
226.952
869.757804.708
1. 4
86 4
856.739
00 0
610.184
838.777
52 .13
602. 8
5. 96
811.68
986.911 6 0.563
590.426810.558
768.544
933.867
603.46
79 .72
914.823
673.538
810.75
1.
381.132
167.013
880.825
79 .66
74 .5
08.73
3 8
725.649
1. 9
783.648
852.708
171.138
429.089
226.952
814.663
233.915
532.44
690.507
86.202
864.802
48.771
425.32
7. 6
560.131
906.848
151.096
839.789
6. 73
734.57
51. 11
59 67
717.591
226.952
841.711
544.34
253.128
5 9
774.601
854.584
675.496
5 16
32. 8
9.
880.834
809.585
687.553
613.182
681.585
881.757 9
730.539
768 59
809.588
27.07
850.787
946.8
.
538.5
173.079
847.679
920.312
909.788
741.6
7 . 46
72 . 05
945.868
8 0.818
8 3.
762.601
752.667
10.59
683.602
7 6.56
881.758
839. 1
447.099
229.141
871.758
825.695
1. 4
756.552132.077
5 2
9. 1
3. 4
687.553
279. 59
8 1.725
914.824
527. 92
934. 1
704.523
9 . 1 3. 7
463.131
360.153
667.57
869.741
739.664
853.727
669.507695.602
4 0.308
878.817
702.572
8. 7
778.535
5. 8
840.708
209.102
736.577
151.096
750.54251 .41
1 4
693.527
884.77
753.6
640.232
669.586
839.711
85 .71
09. 78
7 6 53
481.349
326.378
824.7719 2.254
780.551
790.622
104.107
795.573
68 .522
1. 3
173.079
767.541
173.079
38.162
173.079
795.629
3
752.559
745.595
673.185
53.68
713. 5
766.531
960.896
8 6
633.15
813.62
720.497
820. 9
755.616
455 3 4 59 . 04
638.535
1. 3 151.09
747.574
795. 28
919.852
95. 5
8 0.676
2 7.2 8 61.131
746.606
6 1.481
8 3.727
824. 8
3.2 5
62.558
113.107
55 . 7
655.57
772.585685.20
518.321
5. 3
699.553
71. 01
880.591
643.49
2 7
727.585
808.576
961.898
826.693
767.615
855.742
787.6
83.773
759. 3
2 6.952
735. 33
. 64
173.079
9 06
4 9.089
830.568
546.4
788.52
90 . 56
20 09
704
173.079
749.5882 5.
958.88
3. 8
774.661
81 69
937.267
750.543
77 .2
809.663
848.761
928.833
783.648
2 .492
7 694
66 . 18
868.7
445.12
185.154
64.802
926.818
1 . 2
542.324
151.097
811.669
123.055
886.785
796.584
4 0.36
1
708.496
934.88
743.542
806
852.707
173.079
767.695
8.7865.2
7 .
226.952
173.079
873.773
42 . 48
3
778.683
837.619
313.199
914.824
959.883
7 5
173.079
764.522
839.692
671. 24
668.619
765.561
.
744.59
226.952
814.632
825.774 102. 92
853.563
399
794.715
3 9. 25
881.83
299.183
932.865
880.74
445.12
853.711
454.293
668.262
706.594
837.695
173.079
895.772
641.554
256.176
818.613
704.523
8 3.6
782.635
173.079
642.558
922. 1
847.679
6
469.314
415.212
1 155
6. 3
716.229
815.697
647.465
2 6.952
5 62
715.51
227.071
930.849
486.113
564.447
319.137
26.952
173.079
1. 21
6 7.5 6
508.34
811.679
881.836
790.575
80. 89
918.849
4 4050
803.538
728. 65
774.59
722.561
833. 86
756.62
7 7.663
808.585
6 474
886.785
45 6
26.952
173.079
702.508
738.544
701.559
814.664
9. 7
880.824
818.614
638.608
899.79
788.23
226.952
4 .
920.864
8 8770.606
4 8.347
352.321
226.952 711.632
625.519
239.149
826.692728.52
607.566
924.802
860.771
756.619
.
810.745
835.67
790.538
909.78
100.112
880.716
03 05
747. 09
20 5
173.079
908.776 58 . 02
753.6
7 9.617
75.789
600.52
151.096
441.319
788.617
392.337
. 4
6 2 2
173.079
696.65
987.914
898.786
5 4
810.598
713.5 8
2.
321.227
342.176284.331
5. 4
793.632
173.079
2 695
742.537
848.272
41 2
834.602
753.563
173.079
275.11
693.526
770.56
1.
781.632
96.739
13. 2
226.952
944.864
684. 13
670. 89
173.07
46.293
2 4
675.554
168.123
871.678
86.7 6
840.793
5. 5
173.0791 3.078 173.079
827.69
2
231.084
849.774
173.079
911.874
6 . 58
805.554
754.538
26 18
7.527
226.952
856.738
706.529
1 5
702.544
83 .726
689.512
9 . 14
2 . 1
622.444
715.585
49 .327
744.545
1 3.079
489.146
5
59. 5
719.543
392.33
186.044
173.079
796.631
798.601
684.203
441.318
892.73
173.079
934.871
822.756
151.097
. 6
90.703.23
759.638853.806
8
173.079
171.138
7 . 6
959.883
34.744
794.606
68 60
414.321
207.15
5 5. 1
739.51
885.772
807.648
729.601
885.549
1. 5430.389
226.952
736.491
785.663
866.818
173.079
38. 54
226.952
34.63
46 .394
832.24
173.079
0 .616
173.078
764.667
7 5.649
798.552.178
2 1
173.079
173.079
6
393. 21
805.557
9 .133.086
789.68
910.871
4 81
892.738
415.128
759.572
38.
736.576
8. 78
173.079
17 .079
55.727
1
226.952
698.63
753.526
755.539
61 .2 1
8 4.687
707.601
807.648
821. 63
60.644
173.079
819.648
780.698
682.588
79 . 68
34 45
793.594
800.676
83 . 5
332.331
371.101
78 .635
689.496
869.757
38.691832.73
70 .5 8
471.329
627.5 5
220.133
759.637
672.526
419.337
19.
6 1.484
8 4.72
898.61
432.238
763.604
374.303
63.
920. 54
121.122
825.694
972.895
833.586
646.51
906.85
614.18
8 1. 83
54.809
68 .496
226.952
31. 7
7 9 5
9 4. 8
714.26
634.51
226.952
575.503
468.309
892.823
1 3.079
760.586
863.247
947.883
503.108
648.526
2 . 05
173.079
74.183
822.746
71 .584
702.573
9 . 51
7 3.569
173.079
2. 7
520.34
4.567
8. 4
8. 9
720.614
9. 11
776.2 3 22 128
664.457
1. 59
760. 2
369.384
649.538
929.835
. 41 0.636
799.668
708.545
52. 9
907.852
6.952
615.1 3
933.868
935.883
173.079
215.125
8. 7
17
173.079
813.619
27
552.1
653.554
627.539
799.668
2. 5
883.772
173.079
865.806
961.898
891. 2
666.64
775.664
4 5.37
226.95
5
151.097
7 8.5 9
86.6
854.723
762.543
728.521
766.574
76. 47
502.373
2
839.668
90 5
700. 56
890.808
91 .791
793.632
0 .5. 11
792. 9
806.567
8 2
05.475
930. 48
173.0 9
929.79
702.566
226.952
226.952
26
22 .95
9 .
73. 8
795.629632.494
675.554
811.667
32.854
819.648
774.271
9 0.2
151.097
9. 3
813.685
224.128
7. 8
830.57
2.
762.508
611.1 5
835.679
711.55315. 42
18. 95
679.57
853.711
2.1
929.794
770.569
797.664
438.298
710.629
722.561
09. 02
959.883
375.311
50 .104
895.773
776.606
656.583
843.742
607.566
932.865
770.635
87 .563
223.064
7 375.311
935.882
852.792
628.551
575.104
2 42
742.604
05. 21
668.573
729.601
480. 57
80 .583
4.2 4
822 746
403.187
151.096
2 3. 08
1. 28
836.771
11.
97.538
644.58
129.102
812.6
25 .217
726.56
404.207
879.821788. 68
986.911
4 0. 64
754.692
88 .761
430 229
803. 39
1 9
715.58
887.5 5
849.694
660.526
4. 76
663.454
209.102 812.676
08.496
897.773
796.651
151.097
521 1
816.552
2 7.082
714.251
779.539
785.663
980.279
25.805
73 .633
378.322
550.629
794.569
5.
510.355
2. 7
1 7
2 76
838.23
63 1
851.7173.098
462.146
7 8 651
03. 0
854.722
840.713
739. 84
704.578
28. 8
0.5
758.222
253.129
2. 11
956.864
7 . 7
848.682
685.43
42.729 664.551
9 1.875
928.83
827.71
27.821
6 .523
288.29
272. 95
684.614
740.521
151.097
852.712
838.632
244.191
226.952
1 16
6 7
731.606
1
2. 04
151.097
69 .586
6 .146
960.896
933.868
743.578
906.259
788.606
686.541
890.575
7 4.149
6.808
30. 78
786.66
173.079
60.578
935.804
809.6 4
53.128
452.278
811.668
834.745
51.7
810.667305.157
151.097
464.314
151.097
2 . 4
701.511
3 1.227
8 2.67
906.839
0 .259
607.567
826.699
799.669
8
702.544
324.846
931.852
866.723
841.711
833.241
435.184
151.097
82 4
882.754
0.698
151.097
343.209
908.855
1 8
88 58
833. 63
770 561
906.84 692.583
686.2
884.771 4 0 381
5. 9
23. 32
73 .
935. 04
796.586
40 1
778.5 9
67.281
402.358
960.895
702.507
7.632
825.774
764.667
429.373
5. 05
739.51
800.676
4. 72
77 .233
711.214
525.333
173.079
.163
6 2. 2
871.679
716.559
776.607
1
678.567 18.479
716. 82
916 83
167.013
151.097
522.597
173.079
561.505
784.6 1
54. 3
9 . 67
796.632
766.683
00.528
82 .696
909. 88
845.663
8 3.679
897.773
658.509
6 .555
709.617
744.593
732.543
716.522
856.745
3 5
839.7
173.079
827.696
173.079 75 1
748.585
1 3 79
771.5
919.853
763.604
415.127
73.07
909.788
89 .789
720.554
1 6
945.866
151.09
705.592
680.48
875.711
893.741
839.669
853.711
197.081
37 4
823.679
355.0
82.
186.044
839.654
85 . 4
553.3
624.236
923.747
338.342
644.495
94 4
778.574
151.097
2.
1 3.079
573.126
763.594
8.
73.079
676.492
764.216
414.27
893.756
226.951
39. 39
813.696
173.079
754.69
3 9
1
267.172
50. 1
55.741
151.097
698.6
4.
711.542
760.645
916.834
23
704.582
865.726
887. 88
363.163
706.598
742.603
733.557
1. 6
217.105
905.756
277.201
763.604
33.506
151.
. 6
922. 86
881.719
5 7
910.792
793.632
835.533
744.59
648.629
5 7.1 9
852.803
. 1
988.927
8 1.743
914.8 3
2. 8
4 . 069. 22
935.882
437.193
7 4.603
674.541
710.513
707.521
757.556
861. 74
537.394
848.681
883.774
8 5.71
7 21
151.097
738.651
769.593
88 .594
924.802
151.097
775.664
778.683
813.639
960.895
498.345
732.609
933.26
669.506
151.097
377.18759.638
151.097
718.574
800.616
852.80
281.142
78 6
371.101
7
.
616.551
743.61
1.374
764.66
603.535
738.651
.35 752.66
888.802
883.7
25 49
946.88
36.682
986.912
137.071
233.079
38 54
623.448
738. 44
151.097
158.964
7 6
81 .698
3 61
758.57
887.788
565.567
1 51
5. 4
696. 3
263.082
409.312
752.6 6
151.09
878.809
.
489.146
784.652
973.898
1 69
447.181
391.28 849 5
33.663
2
929. 32
892.834
57.757
163.133
663.496
70 .527.
691.5
208.04
768.62
773.59
299.41 . 6
717. 3
798.601
729.591
37. 19
868. 28
91 .805
735.57
8 .
622.444
2 .601
883.716
757.633
786.66
151.097
904.582
900.802
174.082
4
27. 3
4 7.303
8 9
467. 58 857.742
564.165
357. 89
801.682
52.411781.555
890.807
704.56
2 .69
151.09
648
.
53 .
381.3792.59
865.725
9
91 57
71 .51
792.554
994. 3
3 2
1. 2
946.88
12.617
471.3 2
765.526
789.609
55912.802
647. 4
5. 4098
904.824
9 7.7729 82
728.56
960.896
8 .734
41 .127
151.097
96 25
822.6
731.543
690.508
8. 6
893.742
894.755
09 16
9.
5 6
2 9
288.254
5
61.694
226.95
612.2
831.572
174.16
79 .66
750. 43
756.544
50.
7 9.584
554.39
36 .9 6
825.6
8 0 77
688. 56
742.57
677.512
987.
599.504
834.239
796.576
753.563
844.7 9
604. 63
533.191
808.651
728.588
2.71
6 2.54
715 1
718.594
464.207
151.097
894. 8
613.523
669 550.628
168.123
867.822
756.62
60 .567
708.512
325.15
270.1 5
10.489
441.298
6. 41
7. 09
750.651
797.606
815.635 845.663
32.2 1
51.097
491.089
717.543
5 6.169
445.12
90 .853
747.61
707.54
3 9 2 9
300.203
778.6 2
816.6 9
60.
97.588
151.097
794.636
270.155
895. 16
140.068
71.101
661.528
733.548
813.6 4
3 0 9
9 0.312
341.109
878.576
920.77
619.491
647.522
691.51
269.209
246.101
790.538
151.0 6
536.166
298 5
5 0.
8
5. 9
7 9.524
592.442
2 3.064
2 5
6 . 22
783.591
777.25
1 7
754.538
610.185
85 . 26
980.278 00.557277.201
659.522
721.5
68 .525
7 .60
3 3 11835.2 5
724.636
43. 09
68.589
811.601
709.5
8
794.5 9
774.66
84 .
383.316
3.522
8 0.824
850.251
790.683
8 2.719
63 .171
757.574
67 .509
151.097
1
872.681
818.713
95 .
6. 91 .6 2
587.549
929.794
792.698
7 7.743
197.081
2 3.2
9. 3
5 9. 25
38 .394
806.715
783.563
. 8
82 .759
705.5 6
151.097
383.3 5
876.801
779.538
697. 38
360.3 3
745.594
782.635
8 5.726
649.124
94 .8 6
2 6 6
934.269
6 0
742.538
3.64
18 .07
837. 38
857.663
804.698
862.776
7
283.176
725 95
5. 53
149.0 3
893. 56 738.624
4 6.2 3
9 4. 9
63.097
839 653
7
80 . 51
834.6
4 .726
92.44
5
2. 2
96.611
780.544
6. 3
775.272
933.868
648.629
771.648
661.48
7 3
73 6
791.577
00.5 7372.102
988.927
886.5 2
875.
930.797
382 245
547.356
05.757
151.096
4.3
469.349
796.741
870.761
3 1.3
754. 04
475.0 4
480.345
935.804
867.6
52 . 1
430. 14
946.88
840.668
670.187
151.097
716. 6
86 . 95
67.013
50.818
736.528
1.303
250.178
43 . 28
6. 4
4 .622
644.494
160.133
610.577
445.12
799.605
621.506
935.879
33.1
675.6 6
96 127
182.139
829.689
687.49
167.013
921.313
864.765
233.915
867.81
77 .31
78.231
75.49
920.86
7 6.507
538. 44
493.05
4 48
82 .712
. 6
835.605
151.097
915.826
771.59
880.834
54.1
6 7. 53
832. 1
785.652
836.682
934.88
151.097
7 .23
716.589
942.636
863 71
81.807
6.3 9
46 .131
90 .788
930. 97
626.522
897.787
61 .536
174.082
7 6.632
2 7
151.097
274.274
208.04
820.651
448.
5 9.52
1
703.566
87 .6 4
662.484
686.219
799. 79 599.508
739.548
35 07
7 4
766.536
911.804
734.571
797.606
896. 2
1. 9
707.1
151.097
593.59
95 8
963.834
400.379
843.646
382.28
185.115
4
501.086
507.02
3. 98
735.149
9. 6
70 .252
961.899
936.807
09 391 .87
554. 6
319.284
2.194
905.828
647.4
697. 38
227.071
881.837
22.444
3 613
596.437
16 .0 3
158.964
395. 1
726.652
2. 1
2 3.915 297.155
233.915
887.564
6 7
7 5 06
690.19
14.572
703.571
2 9
9. 2
151.097
51.097
6 .684
944.864
1. 9
129.102
557.152
929.793
9 0.23
27. 3
526.377
703.51
16 .0 3
932.855
651.14
9. 22
879 742
793.191
791.5 1
5
71 .569
801.679
639.538
.734
721.538
373.0
6 38
855.725
158.964
639.611
772. 75
563.503
47 3
715.528
74.
6 37
91 . 36
736.528
931.772
35.875
761.648
223.0 4
958.88
794.636
29 26
813.62
04
926.817
8 5.772
923.805 8.878.729
252.145
8 8. 2
795.609
9.69
907.842
895.27
8 3.7 5
934.88
223.064
801.619
83 .7 1
829 55
13 3
918.849
8. 4
167 0
. 2
16 . 13
853.805
85 7
680.5 2
911.805
30. 4
5.243
77 . 74
54 . 73
743.541
5. 55 352.27
167.013
803.543
989.931
7 1 648
5 33
369.176
67 .557
0. 5
113. 07
151.097
67.013
721.548
725.569
702.507
45. 7
850.699
.
8 8.723
7 2. 8
36. 94
923. 89
929.794
4 3.319
798.6
60 .53
786.307
.228
518.405
55 .366
537.535
925.763
167.013
883.757
6 8.468
755.542
150.113
83.175
0 553
961.898
858.744
246.17
67.013
897.788
1 2
0. 305. 167.013
790.535
. 4
913.254
9 3 27
838.622
850.7
670.6
915.826
718.574
94 39
79 . 79
705.526
809. 43
2. 245.101
768.552
44 .
936.808
. 02
398.296
47 36
30 1
987.914
8
728.5 3
235.913
3 9.3
677. 5
934.88
533.4 4
790.682
700. 91
43 .086
28 29
10.66
09.66
633.45
. 12
553.371
831.5 3
787. 79
429.089
768. 99
4 .
553. 9
08 63
761.589
3 7.105
89 . 4
787. 04
55
409.292
917.8 6
772.526
255.1 7
752.523
0 9
8 7.
20 4 2
281. 23
52 .1 6
5 8.4 5
785.6 2
760. 4
784.576
6
836.616
920. 65
15. 1
806.714
848. 7
483.328
89 .83
78 .579
787.679
71.522
1. 4
246.102
20. 51
702.562
838.75
146.129
24 35
2 3
772.621
819.648
918.8 9
1. 5
737.495
113.06
440 5
906.84
7 9.61
64 1
677.569
880.716
831.647
12 2
962.912
96.776
552.411
553.179
1 1.097
869.721
429.088
5. 3
0 .27
71 .5 9
8 2.748
16 .1235 7.366
39 .2 4
699.633
703.548
923.7 8
235.913
467.371
01.52
720.591
2 . 9
744.611
79 .647
0 .128
393.2 8
718. 29
75 62
910. 91
398.
60
.
712.415
. 82
97. 5
7.508
814.632
783.563
49.4 7
5 .097
906.59
837.7 4
628.538
151.097
0.
892.31
608.56
621.489
362.926
348. 0
859.533
67.0 3
863.654
5. 06
.
841.669
870.744
165.076
812.672
2 1.217
314
3. 52
820.58
830.71
8 9.7
846.745
5
659.465
789. 09
391.285
353.266
2 . 1
855.6 5
88.529
855.70
746.57
610.184
6
828. 4
635.14
2 .07
12.5 7
5 0
122.925
1 7.0
229.141
19 . 23
672.614
932.8 5
65. 66
78 .59
133.0 6
824.677
792.554
961.899
882. 1
719.58
. 1
7 8.556
362.92
151.097
184 073
714.572
617.474
701.511
8 8.632
802.69
7 8.667
840.793
8 9. 79
712.6 9
769.547
8 3. 9
445.13
867 741
898.785
223. 64 497.345
. 11
355.0
615.497
909.547
67.284
763.547
766.682
7 6 7
6 . 71
. 5
726.535
407.189
6 0 11
832.58
947.285
5 . 32
932.865
205.086
69
858.7 5
5 1.512
41 58
690. 15
836 27
147.066
9 .
799. 7
235.118
. 66
. 6
596.223
60.759
698.541
947. 3
712.635
879.811
850.699
721.6 7
8 7.7 2594. 61
759.563
96. 3
718.597
8 4. 6
1 2
06.951
867. 26
636.628
764. 8
89.22
8. 27
79 .624
22.7
1 2
43 .088
857.
797.589
770.559
876.714
347.13
577.12
640.588
906.2
922.786
851.653
0 1
799 22
8.148
922.291
1 2.113
387.202
91 26
5 4
577.519
7 3.558
151.097
942.84
872.682
946.88
85.607
829.668
429.211
1 4
812.672
746.512
170.066
8 688.499
807.5
79. 16
3. 8
962.901
685.61
7 4 6 2
75 . 96
880. 39
11 5
947.883
8
74
11
362.926
7 5. 98
909.788
8 9
7 2
838.787
447.026
195.123929.793
95.522902.8 7
446.12
369.
553.37
9 1.806
6 4
746. 7
16 013
9.
370.295
235.9 4
40. 7 5 . 4
671.602
846.666
689.512
869.701
1 . 76
9 6.76
302. 45
710.618
482.324
39.635
585.361
730.604
776.559
845. 42
158 96
15 .097
53. 26
8 0.724
4 88
233.916
53.
0.535
650. 46
750.651
643.57
893.827
7 1
902.817
936.894
68 .2
770.606
729.524
08.569
985.89707.159
1 9. 6
843.705
906.85
49 488
833. 82
489.146
16.833
986.911
281. 42
698.63
800.672
716.588
578.426
840. 68
35.4 2
5 .5 4
923.804
8 5 71
63. 35
656.17
168.12
913.80
.56
704. 31
6 .318
1.489
895.773
8 4 777
17 586
164.921
730.575
64.5 1783.59
193.144
3 2.347
23 .915
740.588
859
860 9.1 8
9 4.91165.113
8 .71
7 6.668
646.614
771.573
71
404. 0
43. 41
800. 5
.562
294.228
171.149
716.588
752.54928
47 .21
45.622
629.555
750.592
891.579
0 928 6
795.572
. 7
76 .57
804.5 1
67 . 89
6 .
12. 2
532. 84
516.417
15 .964
7
772.594
686.439
852.766
3 7.225
645.449
49.764
97. 1
. 2
892.833
32. 13
896.761
895.77
33 62
519.139
44.982
76. 1
824.682
9.251
29
7 04
77 .2 9
674.484
877.72363.311
4 .
603.5 5
72 .569
949. 99
608.473
667.643
31 .18 98 . 1
921.773
89 . 2
9 9.883
6 7 5 7
711.633
911.805
253. 29
158.964
. 94
853.66
729.56
55
4. 5
846.666
5.4 5
.
7 .668
482.
895.758
733.612
752. 67
158.964
3 . 66. 6
29 .171
7 .6
983 277
113.107 607.567
167.013
3.195
6 6.557
8 7.796
7 9.543
6 7. 7
2 5
430.914
9 9.794
502. 4
915.827
724.519
4. 48
6 .
. 4
60 392
565. 6
582.457
539.163
57 . 0
834.667
907.531
195. 23
30.089
8 3.805
53 .333796.622
58. 89
270.156
3. 7
814.682
158.964
415.1 7 4 . 31
94. 6
864.705
948.287
30. 7
1 7.013
490.14 9.578
989.931
794.5 8
774.271
73 .5 4
1 7.013
862.823
5 5
508 3 6
72.89
5 6.507
704.23
33 7
64.707
403.187
4 91
506.44
54. 81
741.52
7.355
94.332
09.2 2
63 . 65
705.58
41.689
768.579
47 512
513.34
9 3.2
6 .237
22 .07
559.517
813.609
657.5 6
57. 22
6 . 4
703.575
718.
455. 13
764.559
726.652
227.071
673.48
9
.013
158.964
274.274
947.883
548.416396.296
738.543
936. 08
630.619
226.95
787.668
9 2
984.895
4.7 4
0.541
3. 5
158.964
430.914
8 0.698
435.308
3 .284
24.282
911.74
834.792
2 6
6
849.6 3
792 6
77 .578
15 .964
696.613
158.964
937.819
73.098
712.646
3. 14
821.734
96. 19
1 1.051
8 1
720.572
869.758
2 6
916.739
857. 6
735.562
9 22
.3
3 7
2
. 3
5 2 447
342. 7
281.14
709.499
915.827
47 .299
833.583
779.541
186.044
343.175
3 5.284
315.253
1 1.0 5
235.914 233.915
.9
158. 64
233.915
8. 7
100.076
508.385
717.56
8
664.457
715.527
749.588
685.436
97. 74
90 .2
831.647
.
191.165
700.216 73.266
253 08
65.555
867. 03
566.55
107.071
75 .6
829.668
760.574
32. 03
732.591
78. 2 908.7 6
8 2
9. 6772.644
761.649
168.12
99 622
6654.265
71 .491
233.915
50 .1 8
76 . 99
8. 9
03.527
53 .403
5
711.553
124.087
85 . 7
854.575
130.159
9.
626.484
69 .566
3 . 01
801.62
822.601
841. 27
704.5 9
141.113
68. 8
706.595
6 0. 1
315.253
732.61
62 98
399.251
930.
4 .3
195.123
50.555
71 .2
4 .734
694.481
09.538
685.617
.
9 . 32
36 .325
386.327
49.5 9
6 4
69. 4
746.511
.4
755.697
9
615.58
671.188
17 .081 805. 32
813.686
1 4.074
70 .515
4 5. 08
83 .623
682.588
235.913
55 2
81 .
362. 264.939
22 .144
158.964
648.505
7. 5
836.537
227.071
76.714
876.793
2
152.1
6. 4
463.147
7.
36 . 27
8 3.6 4
845.663
498.901
6 6 479
551.6
294.939
906.7 1
630.55
886.735
5 8. 6
603.
. 2
70.74
780.589
844.745
4 . 1
.
08.243
954.848
03.742
8. 9
913.805
841.
608.57
881 74
6. 8
5 4 226.129
986.911
2
7 .211
504.10
975.914
524.371
6 .491
27.07
65 4
81.48
40 66
7 . 7
760. 41
67.013 60 .5
691.52
9 71
6 .358 6 2.613
7 2.217
762.601
4 1.312
304.3895.77
362.926
9.
854.566
873.722
46 60
226.129
3 5.2 41.393
703.547
22 . 71
9 5.331
519.325
415. 28 4 3.0 7
793.59
2 .07
814. 2
245.175
814.627
58 .
864.708
852.25 8.6 9
9 .3 6
7 7.574690.544
921.868
411.094
224.128
96. 04
7 2.568
962.912
863. 1
2 7.07
40.
650.645
909.78
744.62
.
95 .883
759.572
235. 3
772 . 67
163.097
6 5
4 5. 28
649.633
5 415
830.6 1
693.586
156.042
52 . 5
784.587
4 5.34
23 .915
75 .6
45 .34
887.652
712.645
5
786.54
919.852
1 6
816.587
0 2
816. 47
614.17
858.
7. 82
684.6042
77.79
40.4 3
9 4. 8
58.59
80 .631
3 .32
25.637
2. 26
0 7
2 3
7 .
207.159
.
227.071
84 . 168.123
227.071
619.434
233.915
4
908.258
158.964
773.651
. 6
877.805
933.867
4 026
.
281.1 2
591.
835.239
235.913
3 1. 77
47.609
77 . 9 642.4 6
819.617
890.724
50 . 0
801. 38 825. 3
6 5.1
448.362
7.
839. 8
6 .
6 5 3 674.512195.123
. 1
575 0 3 3. 1
901. 2 899.747
920.865
113.06
8 5.742
20 . 81
727.245
815.665
190.056
233.915
5
8 7.663
63 .468
861.694
114.066
233.915
362.9
740.523
791.541
96 .2 9
897.789
848.5 9
8
7 9.574
610.504
5 3.1
703. 5
3 3.
519.441
921.7
35. 72
75 .5625 5.152
92 . 03
7 .
22 .07
0.261
67 .551
846.309
91. 25
489.146 2 . 41
761.577
22 . 96
8 2.633
83 . 9
184.073
718.576
853.796
745.575
8.2 4
2. 0
376.319
77 .3
813.637
9.
5
. 6
.
415.127
60 . 6
869. 57
44.62
07.2 3
1.
73 .591
5 3
34 .
309. 7
213.146
285.29
158.964
796.
3
766.536
9 8.86
730. 91
883.773
87. 19
1 8.964
92 7
703.51
235.9 3
3
924.802
9 .331
5 8.5 3
54. 84
685.48
5 8.42
167.013
464.314
9. 3
5 .304
823.62
85 .809
4 4.566
22 .952
07.602
704.531
52 . 1
838 751
730.594
909.546
577.519
77 .652
679.57
770.509
77 .651
750.592
7 7.596
9 .8
850. 5824.735
32. 29
981.805
838.6 1
10. 7
1
409. 31
421.3
6 9 5
613.2
4.529
342.373
743.5 9
.
740.588
2 .913
.
972.895
62 .444
982.81
158. 64
4 1.215
0.18
560.501
878.7 3
892.824
341. 0
3 . 6
742.525
237.91
79 03
610. 84
4
8 2. 6
0. 8
42.598182.98
729.543
39 47
630.618
36
880.745
9 3. 1
7 .604
2 7 07
84 .649
91 . 3
629.387
95.123
9 .604
8. 3
6 0 1
307.263
762.591
906. 97
911.805
985.898
158.964
833.242
12. 4
7 1.602
167.128
163.097
865.769
829.726
793.558
6 6 68
1 .69
705.58
751.546
88 .758
9.2 3
851.752
876.57
75. 4
750.533
34 1
857.721
174.938
5 .
22 . 1
144.982
9 . 6
358.207
03. 8 19 .12227.071
935.883
9 4.7 1
903.82
1 4
235.913
8 3. 9
689.5827.653
824.616
880 33
1
21.16
207.159
158.964
519.441
826.544
65. 27
34. 2
362.927
35 80
75.2
355.07 5 1.0
729.56
29
288.29
22 .071
79 . 35
430.914
3.
3.742
874.698
730.60
171.149
744.207 622.444
798.609
861. 95
61 .185
130.159
768.544
6 6. 9
78.575. 3
53. 2
6 .3 7
95 3
860.7
753 9
876.766
28 .167
699.496
91 . 07
78 .594
91
814.536
8 9
840.69
734.512
5 5. 19
7 . 08
7 9 60
524. 7 2.6 1
937.
7 4.
5. 3
86. 73
416.215
818.5 7775.664
195.12
36 .926
459. 1
914.723
8
3 0. 2
195.123
358.208
430.91
963.835
9. 7
5 4.361
3 .179
956.864
4. 09
665.548
950.81
4 34
. 29
.
57.622
823.60
780.59
MZ
SIMCA-P+ 12.0.1 - 2012-12-07 14:31:29 (UTC+0) 
-0.16
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
-0.00
0.02
0.04
0.06
0.08
-0.12 -0.11 -0.10 -0.09 -0.08 -0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 -0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10 0.11 0.12
w
*
c
[
2
]
w *c[1]
R2X[1] = 0.161276 R2X[2] = 0.112653 
X
Y
684.203
758.222
685.204
536.165
622.445
759.223
906.26
980.279
686.202
981.279
832.241
907.26
982.277
760.221
906.26
832.241
908.258
610.185
907.26
833.242
758.223
908.259
760.586
730.539
834.24
833.242
537.166
758.57
908.864
718.539
908.865
786.6
834.241
536.165
983.277
718.54
759.224
780.553
786.599
908.864
732.554538.163
746.571
908.865
703.576
611.185
766.539
909.258
760.585
980.28
744.553
782.569
810.601
760.222
756.554
981.28
909.868
746.57
760.584
761.22687.201
744.555
684.204
982.278
909.258
780.554
902.817
908.865
623.448
909.868168.123
810.601
784.585
835.239
612.183
786.6
684.203
756.553
718.539
908.865
654.567
864.802
761.589
862.786
806.569
496.339
759.573
909.868
874.787
731.542
746.569835.24
668.583
537.166
984.275
734.571
909.868818.724
02.817
788.616
15 .097
719.542
787.604
536.166
640.552
788.616
610.184 758.57
834.755
874.786
654.567
904.834
439.3 9
876.802
744.554
730.538
904.833
908.865
890.817
903.82
808.586
909.868
756.554 781.557
806.569
668.583
704.523
778.693
902.818
983.278
846.755
902.817
787.603
878.818
910.256
720.555
730.538
680.583
792.709
908.865
173.079
876.802
782.57
304.3
685.204
811.604750.661
776.676
783.573
719.543 10.184
806.724
780.554
767.542706.539
804.708
788.616
74 .574
761.588
750.661
909.868
666.567
772.586733.557
761.22
682.598
742.539
848.772
524.371
876.802
704.579
757.557
745.557
784.584
3 54
626.215
538.163
747.573
910.256
862.786
772.58
720.555
865.805
850.786
761.588
836.77
811. 4
863.789
781.557
875.79478.41
816.708
626.536
776.676
682.598
652.551
760.585
734.57
903. 2848.771
768.554
745.558
790.693
864.802
680.582
76 . 18
376.176
785.589 764.677
820.74
7 .078836. 37
834.756
909.86975.789
792.708
787.604
878.817
818.723
905.836
790.692
720.554
686.202
626.536
905.836
878.818
776.676
877.805
819.728
807.572
750.661
812.654
806. 24
780.554
611.184
812.654
891.82
764.677
36.771
903.82
878.818
903.821
768.554
788.616
537.396
730.538
794.57
762.661
35. 58
734.57
90 .832
757.556
808.739
539.16
842.724
689.56
89 . 18
774.601
860.7
768.554
772.584
909.868
224.186
732.554
772.274
698.256
846.755
792.708 688.199
847.758
694.599
879.821
788.617
537.166
808.739
719.542
864.802
910.871
832.739 838.787
778.693
655.57
806.724
810.6
750.544
689.559
59 2 2
740.64
359.15
906.259
750.661
7 4.677
877.80
498.4
696.615876.8 2
789.62
836.238
816.708
933.269 195.124
7 4.538
930.84
7 8.691
7 4.601
984.276
694.598
818.724
528.411 . 3
434.384
659.522
904 83
718.539
789.619
552.197
747.572
736.646
8 8.818
902.817
804.708
809.589910.8 1
6. 5
792.554
756.553
794.569734.57
669.586
613.182
832. 39
611.185
790. 92
92.708
762.661
645.507
93.712
519.1 9
779.6 6
645.507
877.805
7.
776.676
52. 2
806.723
542.426
759.573
696.614
666.567
8 0.724
812. 5
807.573
863. 8
49.775
985.275
790.692
640. 52
820. 41
836.771
762.66
735.574
612.182
72. 37
777.679
80 . 27
537.395
745.557
522.436
805.711
722.63
627.216
631.491
482.324
930.849
757.557 675.544
851.79
768.553
70 . 35
652.551859.252
731.542
701.56
736.646
934.269
82. 69
773.274
65 .57
77 .69
641.555
86 02
151. 96
835.758
76.802
1 9.0 3
820.739
736.645
656.583
802.692
708.614
7.77
865.806
151.097
908.258
872.77
860.252
766.574 5 . 1
22.355
751.664
751.664
762.661
849. 75
8 7.712
586.453
783.573
484.384
708.613
706.539
808.585
669.586
813.659
483 365
858. 55
780.708
30.723
642.568
9. 2
731.541
78 .62 681.5 6
371.101
64. 7
659.522813.658791.6946.7 4
716.522781.557
748.645
736.645906. 48
62 .55
207.159
311.294
721.557
538.164
792.708
610. 1
628. 95
699.256
821. 43
30 4 04.708
705.526
673.538
7 . 89
785.589
891.821
832.739
8 0.786
777.68
879.822
879.821
888.801
935.268
1 84
819. 26
866.723
835.759
904.833
656.583861.773
910.871
8 8 739
30 7
1.251
16.463
743.542
806.569
770.57
657.506
860.252
724.646
683.602
809.589
86 .77
773.5 8
3.727
4 5
791.696
7 4.272
850.786
785.232
778. 3838.787
793.712
64 .427
911.256
902. 6
381.132
22. 55
411 308 .67
860.7 1
64 .567
47 58904.
807.726
44.5 4
612.182
724.529
685.204
765.68
64.801
81 . 08
667.571
58 5 5
4 9
.
09. 42
8 2.692
802.6 2
671.522
786.601
687.201
814.69
8 8. 01
707.542638.234
774.601
628.214
769.557
4 9.3700.234
794.605
0. 08
906
90 .82 497.3 3
7. 5
830.723
81 .723
78 .585
763.664
6 .681
74 .529
683.601
94.324
118.0 6
761.58
50.787
4 7 357
762.592
900. 0
890. 18
673.538
782.568
836.771
291.253
630.479
96.614
804.708
843.72
814.6 2
8 3.7
786.601
554. 75
900.802
806.57
740.521
722.629
2
7 2.21
751. 64802.691
1 . 7
839.79
628.552
624.451
735.573
731.606
88.677
87 . 2
930.848
78
93.711
809.742
21.55
7 2. 13
795.573
81.585
878.81790 .833 760.576
371.101
195.12
8 771
764.523
812.655
2.57
892.833
689.559
766.693
17. 1
454.374
653.555
931.852
746. 71
822.756
781.557
792.70
627.539
07
748.585
788.617
769.557
748.645
1.2
819. 26
700.254 7 03
62.786
7 9. 96
13.659
752.67
778.538
796.584
848.77
861.25
4 .294
305.269
704.523
735.573
788.677
732.545
8 5.711
503.108
91 . 5
710.629
918 848
9 17
89.62
33.743
654.567
73. 87
8 . 66
6 5 37
828.708
842.723
721.557
9 .833
3 6.176
692.523
7 9.558
8. 93
775.604
703.575
60.49
680.582
814.692
40. 4266. 23
3 . 3
87 .786
811.604
816.7
9. 95
724.645
769.557
780.708
07. 26
831.727
686.202
. 4
865.806
8 3. 0
5 3.197
791.695
3 7
821.744
788.606
694.598
722. 1265 8
66.693
74. 8
760.585
682. 99
756.553
40.358
840.70
7 2.5
866.723
8 8 2
791.69
748. 28
873.7 3
687.553
751.547
8 .805
6 .56
4 39
910.871
751.664
913. 9
8 123
782.559
763.664
2.786
88 .802
77 79
40 .3
750.544
6.723
692.523
904.592
720.544
52.
1 64 838.78785 . 948 77
668.583
687.2018 . 85 0
786.232 695.602
83 . 16
906.849
731.541
7 . 18 4 .394
821 42
685.537
902. 1
79 . 2
859.758
627.
62.78
5 0.355
701.5 9
774.6
793.5 7
808.582
763.6 3
671.522
8 7 9
813.682
690.563
3 1.1 1
450 79
0.551
.
559.13
750.507
674. 05 . 5
788.60
733.557
8 0.755
789.62
1 . 0
697. 17
7 .60
737.649
755.541
904.591
695.601
69 .598
831.7 5
794.724
808.582
0. 7
7.5 3
2 .70
670.5
764.522
7 6.6 2
824.771
8 .793
905.835
866. 0
738.661
705.59
47. 5
889.80482 .70
.0 2
71 .62
33 .2848.
4 .585
74 .538
.551
5 7
757.55
614 36
525.374
668.583
810. 5
779.695
349.295
766.538
3 664 748. 85
906.849
746.569
61 .1 2
8 4. 4
867.726
690.5 3
70 235
901. 4
803.695
670.5485.11
702. 14
737.648
794.57
622.445
22 6
828.708751.664
892.833
52.
909.257
61. 7386
714.507
359.15
913. 2
831.726
766.575
1.789
734.629
4.
2 39 195
783.57
4. 58 697.617
61. 4
3 .162
735. 3
719.542
58 55
5.7
.
1 . 8
678.506
804.708
8
752.6 768 45
718.539
781.711
793 1
6.771
936.267
7 648
9. 1
738.66738.661
837.236
4 7 3
52.56
52.676
833.74
.139
67.57
723 633
660.525
90 . 05
812.616
7 2.566
931.8 17 0. 7
904.834
70 . 1
720.546
810.601
341.109
732.554
4 7
762.591
2
840 70
876.7 3
519.139 851 9
985.2 5
46.51
7 .723
6 8.492
906 839
910.872
7 4 58 3.741
4 0. 69
46.6 6
3 9
746.
765.68
09. 42
2 .
633.506
768. 53
7 4.724
767.5 8
769.558
04.516 7
26 42
749. 48
9. 17
301.141
641.555
908.865
7 . 55
814.691
3. 597 1
710.629
2.535
7 4.535
836.616
63.217
536.166
88.606
905.
904 824
0
. 1
60. 9
716.523
31 7294. 2
2 7
766.692
758.56
750 44
8 9.7 7
782. 3
812.607
705.5 2
7 .7 1
1 .82
788.676
195.123
774.6
794.606
40
3 . 91787.2
. 54
734. 6
73 .629
7
738. 06754.53
30 .303
531. 08 .6
70 .563
813.659
171.149
2 .6 6
725.64
672.1 5 62.5
781.631
730.539
538 399
5 . 9
514.395
748.575
0 .695
832.582
890. 18
647. 23
755.61
906. 39 632.494
752.559
89 . 37
7 4.6 6
84 .755 4 . 06
813.683
2
347.13
93 .865
228.1 6
670.223
932.864
639 35
731.606
913.829 821
74 .522
2 . 46
864. 3
820.731
758.578
75 .559
78 .6 7
71.522
83 .774
8 5. 5
838.69
810.755
5
910. 71
70 .59
9 7. 72
1 .01804.551
8 4.7 1
91 .836
815 69
283 .7 1
6 8. 67
52. 515
3. 6
7 .5 9
6 2.523
39 .33554.195
862 5
3. 2
8 . 11
892.834
9
868. 9
8 . 42
2 26
903.57
8 .232
918 49
9 2
49. 7
1 491
37 237
3. 8
05. 11
8 . 5
6 . 0284 .
12 . 02
7.5 6
24.5 8
795.60
624.519
707.5 3
566.46
6 9.5226 .481564. 5
4 2
62 . 648.
2 . 1
3 1.1018 9.805
2 1.0 4
779. 42
6527 6 69
80 .576
0 1
913.8
90 .82
661.5385 6 62
67 . 47
88 .83
787.604
63.45613.182
846.293 849.774
04.5
762.6
6 3.5719 6.274
803.696
78. 08
856. 31 .15
1 . 9633. 0
17.61
752.523
9 6.833
67 .5 1
752 7
6 0.
2 6.952
5 9
746.56
6 39. 2
839.71
717.5 1
789.68
90 9
6 9.5 4
1 .2
5
4 . 8
5.313
807. 73
538.39
7 6
6 3 3
7.4
71.5
1 .7557 5.
5 0.50
.755
66. 18
75.604
91 8 3 629.475555 176
8.536
9. 7
69 .5 4
6 0.193
4 .1
5 . 0
8 1.679
5
5 8.42
7
16.523
151.09
4 0.347
740.521
63.7
725. 32817. 09
.59
788.679. 53
1 .0 30. 9
18. 31
701.56
8 2
3 2
619. 91
13 686
852. 7
1 .711
8.51
2 . 4
717. 26
63.
67.726
643.57
785.5 9
814.691
6 1
87 . 4
781.6 2
9.53
0.895
553.3
32 .264
6 7. 86
868.738
90 .8 2
87 .821 .
9 2
.582
5. 3
812.616
795 64 01. 69
768.552
841 711
9 37
92.583
38. 35
809. 63
807.573
18. 23
913.82839.79
89. 8
755.615
02.2.295 4 2.324
863.7
768.553
845. 2
70 .4 7 .
3 049 . 3
48.
762.601
958.88
75 .222826.69
862.25
6 93
2
5
54.
787.604
382 3
904. 33
573.4
834.755
720.554
786. 91
66 326 .4 3
377.18
8 726
674
. 2
779. 96
11 295
2. 3
7 4
876.56
1
758.559
717.591
702.232
720. 14
49. 48
790.623
94. 05
748.585
7.774
767.616
51. 9
78 .6 2
2.72
83.571
7 5.55744
8 5.695
7 7. 96 7. 7
61 .
672.52
872.77
7 6.601
. 2
7.
8 0 74
. 11
765.5
829.71
810.6
7 .62 . 14
.
70 .214
9 .8
.79
734.63
822.7
540.1 9
732.61
151.09
433 52
8 . 16 779.54
797.5 8
.306
95.6 8
8 8.7 1
90 .853
795.628
23.6 8
742.5
5 . 93
741.601
. 4
89 .
783.573
1. 63587.45
37.619
727. 85
37 01
1.
9. 2
1
2 . 1
5 .
2. 5
74.61.5 8
614.
269. 4
796.585664.55
789.62
741.6
81 .592
5 4
913.82
643.491680.4
7 2 3
893.837
663.454
64.5 1
5 2
38 9
7 0.622
28.55
723.516
299 3
8 .625 .754
.66 . 9
406.351
1 3.0 9
90. 1
666.5 7
814.6 1
397.10
8
732. 54
6 537
4
5 . 1711. 3
867 742
71 .628
7.
741.524
9 8.10
870. 5
1 .52826.69
5. 39
749.589
3
8 6 7 2
8 8. 3
794.569
7
25. 48
1 29
70 . 9
705.526
76 .61
3.569
795.6
74 . 7
9 . 54
714.5
63
226. 2
4. 91
9
732.554
7
795. 4
686 5419
9 0 803
13.684
3 . 7
239. 9521.13
62 .55
0 .4
905.596
1 .
980.279
9 . 11
32.545
59 .
10 5
49. 31
8 9. 11
3 867
8 8.9 8.832 647.52
8 5.69
.233
60 . 6
96.614
.
5. 05
. 6
14.8 3
610.185
10. 5
3 .
850.
701.254
1 097
38 . 2
7 . 1
880. 25
730 53
89 .82
9 .663
74 . 41
847. 93
23. 8
. 9
9. 2
3.
1
29.08
226.952
. 6
. 1
2 . 5
53 .44
90.507
8 2
69 .602
841. 1
5 7
5 .556
760.58
909.8
. 6
560.131
646.51
7 1.5899 6.84981.279
1 1.096
5 57769.6
2. 22
744. 53
6.5 3
. 4
75 .51
59. 7
1 591
39 79
226. 52
544.34
5 1
3 1
645.429
3.07
774.601
854.5
675.496
63.164
4 2 68
704.578
. 9629.214
742.538
8 . 3
690.563
09.58
7 3.515
.63
613. 2
90 .
81. 858 . 7
4 3
30.539
76 .5 2.80
.662
22 .07
5 . 48
858.7
539.163
9 8
0 .10
92. 825 6 4
1 . 2
5 8.
1 3.0 9
84 .6 9
920.3 2
09. 88
7 .12 50
890
3. 7446 6
0 59
1.3 744 .0 9
503. 0
2 14
78 6 . 7
. 4
756.552
1 2.0 7
713.5 9
90 .594 7 . 367 2
84 . 1
765.526
53 24
6 5
7 4.56
720.544
9.159
9 9 7 8
982.277
2
914.824
226 952
92.833
9 .7 1
483.32. 09463. 3
3 0.1 3
6 7 57
2
9. 1
7 .6 4
2.7
. 7
847. 79
81. 54
670.589
88.617
11
.50. 2
48 .308
. 177 2.5
6 8.5
7 .535
753
485.38
74.6 1
4
1
619.491
736 5
151.096
67 .495
515.414
74
8 6.57
614.53
93.527
4. 7
933.8
7 3.6
9 4.8 3
6 . 69
3 1
4
851.7
. 78
6 62
7 4.5 3
7 2. 61
9
812.616
6. 8
4.7 1
226.9 2
844.
912.
8 29 780. 51
7 0.6204.1 7
795.5 3
95 .888 . 2
9 0. 1
95.64
3 8 5
758.5 9
9 .31
6 3. 2
31.4
1 3.079767.541
1 3.079
7 . 7
6 9.
7 .7
75 . 59
4 . 95
673.1
7 0. 14
. 8
713.2
93 5 6
6 1
1
9 .895 41
6 3.15
. 71
813. 2
904 8 3
.66 7 0. 97
820.729
68 . 577
4. 4
7.83
4 33
6 2. 6
811.604
598. 04
3 .
921.313
1.0
6 .54
4.1
.7
1 .85
90 . 3
5
933.2
673. 38
0.
11
00.676
7.238
2 1 3
. 06
6
.45 2
4 831 .62 55
3.
50. 7
692.52
734. 7
18.321
1 3.079
93.837
5. 1
6 55
4.5
906.849
1 3.07
6 1. 0
880. 91
2
931.8517 585
74 .571
.80
5 .67
67.57
771. 73
. 98
8 5. 2
787.6 7
7 2
3 . 33
68.7 5
3 1 3.079
2 9 222 .9
772.585
.
4 .0
830.5 8
9 0.2
54 .
8.5
90 56
20. 004 2.
4 6167.013
17 .0 94 8
5 5 .13. 9
.2
0. 3 70 .591797. 4
6. 59. 6
9. 54
928 33
732. 4
3.648 24. 2
6 . 06
661.48
747.573
37.6 4
.61
5
44 .1
1 .14 292 .8 8
542.324
51.097
811.669
123.0 5
9. 4
.7 5
796.584
749. 9
4 . 64.6
708.49
704.522
934.88
743.542
806.
2 07
17 .079
75 .5 9
3 .
78 . 2
226. 52173.079
5 . 7
.
78369.74
8 4
. 0
13. 9
7 .5 4
783.57
.824
959.883
32 .2
73.079
3 . 92
809.588
768.589
67 .224
66 . 1
7 5.561
74 .5
226. 52
91 .849
814.632
0 . 92
4. 253.5 3
173.0 954 .399
12 6 6
7 7.64
. 34
6. 2
7 3. 8
2 6.9 21.7
6.693
8
9 .
7 5.632
1 .0 9
9 .
62.77
445.12
2 .
7
5 1 54. 9
94.3 5
668. 2
70 .594
7 6
1
9 . 2
6
8 8. 1
04. 23
956. 4
21.3 2
1 4
2 6
7 .079
8 0.7 5
42.558
19 1
2
767.69
669 58
7 4.537
469.314
1 . 64 5 212
19
789.679
5 .173 . 9
647. 6
173.0795 62
715.
9 49
1 .079
26.9 2
486.113
1 0 9
58.57
6
3 9.1 226.952
1 3.07
95.60
.34
11
26 9 2
836
480 389
73.079
4 7
44 40
167.013
4 3
8 3. 8
72 .26
722.561
3 .586
.62
815 6 8
7 .
3 79
. 6
7 7.6 7
4 4
. 85
4 .3
8 .
. 1 3.079
702.508
8.544
1. 59
1 6
169.127
1 3.0 9
1 .6 4
38.608
9 9
788.23
6. 2
4 .
7 5.6
2 .159
70.
.
35 .
. 2
711. 32
6 5.5 9
3 .1 9 9
9
28.522
.
9 4. 02
671.602
756.61
8
7 . 7
1 1
1 3.079
.6
7 0.5
00.
. 1
905. 36
74 .609
78.8 7
226.95
173.079
908.7
22 .9 2
5 1 4
94 7
5 .
0
0. 28
4 1 31
173.079
8 2. 2
934.27
15 .097
7. 1
9 37 706. 8
8 0 4
94 . 8
86 202
96
. 4
742 37
8 .7
91 .823
732.61
810.59
7 .1
94
515.413
1 3.079
1 7
2 . 31
615.
3. 2
173.07
. 5
3 .
848.8 .
8 4.60
3
275.1
733.557
93
4
96. 39
2 9500.
62.6 1
35. 79
6
13
6 0 8
173.079
2
0 .
3.0 9
4.
45 .
853. 1
168 12
8 .68 .7
8 .567
.
865.725
1 3 079
8
92 .3
1 3.079
8 7. 92 82
2
.
8 0.59
.
69 5
.
7 5. 41
0 54
173.078
151.09
912. 54
6 1. 91
717. 27
2 .9
706.5 9
9 .8
.74
02.
731.542
689.5
828. 1
4 7
622.44
7 8.64
.58
4 5. 7
. 9
51.547
7 . 4
1 3.0
17 .0 9
64 80
89.
8 .
.5 3
4
173.079
798. 01
684.203
722.56
3. 798 9
173.079
73.
765.563
9 8 1
1. 97
10. 6
6 16
90.
52.6
0 .
37.166 759. 38
8 3 80
12. 98
1 .0 9
7 3
78 . 68
. 4
4. 06
.5 5 . 01
414.3 1
.173.0 9
. 4
3 .5
1 .0 9
77 .273 5
0 . 4
29.601
88 .549
911. 5
30.389
226.76 .
736.49
.
21.
. 6
9 9
. 38 .818
1 3.0
89 . 1
2 .9 22 6. 2341 1 9
1.. 1
3 4
800.616
4 . 2
64.
9
68 .1 9.
5 2 1. 6
1 1
3.079
86 .
393 3 1
2. 2
5. 57
.
3 0
7 9.6
. 9
814.63
824.
.. 3
105.04
.
5.758
.3 8
3
754.53
838.7
. 7.9 7.8 5
8. 6
22 .
28. 3
173.079
3.0 9
.6
98
11. 68
7 . 2
5 . 39
611. 21
173.08 .69
1 6
.197
0 1
648
21
7 0.6 4
9
780.6 8
.95
6 .5 8
1 3. 79
93.5 4
.
937.266
17 . 9
. 6
5 0 13
2 . 5
59. 4
4 52
8 .
. . 0
7 2.6 5
. 9
9
8
703.52
3.079
6 . 83
7 .0 9
. 3
22 1 3
59. 37
1 3.0 980.718
827.
6 .
898 . 3 3. 4
2 6. 5
3 0
. 9
3.448
4
.
.8 5
70 5 5
92.5 2
5 6
.
1 .
900.80
173.079
6 18 796.63
.60
1
813.6 36
. 6
8 9
8 4967
9 5.2 9
2 .952
8 .586
3 7
934. 8
1 .2
4.51
762.601
7 .5 3
7 .53
5 8
3.079
6 30
892.823
1 3.079
0 . 3
4 5 4
863.247 .
0.598
5 1 8
4 .5
. 0
726 5 95 . 8
6
67 .1
70 .573
6
38.66
13 5
0 9
. 7
0.
7 6.619
7 8. 9
6.9 2
0
60.585
6 9
.2 3
23. 9
9 .5 1
22 .1
6 .
75
92 958.88
.
7 .2 3
7
799.6
. 4
.8 2
. 5 0. 55
986.27
17 079
66 . 3
2 . 1 3.0 9
5
5 .1
2 6.952
5
.
8 727
55 .
1 .611
0. 3
3
. 38
.
. 39
7 9. 6
.13
2 . 52
.
782.635
9.8
.
6 . 4
. 64
4 5
5
1 1.0972 . 9 799.669
7 6.6
1 3.079
59. 3
.8 6
. 11 .5 3
2 . 2
80 . 63
.574
5 44
4
. 25
4.755
502.3
.
8 9.5
958. 8
8 8
0.
4 15
728 52
.6
7 3.6 2
92.1
790. 37
173.079
173.0 9
.56 8 628 5
0 .475
930 4
815.
92 .7 3
6
26.
26. 5 2 .
.
8 7. 6
5
.
17 0 9
73.467
6
. 7
. 72
819. 8
1 . 97
8 .2 . 22
74 .6
53 .519
8 1.6 3
0
932.8 5
3 8
8
30.
62.508
7 .0 9
9.557
611.1 5 3 .
11
71 .5
932 854
. 01
6 9.5719
627 534
.1
. 4
7 0.569
6 .61
. 4
3 .2.5 12
8 .2
.9 . 5
9 8 3
7 . 6
3 1
6.911
505. 0
.
9
. 06
8
73.079
700.
3
.3 4
. 66
2. 5
7 .
. 63
064 94 .5. 8
. 9
9 6628.
575.104
2
7
763. 04
536.165
797.589
4 .
22 .
0 .
2
4 .
15 .096
2 3.1 8
561.
90.5 4
6.
151.09
.
5
6 7.5
4
1 9. 02 2
52. 1
2 .404.20
79 . 2
7.5 8
173.079
.604
1
742 603
8 9 8
98 911
4 .3
3. 3
7.01
2 19
80 .5
.35
7 5.584
813.619
8 .
790.623
6 .
812. 7
774.67.
7 6.651
1 1.
.
5 1.
5
.
4.
.
1 5
05.594
92 .
22 . 7
718.539
.
3
3 4
3 2
550.629
1 3. 79
70 .5 .5 4
7 .5
5 0 5
6 . 5 9 8
902 0
600.52
6
7 .572
. 35
6 38
863
98
46 . 46 4 2
2.4 .
4
3 .
. 9
7 8. 94
.
5
2 . 8
.55 2. 1 . 6
93 .8 4
85.
42
6 4
48.585
. 5
9 .8 3 .8
27 8
6 23
288.29
84. 1
1 3.0
8 8.682
5 .09
0.
838.632
8 9.
44.
6
66
5
5
.0
93. 8
. 6
3. 8
4 .5
3 12
94.
86 .75
151. 7
1 .
90..
6
90.50
30.4 8
7 .
2 .
5
2.5885
452.2787 5
10
2
0 5
1 .
02.5
4 4.314
5 .
62 . 4701. 1
32. 2
. 4 907.8
3
2.6
0 . 3
1.0
94 .867
610 5
3.
151 09
3
34. 1
.8 .
.0979 .666
. 4
983.276
2 6
13 .
4 1
3 . 07 1 0
9 .
829.
0
82
0 55
. 7
7 0.
49.
5
8 . 5
758.222
33 3
14.
5 .097
770.561
1
79.159
3 38
5 9
423 332
2 .95
.6
4. 1.
. 2 83
35. 0
2 3
0 .7
0 . 9 0.89
7 2.507
. 1
757.632
5.7 4
429.0
7 9. 1
800.676
71 .
3. 4
8
3. 79
7
6 2
173.0796 5. 36
6 9
5 7 18.479
1 82
744.555
9 3
.
3 721.557
2 9
. 3
6 15
73.07
.5 .
6 7
3.079
96
66.6
. 89
9 9
.
.
.
1 1. 97
7 4 5 3
3 6 .
. 4
5
9 . 4
8 .4 4.07
2 6.952
7 1
3.07
8 .
1.
.5
7 . 1
7 .
3.079
8 9.7 9
62. 4
73.07
0
44
7
1 3.07 4
. 7
18 3.
8 . 6
3 7 1
173.079
13 684
7
.7 6.3 5.0
1.
173.07
2
03. 8
76.7 2
1 .097
54
1.0
3 2
3 37
19 1
. 84
.
. 2
4.4
7 8.5 4
693. 86
. 9
102
5 .
73. 9
38
9
.
99
6 2
4 21
41 .
797. 17
9
5 . 7
3 .5
5. 3
64.
. 7
. 9.86
4 6
991 2 7
28 .2
58. 6
5 7
. 7
55 .62
6 . 2
.8 3.6
15 .097
92.
7.
734.5
3 .1
1.
.
.9
6
.0 72
1.2
0 . 25 801.
0 0
8
3 27
1
9
.
33.55
629. 5
.
. 01
5
2 1
722.629
51.097
4.
2 6
980.2 9
8 . 6
881.
8 5 8
45.5 7
62
8 .
16.5 18 .74 . 9
0.824
7
5
8
9
.013
83 6 .
.
79 .
. 37 .6 3
1
7 6 0. 12
7. 56
4.5 5
761 88
7
2 .9
7 47
8
9 7. 21
1 1.0
76 7 . 1
881. 9
3
22 . 59 . 9598.3093 .2 9
3 . 2
73 .
1 1.091
.74
718.5
.
.
766.538
.
.1
8 .6
3 07 .
29
5
6. 5
62.6
.617
.
.61
1 3
. 9 90 5
3 . 51
5 65. 51
3
8 937 0
2
. 62
2
4
5
82 . 6
15 . 4
9. 21
3
.87
.
7 8 577
4. 8
3 . 15 .0
7 6
981.279
9 1.
7 5.6
696.
7 6
0
.6 2
6 . 12
0
7 5. 5
.
8 . 0
5 .
5
48 4
.
. 5
9 8
40.15 .
052
4
.
6
. 0
2 4
0 . 7
1 .0 7
833.241 9 9. 3
5
.
3 4
4.
5
6 1.56
. 8
208.04
2 70.569
02.50
6 .
.5. 3
8 .
15 51
7 .6 3
9
6 . 44
040 . 49
6.66
79 7
8 3
1.09
1 4.0 2
3.633
827.
.3 1. 2
. 5
2 5
7
743.542
.
90 .8 4
5 2 98
.5
. 0
4
70
792.553
8 .698
.
.
3
8 .
.
1 .149
4. 13
849. 1
9 8
.
.854
5 2
1 . 4
7
748.587
8 .
7 .5 7
9
702. 1 7. 9
53. 2
99
3
6. 8
..
8 6 9
0 7
1 . 0
.519
..3
904. 24
0. 5
.
8 .
.
0 8
36 4
.
415.1 7
0
6.54
90
95 8 3.60
7 2
1 ..
76 .5 9
.5 4
6
1 4
2 9
12
832
.
32 1
6614.1 9
7 .
. 2
7. 1. 0
. 5
46
.
7
. 4
8 6
2
9
. 9
6 .207
.
0 6
9 .
. 3
0 .
6 22
6 2.444
0 9 3
1.0
9 9 . 1
2 0 55
.
16.1
744.59
10
5
.6
815.635
4
3 15 . 7
9 .
7 43
.
0
5 .
0 .
0. 447 .7 6 .
1 . 9
97.588
3.6
4
. 59
559 . 6 81
3 .
9
8 76
1
7 22
691 1
56 .
4
. 1
97.60
8.
0
9
89 .7
2
15
946. 8
8 524
3. 88
538.162
47 .4 9
2.
.
5
738.
4 5 8
2
76 58
0.
2 5
7 3
.7 82
. 7933. 6
0
5 81 60
0
. 41
74.66
8 .6.
4 72
8 . 168. 66.
7 7.574
7.
.50
.
. 7 . 8
.335
208.0
1
.
58.2 4
6 . 9
8
. 49
. 3
. 4
9
8 .39
.0
83.
41 0
5 5 2
. 13
.0 7
7 7. 3
8 0.7
982.277
1
7 . 38
.6.
5
4.
64 .
6
.
.
.
.5 9
68 .204
932.865
832.241
.
8 .
1 4.0
5 .54
6
.
.5 6
. 6
. 1
.
5 9
.494
.
25 4
4 .02
8 3. 2
4.895
8 9. 3
6 7 47
76 5
. 4
.
9 4
22 71
.
6 4
75 2
3 6
9 . 68
9
.
4
752 66
98 .2 3
1. 9
8 4.24
4 52
7 0 . 5
7
7
5 .
2.563
06. 94
. .3
.0
8 .
5
. 9
.3
4 .3
30
8 . 2
4
.
35. 35 . 3 .9 4
746.60
. 50 6
1
9 .
74 7
16
1
0 . 9
6. 87
7 2
7 9.
1
1 09
73
61 . 7
7 9
4
4 6
7
06. 49
.
5.526
.
8 6
23 . 1
.
8 2
8 .
.
778.536
6 .4
80 .
. 6
.
0.
.626
94 .
49 .05
7
6 1
78 .6 7
.614
9
.
3
3 .605
1 1.
3 .38
.
4
.
90 .8 9
.
3
71
0 .68436
2
2
.0 3
2 69 .
9 4.88
7 7.
6
12 182
1.
1 1.
.
01. 41
464.1
7
9 9
800.
5
62 .5
.
7
8 . 7
74. 74
4 .
3
48.
.
9
.
. 4
. 8
9
5 .1 4
1 0
7 7. 6
.59
.
9 .
6 9
0 .16
. 9
.
9
. 6
4 .
1 04 .
8 .
850 .
9
. 32. 2
9 9
5 9
.. 51 . 8
7 7
. 6
.
1 7.7 . 4
4 3
15 .9 4
32.
3
6 . 3
.
2 .
6 2.218
.9
. 9
.
15 . 7
034
9
5
8 14
.
7
4
8 .
0
5 .0 7
0
4. 2 . 5.
59 . 9
.
7.
.
. 13
.
7.
9. 2.
4
.
7 0. 36
6
6.
49.6
21.
4 . 9
0
1 8. 4
3 11
.
.
0 0
. 5..
3 . 2
3 .
04. 5
4
. 47 . 432 25 ..
2
.
.
5 .
58.8
5 .090
79 .609
.
9 4.88
. 7.
8 .61
.
.7
8.
8 .55
8 3.
1 1 9
2
1 52
9 8 84
2
938. 64
.013
6
1
7 1
.
15 . 7
.
03 .2
8.574
02. 3 .9
3. 4
3
7. 14363
6 5
89 . 4
1 . 07
. 3
6
8 .6
7 5 9
3
.
. 1
.
6
3
2 24
4
.6
2
903.579
. 38 .3
6 3.535
7 0
92
.
.
9 .
5. 3
7 .
41 0 3
0 3
0
4
7. 3
08 5
.
5 9
4 . 7
. 3
.7 1
. 1
. 0.7 2
. 6
.
. 2
.
5.82
71 . 4
2 .
9 05. 26
4
63 .8
9. 0
4
7 0.
8
3
.0
.
.
. 5 8. 8
33 4
9
91
0
7 .5
8
7
. 5
.
83 . 30
8 . 79
.
9.0
.1
.6
8 . 3
. 2
. 3
. 5
4
4
4 2
9
917.
4 6.
.
.
5 4 107
523
1 9
.
11
760.64
808.576
.
1
2
.
9 .
4
5 .
3
4
8 3.
5.
2 .
1
2 . 50 .
.
.
1.0
.
2. 21
9.6
.
4
1 0
4 0 5
2 . 6
.9
.
25
5 6 7
3 1 2 . 85
.0.
42 8
1 78 . 8
862.748
32
0
3 .9172 5
.
. 1.
11 01
. 4
2
39 2 8
. 2
29
0.
.9 4
41
4
93
5
0.
7 .
0.
6.
7.
8.
.
4
39
8
6
4 12
. 2
.9
2
0 . 75 3
704.523
.
742. 3
.6
1 .0
9 . 06
6
.
70. 05
.
1
3
.
51.0
7 7.
4
.
.
. 50
.
1
68
3 1.
0 9
7.
8 .60
8.
1
5 .705
6 5.14 0
12.5
7
.
7 6.6
. 99
8
773.65
29
6 . 4
20
4
.
. 7 0.534.76
.
6 .
0 . 3
4. 07
92 .097
.
5 .5
2
8 9.5
5 3
.
2 5 2
0 7
..9
4. 8
5 . 7
.
80 5
2
9 .
7.3 .
7
6 2
2 .9
13 4
8
7
.
9. 82
.
.4
541
.5
.6
4
.2
3 . 1
9
5 3
. .
5
.4
3
.5 5 3
8 9
3
5
. 97
.5
4
7 9
. 7
. 948
2 4.128
30.
7.
9 .5
7
7
0.
.0
4
0 . 89
1.
04. 79
1
68 9
8 1
9
558
1 1 7
8
2
9 6.8
1
1
0
79
..0
1 .
. 3
7. 3
1
02.3 2.
49 .
6 .
35
3
3
9 .7
. 6
4.
6.1.
9
4 6. 4
.2
.
. 89
4
288.29
6 6
87
28 2
909. 68
.710. 18.4 4
839 635
.2
585.361
40. 5
. 23
0
7 59
. 2
0.5 5
6 491
0.
. 5
0
5
0
.
9
1 .5
0 6 8
686. 1
1
9 .89
7 6
.
5 1
.
. 8
9
7 .543
34 6.
.16.
. 1. 8
.
984.275 6 8
56.1 2
.
758 3
7 13 86
5
2
7 7 1 .
.
9
. 44.
2 3 7
.0 6
. 3
2
8 0.6 6
1
7.
4.
.
7 . 73
.
9
3
.
0 2
.6
7 .
2 9
2
4 5
4
.92 .5 5
8
0 5 2
.
0
.
5 1
5 4
.417
1 4.
.79
. 3
.
. 9.6
3
36
.
1 2
. 49
4
. 94
0
.31
9 .
3
608.4
2 .554
. 6
.
95 8
689. 9
7.
.
1 .
2
.
7
.
7
918 84
9
3
8
4 68. 4 .61
.
.1
8
58 .
.7
1
2 .
0
2.
6
5
0 4
7
. 968
.
6
75
4 6
..
8 .
2 8
23
79 . 2
2
5.
.
990 49 7
3
8.8
7 4
25
2 7
11. 3
6 .0
0
9 .
7
684 203
6
898
2 3
9 8 8
.
9
7. 1
5
9
0
.
13
. 0
. 75
.
. 83
7.3
3
. . 0
0
.
. 8899.7
2 5
7
2.
89
0.
59
0
.
4
3 .
8
8 .5
.
9
3 .7
.
0
0
3 0MZ
SIMCA-P+ 12.0.1 - 2012-10-08 22:53:14 (UTC+0) 
-0.16
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
-0.00
0.02
0.04
0.06
0.08
-0.13 -0.12 -0.11 -0.10 -0.09 -0.08 -0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 -0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10 0.11
w
*
c
[
2
]
w *c[1]
R2X[1] = 0.174014 R2X[2] = 0.172334 
X
Y
684.203 758.222
685.204
536.165
622.445
759.223
906.26
980.279
686.202
981.279
832.241
907.26
982.277
760.221
906.26
832.241
908.258
610.185 907.26
833.242
758.223
908.259
760.586
730.539
834.24
833.242
537.166 758.57
908.864
718.539
908.865
786.6
834.241
536.165
983.277
718.54
759.224
780.553
786.599
908.864
732.554
538.163
746.571
908.865
703.576611.185
766.539
909.258
760.585
980.28
744.553
782.569810.601
760.222
756.554
981.28
909.868
746.57
760.584
761.22
687.201
744.555
684.204
98 .278
909.258
780.554
902.817
908.865
623.448
909.868
168.123
810.601
784.58
835.239
612.183
786.6
684.203
756.553
718.539
908.865
654.567
864.802
761.589
862.786
806.569
496.339
759.573
909.868
874.787
731.542
746.569
835.24
668.583
537.166
984.275
734.571
909.868
818.724
902.817
788.616
151.097
719.542
787.604
536.166
640.552
788.616
610.184
758.57
834.755
874.786
654.567
904.834
439.339
76 8 2
744.554
730.538
904.833
908.865
890.817
903.82
808.586909.868
756.554
781.557
806.569
668.583
704.523
778.693
902.818
983.278
846.755
902.817
787.603
878.818
910.256
720.555
730.538
680.583
792.709
908.865173.079
876. 02
782.57
304.3
685.204
811.604
750.661
776.676
783.573
719.543
610.184
806.724
780.554
767.542
706.539
804.708
788.616
747.574
761.588
750.661909.868
666.567
772.586
733.557
761.22
682.598
742.539
848.772
524.371
876.802
704.579
757.557
745.557
784.584
834.754
62 .215
538.163
747.573
910.256
62.
772.5 5
720.555
8 5.805
850.786
7 1.58
836 77
811.604 63.78
781.557
875.79
478.41
816.708
626.536
776.676
682.598
652.551
760.585
734.57
903. 2
84 .771
768.554
745.558
790.693
864.802
6 .582
762.218
376.176
785.589
764.677
820.74
173.078
836.237
834.756
909.869875.789
792.708
787.604
8 8.817
818.723
905.836
790.692
720.554686.202
626.536
905.836
878.818
776.676
877.805
819 28
807.572
750.661
812.654
806.724
780.554
611.184
812.654
91.82
764.6 7
836.771
903.82
878.818
903.821
768.554
788.616
537.396
730.538
794.57
762.661
3 . 58
734.57
904.832
757.55
808.739
539.163
842.724
689.56
890.818
774.601
860.77
768.554 772.584
909.868224.1 6
732.554
772.274698.256
846.755
792.708
688.199
8 7.758
694.599
9. 21
788.61
537.166
808.739
719.542
64. 2
910.8 1
832.739
838.787
778.693
655.57
806.724
810.6
50 544
689.5 9859.252
0.64
359.15
906.259
750. 61
764.677
877. 0
498.4
696.615
876.802
789.62
836.238
816.708
933.269
195.124
754.538
930 4
778.691
774.601984.276
694.598
818.724528.411
42. 23
43 .3 659.522
0 .833
1 .539
789.619
552. 97
747.572
36. 6
8 8
902.817
804.708
809.589
910. 71
6 5
792.554
756.553
794.569
734.57
669.58
613.182
832.739
611.185
790.692
92.708
762.661
645.507
7 3.71
519.139
779.696 645.507
7. 05
907.259
776.676
5
806.723
542.426
759.573
696.614
666.567
830. 24
812.655
807.573
63 8
49. 75985.275 790.692
640.552
820.741
36.
762.66
735.574
612.182
572.437
777.679
807.727
37.395
745.557
522. 6805.711
722.63
627.216
631.491
482.324
930.849
757.557
675.544
851.79
768.553
700.235
652.551
859.252
731.542
701.56
736.646
9 4. 69
782.569
773.2 4
655.57
778.692
641.555
864.802
151. 96
835.75
76.802
189.053
20 739
736.645
656.583
802.692
708.614
837.7 4
86 .806
151.097
908.258
8 2.77
860.252
766.574
50.6 1 522.35
751.664
751.664
762.661849.775
817.712
58 453
783.573
4 4.384
708.613
706.539
808.585
669.
8 3.659
4 3.365
858.755
780.708
830. 23
64 .568
8 .82
731.541
789.6
681.586
371.101
764.676 659.522
3.658791.696
4 5
716.522
781.557
748.645
736.645
628. 1
207.159
11 294
721.5 7
538.164
792.708
7 67710. 71
628.195
699.256
21. 43
930.848
804.708
705.52
73 38
773.589
785.589
891.821
832.739
8 0.786
777.68
879.822
879.82
8. 0
935.268
61. 84
819.726
866.723
835.759
904.833
65 .583
861. 73
910.871
808.739
830.7
861. 51
616.4 3
743.542 806.569
770.57
657.50
860.252 724.646
3.602
809.589
860.7
773.58
843.727
464 35
791.696
774.272
850.786
785.232
7 8.53887
793.712
644.427
911.256
902.576
381.1 2
22.755
11.3078 . 7
60.
642.567
84 .75880 .7 6
7 4.554
612 182
724.529
685.204
765.68
1 .7 667.571
15 5846 93
.
9.742
802.692
8 2.6 2
671.522
786.601
687.201
814.692
88 . 01
707.542
63 .234
774.601
628.214
769.557
4 9 36700.234
794.605
0. 08
9 8903. 2
497.343
8 8 5
830.723
81 . 3
784.585
763.664
5.
748.529
683.601
494.3 4
118.086
761.588
850.78
3
762.592
900.802
9 .8 8
673.5 8
82.568
836. 71
291. 330. 9 . 14
804.708
43.7 6
814.6923 .742
786.601554.175 900. 0
06 57
740.521
722.6292 . 3
762.219751.664
80 .691
9 8
39. 9
628.552
624. 51
35.5
731. 0
7 8.677
930.848
8 4.7 6
79 .711809.742
721.557
7 2. 13 795.573
681. 85
8 8.817
904.833
760.576
371.101
195.1 3 84 .771
764.523
812.655
782.5792. 33
689.559
766.693
817 11
5 .374
653.555
931.852
746.571
2 .756
781.5572.708 627.539807 27
74 .58
788.617
769.557
8. 45
701.235
19. 26
700.254
87 . 0
86 .786
779 696
8 . 59
52.67
778.538
796.584
4 . 7
861.25
47. 94 305.269
704.523
735.573
788. 77
732.545
0 . 11
503.10 911.256
10.629
.9
89.62
. 43
654.567
7 3. 8
7 .
685.5 7
28. 08
84 .
721.557
16.833
3 .176
692.523
769. 58
8.693
775.604
703.575
660.49 0 2
814.692
0 42
66 383 .773 874.78
811.604816 70
79 695
724.645769.557
7 0 08807.726
83
686.202
43 .324
65 8 6
553.197
91. 95
93. 1
821.744
788.606
694.598
72 .51265. 8
766. 93
74 7
760.585
82. 9
75 .553
440.358
840.707
7 2.52
866.723
8 779 695 748.528
87 .7 3
6 .553
51 547
7 . 0
666.5 7
44
910.871
751.664
913.811 8.123
782.55
3.664
.
888.802
77 79
0 .309 750. 4
866 72
692.523
9 92
20.544
5 . 2
6 33 . 87
8 .7397 83
687.201
50.78
5 .506
7 6. 32
9 .602
836.616
906.849
731.541
878. 8 76 9
821.742
85. 302.
795.5 2
59.
627.539
62.787
0.355
.5 9
774.6
793.557
808.582
7 3.663
6 1.522
44.739
8 3.682
690.563
371.1 1
5
780.551
559.13
750.50
7 5 78 . 0
733.557
8 .755
789.62
812.607
697.617
7 5.
737.649
755.541
904.591
69 .601
6 . 98 1.725
79 . 24
808. 82
30.847
687.553
2 08 . 9
764.522
66.692
24.77
64. 9
905.835
6 808
738.661
705.59
47 5
8 9.28.7 7
05.042
71 .629
335.2
48.292
74 .5 5
742.538
640 551
5 39
757.557
61 .536
525.374
6 8.583
810.755
. 5
349.2 5
766. 3864
48.585
906. 49
746.569
612.1 2
44 4
67.726
690.563
701.2 5
901. 4
803. 95
670.598
485. 12
7 2.214
737.64
4. 7
22. 45
2 5
42.
8 8.708
. 4 892. 33
52.6 7
909.25
8 1. 3
71 .50
59. 5
9 . 2
766.575
85 . 89
734.629
2
702.23629.195
783.574
7 4.5 8
697.617
861.7 4
539.162 735.573
719.542
858.755
5 1
813. 3
678.506
04.708
9.8 3
752. 7
768.545
71 . 3981.711
3.711
8 .771
936.267
73 .
4 .41
3 61
738.661
837.236
2
8 2.5
752.676
3
520.139
6 7.57
723. 3
60.52901.8 5
812.616
782.566
931.85170.5
904.834
709. 16
720.546
810.601
341. 0
732.554
840.707
762.591
91.
76 93
39
851.79
85.2 5 46. 1
8 .
.49
90 .839
910.872784 57
8 3. 1
70. 9
746.606
746.559
7 5.
4
23 5 633 06
68 3
9 24
7 7.57
769.558
70 .5166 42
749.648
7 9.617
301.141
641. 55
908.865
814.691
3. 59817.71
7 0. 29
802.535
754.535
3 .6
3.21
5 6.166
87 .7 9
8 .606
9 5.836
04.8 4
1
7 5. 6
96
716.523
1 72
94.
383 2
766.6
758.56
0.544
819.727
2.7 3
81 .60
705.5 2
7 71
9 . 2
88 676
19 .123 4 6
7 4. 06
8
63 .491
87. 3
653.554
.56
7 4.629
774.253
7 8.50654.53
. 0331.408 23.6
0 .563
813.659
1 .1 9
724.646
725.649
672. 5
762. 9
781. 1
730.539
538.399
515 . 95
748.575
3. 95
2.582
890.818
647.523
75 .616
906.839
632.494
752.559
93.837
7 4. 76
846 75
6 .
13. 83
. 91
932.865
2 . 9
6 .2
932.864
6 9.235
731.60691 .82
8 . 21
4 .52
4 6.
64. 382 .731
58
8 7.8
752.55
. 4 . 2
3 4
815.6 838.69
810. 55
10.871
70 .598
907. 2
167. 3
804.551
24.
917.83
815.695
1 . 5
836.761 . 67
2.5 1
803.696 764 559692.523
96.33
554.195
6 .2
3. 2
.7 1
.834
9
86 .73
67. 2
2 2 903.579
7 5 32
91 .84
. 7431 91
237
8 .78911
823.759
.284 .129 02
657.58624.528
79 .60 624. 19
707.543
. 59.522
680. 8
564. 1
6 2
.
.
75. 1
71.101
88 0
2 1 4
9.
67520
66.692
808.576
13
90
661.538
66 2
676. 4
80 3
787.604
63. 4613.182
846.293
84 . 74
804.554
762.6
643.571986.274
803.696
8 8
85 .7
2 .1
918.849
633.5071 .61
7 2.523
91 .833
. 41
7 .67
0. 2
2 6.952
. 9
746.56
68 38. 2
. 1
717.591
789.68
0.692
6 .55
610.
51. 1
.5 313
807.573
38. 9. 4
.353
6 7. 75
771. 73
0 575. 2
6 . 024.75
775. 04
1 8 9.47555 6
778 536
689. 9
829.711
99.55
630.19 34 13
852. 0811. 79
75.
8.
716.5
1 1. 96
7
740. 1
863. 9
725.532
1
9 5
788.676
699.553
67.013
7 0. 09
1 . 3
701.56
308.28 . 32 619.491
813.686
8 .717.7
65 .
717.526
86 .726
643. 7 85.58
14. 91
6 . 1
9 4
7 1. 3
7 9.532
960.895
553.3 .264
657.586
868. 3
907.852
79. 2 4 . 49
832. 2
45 4
812. 16
5
701.569768.552.711
2.5
38. 3
6 2
9.66
807.573
1 3
913.
9.7
89.68
7 5. 5
102.12832 .2 5
482.3 4
63. 9
768. 345 74
7.4 767. 6
5 54 .40 48. 4
76 .601
958.88
5 . 2
82 . 93
862 5
5 24
787.6043
904. 3
3
83 .
720.554
86.591
6 .321. 3
3 7 18
74.541
3.429
9.696
52.
1 4
76. 6
71. 5
758.559
717.591
02.2
720.614
49.
790.623
0
48.585
74
767.616
851.
81.632
2.723
3.571
5.557
1 6 5
99
61 .18
672.525
. 7
6. 01
90 .
5 620. 4
8 11
765.526
8 71
810.6
7 .9. 14
6
703. 1 1 823
6 .792
.62 5
40. 59
732. 1
51.0 .
788.616
79.5 1
7.588
6
. 24 61
90 .8
95.628
823. 82.575
552
41. 0
7 5. 5
898.786
783.57
821.6 3
58
83 .619
727.585
372 0
1. 3
769. 2
9
29.
5 .
2. 35
7 .66
1.538
1 .
2
796.585
664.
789.62
741.6
. 2
5.
3
43. 91
0.48
9 893.837
3 4
64.5514.69
790.622
82 .55
723 5162 9. 3
789.62
5 .754
73 6 5
78. 79
5
173.079
18
6 6.5 7
4.
9 .106
2
732.554
7
755. 16
711. 32
67. 2
710.628
90
41 2
5
217 05
870.754
612. 22 .
. 3
66. 0
749.589
6. 92
08. 3
73 . 07
794.569
7 . 27
5.648
3 9
706. 97
70 .526
67.6 5
13. 69
9 .
747. 73
5
7 .
2 .95
90 91 732.554
5
95 64
6 .5416 39
9 0 803
13.6 4
8
4
5 1. 36
6 9.5550 .
811. 8
980.279
9 .911
732.545
59 0 5 .5 1
29.71
33. 67
08.576
8
647.523
15. 9
78 . 3
0 .4
6.6149 7
5 0
8 2. 6
23
7 . 8
610.185
1
30.7 7
701.25
1 .0
1. 2
73 .6
880. 5
.53
91.
79 .6 3
4 . 1
847.293 523.3 8
8 1.
69.632
71. 8
29 08 .
14. 33. 5
532.44
90. 07
6 5. 02
8 1.71
0 7
.
7 0.58909.86
.4560.1 1
1
761.589
906. 48
981.279
51 0 6
5 79. 2
75 .522
7 4.553
6.5731
5 .5119 6
71 .591
2 .9 2
4 .
44.34
05. 11
645. 29
1 3.
774.601
. 5.4
563. 6
8
704.578
6
629.2 4
742.538
690. 3
9 5
2 .51
81 632
6 .
90 2
.
8 1.75
4
73 39
768.59 2. 02
1 62
22 .07
.
53 .163
.88
04.
92. 2
775.604
3.182
173.079
47 7
920.31
9 9. 8
6 .142. 5
.81
7 .
0
7 .56
70 .559
81.75. 17.
5 3.108
. 4
25. 5
.8
796. 4
56 552
132.077
13.569
905.594
66.5365. 7
49 29
6 . 263. 2
. 9
. 44
79.15
09.7 8
98 .277
4 25
91 .824
2 .9 2
892.833
. 1
4 3. 27
2.7094 3. 3
6 .1
.
91 .852
6.95
. 41
739.664
.7 6
84 679
781.5 4
670.58
7 8.617
. 2 .5070
0. 0
87 . 7
7
6 8.5 7
.535
5 8485. 8
7 4.6 1
00 1
619. 9
73 .57
.
75 9
51 .4 4
11. 4
806.57
614.5
6 . 27
.
9 8753.6
0. 3
4.823
0
3 . 1
25.5 4 4
3
6 62
704.523
7 2.561
4 1 9
81 . 16
3
226.44.912.254
8 8 2
780 551
7 .6 204.1 7 7 5.5 35 .
848.292
9
. 4
9 2.8
758.5
92 .3
68 5 2
3 3
173.0 9
7 . 1
173.079
95 29
8 . 8 7
5.5 5
720. 1
3
693. 26
766 0. 988 1633.1
. 71
813. 2
904.823
1. 6
20. 7
688.557
4.8
17.8
4
672. 26
811. 04
.5921.3 3
151.09
68 . 1
2 4.186
8
9. 52
90 . 395
933.
673 389 0 9
00. 76
. 1
746. 6
6 1. 1
8 .
4 331 .23576 .
3. 0
7
92.523
734.57
2 8 1
.
8 3. 37
5.
9 3
804.
906.849.07
671. 01
880.
931.8
58
746.571
8 80
2.
7 578
. 3. 85 .742
7. 6
3 . 3
4
. 4
173.079
2 .9.
772.585
2 .0 9 30 8
10.2 6 5
5
4
772.2 314.6 8
167.013
1 3.079
9
.
7 6
813.
93 .267
0.543
705.591
77 6.
7 9. 5
9 . 42 . 3 32 54
7 .648
4. 92669.50
61.48
747.573
6 1 8 5
45 2
185.15464.
9 .81
5 . 24151 0 7
811.669
1 3.0 5
69. 4
8 6. 8
79 .5 4
749.5
4
7 4
08. 96
704.5 2
934.8
743.542
806.71
1 3.0 9
9
. 59
3 2
3
2 . 2
173.0 9
6 6. 73
3
783.64
6
8 . 4
5 9
3 9
. 84
783.5
4. 2
. 8
327.
73. 9
2
8 9.588
7 8.589
6 .6
5.5 1
4 . 9
2 . 2
918. 49
814.632
2 .
8 4 2
853. 63
173.079
9
2.
3 .
29 34
. 52
763.218
9
1.
826.693
8
73 . 2
173. 79
3 865
862. 7
445.
. 2.29
494.
8 2
06.59
. 5
1 3 079
7
1 818. 1
704.523
6. 6
1
13 694
7 . 3
1 3.079
64 .
19.
.3
76 6
6 .586
54. 3
4
1 96
4 .212
89. 79
. 2
25 4
47 4
173.07
715 5
30
173.079
26 958 1 3
75 .5
5 . 7
.37. 6
795.609
508.34.9
0.5
8
.
8 .4
6 .013
5 3
03.5 8
2 5
722.561
33. 8
56. 8 .698
7
173.0 9
. 6
78 .667
4 .78 2 7
6. 2
173.079
2
. 0
. 44
. 5
.
.
63 8
9
788.23 2 .
4207.1 97 0
.3 .
.9 2
11. 32
2 . 19 4
1
72 . 2
9 4 80
.
1.602
5 . 9
3 4.
1 3.079
790.538
00.1
05.836
74 6
8 8. 7
2 .95
173.0 9
90 .
6. 25 .
0.528. 0
.
8 .824
9 4.
151. 9
78 1
06.538
4
94
73.079
96.6
.
42. 37
89 .7 6 .8
732.61
810 98
72. 02 . 515.
7 .0 9
23. 16
1 3.07
95
8. 7
4 . 2
41 6
34.6
7 5
33 557
69 .5 6
0.
6 .49
800 6
62.661
.
173.079
944.864
4.60 9
7
5
.
173.0 9
44 4
6 .5 45 . 39
. 1.
8 6
.
.
173.0 98
9 2. 1
7 .
8 .
1 82
173.0
.59
9 8
1 . 79
755. 41
8 .5
1 3.078
151.09
91 54
63 . 91
714.50
1 3.079
1
17.52
6. 5
06
90 .80
10 45
702.544
731.542
689. 12
828.5 1
4 3
22.444
748.645
1 . 5
4
3 .
744.54
173.079
173.0 9
4 048 . 0
9. 71 .
.
.809
1 3.0 9
6
98 01
684. 03 7 2.56
173.079
. 7
4
2
.
3.079
7 5.5
15 .0 7
. 9
.
3 . 16
0.2
. 6
7 .
7. 6
75 .685 . 0
2
173 79
1
8
4 4
794.60
8 8
3
5 . 0
1 . 21
17 .0 9
207.1
173.079
6
7 60
3 .51
. 7
772.273
80 . 8
.60
88 . 49
843 9 2 6.9 2
6 .5
73 .4 1
91
8 . 63
0.8 5
32 . 1
173.079
1 1
952
4
. 5
341.
.6 91. 1
4.
800.61
44 .12
4 7
8 . 9
. 6
.
173.079
6
7 .52
0 . 7
173.0 9
33
7 9. 8
32.4
814. 32
4.6 1
. 7
7.043
415.12
173.0 9
29
4.
. 33 8
173.079
5
9 2
26. 52
.1 3.079
3
698 3
11 8
7 3. 2
5 .
38. 1
5 .1
0 . 0
8
2 3 760. 44
173.079
780.69
9.5
173. 4. 4
4 2
93 266
173.079
800.6
5 0.13
2 . 52
9 7
7 .5
2.65
3 3
. 0
7 2.
89.
2.7
703.5 8
680.5 3
1 3.0 9
3
3 7 . 7
1 3.079
.
. 9
4
9
43 .23876 4
22 .952
9 .
25
. 95
703. 5
692. 2
8
.
906.85
9 . 1
173.0 9
6 .
. 3
6
0
813.683
9 7687
9 5.2 9 6. 2
80 .586
2
8
. .512 . 2
762.6 1
. 3
7 8.536
95
173.079
.3
92. 3
. 7
808.58
56 . 6 84. 84
3.
9 7.8 3
10 59
1 64 .52
4
72 .505
58. 8
.7
9
5 584
7 5 3
.
3 . 1
63.
22.667
.34
56.619
7 .
1
. 76 85
79. 1
2 .
2
64.
. 5
92.69 9 88
774. 54
799. 8
7 . 0 .8521
510. 55
9 6.2
.
68 39 2
.
5.125
3
. 7 6 95
98 .72
1 .
0. 3
718.5
.95
9 6
3 1 5
. 5
83 7
.
2. 35
. 8.
5
151.097
666.6
775 4
9151.
72 . 9 79 .
7
73.0 9
9.883
.
2.
6 . 43
6.
6. 44
7
.
3 6
4
151.097
39.668
8 757 0.5
9 .88
8 0. 0
0 91
5
728.523
.6
3.6
2.
9 . 3
173.0
.
06.5
8 6
.
6 .47
30. 8
. 9 02.
2 69
226.9
2 . 52
.
.7 6
.
173.0 9
3.48.
.
8 . 721 .6 8
7
15 .0
.
7 .
3
811.603
32.865
93 .8 8
.
8 2.
. 08
173.079
. 7
611.18
5 3
1 5
2 .6
.
62 . 34
15 .
9 9
.5 9
7 8. 1
9
2. 6
7
7 .57
7 4.
9 . 4 .5 6.9 1
505. 0
895.7
7 6.606
.
0.
.
756.5 2
4 . 4
9 .877 5
. 2
8 5 3
23.
.8
52. 92
7 . 24
8.
57 42
7 2.604
6 . 04
53 .165
797.589
.
1
4
9 5
06
2 440 .1
15 .0
5 .
1
. 74
8 6.71 .09
1
69 538
8
29 02
.
.5
4 .
7 5.628
9 .
17 . 79
. 0
9 1
4 0
6
8 9. 8
986.91
4 .
8 . 371 7.
7 4.24 2
80 .53
5
5.584
81 . 19
9 4
790.623
6 .8 2
1 76
774.
70 .49
97 .65
151.09
7 5 16.55
.0
779.5
5
.5949 5
7 0
7 8.539
1
0.
1 07
44
7 6.576
5
68 5
8.
9 . 6 0 2
795.572
838.235
6.
63 . 8
6 .14
0
70 .572
.. 39. 8
7 94
71 .594
.
1
9
72 . 88
9
72 . 2
3 4
.8 4
8 4
4 .
748.58
7 9. 55
92 . 3 .
3.
92 .8
3
28 .29
614
73.0 9
8 8.6
151 9 1
7
0 9
838.632
.
2 6
5
151.0
3. 8
7 .
9 0. 96
3. 6
7 .5
71
79 . 7
51.0
1 .8 2
1 9 .
4.69 50
7786.
2 .
8 880 .
. 7 8.0
02. 6
4
51.0 7
20.4 40 . 1
9 9 7. 2
2
1 .676
9
151.097
945. 7
610. 8
.0 9
15 . 9
. 3
63 .51
0 56
9
22 .0
98.
983.276
3 4.
.
38. 0
15 . 7
9 .5
2 .55
82
0
0 7
70 6
749. 8
6.
.
58.222
3 .
814.688
770.561
884. 1 54 1
3
2 .9
8 .
.519
. 7. 8 2. 33
9 04
9 882 5
9 .8
2. 7
.13
75 1
.
4 38
1
80 .67
14. 72
.11.
.
3
1 . 9
173.079
151.
.1 3
8
173.079
5 4 6
.
6
6 8.479
8
744.555
.
6
21 5
522 5 7
. 8
151.097
6
7 .
3 . 6
3.0
.
00.5
2 9
0 . 8
.6 3
5
7.
151.097
.5 3 7. 7
. 49
.
44. 64
4
173.079
2 . 2
7 . 6
7 .
711. 3
784.
3.
9. . 1
17 .07 7.
1 .
.0
8 .49151.0 7
5
.7 1.
0
8 .
1 81
5
. 7 1. 1
17 .079
7
503.
6. 2
15 . 9
3 .65 .
55
773.274 55 7
1 08
3 . 4
6 . 8
4 . 5
. 8
9
3.
6 .5
17 .0 3
1 9
. 9
6 4 2
.
173.079
1
5.09
63
. 6 64.6 7
.
45. 7
4.6
30.
288.
58.56
51 09
0.62
9
7
813.62
151.09
9
0 . 2
3 56
634 5
.760. 4
26 9 2
8 .5 4
.
4 5.
9 .2
04.5 2
6 801.6
. 0. 0 . 27
3.5 7
733.557
9.475
. 09 . 0
722.629
6 . 04
151 9
5 .
980.279
6
8 . 9
5
36
9
.
5.
744.5
8 .
8.62
05 7
.1 7
3
. 5
6 . 49. 2
37.19
6
1.
. 1
. 1
5 .
7 1 8
.
8.
9 1
15 .0
76 . 2 5
81.5 4
226.
9 0 1
9 0.
3 . 1.
3 41 7
3
18.5 4
1.097
766.538
5
.
3
8 . 5
1
2 .
2 01
788. 17
8 . 1743.617
1 34 .
..
5.6536.
8
.8
6.
913 .07123 . 79
30.568
. 4 7.15 .
7 9. 21
83 5
91 7
1 .
.61
7 .5
88
4. 0
6.
5 97
. 3
65.5
981.2 9
5
7 5.604
3. 0
0
8 2.6 2
8 5 2
.7 5
.87 .8 9
8
8
. 4 1 .5 2
3. 88 . 9
5 . 58 44 .1 15
1.05 5
..68 7
51. 97
1.8
833.241
9 . 3
63.
3. 9
7 .6
67
3 8
4 1.
8 1.7 1
.15 6
3
1
7
1
444
.0
0
0 5 633
.6 4
8
6 6
.
51. 9
4.
23. 33
.
64.16
75 .5
743.542
28. 95
90 .864
22 9
5
0 0
704.56
792.5 3
1 1.097
5 . 42 .
. 72
1
4.613
.29
9 9.883
7
93 .
6
41
.
48. 8
.
7 .5
79 .587
79 .
702. 9
. 2
2
9 .
6
8 . 00.
.
. 47
04.824
.0
2 8
9 . 6
. 46
5.12
151.09
21 1
.
1.
787 66
95 . 3
6 0
789 9
0 17
1 .0151.0
6 .5
.
.
. 26 .8 0.
6
2
61 9
769 59
6 .
. 14
8 .
599. 04
3 .4 3
.
4
8 .
15 .09
8 .
95
8.5 4
07
.0
6 0. 6
1 59 6
.4
1 9 7 0
9 6.259
4
7 .
4
.
7. 0
81 .635
.
2 5 3
1. 9
. 43
5 .09
.
6
.0 7
9 7.85
.544
4 . 1
4.7
2
2
.
79 .5
9 .6315 . 97
.
2 . 5
9
33. 48
3 .
6
0
6
63.
694
0 79 .6
4 1
15 . 9
.
.8
2
3 88
5
538.162
603
83.5 1
4
3 1
54.
3
8
0
21.
3. 6
. 27 . 3.
9 479 3.868
01.7 .
1 . 01
.
1
7 .66
10
37
5 . 4
.
0.
. 7
1. 5
2 .
51. 99 8 8
5 7. 4
.
9 94
.
5
56
3 .
.09
563
41 01
3
52 135
05 2
31
. 3
.77
9 2.2 7
3
9.5
3
4 59
8
6 .1
8 . 36
46.569
85.204
9 2.832.241
.
9 3
1 4.
.6 4
6
2.586
91
7 3
3.
9
2 4
3
9 .
4. 95
.
17.475
6
0 .6
4.
5
22 . 7
.
1
.6 1 4
.
3
.8. 5
1
2. 7
7
5834.24
5
.
700 7
5 . 9
86.552 6
0 9
1
93 .
51. 96
8 2
.
7 5
.
4 5.
.3
30
11 2
5.8
73 .573
8. 4
5 . 4 . 4.8
746.60
.5
0.675
7. 4
6 1
9 9
6
. 3
. 22
759.2 3
6
.
7 9.573
5
4
9
818.6 4
5
906. 49
. 5.
. 1
0 .5 6
942
.8
5 5
778.536
.
80 . 75
.7 . 7
18. 74
7 4. 5
6
3 6.80
1 . 7
. 8
7 6
4. 14
9 .
93.6 2
. 0
0
.3 .4
. 53. 4
53 .16
.371
8 1.
. 86
. 2
3
8
.
612.18
1 1. 97
.
01 1
6
.
800.676
0
274. 74
8 . 7
6 499
3.7
4 49
1 .09
39
0
4
8 .6
.
.
1. 9
.
7.8 2
.
.866
5.
93
00
.
.6
5. 1
3 3
29 5 6
. 9
151.097
..9 0 7
3
6 0
7 .5 4
. 8
.
3 6
16
. . 3
.
1.09
. 03133 551.
0 . 1
743.54
9
. 7.
26
774.272
10
2
6
52 3
0 1
. 6
. 4
936
907.26
7 0.536
49.6 84 . 9
0
39 6 1
035
2
.6 1
6 2
3
.
. 1 48. 3
0.
4
2 7
41 0
5.54
58
.
795.6
.
4
.
801.61
. 7 8
2 . 5
8 2
8 4
9 .
.0.
.
80
7 6
. 4
702.54
.
.0 315 9
5
0
1 .107
.
81 35
725.56
.. 9
.
. 2
6
90 .579
167.0 3
3 9
3. 5
15 .097
48
.539 4.833
44
31 07
4 8.
0 6
1 1
0 5.0
2 .
.5 91
1 .0
8 . ..
9 3.
. 2
0.
71 4
39
0
0
.
.552
08
2
7. .
. 74
6 .5
8
8
3 .4
700
. 9
8 .
33 4
17
3 .0 11
4 9.089536.
. 3
.
0.8 4
0 5 . 4
.09
6
64 . 7
5 8
504 07
2.5 3
2.
808.5 6
.5
5 5 1
8 6. 02
.
3.
. 8
0. 9
5 .
7 1. 4
3.
.7 5
20.
02
.
6
5
51. 9
. 3.62
9..
49
4 20
1
70 .525
0
. 7
12
9
2 .5 5
5 . 9
.7 1
85
3 .61
8 8
2
..
0 .5
7.92 .98
20. 91
.44
610. 8
8 1 01
.
0
.
871 2
9
151 6
8.
1
7 .
71 . 1
.
5 0 4
72 .
814.632
0 6
.
2 4
.0
1 9
.
3 .
6 5
4 .
.5. 0.
9 9
.
0 .52
4
7 .53
.
0
4
0
0. 0
. .
. 7 7 54
3
3. 2
.
4
9
615. .
391.2
800.673
6 .5 9
2
8 .
5
29 . 6
.529
77 . 1
.
6 5
. .
0 .
7 .
. 59
73.
2 .1
1
.0 5
9 .
5 534
7
6 0.1
80 .53
714.5
4. 71.54
.
4 .
1 .0
. 1
5
4 9
5. 7 5
9 0 . 7
7
7 .5.
9
.
6 .
. 8
94 . 5
2 82
3 .
484 .5 5
. 3
1
0
..49
7 . 6
0 839
3
.7 4
.
7
3 8772 . 4
8
1 .0
.
. .49
589
70 5 9
.
. 1
2 7
. 91
0 .5
688.1 8
.
6 3
.
2
6. 8
4 . .
. 1
8
2
0
0 3
947
. 8
76 .22
0. .
2 . .6 67
.
8
72 .288.29
4 .
.
..
9 . 68
5 1
3
839.6
2
40. 51
3
4
.
.
6
4
5
643.491
7 . 8
20.
1 607 8.5
68 01
.
8 89
1
6
0.
675.54
6. 11
.
1 .
4
.
2. 4
1
984.2 5 8
908.258
7 8.222 7 . 1. 7 0. 4
9
. 7
9 1 81 4 1
.
.
2 .
1
. 1
.
6
2
7 .
. 4
.604
4 .
0.5
.
8 .
9
5
0. 92
7
6
80 . 1
.8
.5
9 33
.331
5 6 6
.61
3
.
.
9 .
3
8
3
7 0 5
64
6 4
85
9 .
689.19 0 0
918.8
5
.
. 2
.
.
29
0
9
7.
4
610. 84
5 .
.5 .
.
.
796.62
3264
4 5.
0
94 . .
.
.
3
.
.
1 3
5
8 . 6
684.203
4
6 . 8
. 8
. 1
559.
8 09
2.
.3 .8 3.2
3
7 6
16
5
.
7 7.668
. 7
89
.
. 5910.
.
3
8
.
. 92
2
5
98
0
.7 66
MZ
SIMCA-P+ 12.0.1 - 2012-10-08 22:34:48 (UTC+0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. PLS loadings plots representing positive ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis  
3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase was analysed by LC-MS in positive ion mode. Before multivariate data analysis, the data 
was processed using SIEVE.  The data represented here have been Pareto scaled, and the RT window 
was set at either 1min, 30sec or 15sec.  Either the raw data or data which were normalised to the total 
ion current were analysed.  Each time point consisted of three biological replicates.  The panels 
represent: 1min RT window, no-norm (A); 1min RT window, TIC norm (B); 30sec RT window, no-norm 
(C); 30sec RT window, TIC-norm (D); 15sec RT window, no-norm  (E) and 15sec RT window, TIC-norm 
(F). 
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3.4.3. Negative ion LC-MS analysis 
Representative chromatograms of days 0, 5, 10 and 25 post-differentiation from negative ion 
LC-MS analysis are shown in Figure 3.15.  Fewer peaks were observed in these 
chromatograms when compared to those from positive ion analyses.  The most abundant ion 
associated with the chromatographic peaks at day 0 (A) and day 25 (B) post-differentiation 
are identified in Table 3.5.  The majority of these had a mass accuracy much greater than 
5ppm, and so these identifications were not confident ones.   
 
The three RT windows which were analysed with positive ion mode data above were also 
used to investigate data acquired in negative ion mode.  As before, the datasets were first 
analysed by PCA, and the scores plots of the non- and TIC-normalised data for all RT windows 
are presented in Figure 3.16.  The sample data in all of the plots present in the figure were 
interpreted as forming two groups, and these were: days 0-6, and days 7-25 post-
differentiation.  Some overlap was observed between these two groups with the two larger 
RT windows (1 min and 30 sec).  The QCs were located inside of the tolerance regions in all 
plots.  Slight differences were observed between the non- and TIC-normalised data, for 
example, in the 1 min RT window models, a point relating to a day 25 post-differentiation 
sample was located outside of the 95% tolerance region with the TIC-normalised dataset (B).  
With the 30 sec RT window models, the non-normalised data (D) also mirrored (B) in the fact 
that one of the day 25 replicates was located outside of the 95% tolerance region.  This point 
moved inside of the tolerance region when the data were TIC-normalised (C) prior to PCA 
analysis. 
 
The R2 and Q2 were calculated for all models, and for the 1 min RT window, these were: 
0.989 and 0.970; and 0.987 and 0.965 for non- and TIC-normalised data, respectively.  When 
the RT window was set to 30 sec, the R2 and Q2 for the non-normalised dataset were: 0.991 
and 0.973, and for the TIC-normalised dataset they were: 0.986 and 0.959, respectively.  
When narrowed to 15 sec, the R2 and Q2 for these models were 0.963 and 0.934 for non-
normalised data, and 0.974 and 0.942 for TIC-normalised data, respectively. 
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Figure 3.15. Negative ion LC-MS analysis of 3T3-L1 cells during adipogenesis 
Representative chromatograms of 3T3-L1 adipocytes, which were induced at day 0 and harvested at 
the following time points post-differentiation:  0 (A), 7 (B), 15 (C) and 25 (D).  Lipids were extracted 
from the cell samples using a Folch extraction.  The lower phase was dried down under nitrogen and 
reconstituted in 600µL chloroform/methanol (2/1, v/v).  The samples were analysed by LC-MS in 
negative ion mode over 18 min for a scan range of m/z 100 – 1000Da.  An increase in the abundance of 
species with RT between 5 and 7.5 min was seen from day 5 post-differentiation onwards, and from 
day 10, the abundance of lipids with RT between 7.5 and 9 min also increased.  
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Retention time  Ion mass Theoretical mass  Δ Mass accuracy (ppm) Ion  Empirical composition  Identification  
(min) 
Day 0 
2.60   311.1686 
2.75   325.1837 
2.89   339.1996 
4.02   564.3447  564.3671   -39.691   [M-H]-  C28H56NO8P  PC (20:0) 
5.12   885.5524  885.5499   2.823   [M-H]-  C47H83O13P  PI (38:4) 
5.58   572.4824  572.5303   -83.664   [M-H]-  C35H63D5O5  DG (32:0) 
5.70   748.5302  748.5498   -26.184   [M-H]-  C40H80NO9P    
6.45   680.6120 
6.85   682.5999 
8.06   158.9750  159.0299   -345.218  [M-H]-  C6H8O5 
9.54   112.9849  113.0608   -671.320  [M-H]-  C6H10O2 
 
 
 
1
5
2
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Day 25 
5.14   885.5503  885.5499   0.4517   [M-H]-  C47H83O13P  PI (38:4) 
5.36   558.4661 
5.59   572.4808  572.5303   -86.458   [M-H]-  C35H63D5O5  DG (32:0) 
5.72   748.5382  748.5134   33.132   [M-H]-  C39H76NO10P  PC (33:0) 
6.85   656.5549  656.6242   -105.540  [M-H]-  C41H75D5O5  DG (38:0) 
7.05   670.5987  670.5264   107.826   [M-H]-  C38H73NO8 
7.23   684.6792  684.6555   34.616   [M-H]-  C43H79D5O5  DG (40:0) 
 
Table 3.5.  Retention times and the associated abundant ion mass of each major chromatographic peak from negative ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis 
 
 
1
5
3
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The loadings plots relating to these PCA plots are presented in Figure 3.17.  Points of 
interest were similar between all loadings plots.  The majority of the points identified 
were phospholipid species, and trend analysis revealed that a large increase in their 
abundance was seen at day 1 post-differentiation, which then steadily decreased until day 
7 where it plateaued for the remainder of the time course.  Individual identifications of 
these points are shown in Table 3.6.    
 
The supervised PLS analysis was also employed on the negative ion data with all three RT 
windows, and this is presented in Figure 3.18.  The grouping of points on these plots 
varied depending on the RT window and normalisation conditions.  When the RT window 
was set to 1 min, three groups were apparent in the data which had not been normalised 
(A).  These groups corresponded to the QCs which were located either on the edge, or 
outside of the 95% tolerance region, and then day 0-6 and 7-25 post-differentiation.  
There was some overlap between the groups, with three points representing day 4 post-
differentiation samples being present in the day 7-25 group.  After these data were 
normalised to the TIC (B), the PLS plot looked slightly different, with two definite groups 
being produced, which were days 0-6 and 7-25 post-differentiation.  The QCs had moved 
from the tolerance region, and were situated within the days 7-25 group.  The overlap of 
day four samples was still seen.  The R2X, R2Y and Q2 for the 1 min RT window model 
were: 0.908, 0.967 and 0.849; and 0.939, 0.977 and 0.954 for non- and TIC-normalised 
data respectively. 
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Figure 3.16. PCA scores plots representing negative ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis 
3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase analysed by LC-MS in negative ion mode. Before multivariate data analysis, the data was 
processed using SIEVE.  The data represented here have been Pareto scaled, and the RT window was 
set at either 1min, 30sec or 15sec.  Either the raw data or data which were normalised to the total ion 
current were analysed.  Each time point consisted of three biological replicates.  The panels represent: 
1min RT window, no-norm (A); 1min RT window, TIC norm (B); 30sec RT window, no-norm (C); 30sec 
RT window, TIC-norm (D); 15sec RT window, no-norm  (E) and 15sec RT window, TIC-norm (F). 
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Figure 3.17. PCA loadings plots representing negative ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis  
 3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase was analysed by LC-MS in negative ion mode. Before multivariate data analysis, the data 
was processed using SIEVE.  The data represented here have been Pareto scaled, and the RT window 
was set at either 1min, 30sec or 15sec.  Either the raw data or data which were normalised to the total 
ion current were analysed.  Each time point consisted of three biological replicates.  The panels 
represent: 1min RT window, no-norm (A); 1min RT window, TIC norm (B); 30sec RT window, no-norm 
(C); 30sec RT window, TIC-norm (D); 15sec RT window, no-norm  (E) and 15sec RT window, TIC-norm. 
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With the 30 sec RT window, the PLS plots were similar for both non-normalised (C) data, 
and data which had been normalised to the TIC (D).  These plots were interpreted as 
having three groups: the QCs which were located outside of the 95% tolerance region; 
and then day 0-6; and 7-25 post-differentiation.  As with the 1 min data, an overlap was 
observed, with the day four samples being present in the day 7-25 group.  Both plots also 
showed one sample from the 7-25 group outside of the 95% tolerance region, and this 
was identified as one of the day 25 samples.  The R2X, R2Y and Q2 for these models were 
0.938, 0.969 and 0.946 for non-normalised data; and 0.913, 0.976 and 0.948 for TIC-
normalised data, respectively. 
 
The final RT window was set at 15 sec, and when the data were not normalised before 
analysis (E), three groups were found.  These were: QCs, day 0-6, and day 7-25 post-
differentiation.  The QCs were located close to the day 7-25 group, and one replicate from 
the day 25 samples was still found outside of the 95% tolerance region.   Another group of 
samples were also found outside this region, and these points related to day one post-
differentiation samples.  The overlap between the sample groups had now disappeared, 
and a clear separation was observed between them.  Once the data had been normalised 
to the TIC (F), the groupings remained the same, although the day one samples were now 
inside the tolerance region.  Clear separation between the sample groups was also seen, 
and the clustering within groups was tighter than that seen in the non-normalised data.  
The R2X, R2Y and Q2 for these models were: 0.892, 0.982 and 0.957; and 0.766, 0.976 and 
0.963 for non- and TIC-normalised data, respectively. 
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Figure 3.18. PLS scores plots representing negative ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis  
3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase was analysed by LC-MS in negative ion mode. Before multivariate data analysis, the data 
was processed using SIEVE.  The data represented have been Pareto scaled, and the RT window was 
set at either 1min, 30sec or 15sec.  Either the raw data or data which were normalised to the total ion 
current were analysed.  Each time point consisted of three biological replicates.  The panels represent: 
1min RT window, no-norm (A); 1min RT window, TIC norm (B); 30sec RT window, no-norm (C); 30sec 
RT window, TIC-norm (D); 15sec RT window, no-norm  (E) and 15sec RT window, TIC-norm. 
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The PLS loadings plots relating to these scores plots are presented in Figure 3.19, and are 
labelled according to their m/z.  Although the plots in the figure looked different from 
each other, the majority of the relevant masses are the same, and are also the same as 
those observed in the PCA loadings plots, and so are also presented in Table 3.6.  These 
selected points were mainly phospholipid species, and once trend analysis was employed, 
it was evident that their abundance over the time course changed in various ways.  The 
abundance of the phospholipids with m/z 722.5130, 748.5313 and 885.5515 initially 
increased at day 1 post-differentiation, and remained so until day 4.  At day 4, their 
abundance sharply decreased and stayed low for the remainder of the time course.  These 
were identified as PE (P-36:4) / PE (O-36:5), PE (P-38:5) / PE (O-37:6) and PI (38:4), 
respectively.    The abundance of another phospholipid with m/z 830.5933 fluctuated until 
day 6 post-differentiation, where it decreased and stabilised over the rest of the time 
course.  This was identified as PS (39:1).   
 
After comparing non-normalised and TIC normalised datasets from both PCA and PLS 
models, for both ion modes, the models were auto-transformed; however, no changes 
were observed, and so these data are not shown. 
 
3.4.4. Eicosanoid analysis by LC-MS/MS 
A targeted lipidomic approach was employed to analyse the secretion of eicosanoid 
species from 3T3-L1 cells over the course of differentiation. Only seven eicosanoids were 
detectable in the 3T3-L1 cell media samples.  These were: Prostaglandin (PG)D2, PGE2, 
PGF2α, thromboxane (Tx) B2, 11β-PGF2α, 6-keto PGF1α and 15-HETE. 
 
The concentration of these eicosanoids showed a trend over the course of differentiation 
(P<0.03 for all; 2 sided), with the exception of 6-keto PGF1α, as presented in Figures 3.20 
and 3.21.   The greatest concentrations of all seven eicosanoids were observed between 
days 0 and 1 post-differentiation.  By day 2, the concentration of these species had 
decreased, and this continued until the end of the time course, with some fluctuation.  
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Figure 3.19. PLS loadings plots representing negative ion LC-MS analysis of 3T3-L1 cells during 
adipogenesis  
3T3-L1 adipocytes were induced to differentiate at day 0, and harvested at the following days post-
differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  Lipids were extracted using a Folch extraction, and the 
lower phase was analysed by LC-MS in negative ion mode. Before multivariate data analysis, the data 
was processed using SIEVE.  The data represented here have been Pareto scaled, and the RT window 
was set at either 1min, 30sec or 15sec.  Either the raw data or data which were normalised to the total 
ion current were analysed.  Each time point consisted of three biological replicates.  The panels 
represent: 1min RT window, no-norm (A); 1min RT window, TIC norm (B); 30sec RT window, no-norm 
(C); 30sec RT window, TIC-norm (D); 15sec RT window, no-norm  (E) and 15sec RT window, TIC-norm. 
(A) 
(E) 
(C) 
(B) 
(D) 
(F) 
Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification  
722.513        722.5130  0    [M-H]
-  
       C41H74NO7P               PE (P-36:4) 
                PE (O-36:5) 
748.5313       748.5287  3.473    [M-H]
-
  C43H76NO7P   PE (P-38:5) 
                PE (O-37:6) 
749.532        749.5338  -2.401    [M-H]
-
 
  
       C40H79O10P               PC (34:0) 
750.553        750.5443  11.592    [M-H]
-
 
  
       C43H78NO7P               PE (P-38:4) 
 PE (O-38:5) 
764.524        764.5236  0.523    [M-H]
-
            C43H76NO8P               PC (35:5) 
766.539        766.5392  -0.261    [M-H]
-
            C43H78NO8P               PC (35:4) 
804.577       804.5549  27.469    [M-H]
-
            C46H80NO8P               PC (38:6) 
830.5933       830.5917  1.926    [M-H]
-
          C45H86NO10P   PS (39:1) 
885.5515       885.5499  1.807    [M-H]
-
          C47H83O13P   PI (38:4) 
886.553        886.5604  -8.347    [M-H]
-
          C50H82NO10P   PS (44:8) 
 
Table 3.6. Lipid species identified as causes of variance from negative ion loadings plots 
1
6
1
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Figure 3.20.  Secretion of eicosanoid lipids by 3T3-L1 cells during adipogenesis 
Eicosanoids were extracted from 3T3-L1 cell culture medium by solid phase extraction chromatography 
for the following days post-differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  The extracted samples were 
analysed by LC-MS/MS in negative ion mode, and individual eicosanoids were monitored using specific 
precursor to product ion m/z transitions. Selected eicosanoids were quantified using relevant internal 
standards (either 15S-HETE-d
8
, LTB
4
-d
4
 or PGE
2
-d
4
) and then normalised to the protein concentration of 
the cell sample.  Results are presented as median ± range, for a group size of 3.  The selected 
eicosanoids are PGD
2
 (A), PGE
2
 (B), PGF
2α 
(C) and TxB
2
 (D).  A 2-sided Cuzick’s test for trend was 
applied, and a trend was observed in the secretion of all eicosanoids (P<0.03 for all).  
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Figure 3.21.  Secretion of eicosanoid lipids by 3T3-L1 cells during adipogenesis 
Eicosanoids were extracted from 3T3-L1 cell culture medium samples by solid phase extraction 
chromatography for the following days post-differentiation: 0-10, 12, 15, 18, 20, 22 and 25.  The 
extracted samples were analysed by LC-MS/MS in negative ion mode, and individual eicosanoids were 
monitored using specific precursor to product ion m/z transitions. Selected eicosanoids were 
quantified using relevant internal standards (either 15S-HETE-d
8
, LTB
4
-d
4
 or PGE
2
-d
4
) and then 
normalised to the protein concentration of the cell sample.  Results are presented as medium ± range, 
for a group size of 3.  The selected eicosanoids are 11β-PGF
2α
 (A), 6-keto PGF1α (B) and 15-HETE (C).  A 
2-sided Cuzick’s test for trend was applied, and a trend was observed in the secretion of all 
eicosanoids, with exception of 6-keto (P<0.03 for all). 
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3.5. DISCUSSION 
An increase in adiposity is observed in the obese state, which is caused by hypertrophy of 
mature white adipocytes, and/or adipogenesis of pre-adipocytes (Johnson et al., 1971; Faust 
et al., 1978; Johnson et al., 1978).   This process was explored in the current study in vitro, 
using the established 3T3-L1 cell line and a combination of morphological, transcriptional and 
lipidomic analyses were used to investigate specific areas of adipogenesis.  The 3T3-L1 cell 
line was validated histologically, and by the expression of key adipokines by comparison with 
previous studies.  Once validated, this model was then used to explore lipid profile changes 
associated with adipocyte differentiation. 
 
3.5.1. Validation of the 3T3-L1 cell line  
During adipogenesis, the 3T3-L1 cells start to accumulate lipids in the form of droplets, and 
change from a fibroblast appearance, to a spherical one (Green and Meuth, 1974; Green and 
Kehinde, 1976).  These morphological changes were evident in the current study. By 
successfully inducing pre-adipocytes to differentiate into fully mature adipocytes, as proved 
by the accumulation of lipid droplets, the 3T3-L1 pre-adipocyte cell line was considered a 
suitable model for the analysis of adipogenesis.   
 
To validate this cell culture system further, the gene expression and secretion of the 
differentiation dependent proteins leptin and adiponectin were profiled.  The gene 
expression of leptin (MacDougald et al., 1995) and adiponectin (Ouchi et al., 1999) only 
occurs after the induction of adipogenesis.  These findings were replicated in the current 
study, as RT-PCR and qPCR, and ELISA analyses only detected gene expression and secretion 
of these proteins after the differentiation process had been initiated.  
 
 
For qPCR analyses, a normalisation step is required to correct for sample to sample errors.  A 
common normalisation method is to use an internal control, or housekeeping gene, whose 
expression should remain stable between cells or tissues, and environmental conditions 
(Dheda et al., 2004; Radonic et al., 2004).  Many of the well-used housekeeping genes have 
shown varying levels of expression between tissues, and so are unsuitable for use as a 
control.  One way to counteract this is to use a number of housekeepers for each 
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experimental condition (Schmid et al., 2003).  For that reason, three housekeeping genes 
were used in the current study.  Both β-actin and GAPDH produced similar profiles for both 
adipokines, suggesting little variability between them, whereas RNApol2 produced a different 
profile for both leptin and adiponectin.  On inspection of the raw data it was noted that there 
was a great degree of variability in the CT values for RNApol2 between samples.  This suggests 
that RNApol2 was not an adequate housekeeping gene, and so it was decided to remove it 
from future qPCR analyses.   
 
3.5.2. Changes in global lipid profiles during adipogenesis 
Changes across the course of differentiation were also observed with global lipidomic 
techniques.  Both DI-MS and LC-MS analyses were undertaken in positive and negative ion 
modes to maximise the coverage of the lipidome within the 3T3-L1 adipocytes.  Positive ion 
DI-MS analysis showed a shift in the abundant lipids present from phospholipids (mainly PCs) 
to TGs over the course of differentiation.  It has been documented that an increase in odd-
chain FAs, mainly in the form of TG, occurs as 3T3-L1 cells differentiate (Su et al., 2004).  A 
previous study found that FAs could be generated during 3T3-L1 metabolism by the 
utilisation of glucose.  Once synthesised, they were either Δ9 desaturated, or underwent α-
oxidation to produce odd-chain FAs (Roberts et al., 2009).  However, this α-oxidation only 
occurred after differentiation, and pre-adipocytes contain minute concentrations of odd 
chain FAs, which increase after differentiation (Su et al., 2004). The synthesis of unsaturated 
FAs is catalysed by the enzyme stearoyl-CoA desaturase 1 (SCD1). The gene encoding this 
enzyme is differentiation-dependent, and has been isolated from 3T3-L1 pre-adipocytes 
(Ntambi et al., 1988).   
 
With the negative ion DI-MS data in this study, the most abundant lipid present in the 3T3-L1 
cells from approximately day 3 post-differentiation onwards was the monounsaturated long-
chain FA C18:1, identified as oleic acid.  A very recent study found that oleic acid is involved in 
the proliferation of 3T3-L1 pre-adipocytes.  When post confluent pre-adipocytes were 
exposed to low concentrations of oleate, an increase in the division and proliferation of these 
cells was observed; however, no effects were seen at a greater concentration.  In mature 
3T3-L1 adipocytes, as the concentration of oleate increased, the number of viable cells 
decreased due to apoptosis and necrosis, suggesting that this FA has cytotoxic effects in 
mature adipocytes (Rohana et al., 2011).  
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Principal component analysis and partial least squares analysis were used to analyse both 
positive and negative LC-MS data.  Three RT window values selected at the pre-processing 
stage were tested in the current study for each of the models.  As the RT window narrowed, 
the clustering of groups became tighter, showing greater separation between early and late 
time points during the process of adipogenesis.    This may be because as the RT window 
narrows, more frames are created, providing a more thorough representation of the 
chromatogram.  A reduction in R2 and Q2 for PCA, and R2X, R2Y and Q2 for PLS models 
occurred as the RT window decreased; however, these values were above 0.5 in all models, 
which indicates a good fit and good predictability.  It was, therefore, decided that, for further 
PCA and PLS analyses, the RT window would be set at 15 sec. 
 
Variation in the abundance of various lipid species was observed over the course of 
differentiation in the loadings plots.  The majority of the selected points were phospholipid 
species, and the abundance of those identified in positive ion mode increased from as early 
as day 5 post-differentiation.  Those identified in negative ion mode showed an initial 
increase in abundance between days 0 and 3, followed by a decrease until the end of the 
time course.  Therefore, opposing actions occurred in the abundance of the phospholipid 
species identified.  A previous study has demonstrated that phospholipid content of cultured 
3T3-L1 adipocytes was approximately 8-fold greater than that of pre-adipocytes, and the 
majority of these lipids present were PC and PE species.  This increase in the phospholipids, 
along with TG species and cellular protein was observed from day 3 post-differentiation 
onwards (Kasturi and Wakil, 1983).  The authors of this study suggested that the increase in 
phospholipid and protein content observed during the differentiation process may be due to 
a requirement for membrane synthesis and assembly.   
 
 
The decrease in phospholipid species abundance from the negative ion datasets were seen 
from approximately day 4 post-differentiation, which may explain why samples from this 
time point were situated closer to the day 7-25 group rather than the day 0-6 group in the 
majority of PCA and PLS models.   
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3.5.3. Changes in eicosanoid secretion during adipogenesis 
A change in the production of AA-derived eicosanoid species by these cells was also observed 
as the 3T3-L1 cells began the differentiation process.  Only members of the prostanoid family, 
which consists of PG and Tx species produced via the cyclooxygenase pathway, were 
detectable in the media samples of the differentiating cells, with the exception of 15-HETE.  It 
is known that adipocytes can synthesise prostanoids, with the secretion of PGE2, 6-keto-
PGF1α, PGF2α and 15d-PGJ2 by 3T3-L1 adipocytes being documented (Borglum et al., 1999).  A 
previous study demonstrated that 3T3-L1 adipocytes produce different concentrations of 
prostanoids depending on their life cycle.  The formation of PGD2 occurred during the 
maturation phase, whereas PGE2 was more efficiently produced by pre-adipocytes (Lu et al., 
2003).  PGE2 negatively modulates cAMP production and lipolysis in both human and rat 
adipocytes, via interaction with specific receptors, which could explain the increased 
accumulation of TG (Strong et al., 1992; Vassaux et al., 1992b).  In contrast, PGF2α inhibits 
adipocyte differentiation (Miller et al., 1996; Vassaux et al., 1994).  The data presented in the 
current study agree with these findings, PGD2, PGE2 and PGF2α were all detectable in the 
medium from both pre- and fully mature adipocytes.  For all profiles, a transient increase 
occurred, followed by a gradual decline.  Seeing as PGF2α inhibits adipocyte differentiation, 
this decrease could explain the continual accumulation of lipid droplets.  An initial increase of 
PGE2 suggests more efficient production by pre-adipocytes, and although concentration 
decreases over the time course, it is still detectable in mature adipocytes, which may help 
inhibit lipolysis.  Finally, PGD2 was detectable across the course of differentiation, possibly 
aiding maturation of these cells. 
 
 
The AA-derived non-prostanoid 15-HETE was also detected, and this eicosanoid is a product 
of the lipoxygenase pathway, and has been suggested to derive from leukocyte-12/15-LO 
when it reacts with saturated fatty acids (Chakrabarti et al., 2009).  A role in adipocyte 
differentiation has been suggested as the inhibition of 12/15-LO prevents 3T3-L1 cells 
differentiating into mature adipocytes (Madsen et al., 2003).  Even though the present study 
shows a decrease in 15-HETE secretion from day 4 post-differentiation onwards, it is still 
detectable throughout the time course, and so may play a part in adipocyte differentiation.  
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3.5.4. Limitations and future directions  
A few limitations were present in the current study, which related to the global lipidomic 
analyses.  The first was the fact that with the direct infusion data, only the mass-to-charge 
ratio could be used to search the lipid databases for identification of the lipid species.  With 
the LC-MS data, the retention time was also used alongside the mass-to-charge ratio, thereby 
providing extra information to aid in the identification of lipid species.  By only having exact 
mass data, fatty acid compositions could not be assigned to the phospholipid or triglyceride 
species.  For example, PC 16:0/18:1 could also be PC 18:1/16:0, or PC 16:1/18:0 etc. and it is 
impossible to determine which one is correct with only m/z.  Therefore, in the current study, 
this phosphatidylcholine species would be named PC (34:1).  A final limitation was the slight 
shift in retention time observed in some of the global LC-MS chromatograms. These shifts 
could have been occurred due to many reasons, one of which is fluctuations in temperature.    
In the current study, the mobile phases had to be remade occasionally, due to the quantity of 
samples, and so slight variations in mobile phase composition may have been the cause.  
Ideally, all samples would have been run with the same mobile phases (A and B) for all 
samples, to help eliminate these shifts.   
 
5.3.5. Conclusions and future work 
The work presented in this chapter demonstrated that as 3T3-L1 cells were differentiated 
from pre-adipocytes to fully mature adipocytes, changes in lipid metabolism occurred.  
Individual lipid species were identified, and positive ion analyses showed a change from the 
presence of predominantly phospholipid species in the pre-adipocytes, to mainly triglycerides 
in the mature adipocytes.  Analysis of selected individual species also found that the 
concentration of TG (48:2) and TG (50:2) became greater than that of PC (34:1) and PC (36:4) 
at day 7 post-differentiation, and continued to increase throughout the remainder of the 
time course.  This was expected due to the continual accumulation of lipid droplets which is 
characteristic of this cell line during the differentiation process.   
 
Various AA-derived eicosanoid species were secreted by the 3T3-L1 cells in the current study, 
and their concentrations were greatest at the stage of pre-adipocyte and early 
differentiation.  Of interest were the prostanoids PGE2 and PGF2α because they are known to 
have contrasting actions, with PGE2 reducing lipolysis in human and rat adipocytes (Strong et 
al., 1992; Vassaux et al., 1992b) and PGF2α inhibiting adipocyte differentiation (Miller et al., 
1996; Vassaux et al., 1994).  These eicosanoids are produced from AA (Piomelli, 1993), which 
is released from membrane phospholipids.  This fatty acid was identified in the current study 
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(C20:4), and its concentration was seen to decrease in the later time points.  This may also 
play a role in the decreased concentration of all detected eicosanoid species observed after 
differentiation in the current study.   
 
Therefore, it was concluded from the current study that the individual lipid metabolism 
processes investigated could possibly to be linked.  Maturation from a pre-adipocyte to an 
adipocyte led to a lipid profile change from mainly phospholipid species, to predominantly 
triglycerides.  This switch caused a decrease in arachidonic acid, and therefore eicosanoid 
production by the cells further on in the differentiation process.  A decrease in the 
concentration of certain eicosanoids allows the continuation of lipid accumulation associated 
with adipogenesis, for example PGF2α which inhibits the process, and would allow the 
accumulation of TG species, as identified by morphological changes, and also the change in 
lipid profiles. 
 
Various extra experiments would improve these conclusions.  One example would be to 
investigate the gene expression of SCD1 which is expressed in adipocytes in a differentiation 
dependent manner (Ntambi et al., 1988), and aids the synthesis of unsaturated FAs.  It would 
be interesting to observe how the gene expression of SCD1 changes, in relation to the shift in 
lipid species observed in the current study. 
 
Various genes are involved in the induction of adipogenesis, including   PPARγ, C/EBPα and 
ADD1/SREBP1c.  It would be of interest, therefore, to monitor the gene expression of these 
factors, also to see if their expression profiles correlate to the findings in the current study.   
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CHAPTER 4: 
Effect of inflammatory agents on 3T3-L1 adipocyte 
metabolism 
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4.1. INTRODUCTION 
Obesity is characterised by chronic low-grade systemic inflammation (Yudkin et al., 1999; 
Festa et al., 2001), and changes in the gene expression and protein secretion of a number of 
adipokines and cytokines have been linked to this inflammatory state (Trayhurn and Wood, 
2004).  One example is TNF-α, the production of which increases in rodent models of obesity 
(Hotamisligil et al., 1993).  This cytokine acts in both an autocrine and paracrine way to 
influence its own expression, as well as a number of other processes, including the 
production and inhibition of several adipokines and cytokines.  For example, TNF-α treatment 
of human adipocytes caused conflicting effects of the gene expression of various adipokines 
and cytokines, with an increase in that of IL-6 as well as itself being observed.  No effect on 
leptin gene expression was seen, whereas that of adiponectin decreased (Wang et al., 2005). 
 
The cytokine IL-6 also has an autocrine effect on its own gene expression and protein 
secretion in murine adipocytes, and is capable of inducing insulin resistance in these cells 
(Lagathu et al., 2003).  Conflicting reports about the effect of IL-6 on leptin expression exist, 
with a previous study finding that IL-6 decreases leptin expression in rodent adipocyte 
models (Granowitz, 1997).  In contrast, reports in human adipose tissue have shown that IL-6 
either increased or had no effect on leptin gene expression, depending on the experimental 
conditions used (Bruun et al., 2002; Tujillo et al., 2004).  Adiponectin expression has been 
shown to be inhibited by IL-6 (Fasshauer et al., 2003b). 
 
There is increasing evidence demonstrating that TNF-α is involved in the dysfunction of 
normal lipid metabolism, as seen in TNF-α deficient mice which have decreased circulating 
free fatty acids (FFA) and triglycerides (TG) compared to their wild-type littermates (Uysal et 
al., 1997; Ventre et al., 1997).  The addition of TNF-α to 3T3-L1 adipocytes stimulates lipolysis 
(Kawakami et al., 1987).  And a similar finding was observed in primary rat epididymal 
adipocytes, where the addition of TNF-α caused an increase in lipolysis, although no change 
was seen in the concentration of hormone-sensitive lipase (Green et al., 1994).  TNF-α is an 
important mediator of obesity-related insulin resistance (Hotamisligil et al., 1993; 1994 and 
1995).  Stimulation of lipolysis leads to an increase in the concentration of FFA, and so, the 
insulin-resistant state caused by TNF-α may be due to increased lipolysis (Miles et al., 1997; 
Peraldi et al., 1997). 
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A role for IL-6 in lipid metabolism has also been suggested, with a previous study 
demonstrating that it decreases the activity of lipoprotein lipase (LPL) in the 3T3-L1 cell-line 
(Greenberg et al., 1992).  This finding was also supported in obese human patients, who 
demonstrated decreased LPL activity and increased rates of spontaneous or basal lipolysis 
after IL-6 treatment (Trujillo et al., 2004).  A previous in vitro study demonstrated that IL-6 
impaired insulin signalling in 3T3-L1 and human adipocytes (Rotter et al., 2003).   
 
The inflammatory state associated with obesity also has an effect on the production of 
various eicosanoid species.  Treatment with TNF-α is known to decrease lipoprotein lipase LPL 
synthesis and inhibit adipocyte differentiation.  Increased gene expression and protein 
secretion of COX-2 has been observed in response to TNF-α treatment of pre-adipocytes (Xu 
et al., 2007); whereas COX-2 inhibitors have been shown to reverse the inhibition of 
differentiation induced by TNF-α (Yan et al., 2003).  Coupled to this is the fact that TNF-α also 
stimulates the formation of PGE2 in various cell types (Dayer et al., 1985; Bachwich et al., 
1986; Lehmmann et al., 1988), which itself also causes inhibition of adipocyte differentiation 
(Vassaux et al., 1992b). 
 
 
4.1.2. Aims of the current study 
Previous studies have shown that the inflammatory state associated with obesity causes 
normal lipid metabolism processes within the adipocyte to become dysregulated.  Therefore, 
the purpose of the current study was to explore the effects of the inflammatory agents TNF-α 
and IL-6 on the normal function of 3T3-L1 adipocytes.  These cells were treated at day 10 
post-differentiation with either TNF-α or IL-6 at three concentrations for either 2, or 24 hours 
(h). 
 
The first specific aim was to quantify the gene expression of leptin, adiponectin, IL-6 and TNF-
α in both the control day 10 adipocytes, and also in those which had been treated with the 
inflammatory agents.  It was predicted that normal adipokine gene expression would be 
affected, specifically the gene expression of leptin, TNF-α and IL-6 would increase in the 
treated cells when compared to the control cells, whereas the gene expression of adiponectin 
would decrease.  This prediction was based on previous findings after treatment with TNF-α 
(Wang et al., 2005) and IL-6 (Granowitz, 1997; Bruun et al., 2002; Fasshauer et al., 2003b; 
Lagathu et al., 2003; Tujillo et al., 2004). 
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The second aim was to produce global lipid profiles of these adipocytes.  It was predicted that 
the majority of the lipid species present would be both phospholipid and triglyceride species; 
however, the abundance of these species would change after treatment with TNF-α and IL-6, 
causing a lipid profile change. 
 
After global lipid profiles were produced, the final aim was to monitor any changes in the 
concentration of detected eicosanoid species secreted by these adipocytes, and it was 
hypothesised that the concentration of any detected species would increase in the cells 
treated with the inflammatory agents when compared to the controls. 
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4.2 MATERIALS AND METHODS 
4.2.1. Cell culture 
3T3-L1 adipocytes were cultured at 37oC in a humidified atmosphere of 5%CO2 / 95% air as 
previously described in Section 2.1.3.  All media protocols are listed in Section 2.1.2.  The cells 
were induced to differentiate at day 0, and all treatments occurred at day 10 post-
differentiation.  The adipocytes were starved of calf serum (CS) for 24 hours (h) before 
treatment, by feeding with DMEM alone.  After 24h, the cells were treated with CS-free 
medium containing either mouse recombinant TNF-α or IL-6 at the following concentrations: 
5, 25 and 50 ng/mL.  The control cells had the CS-free incubation medium renewed.  The cells 
were harvested at two and 24h post-treatment, along with the medium, and both were 
stored at -80oC until needed.  
 
4.2.2. Real time PCR  
Total RNA was extracted from cultured cells using TRI Reagent® as described in Section 2.4.2.  
Gene expression was quantified by real-time PCR (qPCR) as described in Sections 2.6.2.2 and 
2.6.3.  The genes investigated in this chapter were leptin, adiponectin, TNF-α and IL-6. 
 
4.2.3. Global lipidomic analysis 
4.2.3.1. Cell preparation  
Lipids were extracted from cell and quality control (QC) samples using the Folch extraction 
method (Folch et al., 1957) as described in Section 2.10.2, and the lower chloroform phase 
was dried down under nitrogen, and reconstituted in 600µL chloroform / methanol (2/1, v/v).  
Ammonium formate (10mM) was added to the direct infusion-mass spectrometry (DI-MS) 
analysis samples, but not the liquid chromatography-mass spectrometry (LC-MS) samples.  
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4.2.3.2. DI-MS method 
The lipid extracts were directly infused into an Orbitrap Exactive mass spectrometer in both 
positive and negative ion mode as described in Section 2.10.4.  Selected lipid peaks were 
quantified using an appropriate internal standard, either 1,2-didodecanoyl-sn-glycero-3-
phosphocholine, PC 12:0/12:0, or, 1,2,3-trioctadecanoyl-sn-glycerol TG 18:0/18:0/18:0, and 
then normalised to the protein concentration of the cell samples.  Three databases were used 
to identify the lipid species based on their mass-to-charge ratio (m/z), and they were: the 
Human Metabolome Database (HMDB; www.hmdb.ca), LIPID Metabolites and Pathways 
Strategy (LIPID MAPS; www.lipidmaps.org), and the Metabolite and Tandem MS Database 
(METLIN; http://metlin.scripps.edu).  Confident identifications were assumed when the mass 
accuracy was within 5 parts per million (ppm), and unless stated, all discussed lipid species 
were within this parameter. 
 
4.2.3.3. LC-MS method 
Lipid extracts were analysed by LC-MS as described in Sections 2.10.6.2 and 2.10.6.3.  All LC-
MS raw files were processed using SIEVE to produce m/z, retention time (RT) and intensity 
values.  The RT window was set to 15 seconds (sec).  Lipids were identified with the databases 
mentioned above in either positive or negative ion mode.   
 
4.2.3.4. Multivariate data analysis of LC-MS data  
The RT and m/z pairs, along with their intensities were normalised to the total ion current 
(TIC) intensity.  The multivariate data analysis (MVDA) package SIMCA-P (v12) was used for 
principal component analysis (PCA) and partial least squares (PLS) analysis of the normalised 
and non-normalised datasets, and all models were Pareto scaled. 
 
4.2.4. Targeted eicosanoid analysis 
Eicosanoids were extracted from 3T3-L1 medium samples using solid phase extraction 
chromatography, as described in Section 2.11.1 and 2.11.2.1.  Once the eicosanoids had been 
eluted, they were dried down under a gentle stream of nitrogen and reconstituted in 100µL 
H20:MeOH (1:1, v:v).  The samples were then analysed by LC-MS/MS using a TSQ Quantum 
Ultra triple quadrupole mass spectrometer, as described in Section 2.11.3.  Identification of 
the eicosanoid species was achieved by using specific precursor-to-product ion m/z 
transitions, which are shown in Table 2.3 (Chapter 2).   
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4.2.5. Statistical analysis 
All statistical analyses were completed using StatsDirect.  To determine the normality of the 
sample data, a Shapiro-Wilk W test was used.  All of the mass spectrometry data were not 
normally distributed, and so the non-parametric Friedman's two-way analysis of variance test 
was used followed by an all pairwise comparisons (Conover) post-hoc test to identify 
differences between groups.  Statistical analysis of qPCR data is often completed using non-
parametric tests irrespective of normality (Yuan et al., 2006), and so the Friedman’s two-way 
analysis of variance test was also used for all qPCR analyses.  Normally distributed data were 
presented as mean values ± SD, whereas data which were not normally distributed were 
presented as median ± range.  The group size used is indicated in the figure captions, and a P-
value of < 0.05 was considered statistically significant. 
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4.3. RESULTS  
4.3.1. Gene expression of leptin and adiponectin 
The gene expression of four genes was monitored in response to either IL-6 or TNF-α, and 
these were leptin, adiponectin, IL-6 and TNF-α.  After 2h of TNF-α treatment (Figure 4.1), a 
direct relationship was seen between TNF-α treatment concentration and leptin gene 
expression, although the increase was only significant at the greatest concentration 
(50ng/mL; P=0.014 vs. control; Figure 4.2A).  The inverse relationship was observed at the 
24h treatment time (P<0.05 vs. control for all).  A significant decrease in adiponectin gene 
expression was seen at both time points for the 25 and 50ng/mL TNF-α treatment 
concentrations (P<0.001 vs. control; Figure 4.2B).  A significant increase in IL-6 gene 
expression was seen at the greatest treatment concentration (50ng/mL) after 2h of TNF-α 
treatment (P=0.008) and this profile was similar after 24h of treatment, although the gene 
expression was significant for all concentrations (P<0.01 vs. control for all; Figure 4.1C). TNF-α 
gene expression was undetermined in the majority of the TNF-α treatment concentrations at 
both time points, and so was not presented in the figure. 
 
After 2h of IL-6 treatment (Figure 4.2), an increase was seen in leptin gene expression (A) 
which became significant at 25 and 50 ng/mL (P=0.032 vs. control for both), and an increase 
was also observed after 24h of treatment (P<0.001 vs. control for all concentrations).  No 
significant changes were observed in the gene expression of adiponectin at the 2h treatment 
time; however, after 24h of treatment a decrease was observed at the two greater 
concentrations (P<0.001 vs. control for both 25 and 50ng/mL; Figure 4.2B).  IL-6 treatment 
caused an increase in its own expression after 2h (P=0.007 and P<0.001 vs. control for 25 and 
50ng/mL, respectively).  A similar increase was also seen after 24h of IL-6 treatment (P=0.013 
and P<0.001 vs. control for 5 and 50ng/mL, respectively; Figure 4.2C).  The gene expression of 
TNF-α increased after 2h of IL-6 treatment at 50ng/mL (P<0.001 vs. control; Figure 4.2D).  At 
the 24h IL-6 treatment time, an increase in the gene expression of TNF-α was seen at two of 
the concentrations (P<0.001 vs. control for 5 and 50ng/mL, respectively).  
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Figure 4.1. Adipokine gene expression of TNF-α treated 3T3-L1 adipocytes  
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24h, and then treated with mouse recombinant TNF-α for 2 and 24h.  The concentration of 
TNF-α treatments were 5, 25 and 50ng/mL.  Adipokine gene expression was quantified by qPCR and 
normalised to GAPDH relative to the control group.  Results are represented as means ± SD for a group 
size of 6.  The adipokines quantified were leptin (A), adiponectin (B), and IL-6 (C). Significant increases 
were observed in the gene expression of leptin and IL-6, whereas adiponectin gene expression was 
seen to significantly decrease with TNF-α treatment. Statistical significance from the control cells is 
represented by *P<0.05; **P<0.01 and *** P<0.001. 
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Figure 4.2. Adipokine gene expression of IL-6 treated 3T3-L1 adipocytes  
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24 hours, and then treated with mouse recombinant IL-6 for 2 and 24 hours.  The 
concentration of IL-6 treatments were 5, 25 and 50ng/mL.  Adipokine gene expression was quantified 
by qPCR and normalised to GAPDH relative to the control group.  Results are represented as means ± 
SD for a group size of 6.  The adipokines quantified were leptin (A), adiponectin (B), IL-6 (C) and TNF-α 
(D).  The gene expression of leptin, IL-6 and TNF-α increased after 24h of IL-6 treatment, whereas 
adiponectin gene expression decreased. Statistical significance from the control cells is represented by 
* P<0.05; **P<0.01 and *** P<0.001. 
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4.3.2. Positive ion mode DI-MS analysis 
4.3.2.1. TNF-α treatment  
Representative positive ion spectra of control cells and those treated with 50ng/mL TNF-α at 
24h, are presented in Figure 4.3 (A and B, respectively).  Differences were observed in these 
global lipid profiles between the control and treated cells at both time points.  More peaks 
were present between m/z 700 and 900Da in the control cells when compared to the TNF-α 
treated samples.  The abundance of all peaks seemed to decrease in the treated samples, as 
seen by the increase in the peaks with m/z 622.4432 and 908.8631, which relate to the 
internal standards. 
 
The ten most abundant peaks from the global lipid profiles of the control cells, and the top 
ten from the TNF-α treated samples from Figure 4.3 were identified, and are presented in 
Table 4.1.  In the control cells (A), the lipids identified were all either phosphatidylcholine 
(PC), diglyceride (DG), or triglyceride (TG) species.  In the TNF-α treated cells, the top ten 
abundant peaks were different from those seen in the controls, with exception of the peak 
with m/z 575.50.  The majority of the remaining lipids were either DG or TG species.  There 
were also two phospholipid species present.  The majority of these species had a mass 
accuracy much greater than 5ppm, and so were not considered to be confident 
identifications.   
 
The lipid species identified in Table 4.1 were quantified using the relevant internal standard, 
either PC (12:0/12:0) or TG (18:0/18:0/18:0), with m/z 622.4432 or 908.8631, respectively.  
They were then normalised to the protein content of the sample.  After this stage, the top 
four lipid species from the control cells, and all TNF-α treatments at both 2h (A) and 24h (B) 
were represented graphically in Figure 4.4.  These species had m/z 575.5023, 603.5342, 
846.7528 and 874.7845, and were identified as DG (33:4); DG (35:4); TG (50:3) and TG (52:3).  
After 2h of TNF-α treatment, no changes in the concentration of these lipids was observed, 
with the exception of DG (35:4) which decreased (P=0.005 and P<0.001 vs. control for 5 and 
50ng/mL, respectively).  The concentration of this lipid species also decreased after 24h of 
TNF-α treatment (P=0.0134 and P<0.001 vs. control for 5 and 25ng/mL, respectively).  The 
remaining lipids all behaved in the same way, with a decrease in their concentration at 5 and 
25ng/mL, followed by an increase at the greatest treatment concentration (P=0.05 for all).   
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Figure 4.3. Positive ion DI-MS analysis of TNF-α and IL-6 treated 3T3-L1 adipocytes                                                                                                                
Representative spectra of differentiated 3T3-L1 adipocytes at day 10 post-differentiation which were 
pre-incubated with CS-free medium for 24h, and then treated with mouse recombinant TNF-α or IL-6 
for 2 and 24h.  The treatments represented are: control 24h (A); 50ng/mL TNF-α 24h (B) and 50ng/mL 
IL-6 24h (C). Lipids were extracted from the cell samples using a Folch extraction.  The lower phase was 
dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 150µL 
aliquot was removed and had 10mM ammonium formate added to it.  The samples were then directly 
infused into an Orbitrap Exactive mass spectrometer at a flow rate of 5µL/min for 90 seconds (450 
scans) in positive ion mode.  The m/z range represented is between 500 and 950Da.  A greater relative 
abundance of peaks with m/z 622.44, 874.78 and 908.86 were observed in the treated cells compared 
to the controls. 
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Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification  
 
(A) Control  
535.4715  535.4387  61.258    [M+H]
+ 
 C33H58O5    DG (30:3) 
547.4713 
549.4868  549.4513  64.610    [M+H]
+ 
 C34H60O5    DG (31:3) 
563.5025  563.4670  63.003    [M+H]
+ 
 C35H62O5    DG (32:3) 
575.5023  575.4670  61.341    [M+H]
+ 
 C36H62O5    DG (33:4) 
834.7528       834.7545  -2.037    [M+NH4]
+
       C52H96O6                TG (49:2) 
841.6669       841.6429  28.516    [M+NH4]
+
       C47H86NO8P                PC (39:4) 
855.6821       855.6586  27.464    [M+NH4]
+
       C48H88NO8P                PC (40:4) 
867.6822       867.6586  27.200    [M+NH4]
+
       C49H88NO8P                PC (41:5) 
895.7122       895.7263  -15.741    [M+NH4]
+
       C52H96NO7P                PC (O-44:5) 
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(B) Extra identifications from TNF-α treatment at 50ng/mL 
603.5342  603.4994  57.664    [M+H]
+ 
 C38H66O5    DG (35:4) 
607.5654  607.5296  58.927    [M+H]
+ 
 C38H70O5    DG (35:2) 
622.4432       622.4442  -1.607    [M+H]
+
       C32H64NO8P                PC (24:0) 
663.4535       663.4708  -26.075    [M+H]
+
       C34H63O10P                PG (28:2) 
846.7528       846.7545  -2.008    [M+NH4]
+
       C53H96O6                TG (50:3) 
 848.7686       848.7701  -1.767    [M+NH4]
+
       C53H98O6                TG (50:2) 
874.7845       874.7858  -1.486    [M+NH4]
+
       C55H104NO6                TG (52:3) 
902.8155       902.8171  -1.772    [M+NH4]
+
       C57H104O6                TG (52:2) 
908.8631       908.8641  -1.100    [M+NH4]
+
       C57H110O6                TG (54:0) 
 
 
Table 4.1. Identifications of selected positive ions from control and TNF-α treated 3T3-L1 adipocytes 
Abbreviations used: DG, diglyceride; PC, phosphatidylcholine; TG, triglyceride; ppm, parts per million 
Underlined masses are present in both control and TNF-α treated cells, and those highlighted in red represent the internal standards 
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Figure 4.4. Individual lipid concentrations from positive ion DI-MS analysis of TNF-α treated 3T3-L1 
adipocytes 
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24 hours, and then treated with mouse recombinant TNF-α for 2 and 24h at the following 
concentrations: 5, 25 and 50ng/mL. Lipids were extracted from the cell samples using a Folch 
extraction, and the lower phase was dried down under nitrogen and reconstituted in 600µL 
chloroform/methanol (2/1, v/v). A 150µL aliquot was removed and had 10mM ammonium formate 
added to it. The samples were then directly infused into an Orbitrap Exactive mass spectrometer at a 
flow rate of 5µL/min for 90 seconds (450 scans) in positive ion mode. The raw data intensities were 
normalised to that of the relevant internal standard which were PC (12:0/12:0) or TG (18:0/18:0/18:0), 
and had m/z 622.44 and 908.86, respectively.  They were then normlaised to the protein concentration 
of the cell sample. 
 
The top four normalised lipids are presented in this figure, and identified in the key. For each time 
point, n=3, with results represented as median ± range. A decrease was seen in the concentration of 
DG (33:4) after 2h, and decreases were seen all species after 24h at 5 and 25ng/mL, whereas an 
increase was observed at the greatest TNF-α treatment concentration. Statistical significance from the 
control cells is represented by *P<0.05; **P<0.01 and ***P<0.001. 
*** 
** 
(A) 
(B) 
*** 
** 
* 
* 
* 
** 
*** 
m/z  575.5023; DG (33:4) 
m/z  603.5342; DG (35:4) 
m/z  846.7528; TG (50:3) 
m/z  874.7845; TG (52:3) 
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4.3.2.2. IL-6 treatment 
 Representative spectra of IL-6 treated cells were also produced, and a representive spectrum 
of 3T3-L1 cells treated with 50ng/mL IL-6 for 24h is shown in Figure 4.3C.  As with the TNF-α 
treated cells, the abundant lipid species present had m/z between 500-650Da; and also 800-
950Da.  The abundance of peaks with m/z 622.4432 and 908.8631 increased in the IL-6 
treated cells compared to the controls, and these peaks correspond to the internal standards, 
suggesting a decrease in the abundance of sample lipid species. 
 
 The top ten most abundant peaks from the lipid profiles of the control cells, and those 
treated with 50ng/mL IL-6 from Figure 4.3C were identified, and are presented in Table 4.2.  
The majority of these identified lipids were either DG or TG species, and were mostly the 
same in both the control and IL-6 treated cells.  As with the lipid species from the TNF-α 
treated samples shown in Table 4.1, approximately half of these lipids had a mass accuracy 
much greater than 5ppm, and so were not confident identifications. 
 
The changes in the top four normalised abundant lipids in response to IL-6 treatment are 
shown in Figure 4.5.  As with the Figure 4.4, these species were identified as DG (33:4); DG 
(35:4); TG (50:3) and TG (52:3).  After 2h of IL-6 treatment, no changes in the concentration of 
these lipids was observed, with the exception of DG (35:4) and TG (52:3) which increased at 
the greatest concentration (50ng/mL; P=0.0231 and 0.0465, respectively vs. control). The 
concentration of DG (35:4) also increased after 24h of TNF-α treatment (P=0.0231 and 0.0408 
vs. control for 25 and 50ng/mL, respectively).  An increase was also seen in the concentration 
of TG (52:3) after 24h of TNF-α treatment at 5 and 25ng/mL (P=0.0231 and 0.0408 vs. control, 
respectively).  The concentration of the remaining lipid species did not change with any of the 
three treatment concentrations after 24h.  
 
 
 
 
Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification  
 
(A) Control  
547.4710 
575.5023  575.4670  61.341    [M+H]
+ 
 C36H62O5    DG (33:4) 
603.5334  603.4994  56.338    [M+H]
+ 
 C38H66O5    DG (35:4) 
820.7366       820.7389  -2.802    [M+NH4]
+ 
      C51H94O6                TG (48:2) 
834.7520       834.7545  -2.995    [M+NH4]
+
       C52H96O6                TG (49:2) 
846.7524       846.7545  -2.480    [M+NH4]
+
       C53H96O6                TG (50:3) 
847.7578       847.7749  -20.170    [M+H]
+
       C54H102O6                TG (51:1) 
848.7670       848.7701  -3.652    [M+NH4]
+
       C53H98O6                TG (50:2) 
874.7833       874.7858  -2.858    [M+NH4]
+
       C55H104NO6                TG (52:3) 
902.8141       902.8171  -3.323    [M+NH4]
+
       C57H104O6                TG (52:2) 
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 (B) Extra identifications from IL-6 treatment at 50ng/mL 
563.5021  563.4670  62.293    [M+H]
+ 
 C35H62O5    DG (32:3) 
867.6825       867.6586  27.545    [M+NH4]
+
       C49H88NO8P                PC (41:5) 
895.7124       895.7263  -15.518    [M+NH4]
+
       C52H96NO7P                PC (O-44:5) 
 
 
Table 4.2. Identifications of selected positive ions from control and IL-6 treated 3T3-L1 adipocytes 
Abbreviations used: DG, diglyceride; PC, phosphatidylcholine; TG, triglyceride; ppm, parts per million 
Underlined masses are present in both control and IL-6 treated cells 
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Figure 4.5. Individual lipid concentrations from positive ion DI-MS analysis of IL-6 treated 3T3-L1 
adipocytes 
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24h, and then treated with mouse recombinant IL-6 for 2 and 24h. The concentration of 
the inflammatory agents were 5, 25 and 50ng/mL.  Lipids were extracted from the cell samples using a 
Folch extraction.  The lower phase was dried down under nitrogen and reconstituted in 600µL 
chloroform/methanol (2/1, v/v). A 150µL aliquot was removed and 10mM ammonium formate was 
added to it. The samples were then directly infused into an Orbitrap Exactive mass spectrometer at a 
flow rate of 5µL/min for 90 seconds (450 scans) in positive ion mode. The raw data intensities were 
normalised to that of the relevant internal standard (PC 12:0/12:0 or TG 18:0/18:0/18:0), and had m/z 
622.44 and 908.86, respectively.  They were then normalised to the protein concentration of the cell 
sample. 
 
The top four normalised lipids are presented in this figure.  An increase in the concentration of DG 
(35:4) and TG (52:3) was seen after 2h of IL-6 treatment at 50ng/mL. Increases were also seen in the 
concentration of these lipids after 24h. For each time point, n=3, with results represented as median ± 
range. Statistical significance from the control cells is represented by *P<0.05; **P<0.01 and *** 
P<0.001. 
(A) 
(B) 
* 
* 
* 
* 
* 
* 
m/z  575.5023; DG (33:4) 
m/z  603.5334; DG (35:4) 
m/z  846.7524; TG (50:3) 
m/z  874.7833; TG (52:3) 
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4.3.3. Negative ion mode DI-MS analysis 
4.3.3.1. TNF-α treatment 
Representative negative ion spectra of control cells, along with cells treated with 50ng/mL 
TNF-α, are presented in Figure 4.6 (A and B, respectively).  The global lipid profile relating to 
cells which had been treated with TNF-α for 24h looked different to the others in the figure.  
The abundance of all lipids present in this profile (B) appeared to have decreased, as seen by 
the increase in the peak relating to the internal standard (m/z 666.4364). The most abundant 
peak present in the control cells had m/z 564.3461, whereas this changed in the TNF-α 
treated cells to two peaks with m/z 281.2552 and 666.4364 (internal standard).   
 
The top ten peaks from the global lipid profiles of the control cells, and the top ten from the 
TNF-α treated cells seen in Figures 4.7 were identified, and are presented in Table 4.2.  Many 
of the abundant lipid species from the treated cells were not present in the global lipid profile 
of the control cells, and so these lipids are identified in Table 4.2(B).  All of the identified lipid 
species in both the control and treated cells were either fatty acids or phospholipid species 
(Table 4.2A).  All identified lipid species were normalised to the internal standard (m/z 
666.4364) and then to the protein content of the cell.  The five most concentrated from both 
the control, and TNF-α treated cells are graphically represented in Figure 4.8.   
 
These five lipid species had m/z 253.2179, 255.2336, 281.2492, 283.2648 and 564.3461, and 
were identified as C16:1, C16:0, C18:1, C18:0 and PC (20:0).  All identifications were 
considered to be good matches, with the exception of PC (20:0) due to its mass error (-
37.210) falling outside of the set parameter of 5ppm.  Therefore this was a tentative 
identification. At the 2h time point (Figure 4.8A); PC (20:0) had the greatest concentration in 
the control cells, and this switched to C18:1 in all of the TNF-α treated samples, with the 
concentration of PC (20:0) decreasing with all of the treatment concentrations (P=0.05 vs. 
control for all).  The concentration of remaining selected lipids all decreased at the 5ng/mL 
TNF-α treatment (P<0.05 for all).  No changes were observed at 25ng/mL, and at the greatest 
TNF-α treatment, a decrease was seen in the concentration of C16:0 and C18:0 (P=0.05 and 
0.005 vs. control, respectively).   
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Figure 4.6. Negative ion DI-MS analysis of TNF-α and IL-6 treated 3T3-L1 adipocytes  
Representative spectra of differentiated 3T3-L1 adipocytes at day 10 post-differentiation which were 
pre-incubated with CS-free medium for 24h, and then treated with mouse recombinant TNF-α or IL-6 
for 24h.  The treatments represented are: control 24h (A); 50ng/mL TNF-α 24h (B) and 50ng/mL IL-6 
24h (D). Lipids were extracted from the cell samples using a Folch extraction.  The lower phase was 
dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 150µL 
aliquot was removed and had 10mM ammonium formate added to it.  The samples were then directly 
infused into an Orbitrap Exactive mass spectrometer at a flow rate of 5µL/min for 90 seconds (450 
scans) in negative ion mode.  The m/z range represented is between 200 and 900Da.  An increase in 
the abundance of the peak with m/z 281.25 is observed in (B), whereas in (C), the abundance of three 
peaks has greatly increased, and these have m/z 311.17, 325.18 and 339.20. 
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Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification 
(A) Control 
253.2179       253.2173  2.370    [M-H]
- 
         C16H30O2    C16:1 
255.2336       255.2330  2.351    [M-H]
- 
         C16H32O2    C16:0 
279.2337       279.2330  2.507    [M-H]
- 
         C18H32O2    C16:2 
281.2492       281.2486  2.133    [M-H]
-         
    C18H34O2    C18:1 
283.2648       283.2643  1.765    [M-H]
-         
    C18H36O2    C18:0 
303.2336       303.2330  1.979    [M-H]
-
          C20H32O2    C20:4 
564.3461       564.3671  -37.210    [M-H]
-
          C28H56NO8P   PC (20:0) 
565.3491       565.3511  -3.538    [M-H]
-
          C28H55O9P   Lyso-phosphatidylglycerol (22:1) 
606.4164       606.3984  29.683    [M-H]
-
          C31H59NO8P   PE (26:1) 
885.5517       885.5499  2.033    [M-H]
-
          C47H83O13P   PI (38:4) 
 
(B) Extra identifications from TNF-α treatment at 50ng/mL 
301.2174       301.2173  0.332    [M-H]
-
          C20H30O2   C20:5 
666.4364 
 
Table 4.3. Identifications of selected negative ions from control and TNF-α treated 3T3-L1 adipocytes  
Abbreviations used: PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; ppm, parts per million 
Underlined masses are present in both control and IL-6 treated cells, and those highlighted in red represent the internal standard 
1
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After 24h (Figure 4.7B) differences were observed in the concentrations of the various lipid 
species depending on the treatment conditions.  The concentration of C16:1 decreased at the 
5 and 25ng/mL treatment, and then increased at the greatest TNF-α treatment concentration 
(P=0.05 vs. control for all).  The species C16:0 had an increase in its concentration at the least, 
and greatest TNF-α treatment, and a decrease at 25ng/mL (P=0.05 vs. control for all).  A 
decrease in the concentration of C18:1 at 25ng/mL, followed by an increase at 50ng/mL was 
also observed (P=0.013 and 0.005 vs. control, respectively).  The concentration of C18:0 
increased after TNF-α treatment at both 5, and 50ng/mL (P<0.01 vs. control for both).  Finally, 
the concentration of PC (20:0) decreased at the 25ng/mL TNF-α treatment (P=0.017 vs. 
control).   
  
4.3.3.2. IL-6 treatment 
A representative spectrum of cells treated with 50ng/mL IL-6 for 24h is presented in Figure 
4.6C.  A gross change was observed between the control and IL-6 treatment profiles.  The 
most abundant peaks present in the control profiles had m/z 281.2488 and 564.3479; 
whereas in the control cells, the abundant peaks had m/z 311.17, 325.18 and 339.20.  These 
last three peaks were thought to be contamination, relating to linear alkylbenzenesulfonates 
(Andreu and Pico, 2004), which are commonly used as surfactants in detergents.  Therefore, 
the peaks with m/z 311.17, 325.18 and 339.20 were excluded from all data analysis.   
 
The top ten most abundant peaks from these profiles were also identified, and are presented 
in Table 4.4.  The majority of abundant peaks were present in both the control and treated 
cells, and related to fatty acids, or phospholipid species, with one sphingomylelin (SM) 
species also being present.  The selected lipids were then quantified as before, and the effect 
of IL-6 treatment on the concentration of the top four species was investigated, as seen in 
Figure 4.8.  These four lipid species had m/z 281.2488, 564.3479, 747.5664 and 830.5933, and 
were identified as C18:1, PC (20:0), a phosphatidylglycerol species (P-35:0) and a 
phosphatidylserine (PS) species (39:1), respectively.  The identifications for m/z 564.3479 and 
747.5664 were only tentative due to their mass error (-34.202 and 15.785, respectively).  
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Figure 4.7. Individual lipid concentrations from negative ion DI-MS analysis of TNF-α treated 3T3-L1 
adipocytes 
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24 hours, and then treated with mouse recombinant TNF-α for 2 and 24 hours at the 
following concentrations: 5, 25 and 50ng/mL.  Lipids were extracted from the cell samples using a 
Folch extraction.  The lower phase was dried down under nitrogen and reconstituted in 600µL 
chloroform/methanol (2/1, v/v). A 150µL aliquot was removed and had 10mM ammonium formate 
added to it.  The samples were then directly infused into an Orbitrap Exactive mass spectrometer at a 
flow rate of 5µL/min for 90 seconds (450 scans) in negative ion mode.  The raw data intensities were 
normalised to that of the relevant internal standard (PC 12:0/12:0; m/z 666.4434) and then to the 
protein concentration of the cell sample. 
 
The top five normalised lipids are presented in this figure, and are identified in the key.  For each time 
point, n=3, with results represented as median ± range. Decreases in the concentration of these lipid 
species were observed with 5ng/mL TNF-α treatment after both 2 and 24h, and this decrease was also 
seen at the 25ng/mL treatment concentration after 24h. Statistical significance from the control cells is 
represented by *P<0.05; **P<0.01 and ***P<0.001. 
* 
(A) 
(B) 
*** 
*** 
* * ** 
* 
* 
* ** 
** 
*** 
* 
* * 
m/z  255.2336; C (16:0) 
m/z  281.2492; C (18:1) 
m/z  283.2648; C (18:0) 
m/z  564.3461; PC (20:0) 
Key: 
Key: (treatment conditions) 
m/z  253.2179; C (16:1) 
Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification 
(A) Control 
281.2488       281.2486  0.711    [M-H]
-         
    C18H34O2    C18:1 
564.3479       564.3671  -34.202    [M-H]
-
          C28H56NO8P   PC (20:0) 
666.4363 
747.5664       747.5546  15.785    [M-H]
-
          C41H81O9P   PG (P-35:0) 
748.5323       748.5287  4.809    [M-H]
-
          C43H76NO7P   PE (P-38:5) 
                PE (O-37:6) 
802.5617       802.5604  1.620    [M-H]
-
          C43H82NO10P   PS (37:1) 
804.5763       804.5549  26.599    [M-H]
-
          C46H80NO8P   PC (38:6) 
830.5933       830.5917  1.926    [M-H]
-
          C45H86NO10P   PS (39:1) 
883.5355       883.5342  1.471    [M-H]
-
          C47H81O13P   PI (38:5) 
885.5506       885.5499  0.790    [M-H]
-
          C47H83O13P   PI (38:4) 
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(B) Extra identifications from IL-6 treatment at 50ng/mL 
687.5469       687.5933  -67.482    [M-H]
-
          C38H77N2O6P   SM (d33:1) 
742.5414       742.5392  2.963    [M-H]
-
          C41H78NO8P   PC (33:2) 
746.5158       746.5705  -73.268    [M-H]
-
          C41H82NO8P   PC (33:0) 
764.5222       764.5236  -1.831    [M-H]
-
          C43H76NO8P   PC (35:5) 
 
Table 4.4. Identifications of selected negative ions from control and IL-6 treated 3T3-L1 adipocytes 
Abbreviations used: PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin; 
ppm, parts per million 
Underlined masses are present in both control and IL-6 treated cells, and those highlighted in red represent the internal standard 
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At the 2h time point (Figure 4.8A); the lipids with the greatest concentrations in the 
control samples were C18:1 and PC (20:0), and the concentration of both decreased at the 
5ng/mL IL-6 treatment concentrations (P=0.05 or less vs. control for both).  Opposite 
actions were observed in the concentration of these two species at the greatest treatment 
(50ng/mL), with that of C18:1 increasing (P=0.01 vs. control) and the concentration of PC 
(20:0) decreasing (P=0.05 vs. control).  An increase in the concentration of both 
phosphatidylglycerol (P-35:0) and PS (39:1) was seen 5 and 50ng/mL IL-6 treatment 
(P<0.01 vs. control for all).  After 24h of IL-6 treatment, no changes were observed in the 
concentration of C18:1 in any of the IL-6 treated samples, whereas the concentration of 
PC (20:0) was seen to decrease with all IL-6 treatments (P=0.05 vs. control for all). Both 
phosphatidlyglycerol (P-35:0) and PS (39:1) behaved in the same way, with an increase in 
their concentration occurring at both 5 and 50ng/mL IL-6 treatment (P=0.049 vs. control 
for all). After 24h (Figure 4.8B) the most concentrated lipids seen in the control samples 
were also C18:1 and PC (20:0).  The concentration of these lipids decreased in the 
treatment samples, although this decrease was only significant for PC (20:0) (P<0.05 vs. 
control for all IL-6 treatment concentrations).   
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Figure 4.8. Individual lipid concentrations from negative ion DI-MS analysis of IL-6 treated 3T3-L1 
adipocytes 
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24h, and were then treated with mouse recombinant IL-6 for 2 and 24h.  The 
concentration of inflammatory agents were 5, 25 and 50ng/mL.  Lipids were extracted from the cell 
samples using a Folch extraction.  The lower phase was dried down under nitrogen and reconstituted 
in 600µL chloroform/methanol (2/1, v/v).  A 150µL aliquot was removed and had 10mM ammonium 
formate added to it.  The samples were then directly infused into an Orbitrap Exactive mass 
spectrometer at 5µL/min for 90 seconds (450 scans) in negative ion mode.  The raw data intensities 
were normalised to that of the relevant internal standard (PC 12:0/12:0; m/z 666.44), and then to the 
protein concentration of the cell sample.  
 
The top four normalised lipids are presented in this figure.  For each time point, n=3, with results 
represented as median ± range.  Flucuations in the concentration of these species were observed after 
2h of IL-6 treatment, and after 24h, a significant decrease was seen in the concentration of PC (20:0) 
with all treatment concentrations, whereas the concentration of PG (P-35:0) and PS (39:1) significantly 
increased at 5, and 50ng/mL IL-6 treatment concentrations.  Statistical significance from the control 
cells is represented by *P<0.05; **P<0.01 and ***P<0.001. 
(A) 
(B) 
* 
** ** 
* 
*** 
** 
* 
** 
* 
* 
* 
m/z  281.2492; C (18:1) 
m/z  564.3479; PC (20:0) 
m/z  747.5664; phosphatidylglycerol (P-35:0) 
m/z  830.5933; PI (38:4) 
Key: 
198 
 
4.3.4. Positive ion LC-MS analysis 
4.3.4.1. TNF-α treatment 
Representative positive ion chromatograms of control cells, and those treated with 
50ng/mL TNF-α for 2 or 24h, are presented in Figure 4.9.  The global lipid profiles between 
the control and TNF-α treated cells appeared similar; however, the abundance of peaks 
present between RT 7.5 and 8.5 min increased in the treated samples.  The most abundant 
ion associated with each chromatographic peak is identified in Table 4.5.  The majority of 
ions were unable to be identified; however, those that could were all TG species.    
 
Multivariate data analyses were employed on the positive ion LC-MS data, starting with 
principal component analysis (PCA).  The PCA scores and loadings plots from the TNF-α 
treated cells are presented in Figure 4.10.  The data, which have not been normalised, 
were analysed first, and this model had an R2 and Q2 of 0.709 and 0.307, respectively.  
The PCA scores plot (A) showed no obvious groupings, with the QCs being integrated in 
with the samples; however, one replicate of the samples relating to 2h of TNF-α treatment 
at 25ng/mL was situated outside of the 95% tolerance limit.  The points seen in the 
loadings plot (C) did not group together around the origin, and so no points of possible 
variance were identified.    
 
Next, the data were normalised to the total ion current (TIC), and the scores plot (B) was 
interpreted as having two groups; one contained the 24h 50ng/mL TNF-α treated samples, 
and also one replicate of the 25ng/mL treated cells, also at the 24h time point.  The 
remaining samples were all clustered together in the second group, and the R2 and Q2 for 
this model were 0.698 and 0.463 respectively.  The majority of points seen as possible 
causes of variance on the loadings plot (D) were located on the left hand side (LHS) of the 
origin.  The majority were unable to be confidently identified; however, trend analysis of 
these points showed that the profile of their abundance were similar throughout with all 
TNF-α treatments; for example, the variance of points relating to m/z 684.204-687.201; 
758.223-761.223 and 832.242-834.241 increased with all of the 24h treatments.  The 
points corresponding to m/z 610.183-162.182 showed an increase in variance in the 24h 
control samples, which then decreased back to the original variance.   
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Figure 4.9. Positive ion LC-MS analysis of TNF-α treated 3T3-L1 adipocytes  
Representative chromatograms of differentiated 3T3-L1 adipocytes at day 10 post-differentiation 
which were pre-incubated with CS-free medium for 24h, and then treated with mouse recombinant 
TNF-α for 2 and 24h.  The treatments represented are: control 2h (A); 50ng/mL 2h (B); control 24h (C); 
and 50ng/mL 24h (D). Lipids were extracted from the cell samples using a Folch extraction.  The lower 
phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  The 
lipids were then separated over 18 min by LC-MS.  Increases in the abundance of lipids present 
between retention time 7.5 and 8.5min was observed in the TNF-α treated samples when compared to 
the control cells. 
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Retention time  Ion mass  Theoretical mass  Δ Mass accuracy (ppm) Ion  Empirical composition  Identification  
(min) 
PEAKS BEFORE 7.55MIN WERE NOT IDENTIFIABLE 
7.55   804.7072  804.7076  -0.497    [M+NH4]
+ 
 C50H90O6    TG (47:0) 
7.69   818.7225  818.7232  -0.855     [M+H]
+ 
      C51H92O8                TG (48:3) 
7.81   832.7382  832.7545  -19.574     [M+NH4]
+
       C52H94O6    TG (49:3) 
7.93   846.7549  846.7545  0.472     [M+NH4]
+
       C53H96O6                 TG (50:3) 
8.06   834.7548  834.7545  0.359     [M+NH4]
+
       C52H96O6                TG (49:2) 
 8.19   874.7851  874.7858  -0.800     [M+NH4]
+
       C55H104NO6                TG (52:3) 
8.31   862.7853  862.7858  -0.580     [M+NH4]
+
       C54H100O6                TG (51:2) 
8.44   902.8159  902.8171  -1.329     [M+NH4]
+
       C57H104O6                TG (52:2) 
8.75   904.8325  904.8327  -0.221    [M+NH4]
+  
C57H106O6    TG (54:2) 
9.33   908.8633  908.8640  -0.770    [M+NH4]
+
  C57H110O6    TG (54:0) 
 
 
Table 4.5.  Retention times and their associated abundant mass of each major peak present in the positive ion LC-MS chromatograms of TNF-α and IL-6 treated 3T3-L1 adipocytes 
Abbreviations used: TG, triglyceride; ppm, parts per million 
Red highlight indicates internal standard 
2
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0
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One identifiable point on the plot was located on the RHS of the origin, and represented m/z 
758.570.  This was identified as PC (34:1), and its variance saw a transient increase after 2h of 
5ng/mL TNF-α concentration, which then decreased at 25ng/mL TNF-α treatment (2h) and 
then a plateau was observed throughout the remaining treatments.  
 
After PCA, both datasets also underwent partial least squares (PLS) analysis, and the scores 
and loadings plots for these models are presented in Figure 4.11.  Both scores plots showed 
similar groupings to those seen in the PCA model scores plots; with two groups seen with the 
non-normalised data (A) and no obvious groupings observed in the TIC-normalised data (B).  
The R2X, R2Y and Q2 for the non-normalised model were 0.494, 0.787 and 0.572, 
respectively.  For the TIC-normalised model, these were; 0.818, 0.97 and 0.68, respectively.  
The loadings plot for the non-normalised data (C) showed that the points at distance from the 
origin were the same as those found in the PCA scores plot.  The only identified point had m/z 
758.570 and, therefore, was PC (34:1).  The trend analysis of this point found that its 
abundance increased with 2h TNF-α treatment at 5ng/mL, and then decreased at the 
25ng/mL concentration (2h time point), and then plateaued with the rest of the treatments. 
This exact variance pattern of PC (34:1) was also observed in the loadings plot of the TIC-
normalised data (D).   
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Figure 4.10. PCA scores and loadings plots representing positive ion LC-MS analysis of TNF-α treated 
3T3-L1 adipocytes 
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant TNF-α for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in positive ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The data 
represented here have been Pareto scaled, and the RT window was set at 15sec.  Either the raw data, 
or data which were normalised to the total ion current were analysed.  Each time point consisted of 
three biological replicates.  The panels represent: no norm, scores plot (A); TIC norm, scores plot (B); 
no norm, loadings plot (C); and TIC norm, loadings plot (D). No obvious groupings were observed in 
either scores plot. 
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Figure 4.11. PLS scores and loadings plots representing positive ion LC-MS analysis of TNFα treated 
3T3-L1 adipocytes 
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant TNF-α for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in positive ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The data 
represented here have been Pareto scaled, and the RT window was set at 15sec.  Either the raw data, 
or data which were normalised to the total ion current were analysed.  Each time point consisted of 
three biological replicates.  The panels represent: no normalisation, scores plot (A); TIC normalisation, 
scores plot (B); no normalisation, loadings plot (C); and TIC normalisation, loadings plot (D).  No 
obvious groupings were seen with either model. 
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4.3.4.2. IL-6 treatment 
Similar chromatograms were produced for the 3T3-L1 adipocytes which had been treated 
with IL-6, as seen in Figure 4.12.  These global lipid profiles between the control and IL-6 
treated cells appeared similar; however, the peaks present between RT 7.5 and 8.5 min 
decreased in the 2h 50ng/mL treated cells compared to the control samples, and vice 
versa with the 24h IL-6 treated cells (50ng/mL).   These chromatograms were also similar 
to those seen with the TNF-α treated adipocytes, and so the abundant ions associated 
with each peak are the same as those in Table 4.5. 
 
Samples treated with IL-6 were analysed by PCA, and the scores and loadings plots are 
presented in Figure 4.13, and the scores plot of the non-normalised data model (A) was 
interpreted as having three groups, which were: QCs; 25 and 50ng/mL (24h); and all other 
samples.  The R2 and Q2 for this model were 0.736 and 0.46, respectively.  The points 
situated on the RHS of the loadings plot (Figure 4.20C) for this model were not confidently 
identified; however, the variance of all of species decreased in the 25 and 50ng/mL (24h) 
treatment samples.  On the LHS of the origin, one point with m/z 537.395 was given a 
tentative identification of PC (18:2), and another point with m/z 902.816 was identified as 
TG (54:3).  The variance of both increased in the 25 and 50ng/mL samples.  These findings 
were replicated when the data were normalised to the TIC, as represented by (D) and the 
R2 and Q2 for this model were 0.736 and 0.435, respectively. 
 
The PLS models of these data were also similar to each other, with the PLS scores plots 
showing that the samples clustered into two groups, as seen in Figure 4.14.  One group 
contained samples treated with IL-6 at either 25 or 50ng/mL for 24h.  The rest of the 
samples formed a second group, with the QCs located within this group.  The R2X, R2Y and 
Q2 for these models were 0.494, 0.737, and 0.572 for the non-normalised data (C); and for 
the TIC-normalised (D) data they were 0.481, 0.78 and 0.556, respectively.  The variance of 
the unidentified points on the LHS of the origin of the loadings plots (C and D) decreased 
in both the 25 and 50ng/mL (24h) IL-6 treated samples.  The points identified as PC (18:2) 
and TG (54:3) were positioned on the RHS of the origin.  Another point with m/z 173.079 
was also found in this location, and a tentative identification was applied to it, which was a 
FA with the formula C8H12O4.  The variance of all three increased in the 25 and 50ng/mL 
(24h) IL-6 treated samples.   
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Figure 4.12. Positive ion LC-MS analysis of IL-6 treated 3T3-L1 adipocytes 
Representative chromatograms of differentiated 3T3-L1 adipocytes at day 10 post-differentiation 
which were pre-incubated with CS-free medium for 24h, and then treated with mouse recombinant IL-
6 for 2 and 24h.  The treatments represented are: control 2h (A); 50ng/mL 2h (B); control 24h (C); and 
50ng/mL 24h (D). Lipids were extracted from the cell samples using a Folch extraction.  The lower 
phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  The 
lipids were then separated over 18 min by LC-MS.  A decrease was observed in the abundance of all 
species after 24h of IL-6 treatment at 50ng/mL as seen by the increase in abundance of the peak at 
retention time 9.21 which corresponds to the internal standard TG (18:0/ 18:0/ 18:0) with m/z 
908.8633.  
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Figure 4.13. PCA loadings and scores plots representing positive ion LC-MS analysis of IL-6 treated 
3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant IL-6 for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in positive ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The data 
represented here have been Pareto scaled, and the RT window was set at 15 seconds.  Either the raw 
data, or data which were normalised to the total ion current were analysed.  Each time point consisted 
of three biological replicates. The panels represent: no normalisation, scores plot (A); TIC 
normalisation, scores plot (B); no normalisation, loadings plot (C); and TIC normalisation, loadings plot 
(D). With both models, a clear separation was seen between the QCs and the experimental samples.  
With the non-normalised model (A), a group consisting of 25 and 50ng/mL IL-6 treated samples after 
24h was clustered away from the other samples; whereas in the TIC-normalised model, this separated 
group contained 2h IL-6 treated samples at 25 and 50ng/mL. 
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Figure 4.14. PLS scores and loadings plots representing positive ion LC-MS analysis of IL-6 treated 
3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant IL-6 for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in positive ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The data 
represented here have been Pareto scaled, and the RT window was set at 15 seconds.  Either the raw 
data, or data which were normalised to the total ion current were analysed.  Each time point consisted 
of three biological replicates. The panels represent: no normalisation, scores plot (A); TIC 
normalisation, scores plot (B); no normalisation, loadings plot (C); and TIC normalisation, loadings plot 
(D).  Both PLS plots demonstrate a separation in the samples, with a group relating to cells which had 
been treated with IL-6 for 24h at 25 and 50ng/mL being situated away from the remaining samples. 
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4.3.5. Negative ion mode LC-MS analysis 
4.3.5.1. TNF-α treatment 
Representative negative ion chromatograms of control cells and those treated with 
50ng/mL TNF-α for 2 and 24h are presented in Figure 4.15.  Fewer peaks were present 
than seen in the positive ion chromatograms.  The most abundant peak present in the 2h 
control cells had a retention time (RT) of 4 min, and this changed to RT 2.45, 2.65 and 2.79 
min in all other chromatograms in the figure.  The most abundant ion associated with each 
chromatographic peak is identified in Table 4.6.  Only one ion was identifiable, which had 
a RT of approximately 4 min.  However, the mass error for this species (-37.564) fell 
outside of the set parameter of 5ppm, and so this identification was only tentative.    
 
Negative ion LC-MS data of TNF-α treated cells were also analysed using PCA and PLS.   
The PCA scores and loadings plots are shown in Figure 4.16, and for the non-normalised 
data (A), the samples were clustered into four groups: QCs; controls (2 and 24h); 5ng 24h 
and all other treatments.  The R2 and Q2 for this dataset were 0.978 and 0.911. Two 
points were identified on the loadings plot (B) and were situated away from the origin on 
the RHS.  These points had m/z 564.345 (ppm=-37.564) and 885.553 and were identified 
as PC (20:0) and PI (38:4), respectively.  Two other points were situated in the same area 
of the loadings plot and had m/z 346.177 and 582.511; however, no identifications were 
obtained for these species.  Trend analysis of the identified species, demonstrated a 
decrease in variance of PC (20:0) in all of the samples, except for those acting as a control 
at the 2h time point.  A decrease in the variance of PI (38:4) was also seen; although this 
decrease only occurred from the 50ng/mL (2h) through to 25ng/mL (24h) samples. 
 
The PCA plot of the TIC-normalised data (B) showed three groups, which were: QCs, 
controls (2 and 24h); all treated samples.  The R2 and Q2 for this model were 0.981 and 
0.909, respectively.  The loadings plot for this model (D) was similar to that of the non-
normalised data model; with the identifiable points PC (20:0) and PI (38:4) being located 
on the RHS of the origin, and the variance of these phospholipid species acting in the same 
way.    
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Figure 4.15. Negative ion LC-MS analysis of TNF-α treated 3T3-L1 adipocytes  
Representative chromatograms of differentiated 3T3-L1 adipocytes at day 10 post-differentiation 
which were pre-incubated with CS-free medium for 24h, and then treated with mouse recombinant 
TNF-α for 2 and 24h.  The treatments represented are: control 2h (A); 50ng/mL 2h (B); control 24h (C); 
and 50ng/mL 24h (D). Lipids were extracted from the cell samples using a Folch extraction.  The lower 
phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  The 
lipids were then separated over 18 min by LC-MS. A change in the lipid profiles was observed, with 
peaks in the retention time region between 2 and 3min being the most abundant in panels (B)-(D). 
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Table 4.6.  Retention times and their associated abundant mass of each major peak present in the negative ion LC-MS chromatograms of TNF-δ treated adipocytes  
Abbreviations used: PC, phosphatidylcholine; ppm, parts per million 
2
1
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PLS analysis of the non-normalised and TIC-normalised data, were very similar, and both 
produced five possible groups on the PLS scores plot (Figure 4.17 A and B, respectively), 
which were interpreted as being: control 2h, control 24h, QCs, 5ng 24h, and all other 
treated samples.  The R2X, R2Y and Q2 for the non-normalised model were 0.954, 0.979 
and 0.927, respectively.  For the TIC-normalised model, these were 0.961, 0.989 and 
0.966, respectively.  The phospholipid species PC (20:0), as well as the unidentified point 
with m/z 346.177 were located on the LHS of both loadings plots (C and D), and the 
abundance of these species decreased in all of the samples, except the control cells at 2h.   
 
4.3.5.2. IL-6 treatment 
Negative ion chromatograms from the IL-6 treated cells are presented in Figure 4.18.  The 
change in global lipid profiles between the control and IL-6 treated cells were the same as 
those seen in the TNF-α treated cells, with a peak at RT 4 min being the most abundant in 
the 2h control samples.  This changed to three peaks with RT 2.45, 2.65 and 2.79 being the 
most abundant in the remaining samples.  The most abundant ion associated with each 
peak were the same as those for the TNF-α treated cells, and so are also presented in 
Table 4.6. 
 
The PCA scores plot, for non-normalised data relating to the cells treated with IL-6 are 
presented in Figure 4.19A.  Three groups were interpreted on the plot, with one 
containing 25ng/mL (24h) and two replicates of the 50ng/mL (24h) samples; another 
consisting of control (2h) cells and the QCs; and the final group was made up of the 
remaining samples.  The R2 and Q2 for this model were 0.944 and 0.841, respectively.  
Three points with m/z 311.17, 325.18 and 339.20 were situated on the RHS of the origin in 
the PCA loadings plot (Figure 4.32), and the variance of all three increased in the 25 and 
50ng/mL treated samples at both two, and 24h.  As mentioned above, these were 
believed to represent contamination, and so their pattern of variance was not considered 
in the interpretation of this model.  For this reason, these points will not be mentioned 
again in the remaining plots. Points representing PC (20:0) and the unidentified species 
with m/z 346.177 were found on the RHS of the origin, and the variance of these lipid 
species decreased with all of the IL-6 treatment concentrations.   
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Figure 4.16. PCA scores and loadings plots representing negative ion LC-MS analysis of TNF-α treated 
3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant TNF-α for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in negative ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The 
data represented here have been Pareto scaled, and the RT window was set at 15 seconds.  Either the 
raw data, or data which were normalised to the total ion current were analysed.  Each time point 
consisted of three biological replicates.  The panels represent: no normalisation, scores plot (A); TIC 
normalisation, scores plot (B); no normalisation, loadings plot (C); and TIC normalisation, loadings plot 
(D).  Both models showed a clear separation between the QCs, control and treated samples. 
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Figure 4.17. PLS scores and loadings plots representing negative ion LC-MS analysis of TNF-α treated 
3T3-L1 adipocytes 
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant TNF-α for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in negative ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The 
data represented here have been Pareto scaled, and the RT window was set at 15 seconds.  Either the 
raw data, or data which were normalised to the total ion current were analysed.  Each time point 
consisted of three biological replicates.  The panels represent: no normalisation, scores plot (A); TIC 
normalisation, scores plot (B); no normalisation, loadings plot (C); and TIC normalisation, loadings plot 
(D).  Both models showed a clear separation between the QCs, control and treated samples. 
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Figure 4.18. Negative ion LC-MS analysis of IL-6 treated 3T3-L1 adipocytes  
Representative chromatograms of differentiated 3T3-L1 adipocytes at day 10 post-differentiation 
which were pre-incubated with CS-free medium for 24h, and then treated with mouse recombinant 
TNF-α for 2 or 24h.  The treatments represented are: control 2h (A); 50ng/mL 2h (B); control 24h (C); 
and 50ng/mL 24h (D). Lipids were extracted from the cell samples using a Folch extraction.  The lower 
phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  The 
lipids were then separated over 18 min by LC-MS. A change in the lipid profiles was observed, with 
peaks in the retention time region between 2 and 3min being the most abundant in panels (B)-(D). 
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The groupings present in the PCA scores plot differed when the data were normalised to 
the TIC before analysis (Figure 4.19B).  All samples clustered into three groups, with the 
first consisting of cells treated with IL-6 for 24h at both 25 and 50ng/mL.  The rest of the 
samples clustered together in a second group, with exception of the QCs, which formed 
the final grouping outside of the 95% tolerance limit.  The R2 and Q2 for this model were 
0.97 and 0.91, respectively.  The PCA loadings plot for this model (D) found points 
representing PC (20:0) and m/z 346.177 on the RHS of the origin.  A trend analysis on 
these points found that their variance decreased in all IL-6 treated samples in comparison 
to the controls at both 2 and 24h.  Another point with m/z 174.956 was also found in this 
area, and its variance increased in the 24h treated samples.   
 
PLS analysis was also undertaken on both datasets, and the PLS scores and loadings plots 
are shown in Figure 4.20, and the PLS model representing the non-normalised data (A) 
showed two groups.  The first consisted of the following: two replicates 25ng/mL (2h), 
50ng/mL (2h) and both 25 and 50ng/mL (24h).  The rest of the samples, including the QCs, 
clustered together to form the second group.  The R2X, R2Y and Q2 for this model were 
0.651, 0.868 and 0.785, respectively.  The loadings plot for this model (B) showed that the 
points corresponding to the phospholipid PC (20:0) and the unidentified species (m/z 
346.177) were found on the RHS of the origin.  A trend analysis was performed on these 
points, which demonstrated that the variance of both species decreased with all IL-6 
treatments, when compared to the controls.   
 
After the data were normalised to the TIC, a difference was observed in the PLS scores 
plot (B).  Three groups were interpreted: the first contained the QCs; and the second 
consisted of the control cells (both time points), 5ng/mL (2 and 24h), and one replicate 
from the 25ng/mL (2h) sample set.  The final group was made up of the remaining 
samples.   The R2X, R2Y and Q2 were 0.745, 0.838 and 0.774, respectively.  The loadings 
for this model had points relating to PC (20:0) and m/z 346.177 on the RHS of the origin, 
and their variance decreased in all of the IL-6 treated cells.   
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Figure 4.19. PCA scores and loadings plots representing negative ion LC-MS analysis of IL-6 treated 
3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant IL-6 for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in negative ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The 
data represented here have been Pareto scaled, and the RT window was set at 15 seconds.  Either the 
raw data, or data which were normalised to the total ion current were analysed.  Each time point 
consisted of three biological replicates.  The panels represent: no normalisation, scores plot (A); TIC 
normalisation, scores plot (B); no normalisation, loadings plot (C); and TIC normalisation, loadings plot 
(D). Two groups were formed in the non-normalised scores plot (A), with one containing the QCs and 
2h control samples, and the remaining samples forming the other group.  With the TIC-normalised 
dataset (B), the control and treated samples formed one group, and the QCs were located outside of 
the 95% tolerance region. 
-0.35
-0.30
-0.25
-0.20
-0.15
-0.10
-0.05
0.00
0.05
0.10
0.15
0.20
0.25
0.30
-0.16 -0.14 -0.12 -0.10 -0.08 -0.06 -0.04 -0.02 -0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20 0.22 0.24 0.26
p
[
2
]
p[1]
R2X[1] = 0.415255 R2X[2] = 0.250831 
564.345
339.2
325.185
565.348
346.177
311.169
353.201
582.511209.949
293.18
585.344
337.207
397.227609.55809.175
381.233
160.842162.839
692.621
637.59
170.833
340.203
130.889
112.985
572.483
441.254
128.959128.892
326.188
172.83
174.956
425.259
182.93
174.956
2. 5
599.53
174.956
566.351
168.836
112.985
583.514
485.28
112.985
112.985
627.562
155.9 1
347.181
65.149
6. 8
407.188
568.496
610.562581.527
112.985693.624
682.593
112.985
112.985
469.285
694.637 112.985
229.861
885.552638.593 690.606
157.908
317.021
174.956
325.185
312.172
248.961316. 48
393.172
248.961
678.606
112.985
112.985
248.961316.948
316.94
562.33
6 0.54
132.886
529.306
66. 06
666.437
248.961
174.828
112.985
174.956
112.985
571.499332. 98
680.621
.
580.34
184.927 164.836
1 2.985112.985
112.985
112.985
112.985
316.948
112.985
573.486
12.985
112.985112.985
224.006
112.985 112.985112.985
558.467
112.985 112.985
112.985
112.985
112.985112.985
513.311 1 2.985
1 2.985
112.985
112.985
112.985
221.105
112.985
112.985112.985.
248.961
12.985
112.9852.985
112.985 112.985
112.985
354.20400. 33
.2.985.
248.961
112.985.
316.948
.1 2.985
174.956
580.341
112.985112.985.
248.961
316.94
316.9
621 21
237.85
1 2.985
112.985
697.527
384.936
339.2
2.985
574.48
297.244
883.536
2.985
112.985
384.936
112.985
398.2
112.985
248.961
112.985
158.975
12.985
138.92
683.596
2.985
317.021
316.948
573.333628.565
248.961
452.9 3
174.956
502.01
384.936
886. 55
12.985
316.949
1 2. 85
666.437
.1 .
311.169
407.258
638.574
5 .975
248.961
316.948452.924
112.985
379.157
520.911
382.236
535.344
158.975
158.975
1 2.985112.985.452.923
112.985
338.21
1 . .
265.148
695.64 112.985112.985
684.609
174.956
680.577
112.985
174.956
112.985
384.9361 2.985
115.92
691.609
520.911
112.985 2.985
158.975 2 . 1
248.961248.961
112.985861. 53
294.183
48.961
6 1.527
115.92
12.985
58 .
248.961
248.961
211.947
06.042
248.961
174.956
SIMCA-P+ 12.0.1 - 2012-10-19 12:48:28 (UTC+0) 
-0.15
-0.10
-0.05
-0.00
0.05
0.10
0.15
0.20
0.25
-0.35 -0.30 -0.25 -0.20 -0.15 -0.10 -0.05 0.00 0.05 0.10 0.15 0.20 0.25 0.30
p
[
2
]
p[1]
R2X[1] = 0.382635 R2X[2] = 0.197444 
564.345
339.2
325.185
565.348
346.177
311.169
353.201
582.511
209.949
293.18
585.344
337.207
397.227
609.558
309.175
381.233
160.842162.839
692.621
637.59
170.833
340.203
130.889
112.985
572.483
441.254
128.959
128.892
326.188
172.83
174.956
425.259 182.93
174.956
112.985
599.53
174.956
566.351
168.836
112.985
583.514
485.28
112.985
112.985
627.562
155.911
347.181
265.149
6. 8
407.188
568.496
10. 62581.527
112.985
693.624
682.593
112.985
112.985
469.285
694.637
112.985
229.861
885.552
638.593
690.606
157.908
317.021
174.956
325.185
312.172
248.961316.948
393.172
248.961
678.606
112.985
112.985
248.961
316.948
316.949
562.33
610.543
132.886
529.306
666.606
666.437
248.961
174.828112.985
174.956
112.985
571.499
332.998
680.621
112.985
5 0.34
184.927
164.836
112.985.
11 .985
112.985
112.985
316.948
112.985
73.4 6
112.985
112.985
.
224.006
112.985
112.985
112.985
112.985
558.467
112.985
1 2.9 5
112.985
112.985
112.985112.985
513.311
112.985
112.985
112.985
112.985112.985 221.105
112.985.112.985112.985112.985
248.961
112.985
112.985
112.985
1 2.985
112.985
354.204
600.533
.248.96
112.985
112.985
3 6. 48
.112. 85
174.956
5 0.341
.
12.985
112.985
248.961
316.949
316.948
621 321
237.855
112.985
112.985
697.527
384.936
339.2 112.985
574.48
297.244
883.536
112.985
2.985
384.936
112.985
398.23
112.985
248.961
112.985
58.975
112.985
138.92
683.596
12.985
317.021
3 6.94
573.333
628.565
248.961
452.923
174.956
502.012
384.936
886.555112.985
316.949
112.985
666.437
112.985
112.985
311.169
407.258
638.57
158.975
248.961
316.948
452.924
112.985
379.157
520.911
382.236
535.344
158.975
112.985
158.975
1 2.985.112.985
452.923
112.985
3 .2
112.985
112.985
265.148
112.985
112.985
695 641
112.985
12.985
6 4. 09
74.956
80.577
112.9 5
74 56
112.985
384.936
1 2.985
115.92
691.609
20.9 1
112.9 5
1 2.985
158.975
520.912
248.961248.961
112.985
61. 53
294.183
248.961
601.527
115.92
1 2.985
588.9
248.961
248.961
211.947
306.042
248.961
174.956
SIMCA-P+ 12.0.1 - 2012-10-19 14:23:00 (UTC+0) 
-2000
-1500
-1000
-500
0
500
1000
1500
2000
-3000 -2500 -2000 -1500 -1000 -500 0 500 1000 1500 2000 2500 3000
t
[
2
]
t[1]
R2X[1] = 0.415255            R2X[2] = 0.250831            Ellipse: Hotelling T2 (0.95) 
SIMCA-P+ 12.0.1 - 2012-10-19 12:47:50 (UTC+0) 
-1800
-1600
-1400
-1200
-1000
-800
-600
-400
-200
0
200
400
600
800
1000
1200
1400
1600
1800
-2400 -2200 -2000 -1800 -1600 -1400 -1200 -1000 -800 -600 -400 -200 0 200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400
t
[
2
]
t[1]
R2X[1] = 0.382635            R2X[2] = 0.197444            
Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2012-10-19 14:22:30 (UTC+0) 
(B) (A) 
(C) (D) 
Key: (treatment conditions) 
QC 
50ng/mL 2h 
25ng/mL 2h 
50ng/mL 24h 
25ng/mL 24h 
Control 2h Control 24h 
5ng/mL 2h 5ng/mL 24h 
217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. PLS scores and loadings plots representing negative ion LC-MS analysis of IL-6 treated  
3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with mouse recombinant IL-6 for 2 and 24h at the following concentrations: 5, 25 and 
50ng/mL.  Lipids were extracted using a Folch extraction, and the lower phase was analysed by LC-MS 
in negative ion mode.  Before multivariate data analysis, the data were processed using SIEVE.  The 
data represented here have been Pareto scaled, and the RT window was set at 15 seconds.  Either the 
raw data, or data which were normalised to the total ion current were analysed.  Each time point 
consisted of three biological replicates.  The panels represent: no normalisation, scores plot (A); TIC 
normalisation, scores plot (B); no normalisation, loadings plot (C); and TIC normalisation, loadings plot 
(D). Both scores plots were identified as having two groups, with the first containing the QCS, along 
with the control cells and those treated with IL-6 at 5ng/mL at both timepoints.  The second group 
consisted of the 25 and 50ng/mL IL-6 treated samples after both 2 and 24h. 
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4.4. Eicosanoid analysis by LC-MS 
Eicosanoids secreted from 3T3-L1 adipocytes treated with either TNF-α or IL-6 were analysed 
by targeted LC-MS in negative ion mode.    Only five were detectable in the medium samples 
of both treatments and they were: PGD2, PGE2, PGF2α, 6-keto PGF2α (6-keto) and 20-OH LTB4 
(20-OH). 
 
The changes in concentration of these eicosanoids in response to the different treatment 
concentrations of TNF-α at both time points are presented in Figure 4.21.  All five eicosanoids 
produced similar profiles with both inflammatory agents.  No significant changes in the 
concentration of the eicosanoid species were observed after 2h of TNF-α treatment, with the 
exception of an increase in the concentration of PGD2 and PGF2α at the 25ng/mL TNF-α 
treatment (P=0.067 and 0.047 vs. control, respectively).  At the 24h treatment time point, a 
direct relationship occurred between the TNF-α treatment concentration, and the 
concentration of the detected eicosanoids.  A significant increase was seen in the 
concentration of both and 20-OH (E) at the greatest TNF-α treatment concentration 
(50ng/mL; P=0.005 vs. control).  The concentrations of the remaining eicosanoids, PGD2 (A), 
PGE2 (B), PGF2α (C) and 6-keto (D) significantly increased at all of the TNF-α treatment 
concentrations (P=0.05 or less vs. control for all). 
 
Different concentration profiles of the eicosanoids were seen after IL-6 treatment, as shown 
in Figure 4.24.  Significant increases were observed after 2h of IL-6 treatment at the least, and 
greatest IL-6 treatment concentrations (5 and 50ng/mL; P=0.05 or less vs. control for all).  A 
significant decrease in the concentration of all five eicosanoid species occurred at the 
25ng/mL IL-6 treatment (P=0.05 or less vs. control for all).  After 24h of IL-6 treatment, the 
concentration of all detected eicosanoid species significantly increased with all IL-6 treatment 
concentrations (P=0.05 or less vs. control for all).  The only exception was PGE2, whose 
concentration did not change with the least concentrated IL-6 treatment.  
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Figure 4.21.  Secretion of eicosanoids by TNF-α treated 3T3-L1 adipocytes  
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24h, and were then treated with mouse recombinant TNF-α for 2 or 24h.  The 
concentration of TNF-α treatments used were 5, 25 and 50ng/mL. Eicosanoids were extracted from cell 
culture medium by solid phase extraction chromatography and were analysed by LC-MS/MS in 
negative ion mode. Detected eicosanoids are represented as median ± range, with a group size of 3, 
and are PGD
2
 (A); PGE
2
 (B); PGF
2α 
(C); 6-keto PGF
1α 
(D); and 20-OH LTB
4 
(E). Increases were observed in 
the concentration of all eicosanoid species after 24h of TNF-α treatment. Statistical significance from 
the control cells is represented by *P<0.05; **P<0.01 and ***P<0.001. 
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Figure 4.22.  Secretion of eicosanoid lipids by IL-6 treated 3T3-L1 adipocytes  
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24h, and were then treated with mouse recombinant IL-6 for 2 or 24h.  The 
concentration of IL-6 treatments used were 5, 25 and 50ng/mL. Eicosanoids were extracted from 
cell culture medium by solid phase extraction chromatography and were analysed by LC-MS/MS in 
negative ion mode. Detected eicosanoids are represented as median ± range, with a group size of 
3, and are PGD
2
 (A); PGE
2
 (B); PGF
2α 
(C); 6-keto PGF
1α 
(D); and 20-OH LTB
4 
(E). The concentration of 
all eicosanoid species increased after 24h of IL-6 treatment. Statistical significance from the control 
cells is represented by *P<0.05; **P<0.01 and ***P<0.001. 
** 
* 
** 
*** 
** 
(A) 
(B) 
(C) 
(D) 
(E) 
*** 
* 
* 
* 
* 
* 
* * 
* 
* 
* 
* 
** 
** *** 
** 
*** 
*** 
* 
*** 
* 
* 
** 
*** 
*** 
*** 
221 
 
4.5. DISCUSSION 
This chapter has used the 3T3-L1 adipocyte model characterised in Chapter 3 to study the 
effect of the pro-inflammatory agents IL-6 and TNF-α on adipokine gene expression of 3T3-L1 
adipocytes, as well as their global lipid profiles and the production of eicosanoids.  The 
purpose of this work was to investigate the effect of these inflammatory mediators on the 
lipid metabolism of 3T3-L1 adipocytes.   
 
4.5.1. Effect of inflammatory mediators on adipokine expression 
Adipocytes were treated with either TNF-α or IL-6 to investigate whether these inflammatory 
agents had an effect on the normal expression of several adipokines within the adipocytes.  A 
previous time-course study demonstrated that an effect by TNF-α treatment at a 
concentration of 25ng/mL was detectable on adipokine and cytokine gene expression and 
protein secretion in human adipocytes from 2h (Wang et al., 2005).  Therefore, a 2h 
treatment time was selected in this study to monitor whether the effect of acute TNF-α 
treatment could be replicated with the 3T3-L1 adipocyte model.  A 24h treatment time was 
also studied, to examine longer term effects of TNF-α treatment.  Extra TNF-α treatment 
concentrations were included in the present work, to study the effect of a lesser (5ng/mL) 
and a greater (50ng/mL) treatment dose.  The treatment of mature 3T3-L1 adipocytes with 
increasing concentrations of TNF-α in this study lead to an overall increase in leptin, and IL-6 
expression, and a decrease in the expression of adiponectin, and these changes became more 
apparent at the greatest concentration, and the longer treatment time.  These findings agree 
with previous studies, for example, leptin gene expression of cultured adipocytes has been 
shown to be inhibited by chronic TNF-α treatment after a transient rise (Kirchgessner et al., 
1997; Yamaguchi et al., 1998).  TNF-α treatment also decreases adiponectin gene expression 
and protein secretion in both human pre-adipocytes (Kappes and Loffler, 2000) and 3T3-L1 
adipocytes (Fasshauer et al., 2002), as well as increase IL-6 gene expression (Wang et al., 
2005).   
 
The effect of IL-6 treatment on 3T3-L1 adipocyte metabolism was also studied with the same 
conditions as above, and gene expression and protein secretion of IL-6 occurs in adipocytes 
(Mohamed-Ali et al., 1997).  In the current study, treatment of 3T3-L1 adipocytes with IL-6 
caused the upregulation of its own gene expression, as well as that of leptin and TNF-α.  In 
contrast, adiponectin expression decreased with IL-6 treatment.  As with the TNF-α 
treatment, these effects were greater with the 24h treatment.   
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These findings agree with previous work, which demonstrate that treatment with IL-6 lead to 
an autocrine effect on its own secretion in murine cells (Fasshauer et al., 2003a; Lagathu et 
al., 2003). Leptin gene expression increases in human adipocytes after IL-6 treatment (Tujillo 
et al., 2004), and adiponectin expression is inhibited by IL-6 (Fasshauer et al., 2003b).   
 
The purpose of this section of work was to validate the expected response of 3T3-L1 
adipocytes to both TNF-α and IL-6 treatment, and, overall, the findings in the current study 
agreed with the well-documented changes seen in adipokine gene expression in the 
inflammatory state. By replicating previous findings, it was proved that the dysfunction of 
adipokine gene expression seen in the 3T3-L1 adipocytes in the current work was as 
expected.  Therefore, this model of adipocyte inflammation was suitable for lipidomic 
analyses.  
 
4.5.2. Effect of inflammatory mediators on global lipid profiles 
In WAT, excess energy intake results in the storage of TG, and this TG pool is constantly 
changing due to the metabolic processes lipolysis and lipogenesis.  Alterations in the lipid 
metabolism of adipocytes are associated with obesity, such as increased basal lipolysis 
(Reynisdottir et al., 1995).  Lipolysis is the process by which stored TG are hydrolysed to 
release FAs in times of energy demand.  The gene expression and protein secretion of TNF-α 
and IL-6 (among others) are known to increase in the obese state (Wang et al., 2005), and so 
may be involved in the changes observed in lipid metabolism.  Increased gene expression and 
protein secretion of TNF-α is observed in obesity, along with increased basal lipolysis (Prins et 
al., 1997; Ryden et al., 2004).  Previous studies have demonstrated that TNF-α deficient mice 
had decreased concentrations of circulating free fatty acids (FFA) and TGs than wild-type 
controls (Uysal et al., 1997; Ventre et al., 1997).  Treatment of 3T3-L1 adipocytes with TNF-α 
suppresses lipoprotein lipase (LPL) activity, and stimulates lipolysis (Kawakami et al., 1982 
and 1987).  This cytokine also decreases the gene expression of FA transport protein (FATP) 
and translocase (FAT) in adipose tissue (Memon et al., 1988). 
 
IL-6 may also have an effect on lipid metabolism, as suggested by previous in vitro and in vivo 
experiments.  A previous study has shown that IL-6 increases lipolysis in human mammary 
adipocytes (Path et al., 2001).  Administration of IL-6 reduced LPL activity in the adipose 
tissue of mice, and also within 3T3-L1 adipocytes (Greenberg et al., 1992).   
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When administered intravenously into rats, IL-6 caused an increase in the serum 
concentration of TGs and FAs, which occurred  in a dose-dependent manner (Nonogaki et al., 
1995).   
 
Therefore, one major effect of both TNF-α and IL-6 in terms of lipid metabolism is an increase 
in lipolysis, and obesity is associated with increased basal lipolysis (Reynisdottir et al., 1995).  
In the current study, positive ion DI-MS analysis found that the concentration of two DG and 
two TG species either decreased, or remained constant in 3T3-L1 adipocytes after treatment 
with TNF-α, when compared to control cells.  This decrease in the concentration of these 
species within the TNF-α treated cells may suggest increased lipolysis. Treatment with IL-6 
showed an increase in the concentration of the DG and TG species after 24h of treatment; 
however, this increase declined as the concentration of IL-6 treatment increased (three 
concentrations were investigated; 5, 25 and 50ng/mL).  This may suggest that more chronic 
IL-6 treatment is necessary for increased rates of lipolysis to be observed. 
 
The gene expression data present in the current study have shown that TNF-α is stimulated 
by IL-6, and vice-versa is also true (Wang et al., 2005).  As described above, both have been 
shown to increase basal lipolysis.  This observed increase with both TNF-α and IL-6 treatment 
may, therefore, be a direct effect of each agent, or a cumulative effect of the two.  The 
adipokine leptin also plays a role in the altered lipolysis seen in dysregulated adipocytes.  
Treatment of lean mice adipocytes with leptin stimulates lipolytic activity, and this 
observation was even greater after leptin treatment in adipocytes from leptin resistant ob/ob 
mice (Fruhbeck et al., 1997).  In the current study, leptin gene expression increased after 
both TNF-α and IL-6 treatment, and so this increase in leptin gene expression may also be 
involved in the changes observed in the DG/TG concentrations after treatment with the 
inflammatory agents. 
 
Clearer separations were observed in the IL-6 treated cells than the TNF-α treated cells with 
multivariate data analysis of positive ion mode data.  In all of the PCA and PLS plots 
presented, points representing 24h of IL-6 treatment at concentrations of 25 and 50ng/mL, 
were grouped away from the rest of the samples.  Of the identifiable points from the loadings 
plots, one was TG (54:3), and the abundance of this lipid species was increased with the all IL-
6 treatment concentrations.  This ties in with the DG/TG species identified by DI-MS analysis 
of these treatments, and so the concentration of these lipid species increase with the greater 
IL-6 concentrations at the longer treatment time (24h).   
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This may suggest that basal lipolysis has not increased in these cells.  In negative ion mode, 
various grouping combinations were observed for both TNF-α and IL-6 treated cells, but, 
overall, a clear separation was observed between the control and treated cells.  The 
abundance of the phospholipid PC (20:0) decreased between the control and treated groups.  
This matched the negative DI-MS analysis data, where the concentration of this lipid 
decreased in both the TNF-α and IL-6 treated cells.   
 
The increase in lipolysis observed in dysregulated adipocytes may be seen as advantageous, 
as the outcome would be a decrease in TG accumulation within the adipocyte.  However, 
hydrolysis of TG leads to an increase in FFAs which has been linked to insulin resistance, 
T2DM and the metabolic syndrome (Randle et al., 1963).  In the current study it has been 
suggested that increased basal lipolysis was observed in TNF-α treatment due to the 
decreased concentration of various DG/TG and also of PC (20:0).  TNF-α is known to be an 
important mediator of obesity-related insulin resistance (Hotamisligil et al., 1993; 1994 and 
1995).  It down-regulates the gene expression of glucose transporter type 4 (GLUT4) in 
adipocytes, causing a decrease in insulin-stimulated intracellular glucose transport (Stephens 
and Pekala, 1992).  This is coupled with an increase in the gene expression of hormone 
sensitive lipase (HSL), which causes increased lipolysis (Sumida et al., 1997).  Therefore, 
increased basal lipolysis may be involved in the insulin resistance caused by TNF-α. 
 
IL-6 treatment in the current study caused increased concentrations of various individual 
DG/TG species after 24h of treatment, and so it was thought that increased basal lipolysis had 
not occurred.  A previous study observed an increase in lipolysis after 24 to 48h of IL-6 
treatment in human adipocytes (Trujillo et al., 2004), therefore, more chronic treatment with 
IL-6 may be needed to observe the decrease in DG / TG concentrations as seen with TNF-α 
treatment.  
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4.5.3. Effect of inflammatory mediators on eicosanoid production 
Changes in the concentration of eicosanoid species were expected in the 3T3-L1 adipocytes 
after treatment with both TNF-α and IL-6, especially because dysfunction of normal adipocyte 
function had already been observed in both the gene expression of several adipokines and 
also the global lipid profiles of these cells.  As with the eicosanoid species detected produced 
by the differentiating 3T3-L1 adipocytes in Chapter 3, only a minority of the eicosanoids 
present in the standard mix were detectable in the inflammatory mediator treated cells, and 
these were all prostanoids.  As described in Chapter 3, the prostanoids are known to have a 
vital role in modulating differentiation and maturation of adipocytes (Shillabeer et al., 1998).   
These prostanoids can also act as lipid mediators of metabolic abnormalities, with both PGE2 
and PGI2 being known to induce adipocyte dysfunction (Kim and Moustaid-Moussa, 2000).   
 
In the current study, an increase in the concentration of the five detectable eicosanoid 
species was observed with TNF-α treatment, and these eicosanoids were: PGD2, PGE2, PGF2α, 
6-keto PGF1α and 20-OH LTB4.  TNF-α stimulates PGE2 and PGD2 synthesis in several cell types 
(Dayer et al., 1985). Both are involved in the synthesis and storage of TG, and inhibition of 
lipolysis (Strong et al., 1992).  A direct relationship was observed between the concentration 
of PGE2 and TNF-α treatment concentration, implying that greater TNF-α concentrations can 
further increase PGE2 production.   
 
Given that PGE2 is a potent inhibitor of TNF-α (Miles et al., 2002), this may explain why gene 
expression of TNF-α was not detectable with the highest TNF-α treatment concentration in 
the current study.  However, a previous study in human adipocytes demonstrated that acute 
TNF-α treatment had a substantial effect on its own expression (Wang et al., 2005).  This 
contradicts the findings in this thesis; however, it was undertaken with human adipocytes 
with a TNF-α treatment concentration of 25ng/mL, and so may not be comparable. The gene 
expression of TNF-α was seen in the treated 3T3-L1 adipocytes in the present study at 
25ng/mL (data not shown), meaning that TNF-α concentration greater than this may have an 
inhibitory effect on its own expression, possibly caused by an increase in PGE2 synthesis.   
 
PGE2 may also have an effect on the adipokine changes seen in obesity as a previous study 
has demonstrated that PGE2 increases leptin production in primary culture of mouse adipose 
tissue (Fain et al., 2000).  Increased circulating concentrations of leptin are known to increase 
lipolysis (Lonnqvist et al., 1995).  In the current study, leptin gene expression in the 3T3-L1 
adipocytes increased after treatment with both TNF-α and IL-6, and so this increase may have 
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been caused by the increase in PGE2 concentration.  One way to test this hypothesis would be 
to block PGE2 formation with the use of a cyclooxygenase (COX) inhibitor and observe the 
effect on leptin gene expression. 
 
Arachidonate and FA products regulate lipolysis within adipocytes, and these are released by 
phospholipase A2. An adipose tissue specific group XVI phospholipase A2 enzyme has been 
characterised in mouse WAT (Duncan et al., 2008), and it acts at the sn2 position of   
phosphatidylcholine acyl chains.  The observed decrease of PC (20:0) in the current study 
could be due to increased lipolysis, which would therefore require increased arachidonate 
release from the phospholipids.   
 
Another prostanoid which significantly increased with TNF-α treatment in this study was 
PGF2α.  This is known to stimulate expression of TNF-α in both pre- and mature adipocytes, 
and both TNF-α (Torti et al., 1985) and PGF2α (Miller et al., 1996) inhibit adipocyte 
differentiation. A significant increase in PGF2α concentration was observed in this study, 
which would lead to dysregulation of the normal adipocyte function.  This increase in the 
concentration of PGF2α may further increase TNF-α gene expression and protein secretion, 
which in turn could stimulate greater PGE2 production and induce the dysfunction of the 
adipocyte. 
 
In the current study, the treatment of 3T3-L1 adipocytes with IL-6 also significantly increased 
the concentrations of all five eicosanoid species at the higher concentrations after 24h, and 
also at 2h for PGE2 and PGF2α.  This may imply that treatment with IL-6 has the same effects 
on prostanoid synthesis.  IL-6 is known to increase TNF-α gene expression and protein 
secretion; therefore, another explanation for the similarities may be that the effects of IL-6 
treatment on eicosanoids may in fact be due to the increased TNF-α synthesis.  Both PGE2 
and PGD2 inhibit lipolysis (Strong et al., 1992), and so the increases in the concentration of 
these prostanoids may explain the increase in the concentration of three TG species from 
both DI-MS and LC-MS analyses present after IL-6 treatment of 3T3-L1 adipocytes. 
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4.5.4. Limitations 
The major limitation of the current study was the lack of successful lipid species 
identifications in the PCA and PLS loadings plots.  With those that could be identified, exact 
fatty acid compositions could not be assigned, and so they were represented as the total fatty 
acid composition; for example PC (34:1) could be PC (16:0/18:1) or PC (18:1/16:0).  The points 
that could not be identified were possibly part of the ‘background noise’ ions from the LC-MS 
analysis.  All PCA and PLS models in the current study were Pareto scaled, and this means that 
areas on the chromatogram with lesser amplitude can influence the model if they show 
variation. This scaling method is commonly used for mass spectrometry data (Eriksson et al., 
1999).  If the unidentified points did represent noise ions, then another scaling method may 
be more appropriate.  One example would be centering with no scaling (Ctr) in which regions 
of less amplitude would have little influence because the influence of a variable is related to 
its signal.   
 
Another problem was the possible contamination seen in the negative ion mass spectrometry 
analyses.  In some of the spectra acquired from both DI-MS and LC-MS analyses, three peaks 
with m/z 311.17, 325.18 and 339.20 were present.  These were thought to be linear 
alkylbenzenesulfonates (Andreu and Pico, 2004), which are found in detergents.  These peaks 
were excluded from data analysis; however, their presence in the samples was evident in the 
PCA and PLS loadings plots.   
 
 
4.5.5. Conclusions and future work 
Obesity is characterised by chronic low-grade inflammation (Yudkin et al., 1999; Festa et al., 
2001).  The work in this chapter used the 3T3-L1 adipocyte model to study the effect of the 
pro-inflammatory agents IL-6 and TNF-α on adipokine gene expression, as well as global lipid 
profiles and the production of eicosanoids.  An increase in the gene expression of leptin and 
IL-6 was observed in these treated cells, along with a decrease in adiponectin expression.  
Adiponectin has an anti-inflammatory action (Ouchi et al., 2000) and so its decrease further 
supports the inflammation state of these adipocytes.   
 
Global lipidomic analyses identified a decrease in the concentration of several DG and TG 
species after treatment with TNF-α and so it was suggested that an increase in lipolysis was 
occurring in these cells.  Conflicting findings were seen after IL-6 treatment, with the 
concentration of TG/DG species increasing.  A previous study demonstrated that IL-6 
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treatment increased lipolysis in human adipocytes after 48h of treatment (Trujillo et al., 
2004), and so the 24h treatment in this study may not have been long enough to replicate the 
effect of TNF-α treatment.   
 
Increases in the concentration of PGD2, PGD2 and PGF2α were observed after the 3T3-L1 
adipocytes were treated with TNF-α and IL-6.  Both PGE2 and PGD2 increase the production 
and storage of TG, and inhibit lipolysis (Strong et al., 1992); whereas PGF2α is known to inhibit 
differentiation. As well as having a role in lipid metabolism, PGE2 also increases leptin 
production in mouse adipose tissue (Fain et al., 2000).  In the current study, leptin gene 
expression was increased after treatment with both TNF-α and IL-6.  Therefore, increased 
PGE2 concentration in the present work may increase leptin gene expression, which in turn 
increases lipolysis.  Increased concentrations of these prostanoid species in response to 
treatment with the inflammatory agents may be associated with disturbances in normal lipid 
metabolism within the adipocyte. 
 
Overall, the findings in this chapter have proved that treatment with inflammatory agents 
causes dysfunction of the normal metabolism of 3T3-L1 adipocytes.  Disturbances in 
adipokine gene expression, global lipid profiles and eicosanoid secretion patterns were 
observed, and seemed to be linked.  The main disturbance suggested was an increase in 
lipolysis.  The result of lipolysis is increased hydrolysis of TG which would lead to decreased 
TG storage and also increased concentrations of FFAs, which have serious implications for 
health, as they are associated with insulin resistance and T2DM (Randle et al., 1963; Bays et 
al., 2004; Poynten et al., 2005), and also increased risk of cardiovascular disease (Carlsson et 
al., 2000; Pirro et al., 2002).   
 
The current work has provided a model for abnormal adipocyte function in relation to 
inflammation.  Increased lipolysis appears to be occurring in the TNF-α treated cells; 
however, this has only been based on the evidence of decreased concentrations of TG/DG 
species.  More thorough investigations are needed for definite proof, and a simple way to 
monitor lipolysis is by measuring glycerol release into the medium (Bradley and Kaslow, 
1989).  Also, it would be interesting to investigate the gene expression of LPL, as it is known 
to be suppressed by TNF-α (Kawakami et al., 1982; Price et al., 1986; Kawakami et al., 1987) 
and IL-6 (Greenberg et al., 1992), and is related to increased lipolysis.  
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Chapter 5 
Effect of dexamethasone treatment on 3T3-L1 
adipocyte metabolism 
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 5.1. INTRODUCTION 
The results described in Chapter 4 demonstrated that 3T3-L1 adipocytes are responsive to 
the effects of the inflammatory mediators, TNF-α and IL-6.  This current study was designed 
to determine whether similar or opposing effects would be observed in response to an anti-
inflammatory agent.  Dexamethasone was chosen because as well as being an anti-
inflammatory agent, it is also a component of the differentiation cocktail used to differentiate 
3T3-L1 pre-adipocytes (Rubin et al., 1978), and therefore has adipogenic properties.  
 
Dexamethasone is a synthetic member of the glucocorticoid class of steroid drugs, and is a 
potent anti-inflammatory agent, as observed by its effects on the gene expression of several 
inflammatory adipokines. For example, dexamethasone treatment of human omental 
adipose tissue explants inhibits the gene expression and protein secretion of IL-6 and IL-8 
(Fain et al., 2005).  It is also an adipogenic agent, and is involved in the adipogenesis of 3T3-L1 
adipocytes (Rubin et al., 1978), as well as other pre-adipocyte cell lines (Chapman et al., 
1984; Grigoriadis et al., 1988; Gaillard et al., 1991).   
 
Glucocorticoids are hormones produced by the adrenal cortex, and are adaptive in activating 
the cardiovascular system in response to a physical stressor by increasing blood pressure and 
cardiac output (Fisher, 1990).  However, chronic glucocorticoid treatment is maladaptive and 
associated with an increase in the concentration of circulating free fatty acids (FFAs) and 
insulin resistance in humans (Divertie et al., 1991; Djurhuus et al., 2002 and 2004) and 
rodents (Severino et al., 2002).  Two potential mechanisms have been suggested for insulin-
resistance caused by glucocorticoid treatment; a decrease in insulin binding to cells, and also 
inhibition of glucose transport (Czech and Fain, 1972; Olefsky, 1975; Olefsky et al., 1975).    
 
Excessive glucocorticoid treatment is known to affect lipid metabolism by increasing the gene 
expression of adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), which in 
turn increase lipolysis (Fain and Saperstein, 1970; Slavin et al., 1994; Xu et al., 2009; Campbell 
et al., 2011).  Increased lipolysis leads to lipid loss, as seen in an in vivo rodent study, whereby 
chronic glucocorticoid treatment induced weight loss (Elliot et al., 1971).  In contrast, chronic 
glucocorticoid excess is the main cause of Cushing’s syndrome (hyperadrenocorticism), which 
is characterised by increased adiposity, particularly in the visceral region (Cushing, 1912).  The 
classical central fat accumulation observed in Cushing’s syndrome is associated with glucose 
intolerance and hypertension, and so the clinical features of this disease are similar to the 
metabolic syndrome (Reaven and Hoffman, 1987).   
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5.1.2. Aims and objectives 
Previous studies have found that the glucocorticoids have lipolytic and adipogenic actions 
which vary according to various factors including the agent used, dose and length of 
treatment and the experimental model used (Masuzaki et al., 2001; Andrews et al., 2002; 
Kershaw et al., 2005; Xu et al., 2009).  Therefore, the purpose of the work presented in the 
current study was to explore the effect of dexamethasone treatment on the normal function 
of 3T3-L1 adipocytes.   These cells were treated at day 10 post-differentiation with 
dexamethasone at two concentrations for either two, or 24 hours (h).   
 
The first specific aim was to measure the gene expression of leptin, adiponectin, IL-6 and 
TNF-α in both the control day 10 adipocytes, and those which had been treated with 
dexamethasone.  It was hypothesised that the expression of these genes would alter when 
compared to control adipocytes; specifically leptin gene expression would increase after 
dexamethasone treatment, whereas the gene expression of adiponectin, IL-6 and TNF-α 
would decrease, as seen in previous studies (Bradley and Cheatham, 1999; Fasshauer et al., 
2002 and 2003). 
 
After the gene expression profiles had been monitored, the second aim was to produce 
global lipid profiles of these adipocytes.  It was predicted that both phospholipid and 
triglyceride species would be the major components of the global lipid profiles, but also that 
the abundance of these lipid species would be altered by dexamethasone intervention.  
 
The final aim was to detect arachidonic acid (AA)-derived eicosanoid species secreted by 
these adipocytes, and to monitor their concentration in both the control and dexamethasone 
treated cells.   
 
  
 
 
 
 
 
 
 
232 
 
5.2 MATERIALS AND METHODS 
5.2.1. Cell culture 
3T3-L1 adipocytes were cultured in a humidified atmosphere of 5%CO2 / 95% air at 37
oC as 
previously described in Section 2.1.3.  All media protocols are listed in Section 2.1.2.  The cells 
were induced to differentiate at day 0, and all treatments occurred at day 10 post-
differentiation.  Before treatment, the adipocytes were starved of calf serum (CS) for 24 
hours (h), by feeding with DMEM alone.  After 24h, the cells were treated with CS-free 
medium containing 2 or 20nM dexamethasone, and the control cells had the CS-free 
incubation medium renewed.  The cells were harvested at 2 and 24h post-treatment, along 
with the medium, and both were stored at -80oC until required.  
 
5.2.2. Reverse transcription PCR  
The gene expression of leptin, adiponectin, TNF-α and IL-6 were quantified using qPCR, as 
described in Sections 2.3 and 2.6. 
 
5.2.3. Global lipidomic analysis 
5.3.2.1. Cell preparation  
A Folch extraction was used to extract lipids from cell and quality control (QC) samples (Folch 
et al., 1957) as described in Section 2.9.1.1.  The lower phase was dried down under a stream 
of nitrogen, and reconstituted into 600µL chloroform/methanol (2,1; v,v).  The direct 
infusion-mass spectrometry (DI-MS) samples had 10mM ammonium formate added to them, 
but not the liquid chromatography-mass spectrometry (LC-MS) samples   
 
5.2.3.1. DI-MS analysis 
The reconstituted samples analysed by DI-MS using an Orbitrap Exactive mass spectrometer, 
with one technical replicate per sample, and analysed in both positive and negative ion mode 
as described in Section 2.9.1.2.   
 
Abundant peaks from both the control and treated cell samples were quantified using the 
relevant internal standard, which were added at 1nmol concentration, and had a mass-to-
charge ratio (m/z) of either 622.4443, or 908.8651 in positive ion mode.  These related to: 
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1,2-didodecanoyl-sn-glycero-3-phosphocholine, PC (12:0/12:0); or 1,2,3-trioctadecanoyl-sn-
glycerol, TG (18:0/18:0/18:0), respectively. The samples were then normalised to the protein 
concentration of the cell samples.  The lipids were identified according to their m/z using the 
following databases: the Human Metabolome Database (HMDB; www.hmdb.ca), LIPID 
Metabolites and Pathways Strategy (LIPID MAPS; www.lipidmaps.org), and the Metabolite 
and Tandem MS Database (METLIN; http://metlin.scripps.edu).  If the mass accuracy was 
within 5 parts per million (ppm), a confident identification was assumed, and all mentioned 
identifications are within this limit, unless stated. 
 
5.2.3.2. LC-MS analysis  
The lipid extracts were also analysed by LC-MS using a binary solvent system to separate the 
samples over 18 minutes (min) as described in Sections 2.9.2.2 and 2.9.2.3.   
 
5.2.3.4. LC-MS data processing and multivariate data analysis 
All LC-MS chromatograms were processed using SIEVE (v1.3) to produce m/z and retention 
time (RT) frames.  The retention time window was set to 15 seconds (s).  These frames, along 
with their related intensities were manually normalised to the total ion current (TIC) of the 
chromatogram.  As with the DI-MS data, the lipids were identified using three databases: 
HMDB, LIPID MAPS and METLIN in both positive and negative ion modes.   
 
The RT and m/z pairs, along with their intensities, were manually normalised the total ion 
current (TIC) intensity.  Both the non-normalised and TIC-normalised data sets were then 
imported into SIMCA-P (v12) for multivariate data analysis (MVDA), starting the unsupervised 
principal component analysis (PCA).  A supervised technique was then used, and due to the 
number of sample groups, as well as the fact that the y-variable data were continuous, partial 
least squares (PLS) analysis was chosen.  All models were Pareto scaled. 
 
5.2.4. Targeted eicosanoid analysis 
Solid phase extraction chromatography was used to extract eicosanoids from 3T3-L1 medium 
samples, and is described in Section 2.9.3.1.  After the eicosanoids had been eluted, the 
samples were dried down under nitrogen and reconstituted in 100µL H20: MeOH (1:1, v: v), 
before being analysed by LC-MS/MS as outlined in Sections 2.9.3.2.1 and 2.9.3.2.2.  Individual 
eicosanoids were identified using specific precursor-to-product ion m/z transitions, as 
detailed in Table 2.3 (Chapter 2).   
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5.2.5. Statistical analysis 
For qPCR analyses, all data were analysed using the non-parametric Friedman’s two-way 
analysis of variance test, followed by a pairwise comparisons (Conver) post-hoc test.  The 
Friedman’s two-way analysis of variance test was chosen, even though the data were 
normally distributed, because it has been suggested that non-parametric tests should be used 
when analysing qPCR data (Yuan et al., 2006).  For the mass spectrometry data, a Shapiro-
Wilk W test was used to determine their normality, and all were not normally distributed. 
Therefore, the non-parametric Friedman's two-way analysis of variance test was used 
followed by an all pairwise comparisons (Conover) post-hoc test to identify differences 
between groups.  All of the statistical tests were performed using the software package 
StatsDirect.  Normally distributed data were presented as mean values ± SD, and non-
normally distributed data as median values ± range. The group size is indicated in the figures, 
and a P-value of less than or equal to 0.05 was considered to be statistically significant. 
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5.3. RESULTS  
5.3.1. Effects of dexamethasone on adipokine gene expression  
The gene expression profiles of leptin, adiponectin and IL-6 from 3T3-L1 adipocytes which 
had been treated with dexamethasone are presented in Figure 5.1.  When dexamethasone 
was added to the medium at 2 and 20nM for 2h, there were no significant changes observed 
in leptin gene expression (A).  When these concentrations of dexamethasone were added to 
the medium for 24h, leptin gene expression significantly increased (P<0.001 for both 
treatment concentrations).  No significant changes were observed in adiponectin gene 
expression when dexamethasone was added to the medium at 2nM.  When dexamethasone 
was added to the medium at 20nM, a significant increase in adiponectin gene expression was 
seen after 2h (P=0.044; Figure 5.1B), with a significant decrease occurring after 24h of 
treatment (P<0.001; Figure 5.1B).  The gene expression of IL-6 showed no significant 
differences when compared to the control cells after 2h of dexamethasone treatment at 
either concentration (C).  After 24h of treatment, IL-6 gene expression significantly decreased 
at both 2 and 20nM (P<0.001 for both concentrations; Figure 5.1C). 
 
 The gene expression of TNF-α was below the detection limit in all of the dexamethasone 
treated samples, and so is not presented. 
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Figure 5.1. Adipokine gene expression of dexamethasone treated 3T3-L1 adipocytes   
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with dexamethasone for 2 or 24h. The concentration of dexamethasone treatments used 
were: 2 and 20nM. Adipokine gene expression was quantified by qPCR and normalised to GAPDH 
relative to the control group. Results are represented as means ± SD for a group size of 6. The 
adipokines quantified were leptin (A), adiponectin (B) and IL-6 (C). The data show a significant increase 
in leptin gene expression, and significant decreases in the gene expression for both adiponectin and IL-
6 at the 24h treatment time. Statistical significance of each treatment group compared to the control 
group is represented by *P<0.05; **P<0.01 and *** P<0.001 vs. control.  
*** 
*** 
(A) 
*** 
* 
(B) 
* 
*** 
(C) 
2h 24h 
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5.3.2. Positive ion mode DI-MS analysis 
Representative spectra of control cells, and cells treated with 20nM dexamethasone for 2 
or 24h in positive ion mode are shown in Figure 5.2.  These spectra show similar lipid 
profiles between the control and dexamethasone treated cells at both 2 and 24h.  A 
decrease in the overall lipid abundance was noted in the 20nM dexamethasone treated 
cells when compared to the  control cells, as seen by the increase in abundance of the 
peaks with m/z 622.4443 and 908.8651 (internal standards; PC 12:0/12:0 and TG 
18:0/18:0/18:0, respectively). 
 
A greater number of the peaks in the positive ion spectra were able to be identified 
compared to those in Chapter 4, and so the top 20 peaks from the global lipid profiles in 
Figure 5.2 were identified, and are presented in Table 5.1.  All of the abundant selected 
lipid species from the control cells (A), as well as the majority of the dexamethasone 
treated cells were either diglyceride (DG) or triglyceride (TG) species.  Three lipid species 
were identified as being within the top 20 abundant peaks in the treated cells (B), and not 
in the control cells.  Of the three, two were the phosphatidylcholine (PC) species (36:2) 
and (38:4), and the third was TG (54:4).  
 
The lipid species identified in Table 5.1 were normalised to the intensity of the relevant 
internal standard, either PC (12:0/12:0) with m/z 622.4443 or TG (18:0/18:0/18:0) at m/z 
908.8651, and then to the protein content of the sample.  After this stage, the top three 
lipid species from both dexamethasone treatment concentrations after 2h (A) and 24h (B) 
were represented graphically in Figure 5.3.  When 2nM of dexamethasone was added into 
the medium for 2h and 24h, an increase was seen in the concentration of two TG species 
with m/z 846.7528 and 874.7837, which were identified as TG (50:3) and TG (52:3) (P=0.05 
vs. control for all).   
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Figure 5.2. Positive ion DI-MS analysis of dexamethasone treated 3T3-L1 adipocytes  
Representative spectra of differentiated 3T3-L1 adipocytes at day 10 post-differentiation which were pre-
incubated with CS-free medium for 24h, and then treated with dexamethasone for 2 and 24h. The 
treatments represented are: control 2h (A), 20nM 2h (B), control 24h (C) and 20nM 24h (D). Lipids were 
extracted from the cell samples using a Folch extraction, and the lower phase was dried down under 
nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 150µL aliquot was removed and 
had 10mM ammonium formate added to it. The samples were then directly infused into an Orbitrap 
Exactive mass spectrometer at a flow rate of 5µL/min for 90 seconds (450 scans) in positive ion mode. The 
mass range analysed was between 100 and 1000Da, and that represented in the figure is between 500 and 
950Da. An increase was observed in the lipid species with m/z between 750 and 900Da in the 
dexamethasone treated samples. However, an increase was observed in the intensity of the internal 
standard peaks (m/z 622.44 and 908.86) which suggests a decrease in the abundance of all lipid species. 
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Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification  
 
(A) Control  
535.4715  535.4387  61.258    [M+H]
+ 
 C33H58O5    DG (30:3) 
547.4715  547.4513  36.898    [M+H]
+ 
 C34H60O5    DG (31:3) 
563.5024  563.4670  62.825    [M+H]
+ 
 C35H62O5    DG (32:3) 
575.5021  575.4670  60.994    [M+H]
+ 
 C36H62O5    DG (33:4) 
577.5177  577.4826  60.781    [M+H]
+ 
 C36H64O5    DG (33:3) 
603.5337  603.4994  56.835    [M+H]
+ 
 C38H68O5    DG (35:4) 
806.7219       806.7232  -1.611    [M+NH4]
+ 
      C50H92O6                TG (47:2) 
820.7370       820.7389  -2.315    [M+NH4]
+ 
      C51H94O6                TG (48:2) 
832.7379       832.7389  -1.200    [M+NH4]
+
       C52H94O6                TG (49:3) 
834.7527       834.7545  -2.156    [M+NH4]
+
       C52H96O6                TG (49:2) 
846.7528       846.7545  -2.008    [M+NH4]
+
       C53H96O6                TG (50:3) 
847.7566       847.7749  -21.586    [M+H]
+
       C54H102O6                TG (51:1) 
848.7674       848.7701  -3.181    [M+NH4]
+
       C53H98O6                TG (50:2) 
860.7686       860.7701  -1.743    [M+NH4]
+
       C54H98O6                TG (51:3) 
862.7836       862.7858  -2.550    [M+NH4]
+
       C54H100O6                TG (51:2) 
2
3
9
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872.7683       872.7701  -2.062    [M+NH4]
+
       C55H98O6                TG (52:4) 
874.7837       874.7858  -2.401    [M+NH4]
+
       C55H100O6                TG (52:3) 
875.7877       875.8062  -21.123    [M+H]
+
       C56H106O6                TG (53:1) 
876.7972       876.8014  -4.790    [M+NH4]
+
       C55H102O6                TG (52:2) 
902.8147       902.8171  -2.658    [M+NH4]
+
       C57H104O6                TG (54:3) 
 
(B) Extra identifications from 20nM dexamethasone treatment 
786.5998       786.6007  -1.144    [M+H]
+
       C44H84NO8P                PC (36:2) 
810.6003       810.6007  -0.493    [M+H]
+
       C46H84NO8P                PC (38:4) 
900.7994       900.8015  -2.331    [M+NH4]
+
       C57H102O6                TG (54:4) 
 
 
Table 5.1. Identifications of selected positive ions from control and dexamethasone treated 3T3-L1 adipocytes 
Abbreviations used: DG, diglyceride; PC, phosphatidylcholine; TG, triglyceride; ppm, parts per million 
Underlined masses are present in both control and dexamethasone treated cells. 
2
4
0
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Figure 5.3. Individual lipid concentrations from positive ion DI-MS analysis of dexamethasone 
treated 3T3-L1 adipocytes 
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, 
and then treated with dexamethasone for 2 or 24h. The concentration of dexamethasone 
treatments used were 2 and 20nM. Lipids were extracted from the cell samples using a Folch 
extraction, and the lower phase was dried down under nitrogen and reconstituted in 600µL 
chloroform/methanol (2/1, v/v). A 150µL aliquot was removed and had 10mM ammonium formate 
added to it. The samples were then directly infused into an Orbitrap Exactive mass spectrometer at 
a flow rate of 5µL/min for 90s (450 scans) in positive ion mode. 
 
Selected abundant lipids are shown in the key and were quantified using a relevant internal 
standard, either PC (12:0/12:0) or TG (18:0/18:0/18:0), with m/z 622.4443 and 908.8651, 
respectively. They were then normalised to the protein concentration of the cell sample. For each 
time point, n=3, and the results are presented as median ± range. The data show a significant 
increase in the two TG species with both dexamethasone treatment concentrations after 2h. An 
increase in the concentration of TG (52:3) was also seen after 24h.  Statistical significance of each 
treatment group compared to the control group is represented by *P=0.05 or less. 
* 
* 
(B) 
* 
* 
* 
* 
* 
(A) 
Key 
m/z 760.5843; PC (34:1) 
m/z 782.5683; PC (36:4) 
m/z 820.7379; PC (48:2) 
m/z 834.7583; PC (49:2) 
m/z 848.7686; PC (50:2) 
Key 
m/z 760.5843; PC (34:1) 
m/z 782.5683; PC (36:4) 
m/z 820.7379; PC (48:2) 
m/z 834.7583; PC (49:2) 
m/z 848.7686; PC (50:2) 
Key 
m/z 760.5843; PC (34:1) 
m/z 782.5683; PC (36:4) 
m/z 820.7379; PC (48:2) 
m/z 834.7583; PC (49:2) 
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m/z 848.7686; PC (50:2) 
Key:  
m/z 575.5021; DG (33:4) 
m/z 846.7528; TG (50:3) 
m/z 874.7837; TG (52:3) 
* 
* 
* 
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An increase was also observed in the concentration of the lipid species with m/z 575.5021, 
which was tentatively identified as DG (33:4), due to its mass accuracy  being outside of the 
parameter set in Section 5.2.3.2 (ppm=60.994; P=0.047 vs. control).   After 24h of 2nM 
dexamethasone treatment (B), the concentration of TG (52:3) increased (P=0.047 vs. 
control).  The concentration of this TG species also increased with the greatest 
dexamethasone treatment, along with that of DG (33:4) (P=0.024 vs. control for both). 
 
5.3.3. Negative ion DI-MS analysis 
Representative negative ion mode spectra of control, and 20nM dexamethasone treated 
cells after 2 or 24h are shown in Figure 5.4.  The most abundant peak in the 2h control cells 
had m/z 564.3457, and this changed to either 281.2583 or 303.2334 in the remaining 
spectra. 
 
The top 20 peaks from these spectra were identified, and are presented in Table 5.2.  All of 
the lipid species in both (A) and (B) were either fatty acid (FA) or phospholipids, with the 
exception of one diglyceride species.  Many phospholipids were represented including, 
phosphatidylcholine (PC); phosphatidylethanolamine (PE); phoshatidylglycerol; 
phosphatidylinositol (PI) and phosphatidylserine (PS) species.  
 
The lipid species from Table 5.2 were quantified using the internal standard, PC (12:0/12:0) 
with m/z 666.4443, and then normalised to the protein content of the sample.  The three 
most concentrated lipid species from both dexamethasone treatment concentrations after 
2h (A) and 24h (B) are presented graphically in Figure 5.5.  These selected lipid species had 
m/z 281.2483, 303.2334, and 564.3457, and the first two were identified as C18:1 and 
C20:4, respectively. The final species was tentatively identified as PC (20:0) due to its mass 
accuracy (ppm=-37.919). After 2h of dexamethasone treatment, an increased 
concentration of the two FAs was seen with the 2nM treatment concentration (P=0.024 vs. 
control for both).  When dexamethasone was added for 24h, an increase was observed in 
the concentration of all lipid species at the 2nM concentration (P=0.05 or less vs. control 
for all).  At the 20nM dexamethasone treatment concentration, an increase was seen in 
the concentration of C20:4 (P=0.05 vs. control). 
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Figure 5.4. Negative ion DI-MS analysis of dexamethasone treated 3T3-L1 adipocytes 
Representative spectra of differentiated 3T3-L1 adipocytes at day 10 post-differentiation which were pre-
incubated with CS-free medium for 24h, and then treated with dexamethasone for 2 and 24h.  The 
treatments represented are: control 2h (A), 20nM 2h (B), control 24h (C) and 20nM 24h (D). Lipids were 
extracted from the cell samples using a Folch extraction, and the lower phase was dried down under 
nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 150µL aliquot was removed and 
had 10mM ammonium formate added to it.  The samples were then directly infused into an Orbitrap 
Exactive mass spectrometer at a flow rate of 5µL/min for 90 seconds (450 scans) in negative ion mode. 
The mass range analysed was between 100 and 1000Da, and that represented in the figure is between 200 
and 900Da. No gross changes were observed between the chromatograms of the control and 
dexamethasone treated cells. 
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Calculated mass       Theoretical mass  Δ Mass accuracy (ppm)  Ion        Elemental composition           Identification 
(A) Control 
253.2178       253.2173  1.975    [M-H]
- 
         C16H30O2    C16:1 
255.2327       255.2330  -1.175    [M-H]
- 
         C16H32O2    C16:0 
279.2328       279.2330  -0.716    [M-H]
- 
         C18H32O2    C16:2 
281.2483       281.2486  -1.067    [M-H]
-         
    C18H34O2    C18:1 
283.2648       283.2643  1.765    [M-H]
-         
    C18H36O2    C18:0 
303.2334       303.2330  1.319    [M-H]
-
          C20H32O2    C20:4 
564.3457       564.3671  -37.919    [M-H]
-
          C28H56NO8P   PC (20:0) 
565.3487       565.3511  -4.245    [M-H]
-
          C28H55O9P   Lyso-PG (22:1) 
606.4159       606.4140  3.133    [M-H]
-
          C31H61NO8P   PE (26:0) 
687.5740       687.5933  -28.069    [M-H]
-
          C44H80O5    DG (41:3) 
722.5156       722.4766  53.981    [M-H]
-
          C40H70NO8P   PC (32:5) 
742.5418       742.5392  3.501    [M-H]
-
          C41H78NO8P   PC (33:2) 
747.5677       747.5546  17.524    [M-H]
-
          C41H81O9P   PG (P-35:0) 
748.5321       748.5287  4.542    [M-H]
-
          C43H76NO7P   PE (O-38:6) / PE (P-38:6)  
750.5473       750.5443  3.997    [M-H]
-
          C43H78NO7P   PE (P-38:4) / PE (O-38:5) 
766.5437       766.5392  5.871    [M-H]
-
          C43H78NO8P   PC (35:4) 
2
4
4
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802.5630       802.5604  3.239    [M-H]
-
          C43H82NO10P   PS (37:1) 
804.5766       804.5760  0.756    [M-H]
-
          C43H84NO10P   PS (37:0) 
826.5620       826.5390  27.827    [M-H]
-
          C48H78NO8P   PC (40:9) 
830.5946       830.5917  3.491    [M-H]
-
          C45H86NO10P   PS (39:1) 
854.5941       854.5917  2.808    [M-H]
-
          C47H86NO10P   PS (41:3) 
883.5368       883.5342  2.943    [M-H]
-
          C47H81O13P   PI (38:5) 
885.5518       885.5499  2.146    [M-H]
-
          C47H83O13P   PI (38:4) 
886.5561       886.5604  -4.850    [M-H]
-
          C50H81NO10P   PS(44:8) 
 
(B) Extra identifications from 20nM dexamethasone treatment  
361.1823       361.1748  20.766    [M-H]
-
          C18H35BrO2   Halogenated FA 
861.5507       861.5499  0.929    [M-H]
-
          C45H83O13P   PI (36:2) 
       
Table 5.2. Identifications of selected negative ions from control and dexamethasone treated 3T3-L1 adipocytes 
Abbreviations used: DG, diglyceride; FA, fatty acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, 
phosphatidylserine; ppm, parts per million  
Underlined masses are present in both control and dexamethasone treated cells. 
2
4
5
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Figure 5.5. Individual lipid concentrations from negative ion DI-MS analysis of dexamethasone 
treated 3T3-L1 adipocytes 
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with dexamethasone for 2 or 24h.  The concentration of dexamethasone treatments used 
were 2 and 20nM.  Lipids were extracted from the cell samples using a Folch extraction, and the lower 
phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 
150µL aliquot was removed and had 10mM ammonium formate added to it. The samples were then 
directly infused into an Orbitrap Exactive mass spectrometer at a flow rate of 5µL/min for 90 seconds 
(450 scans) in negative ion mode. 
 
Selected abundant lipids are shown in the key and were quantified using the relevant internal 
standard, PC (12:0/12:0) with m/z 666.4443.  They were then normalised to the protein concentration 
of the cell sample.  For each time point, n=3, and the results are presented as median ± range. The 
data show an increase in the concentration of the C18:1 and C20:4 at 2nM dexamethasone treatment 
concentration at both 2 and 24h. An increase in the  concentration of PC(20:0) was also observed  with 
2nM dexamethasone treatment at 2nM, and C20:4 with 20nM after 24h of treatment. Statistical 
significance of each treatment group compared to the control group is represented by *P=0.05 or less. 
Key:  
m/z 281.2483; C18:1 
m/z 303.2334; C20:4 
m/z 564.3457; PC (20:0) 
(A) 
(B) 
* 
* 
* 
* 
* 
* 
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5.3.4. Positive ion LC-MS analysis 
Representative chromatograms of control adipocytes, along with those which had been 
treated with dexamethasone for 2 or 24h at 20nM are shown in Figure 5.6.   When 
compared to the 2h control cells (A), a decrease in the abundance of ions with retention 
time (RT) between 7.5 and 8.5 min was observed in the adipocytes which had been 
treated with dexamethasone for 2h (B), as seen by the increase in the peak with RT 9.25 
min, which represents the ion with m/z 908.8651, which is the internal standard TG 
(18:0/18:0/18:0).  The peaks in this RT range increased in the 24h dexamethasone treated 
adipocytes (D) in comparison to the 24h control cells (D).  The most abundant ion 
associated with each chromatographic peak seen in this figure is identified in Table 5.3.  
These abundant ions were only identifiable from a RT of 7.60min, and all ions from this 
time onwards were identified as TG species. 
 
Multivariate data analysis was undertaken on these LC-MS data, starting with principal 
component analysis (PCA) of the raw data (no normalisation), as seen in Figure 5.7.  The 
PCA scores (principal component 1 vs. principal component 2) plot is shown in Figure 5.9A 
and was interpreted as having three groups: QCs; control cells (both time points) and all 
dexamethasone treated samples.  The R2 and Q2 for this model were 0.854 and 0.691, 
respectively.  The loadings plot is presented in (B) and showed many points which were 
distant from the origin, although only a few were able to be confidently identified 
according to the search parameters outlined in Section 5.2.3.2.  All of the identifiable 
masses were positioned on the left hand side (LHS) of the origin.  The first of these had 
m/z 876.803 and was identified as TG (52:2).  Trend analysis of this point showed that its 
concentration increased after 24h dexamethasone treatment at 20nM. The point 
representing m/z 902.816 was identified as TG (54:3) and its concentration increased after 
24h of dexamethasone treatment at both 2 and 20nM.  Finally, two points labelled as m/z 
862.786 and 874.786 were identified as the TG species 51:2 and 52:3, respectively.  Trend 
analysis of these points demonstrated an increase in their concentration in all of the 
dexamethasone treated cells when compared to the control cells.   
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Figure 5.6. Positive ion LC-MS analysis of dexamethasone treated 3T3-L1 adipocytes  
Representative chromatograms of differentiated 3T3-L1 adipocytes at day 10 post-differentiation 
which were pre-incubated with CS-free medium for 24 hours, and then treated with dexamethasone 
for 2 and 24h. The treatments represented are: control 2h (A), 20nM 2h (B), control 24h (C) and 20nM 
24h (D). Lipids were extracted from the cell samples using a Folch extraction. The lower phase was 
dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v). A 150µL 
aliquot was removed and had 10mM ammonium formate added to it. The lipids were then separated 
over 18 min by LC-MS in positive ion mode. The 2h dexamethasone treated cells show an increase in 
the peak with RT between 9 and 9.5 min.  After 24h of dexamethasone treatment, an increase was 
seen in the abundance of peaks with RT between 7.5 and 8.5 min. 
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Retention time  Ion mass Theoretical mass  Δ Mass accuracy (ppm)  Ion  Empirical composition  Identification 
(min) 
7.60   844.7388 844.7389  -0.811    [M+NH4]
+
       C53H94O6                TG (50:4) 
7.72   832.7407 832.7389  -1.200    [M+NH4]
+
       C52H94O6                TG (49:3) 
7.85   846.7549 846.7545  0.472    [M+NH4]
+
       C53H96O6                TG (50:3) 
7.98   860.7704 860.7701  0.349    [M+NH4]
+
       C54H98O6                TG (51:3) 
8.11   874.7858 874.7858  0     [M+NH4]+       C55H104NO6                TG (52:3) 
8.24   862.7865 862.7858  0.811    [M+NH4]
+
       C54H100O6                TG (51:2) 
8.36   902.8119 902.8171  -5.760    [M+NH4]
+
       C57H104O6                TG (54:3) 
9.25   908.8651 908.8640  1.210    [M+NH4]
+
 C57H110O6   TG (54:0) 
 
Table 5.3.  Retention times and their associated abundant mass of each major peak present in the positive ion LC-MS chromatograms of dexamethasone treated adipocytes  
Red highlight indicates internal standard 
2
4
9
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The data were then manually normalised to the total ion current (TIC), and the scores plot 
is shown in Figure 5.7C.  As with the non-normalised data, three groups were present on 
the plot which related to the QCs, all control samples and the treated cells.  The loadings 
plot is presented in (D) and demonstrates points that could be responsible for the variance 
between samples, although none of these could be confidently identified.  The R2 and Q2 
for this model were 0.876 and 0.744, respectively. 
 
After PCA, both datasets had the supervised partial least squares (PLS) analysis applied to 
them, as seen in Figure 5.8.  The samples in the PLS scores plot for the non-normalised 
data (A) still clustered into three groups, although they differed from those seen in the 
PCA plot (Figure 5.9A).  One group contained the QCs and the control cells from both time 
points.  The dexamethasone treated samples were then split into two groups, the first 
consisting of the 2h treatments (2 and 20nM) and the second contained the 24h 
treatments (2 and 20nM).  The R2X, R2Y and Q2 for this model were 0.890, 0.969 and 
0.885, respectively.  The PLS loadings plot identified points which were distant from the 
origin, and of those that could be identified, the first had m/z 862.786 (TG 51:2) and was 
seen to increase after 2h dexamethasone treatment.  A point with m/z 876.803 was 
identified as TG (52:2), and trend analysis of this point showed that the concentration of 
this lipid increased in cells treated with 20nM dexamethasone for 24h.  The final point 
represented m/z 902.816, TG (54:3), and its concentration increased after 24h of 
dexamethasone treatment (2 and 24h).   All three points were situated on the top right 
hand side (RHS) of the origin.   
 
The PLS scores plot of the TIC-normalised dataset is presented in Figure 5.8B.  The 
groupings seen were the same as those in A: QCs and control cells (2 and 24h), 
dexamethasone treated 2h, and dexamethasone treated 24h.  Out of all points with 
possible responsibility for the variance between the samples in the PLS loadings plot (D), 
the identifiable points were labelled with m/z 862.786, 876.803 and 902.816 which were 
identified as the TG species 51:1, 52:2 and 52:2, respectively.  Trend analysis of these 
points showed that the concentration of TG (51:2) increased in the 2h dexamethasone 
treated samples (both time points).  The concentrations of the TG species 52:2 and 54:3 
increased after 24h of dexamethasone treatment, at 20nM and 2 and 20nM, respectively.  
The R2X, R2Y and Q2 for this model were 0.873, 0.968 and 0.878.    
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Figure 5.7. PCA scores and loadings plots representing positive ion LC-MS analysis of dexamethasone 
treated 3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
were then treated with dexamethasone for 2 or 24h.  The concentration of dexamethasone treatments 
used were 2 and 20nM.  Lipids were extracted from the cell samples using a Folch extraction, and the 
lower phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, 
v/v).  These samples were analysed by LC-MS in positive ion mode.  Panels A and B represent the PCA 
scores plot for non- and TIC-normalised data, respectively and these plots show a clear separation 
between the control and dexamethasone treated cells. Panels C and D show the PCA loadings plots for 
the non- and TIC-normalised data, respectively, and are labelled according to the m/z. 
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Figure 5.8. PLS scores and loadings plots representing positive ion LC-MS analysis of dexamethasone 
treated 3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
then treated with dexamethasone for 2 or 24h.  The concentration of dexamethasone treatments used 
were 2 and 20nM.  Lipids were extracted from the cell samples using a Folch extraction, and the lower 
phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  
These samples were analysed by LC-MS in positive ion mode.  Panels A and B represent the PLS scores 
plot for non- and TIC-normalised data, respectively and these plots show a clear separation between 
the control and dexamethasone treated cells. The treated cells were also split into two groups, 
consisting of the 2h and 24h treated samples.  Panels C and D show the PCA loadings plots for the non- 
and TIC-normalised data, respectively, and are labelled according to the m/z. 
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5.3.5. Negative ion LC-MS analysis 
Representative negative ion chromatograms of control adipocytes, and those which had 
been treated with 20nM dexamethasone at both 2 and 24h are shown in Figure 5.9.  
Fewer peaks were present in these chromatograms than those of the positive ion LC-MS 
analysis. The abundance of peaks in this figure with RT between 2.5 and 3min decreased 
in the treated cells when compared to the control cells at both time points.  The most 
abundant peak in the treated cells, as well as 24h control adipocytes had a RT of 
approximately 4min.The most abundant ion associated with each major chromatographic 
peak seen in Figure 5.9 is identified in Table 5.4.  The only identifiable peak in the control 
samples had m/z 564.3547 which was tentatively identified as PC (20:0) due to its mass 
accuracy (ppm=-38.345) being greater than 5 parts per million (ppm).  This PC species was 
also present in adipocytes which had been treated with 20nM dexamethasone for 24h (B), 
along with PI (38:4) and DG (32:2).    
 
Multivariate data analysis was also employed on the negative ion LC-MS data.  The PCA 
scores plot for the negative ion non-normalised dataset is shown in Figure 5.10A.  The 
data were interpreted as clustering into four groups, the first of which containing the QC 
samples.  The control cells were split into two groups, representing 2 and 24h.  The final 
group consisted of all dexamethasone treated samples.  The R2 and Q2 for this model 
were 0.939 and 0.853, respectively.  The PCA loadings plot (C) showed points relating to 
m/z 546.345 and 565.345 distant from the origin on its RHS.  The m/z 564.345 was 
tentatively identified as the phospholipid species (20:0), due to its mass error being 
outside of the search parameters (ppm = -37.919).  The m/z 565.345 was more confidently 
identified as lyso-phosphatidylglycerol (22:1).  Trend analysis of these points found that 
their concentrations increased in all of the dexamethasone treatments when compared to 
the control cells.  
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Figure 5.9. Negative ion LC-MS analysis of dexamethasone treated 3T3-L1 adipocytes  
Representative chromatograms of differentiated 3T3-L1 adipocytes at day 10 post-differentiation 
which were pre-incubated with CS-free medium for 24h, and then treated with dexamethasone for 2 
and 24h.  The treatments represented are: control 2h (A), 20nM 2h (B), control 24h (C) and 20nM 24h 
(D). Lipids were extracted from the cell samples using a Folch extraction.  The lower phase was dried 
down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, v/v).  A 150µL aliquot was 
removed and had 10mM ammonium formate added to it.  The lipids were then separated over 18 min 
by LC-MS in negative ion mode. The chromatograms show a decrease in the abundance of peaks 
between RT 2.5 and 3 min in the dexamethasone treated cells when compared to the control samples.  
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Retention time (min)  Ion mass Theoretical mass  Δ Mass accuracy (ppm)  Ion  Empirical composition Idenification  
(A) Control 24h 
2.46   309.1750  309.1708  13.584    [M-H]
-
  C17H26O5 
2.54   353.2010  353.1970  85.511    [M-H]
-
  C19H29O6 
4.00   564.3451  564.3671  -38.345    [M-H]
-
  C28H56NO8P  PC (20:0) 
 
(B) 20nM, 24h 
3.95   564.3449 564.3671   -39.336    [M-H]
-
  C28H56NO8P  PC (20:0) 
4.84   885.5529 885.5499   3.388    [M-H]
-
          C47H83O13P  PI (38:4) 
5.23   568.4954 568.4990   -6.332    [M-H]
-
  C35H59D5O5  DG (32:2) 
 
 
Table 5.4.  Retention times and their associated abundant mass of each major major peak present in the negative ion LC-MS chromatograms of dexamethasone treated 
adipocytes  
Abbreviations used: DG, diglyceride; PC, phosphatidylcholine; PI, phosphatidylinositol; ppm, parts per million 
2
5
5
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The TIC-normalised dataset was also analysed by PCA, and the R2 and Q2 for this model 
were 0.948 and 0.871, respectively.  The PCA scores plot is presented in (B) and shows the 
data forming four groups, which were; QCs, control 2h, control 24h and all 
dexamethasone treated samples (2 and 24h).  The PCA loadings plot (D) is similar to that 
presented in (B); with trend analysis of the points labelled as m/z 564.35 and 565.35 
showing an increase in their relative abundance after all dexamethasone treatment 
combinations.  These points were also positioned on the RHS of the origin, and identified 
as PC (20:0) and lyso-PG (22:1), respectively.   
 
After PCA, the non- and TIC-normalised negative ion datasets underwent PLS analysis.  The 
PLS scores plot of the non-normalised data is represented in Figure 5.11 (A).  Four groups 
were identified which were: control 2h and QCs; control 24h; 20nM dexamethasone 
treatment after 2h; all remaining dexamethasone treated cells (2nM 2 and 24h, and 20nM 
24h).  The R2X, R2Y and Q2 for this model were 0.976, 0.990 and 0.951, respectively.  The 
PLS loadings plot for this model was able to identify more points of variation than the PCA 
loadings plots seen in Figure 5.10 C and D.  On the RHS of the origin, points corresponding 
to m/z 564.35 and 565.35 (PC 20:0 and lyso-PG 22:1, respectively) were situated, and 
trend analysis of these points showed an increase in the concentration of these lipid 
species in all of the dexamethasone treated samples.   
 
The PLS model for the TIC-normalised had R2X, R2Y and Q2 of 0.958, 0.993 and 0.961, 
respectively.  The scores plot for this model is shown in Figure 5.11B, and was interpreted 
as having four groups, with the first containing the QCs and the second consisting of the 
control samples from both time points.  The dexamethasone treated adipocytes were 
seen to cluster into two groups, the first being cells treated with 20nM dexamethasione 
for 2h and the second group being made up of the remaining treatments (2nM 2 and 24h, 
and 20nM 24h).  The PLS loadings plot is presented in (D), and the identifiable points on 
the RHS of the origin had m/z 564.35, 565.35, which were identified as PC (20:0), lyso-
phosphatidylglycerol (22:1), respectively.  Trend analysis of these three points showed 
that the concentration of these lipid species increased with all dexamethasone treatment 
combinations.  Identifiable points on the LHS of the origin were labelled with m/z 885.55 
and 886.56, and were identified as PI (38:4) and PS (44:8), correspondingly.     
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Figure 5.10. PCA scores and loadings plots representing negative ion LC-MS analysis of 
dexamethasone treated 3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
were then treated with dexamethasone for 2 or 24h.  The concentration of dexamethasone treatments 
used were 2 and 20nM.  Lipids were extracted from the cell samples using a Folch extraction, and the 
lower phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, 
v/v). These samples were analysed by LC-MS in negative ion mode.  Panels A and B represent the PCA 
scores plot for non- and TIC-normalised data, respectively and these plots show a clear separation 
between the control and dexamethasone treated cells. Panels C and D show the PCA loadings plots for 
the non- and TIC-normalised data, respectively, and are labelled according to the m/z. 
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Figure 5.11. PLS scores and loadings plots representing negative ion LC-MS analysis of 
dexamethasone treated 3T3-L1 adipocytes  
3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free medium for 24h, and 
were then treated with dexamethasone for 2 or 24h.  The concentration of dexamethasone treatments 
used were 2 and 20nM.  Lipids were extracted from the cell samples using a Folch extraction, and the 
lower phase was dried down under nitrogen and reconstituted in 600µL chloroform/methanol (2/1, 
v/v).  These samples were analysed by LC-MS in negative ion mode.  Panels A and B represent the PLS 
scores plot for non- and TIC-normalised data, respectively and these plots show a clear separation 
between the control and dexamethasone treated cells. Panels C and D  show the PCA loadings plots for 
the non- and TIC-normalised data, respectively, and are labelled according to the m/z. 
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Trend analysis of these points demonstrated that the concentrations of these lipid species 
fluctuated after 2h of dexamethasone treatment, with an increase being seen with the 
2nM treatment, and then a decrease when this was increased to 20nM.  Finally, the 
unidentified points with m/z 311.17, 325.18 and 339.20 were also found on this area of 
the plot, and their concentration decreased in all of the dexamethasone treated samples. 
 
5.3.4. Eicosanoid analysis by LC-MS 
AA-derived eicosanoids secreted from 3T3-L1 adipocytes treated with dexamethasone 
were analysed by targeted LC-MS in negative ion mode.  The changes in the detected 
eicosanoid species in response to dexamethasone treatment are presented in Figures 5.12 
and 5.13.  Only seven eicosanoids were detectable in the medium samples of all control 
and treated cells and the detected eicosanoid species were PGD2, PGE2, PGF2α, 6-keto 
PGF2α (6-keto) and 20-OH LTB4 (20-OH), 15-HETE and 20-HETE.  The concentration of all 
eicosanoids increased significantly after 2h of dexamethasone treatment at both 
concentrations (P<0.05 vs. control for all).  This significant increase was also seen after 24h 
of dexamethasone treatment at both concentrations, for all eicosanoid species (P<0.05 for 
all).  The one exception was 20-OH which only significantly increased at the 2nM 
dexamethasone treatment concentration for both time points (P=0.047 and 0.024 vs. 
control for 2 and 24h, respectively). 
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Figure 5.12.  Secretion of eicosanoid lipids from dexamethasone treated 3T3-L1 adipocytes  
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24h and were then treated with dexamethasone for 2 and 24h.  The concentrations of 
dexamethasone treatments used were 2 and 20 nM. Eicosanoids were extracted from cell culture 
medium by solid phase extraction chromatography and were analysed by LC-MS/MS in negative ion 
mode. Detected eicosanoids are represented as median ± range, with a group size of 3 and are PGD
2
 
(A), PGE
2
 (B), PGF
2α 
(C) and 6-keto PGF
1α
 (D)
.
 Statistical significance of each eicosanoid is represented 
by *P<0.05 vs. control. The data show an increase in eicosanoid secretion in the treated groups 
compared to the control groups at both time points.  
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* * 
(A) 
(B) 
(C) 
(D) 
2h 24h 
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Figure 5.13.  Secretion of eicosanoid lipids by dexamethasone treated 3T3-L1 adipocytes  
Differentiated 3T3-L1 adipocytes at day 10 post-differentiation were pre-incubated with CS-free 
medium for 24h, and were then treated with dexamethasone for 2 and 24h.  The concentrations of 
dexamethasone treatments used were 2 and 20 nM.  Eicosanoids were extracted from cell culture 
medium by solid phase extraction chromatography and were analysed by LC-MS/MS in negative ion 
mode. Detected eicosanoids are represented as median ± range with a group size of 3. The detected 
eicosanoids are 20-OH LTB
4
 (A), 15-HETE (B), and 20-HETE (C)
.
 Statistical significance of each eicosanoid 
is represented by *P<0.05 vs. control. A significant increase was seen in the dexamethasone treated 
cells with all conditions.  One exception was 20-OH which only significantly increased with the 2nM 
treatment and both timepoints. 
* 
* 
* * 
* 
* (A) 
(B) 
* 
* * * (C) 
2h 24h 
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5.4. DISCUSSION 
This chapter has used the 3T3-L1 adipocyte model to study the effect of the glucocorticoid 
dexamethasone on the metabolism of these cells in terms of the gene expression of several 
adipokines, as well as global lipid profiles and the production of eicosanoids by mature 
adipocytes.  The results indicate that normal adipocyte function is significantly influenced by 
dexamethasone.  
 
5.4.1. Effect of dexamethasone treatment on adipokine gene expression 
Adipocytes were treated with dexamethasone to determine its effect on the normal 
expression of several adipokines.  It was expected, from previous findings that the gene 
expression of leptin would decrease, whereas that of adiponectin, IL-6 and TNF-α would 
increase (Bradley and Cheatham, 1999; Fasshauer et al., 2002 and 2003).  Similar findings 
were found in the current study, with leptin gene expression significantly increasing after 24h 
of dexamethasone treatment at both concentrations (2 and 20nM). Dexamethasone is a 
synthetic glucocorticoid, which increases leptin gene expression and protein expression, as 
seen in a previous study in rat adipocytes after 2h of treatment (Bradley and Cheatham, 
1999).  The current study saw no significant change after 2h of dexamethasone treatment; 
however, Bradley and Cheatham used a treatment concentration of 100nM, whereas the 
current study investigated lesser concentrations.  Another   study with 3T3-L1 adipocytes 
demonstrated that leptin gene expression was marginally inhibited (not significantly) by 
dexamethasone, and this did not vary between the three treatment concentrations used 
which were 10, 100 and 1000nM (Rentsch and Chiesi, 1996).  The dexamethasone treatment 
time in this study was not stated.   
 
Glucocorticoids are known to cause insulin resistance in vivo and a previous study using 3T3-
L1 adipocytes found that chronic dexamethasone treatment impaired insulin-induced glucose 
uptake (Sakoda et al., 2000; Bazuine et al., 2004).  These hormones inhibit the gene 
expression of adiponectin (Fasshauer et al., 2002), as seen in the current study after 24h of 
dexamethasone treatment at 20nM.  Adiponectin is suppressed in insulin resistant and obese 
states (Hu et al, 1996b; Hotta et al., 2000; Weyer et al., 2001), and various hormones and 
agents may promote insulin resistance by inhibition of this protein. These previous findings, 
as well as those from the current study, indicate that one mechanism by which 
glucocorticoids impair insulin sensitivity could be hypoadiponectinemia. 
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As well as a significant decrease in adiponectin gene expression, the current study also 
demonstrated an inhibition in the gene expression of IL-6 after 24h of dexamethasone 
treatment (at both 2 and 20nM).  This supports the idea that this agent is anti-inflammatory, 
and its suppressive effect on the gene expression of IL-6 has also been observed elsewhere 
(Fasshauer et al., 2003). 
 
5.4.2. Effect of dexamethasone treatment on global lipid profiles 
The increase in adiposity as seen in obesity is a consequence of both hyperplasia and 
hypertrophy (Hausman et al., 2001).  The balance of these processes is important to 
determine the size of mature adipocytes and also adipose tissue mass (Gathercole et al., 
2011).  Lipid accumulation is a result of increased fatty acid uptake and lipogenesis, whereas 
lipolysis causes lipid loss (Gathercole et al., 2011).  Glucocorticoids have been reported to 
have both lipolytic and adipogenic actions in many studies, and these actions depend on 
many factors including the concentration and duration of treatment, as well as the 
experimental model and specific glucocorticoid used (Masuzaki et al., 2001; Andrews et al., 
2002; Kershaw et al., 2006; Xu et al., 2009).  Previous studies both in vivo and in vitro have 
demonstrated stimulation of lipolysis by glucocorticoids, caused by action on hormone 
sensitive lipase (HSL) in both in rats and humans (Slavin et al., 1994; Djurhuus et al., 2002).  
On the other hand, prolonged exposure to glucocorticoids is known to promote adiposity, 
and this is seen in patients receiving treatment with synthetic glucocorticoids for various 
inflammatory conditions (Wei et al., 2004). 
 
In the current study, dexamethasone treatment did have an effect on lipid metabolism, as 
seen with the DI-MS analysis.  The concentration of two triglyceride (TG) species significantly 
increased after 2h of dexamethasone treatment when compared to the control cells.   These 
were TG (50:3) and (52:3), and the concentration of TG (50:3) also significantly increased 
after 24h of dexamethasone treatment.  Glucocorticoids can act to increase adipose tissue 
mass, with an increase in visceral adiposity being particularly associated with glucocorticoid 
treatment (Masuzaki et al., 2001; Bujalska et al., 2008; Pantoja et al., 2008), possibly by 
increasing adipogenesis of pre-adipocytes.  The increased concentration of two TG species 
after 2nM of dexamethasone treatment observed in the current study may be indicative of 
dexamethasone acting to decrease lipolysis, and therefore eventually causing TG 
accumulation.   
 
264 
 
On the other hand, the concentration of FAs, identified as C18:1 and C20:4, significantly 
increased with the least concentrated dexamethasone treatment, after both 2 and 24h.  
When the concentration was increased to 20nM; however, C18:1 decreased after 24h of 
treatment.  These findings may suggest an increase in lipolysis, which results in increased free 
fatty acids.  Another possibility is that dexamethasone is acting to increase lipogenesis, which 
would result in increased FA uptake, and TG accumulation.  This process involves either the 
re-esterification of FFAs with glycerol, or de novo lipogenesis (DNL), and a previous study in 
over-fed human subjects found that 40% of the increases in fat mass were due to DNL 
(Lammert et al., 2000).  Glucocorticoids in combination with insulin treatment cause 
increased lipogenesis in subcutaneous adipocytes (Oh et al., 2005).  Whereas, a very recent 
study has demonstrated that dexamethasone treatment alone led to a decrease in 
lipogenesis in the Chub-S7 transformed human subcutaneous pre-adipocyte cell line, which 
originated from an obese female. 
 
 
Therefore, the glucocorticoids appear to have differing actions on lipid metabolism, as seen in 
the current study.  The positive ion DI-MS analysis suggests that TG accumulation is occurring 
following dexamethasone treatment, which could be caused by a decrease in lipolysis.  The 
opposite effect was implied by negative ion DI-MS analysis, in which the concentration of the 
fatty acids C18:1 and C20:4 significantly increased at 2nM dexamethasone treatment at both 
time points, suggesting that an increase in lipolysis was present, which would cause lipid loss.  
These effects appear to be conflicting; however, both support the fact that the general 
consequence of glucocorticoid treatment is an increase in adiposity and circulating free fatty 
acids, which in turn has negative effects on insulin sensitivity and energy metabolism 
(Campbell et al., 2011).  The greatest changes in these species were observed at the 2nM 
dexamethasone treatment dose, possibly suggesting that the effects of dexamethasone 
treatment are dose dependent.    
 
Clear separations were observed between the control and dexamethasone treated samples in 
the PCA and scores plots for both positive and negative ion mode datasets.  In the positive 
data plots, variations were observed in the concentration of certain TG species, including 
those with m/z 862.79, 874.79, 876.80 and 902.82, which were identified as TG (51:2), (52:3), 
(52:2) and (54:3), respectively.  The concentrations of these lipid species increased in various 
combinations of the dexamethasone treatments, and these agree with the DI-MS data and 
therefore suggest a decrease in lipolysis, leading to lipid accumulation in the dexamethasone 
treated cells.  The points of interest in the negative ion models related to phospholipid 
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species, which were PC (20:0) and lyso-phosphatidylglycerol (22:1), and their concentration 
increased in the dexamethasone treated cells when compared to the control cells.  These 
phospholipid species may be the source of the fatty acids which were detected by negative 
ion DI-MS analysis, and seen to increase in the dexamethasone treated cells. 
 
A supervised partial least squares (PLS) model was also used.  Both positive and negative ion 
scores plots showed the same separation between control and dexamethasone treated cells 
as seen in the PCA plots; however, separation was also observed within the treated samples, 
with one group containing the 2h dexamethasone treated samples, and the other consisting 
of cells which had been treated with dexamethasone for 24h.  The DI-MS analysis found that 
the treatment concentration seemed to be more influential in the effect of dexamethasone 
treatment on 3T3-L1 adipocytes; however, LC-MS analysis suggests that the length of 
treatment is important.  These findings agree with the fact that the actions of glucorticoids 
depend on many factors, including the agent and model type use, and the length and 
concentration of treatment (Masuzaki et al., 2001; Andrews et al., 2002; Kershaw et al., 2006; 
Xu et al., 2009). 
 
5.4.3. Effect of dexamethasone treatment on eicosanoid production 
Glucocorticoids are potent anti-inflammatory agents, and early studies found that they can 
suppress the formation of eicosanoids (Moncada et al., 1976) and also inhibit the release of 
AA (Hong and Levine, 1976).  These drugs enhance the synthesis of a family of proteins called 
lipocortins, which are thought to inhibit phospholipase A2 activity, therefore preventing the 
availability of AA, and decreasing eicosanoid synthesis (Di Rosa et al., 1984).  However, 
studies with other inflammatory models have shown inconsistencies with this mechanism 
(Calignano et al., 1985; Foster and McCormick, 1985), suggesting that the effect of 
glucorticoids varies depending on the model used.   
 
In the current study, dexamethasone treatment caused a significant increase in the 
concentration of many AA-derived eicosanoid species, including the prostanoids PGD2, PGE2 
and PGF2α.  Glucocorticoid drugs are known to decrease eicosanoid synthesis (Di Rosa et al., 
1984), which conflicts with the findings described in the present work.   
 
Recently; however, it has been suggested that a number of prostanoid species also have anti-
inflammatory actions.  One example is PGE2, which inhibits the production TNF-α and IL-1 
(Miles et al., 2002), and also induces 15-lipoxygenase, leading to an increase in the formation 
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of anti-inflammatory lipoxins (Levy et al., 2001; Vachier et al., 2002).  This may help to explain 
why dexamethasone treatment caused increased concentrations of various prostanoid 
species.   
 
The global lipidomic analyses described in this current study provided some suggestion of an 
increase in lipolysis in the 3T3-L1 adipocytes after dexamethasone treatment.  Although the 
main source of eicosanoids are the membrane phospholipids (Flower and Blackwell, 1976), 
prostaglandins can also be synthesised from AA released from TG.  A previous study using 
isolated fat cells has shown that during lipolysis, the TGs released sufficient AA to account for 
the prostaglandins formed (Christ and Nugteren, 1970).  Negative ion DI-MS analysis as 
described in Section 5.3.2.2 demonstrated that one of the most abundant lipid species was 
identified as C20:4, which is AA.  The concentration of this lipid species significantly increased 
after 2nM of dexamethasone treatment.  This may suggest that lipolysis had increased in 
these cells, and more AA was released from the TGs, therefore increasing the concentration 
of the detected eicosanoid species in the cell medium samples.  
 
5.4.4. Limitations 
The major limitation of the current study was the possible representation of noise peaks in 
the PCA and PLS plot analyses, as many of the points present in these plots were 
unidentifiable when searching the LIPID MAPS database with the exact mass.  The scaling 
method chosen in the current study was Pareto, because it is the method is commonly used 
for mass spectrometry data (Eriksson et al., 1999); however, it allows regions of the 
chromatogram with lesser amplitude to influence the model if variation is observed.   The 
application of an alternative scaling method may eliminate these points, for example, the use 
of centring with no scaling (Ctr) is influenced by a variable based on its signal, and therefore 
regions of less amplitude would have little influence on the model.  Another limitation was 
the slight retention time (RT) shifts seen with some of the global LC-MS chromatograms.  RT 
shifts are caused by various factors, including temperature, mobile phase composition and 
day-to-day drift.  Ideally, all samples would be run on the same day, with the same mobile 
phase compositions. A final limitation was the inability of assigning the exact fatty acid 
compositions with the exact mass alone.  
 
 
 
 
267 
 
5.4.5. Conclusions and future work 
The current study has shown that the glucocorticoid dexamethasone has potent effects on 
both adipokine expression and lipid metabolism of 3T3-L1 adipocytes.  The first part of this 
study demonstrated dysfunction of adipokine gene expression, specifically significant 
increases in leptin gene expression, and decreases in the gene expression of both adiponectin 
and IL-6.  These findings replicated those found in other studies, whilst the decrease in the 
inflammatory cytokine IL-6 supports the idea that dexamethasone is an anti-inflammatory 
agent.   Dexamethasone treatment of normal adipocytes also caused disturbances in lipid 
metabolism, with both activation and inhibition of lipolysis being observed.  These opposing 
actions could eventually lead to an increase in TG accumulation and therefore adiposity, and 
also an increase in circulating FFAs, both of which cause insulin resistance and disrupted 
energy metabolism (Campbell et al., 2011).  Dexamethasone treatment also caused an 
increase in the production of a number of eicosanoids, particularly prostanoid species.  The 
increase in the concentration of two TG species was coupled with an increase in C20:4, which 
may be the cause of the eicosanoid profiles observed after dexamethasone treatment. 
Therefore this glucocorticoid has anti-inflammatory properties, but also may be involved in 
the increase of eicosanoid production from basal 3T3-L1 adipocytes (no prior induction of 
lipolysis) via an increase in AA (C20:4).     
 
The current work has provided a model for studying the effect of dexamethasone on the 
normal function of 3T3-L1 adipocytes.  Opposing lipolytic effects have been suggested to 
occurring in the dexamethasone treated cells; however, this is only based on observed 
increases and decreases in the concentration of TG and FA species.  Therefore more definite 
proof is needed to ascertain whether lipolysis is being affected by dexamethasone.  One way 
could be to investigate the gene expression of ATGL and HSL.  An increase in the gene 
expression of both cause an increase in lipolysis, as seen after excessive glucocorticoid 
treatment (Fain and Saperstein, 1970; Slavin et al., 1994; Xu et al., 2009; Campbell et al., 
2011).  Another extension to the current study would be to use LC-MS/MS techniques to fully 
identify selected lipid species, as this would allow the discovery of the fatty acid composition 
of phospholipid and triglyceride species.   
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CHAPTER 6: 
General Discussion and Future Perspectives 
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6.1. SUMMARY 
Adipocytes become dysfunctional in the obese state, causing an inflammatory environment 
(Yudkin et al., 1999; Festa et al., 2001) which may contribute to the increased risk of 
developing obesity-associated comorbidities. Changes in normal adipocyte function are seen 
in altered gene expression and protein secretion profiles of many adipokines, cytokines and 
chemokines (Trayhurn and Wood, 2004).  Disturbances in lipid metabolism are also 
connected with obesity, such as changes in the basal rates of lipolysis, which are directly 
correlated with adipocyte size (Large et al., 1999).   
 
The overall purpose of the project was to characterise adipocyte metabolism in terms of gene 
expression of the adipokines leptin and adiponectin, and also the pro-inflammatory cytokines 
TNF-α and IL-6, as well as lipid metabolism in response to different environmental factors.  
The first specific aim was to investigate these mechanisms during adipogenesis, and on the 
whole, this aim was achieved.  The current study demonstrated that the metabolic processes 
of lipolysis and eicosanoid production were both affected by the differentiation process, 
resulting in the accumulation of TG lipid droplets. 
 
The second aim was to investigate these lipid metabolism processes in adipocytes treated 
with the inflammatory mediators, TNF-α and IL-6.  Both caused disruptions in the normal 
metabolism of the adipocyte, involving changes in lipolysis, and eicosanoid production.  A link 
to the gene expression of leptin was also considered, although further investigations would 
be needed to prove this. 
 
The final aim was to study the effect of dexamethasone on the metabolism of adipocytes. The 
current study suggested both activation and inhibition of lipolysis after treatment with 
dexamethasone, although, as before, further investigations are required for confirmation.  
Increases were seen in the concentration of a variety of eicosanoid species, which differs 
from previous findings. Early studies demonstrated that glucocorticoids (including 
dexamethasone) are anti-inflammatory agents, and act by suppressing the formation of 
eicosanoid species (Moncada et al., 1976).  A suggested explanation for this conflict is 
presented in Section 6.5. 
 
The following discussion summarises the current findings and explores ways to address gaps 
in this work and to expand the field. 
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6.2. ADIPOCYTE METABOLISM DURING ADIPOGENESIS 
Obesity is partly characterised by increased adiposity, which is caused by an imbalance in 
energy homeostasis, leading to increased storage of triglyceride (TG)s within white adipose 
tissue, and eventually causing an expansion of adipose tissue mass within the body.  Two 
processes are involved in the increased adiposity observed in the obese state.  These are 
hypertrophy of mature adipocytes, and adipogenesis of pre-adipocytes (Johnson et al., 1971; 
Faust et al., 1978; Johnson et al., 1978).  
 
The first study described in this thesis used the well-established 3T3-L1 pre-adipocyte cell-line 
(Green and Meuth, 1974; Green and Kehinde, 1975) to explore the lipid metabolism of 
adipocytes during adipogenesis in vitro.  The validity of this cell culture was confirmed by 
morphological changes, in which lipid droplets were clearly formed after the induction of 
differentiation, and continued to accumulate over the remainder of the time course.  Gene 
expression and protein secretion of leptin and adiponectin were profiled, and agreed with 
previous findings. Both leptin (MacDougald et al., 1995) and adiponectin (Ouchi et al., 1999) 
are differentiation-dependent genes, and their gene expression and protein secretion were 
only detectable after the induction of differentiation in the current study.  This section of 
work was necessary to authenticate this model of adipogenesis before further analyses, and 
by replicating previous findings, it was concluded that this had been successfully achieved.  
This qPCR validation stage was undertaken for all 3T3-L1 experiments, and so will not be 
mentioned in subsequent sections. 
 
However, rather than simply repeating previous work, the current study extended the course 
of differentiation past days 10-15, which are commonly used end points for this type of study, 
to day 25.  The aim was to investigate whether the phenotype of very mature adipocytes 
would remain similar to those at day 10-15 post-differentiation, or become characteristically 
different.  The current study demonstrated morphologically that these adipocytes continued 
to accumulate lipid droplets up to day 25 post-differentiation.  From approximately day 10 
onwards, the gene expression and protein secretion of both leptin and adiponectin began to 
decrease, which continued until the end of the time course.  This may suggest that the gene 
expression and secretion of these adipokines become dysfunctional as the adipocytes 
become larger and accumulate more lipids.  Alternatively, it might simply be that 3T3-L1 
adipocytes become difficult to maintain in culture past a certain length of time.  
After validation of the model, lipidomic analyses were undertaken to monitor any changes in 
lipid metabolism occurring over the course of differentiation.  The major finding in the 
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current study was that the lipid composition of the pre-adipocytes consisted of mainly 
phospholipid species.  By day 10 post-differentiation, this profile had changed, and 
diglyceride (DG) and TG species were predominantly present.  This was expected from the 
morphology of the cells, as lipid droplets were observed from day 5 post-differentiation, and 
these increased in size and number as the cells matured.  During adipogenesis, the 
development of these lipid droplets is overseen by adipogenic transcription factors such as 
peroxisome proliferator-activated receptor gamma (PPARγ; Schoonjans et al., 1996), and this 
acts to regulate adipogenesis and maintain the phenotype of the mature adipocyte (Rosen et 
al., 1999; Tamori et al., 2002).  Lipoprotein lipase (LPL), adipose triglyceride lipase (ATGL) and 
hormone sensitive lipase (HSL; Zimmermann et al., 2004) are also involved in these processes 
within the mature adipocyte.  AGTL is induced during adipogenesis, and is greatly expressed 
in mature adipocytes where it is situated close to the lipid droplets and causes lipolysis 
(Jenkins et al., 2004; Villena et al., 2004; Zimmermann et al., 2004; Kershaw et al., 2005; 
Smirnova et al., 2006). 
 
Another identifiable fatty acid (FA) was C20:4, arachidonic acid (AA), and its concentration 
also decreased at the later time points, again suggesting changes in the phenotype of the 
very mature adipocyte.  AA is released from membrane phospholipids, and is a precursor in 
the synthesis of eicosanoids (Piomelli, 1993).  Various eicosanoid species were secreted by 
the 3T3-L1 cells in the current study, and their concentrations were the greatest during the 
pre-adipocyte stage. Exogenous FAs are required for the differentiation of 3T3-L1 pre-
adipocytes, and this process is dependent on PPARγ (Barak et al., 1999; Rosen et al., 1999).  
The first identified high-affinity ligand for PPARγ was a derivative of PGJ2 (Forman et al., 
1995), and other PG derivatives can also induce adipogenesis (Forman et al., 1995; Kliewer et 
al., 1995).  Many eicosanoid species are involved in adipocyte differentiation, including the 
prostaglandins (PG) from the COX pathway, although these species have conflicting actions.  
One COX product is PGI2, and it promotes adipogenesis (Negrel et al., 1989; Aubert et al., 
1996).  Another is PGE2, and it is more efficiently produced by pre-adipocytes as seen in the 
current study, and elsewhere (Lu et al., 2004).  It acts to down-regulate cAMP production and 
lipolysis in both human and rat adipocytes, therefore allowing continued TG accumulation 
(Strong et al., 1992; Vassaux et al., 1992).  In contrast, PGF2α inhibits adipocyte differentiation 
(Miller et al., 1996; Vassaux et al., 1994), and this is thought to occur due to the inactivation 
of PPARγ (Hu et al., 1996a).  Eicosanoids are also synthesised via the LOX and P450 
epoxygenase pathways.  A previous study found that inhibition of the LOX pathway 
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prevented 3T3-L1 pre-adipocytes from differentiating, and this was resolved by the addition 
of the PPARγ agonist, rosiglitazone (Madsen et al., 2003).  
 
 
6.3. EFFECT OF INFLAMMATORY AGENTS ON LIPID METABOLISM OF 3T3-L1 ADIPOCYTES 
Obesity is characterised by chronic low-grade inflammation (Yudkin et al., 1999; Festa et al., 
2001), and so investigations into the effect of the pro-inflammatory agents TNF-α and IL-6, 
were carried out (Chapter 4).   
 
Increased rates of lipolysis were suggested by the treatment of 3T3-L1 adipocytes with TNF-α 
for 24h, as decreases in DG/TG species, and an increase in selected FAs, were observed in 
these cells.  This agrees with previous findings, as TNF-α increases adipocyte lipolysis, 
resulting in an increase of free fatty acids (FFA).  In cultured adipocytes, this increase is 
observed after approximately 6h of TNF-α treatment, with maximum rates occurring by 12-
24h (Kawakami et al., 1987; Feingold et al., 1992; Green et al., 1994; Hauner et al., 1995).  
These FAs can then accumulate in other tissue depots, such as those in muscle and liver, and 
contribute to dyslipidaemia and insulin resistance (Bays et al., 2004).   
 
A few mechanisms underlying the involvement of TNF-α in these conditions have been 
proposed, one of which is that the cytokine decreases the gene expression of the perilipins 
(Rosenbaum and Greenberg, 1998; Souza et al., 1998). These are phosphoproteins found on 
the surface of lipid droplets in adipocytes (Greenberg et al., 1991; Blanchette-Mackie et al., 
1995), and are thought to protect against lipolysis (Souza et al., 1998).  This decrease in the 
gene expression of the perilipins is thought to occur via the cAMP-dependent protein kinase 
A (PKA) pathway.  Increased intracellular cAMP activates PKA, leading to phosphorylation of 
HSL and perilipin and increases in the rates of lipolysis (Miyoshi et al., 2006).   TNF-α also 
induces members of the mitogen-activated protein kinase (MAPK) family, including 
extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK) and p38 kinase.  
They act by phosphorylating downstream transcription factors, regulating the expression of 
lipolysis-related genes; for example, both the ERK and JNK pathways are activated by TNF-α 
at concentrations that stimulate lipolysis (Souza et al., 2003).  The JNK pathway is thought to 
have effects on the gene expression of the perilipins (Souza et al., 2003; Ryden et al., 2004), 
whereas, the ERK pathway regulates lipolysis by increasing the activity of HSL (Greenberg et 
al., 2001).  
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In the current study, 24h of IL-6 intervention caused increased concentrations of various 
individual DG and TG species, suggesting that an increase in the rate of lipolysis had not 
occurred.  Previous studies; however, demonstrate that IL-6 is involved in the regulation of 
lipolysis, and has a role in insulin resistance, as seen in 3T3-L1 adipocytes (Lagathu et al., 
2003).  Investigations involving human mammary, and 3T3-L1 adipocytes, have shown 
increased lipolysis after 24h of IL-6 treatment (Path et al., 2001; Petersen et al., 2005).  Two 
in vivo studies using human subjects concluded that IL-6 is a lipolytic agent.  The first 
demonstrated that infusion of human recombinant IL-6 into healthy individuals increased 
lipolysis and fat oxidation in the absence of changes in other lipolytic hormones 
(catecholamines, glucagon, and insulin; van Hall et al., 2003).  The second showed an increase 
in the release of glycerol after IL-6 infusion (Lyngso et al., 2002).  Finally, another in vivo study 
with IL-6 knockout mice also suggested a role for IL-6 in lipid metabolism.  These mice display 
rapid body fat gain in comparison to wild types, and have increased energy intake.  Fat mass 
decreased in these mice after administration of IL-6, without an observed effect on energy 
intake, and these changes were not seen in the wild-type controls (Wallenius et al., 2002).  
Although the studies in human mammary and 3T3-L1 adipocytes mentioned above 
demonstrated increased lipolysis after 24h of IL-6 treatment, in humans IL-6 treatment only 
increased rates of lipolysis after 48h (Trujillo et al., 2004), and so, if the treatment time in the 
current study was increased, these effects may have occurred.  
 
Similar mechanisms to those underpinning the actions of TNF-α on lipolysis have been 
suggested for those of IL-6.  Treatment with both inflammatory agents only caused increases 
in lipolysis after approximately 6h onwards (Kawakami et al., 1987; Feingold et al., 1992; 
Green et al., 1994; Hauner et al., 1995; van Hall et al., 2003).  Definite lipolytic hormones, 
such as adrenaline, work instantaneously, and FA metabolism normalises when they are 
removed.  Therefore, the effect of TNF-α and IL-6 on lipolysis may be indirect by inducing 
changes in other lipolytic factors (van Hall et al., 2003). 
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6.4. EFFECT OF DEXAMETHASONE ON LIPID METABOLISM OF 3T3-L1 ADIPOCYTES 
Treatment of 3T3-L1 adipocytes with dexamethasone in the current study seemed to 
decrease lipolysis, and/or increase the rates of lipogenesis, as seen by increases in both TG 
and FA concentrations.  Dexamethasone is a synthetic glucocorticoid, and these hormones 
have dual roles, the first being lipolytic, with a number of studies demonstrating an increase 
in the release of FFAs after glucocorticoid treatment, both in vivo and in vitro (Slavin et al., 
1994; Xu et al., 2009).  However, excessive glucocorticoid treatment is associated with 
increased visceral adiposity, as seen in Cushing’s disease (Cushing, 1912; Masuzaki et al., 
2001; Bujalska et al., 2008; Pantoja et al., 2008), and this may be caused by either an increase 
in adipogenesis, a reduction in lipolysis, or a combination of the two (Ottosson et al., 2000).  
Glucocorticoids are essential for the differentiation of pre-adipocytes (Hauner et al, 1987; 
Hauner, 1990).  A previous study using corticosterone demonstrated these two actions of the 
agent, with increases in basal lipolysis being observed.  It was proposed that this action 
occurred due to the observed increases in the gene expression of ATGL.  An increase in 
adipogenesis was also observed in this study, leading the authors to conclude that 
corticosterone regulates adipose tissue metabolism by stimulating adipogenesis of pre-
adipocytes, and increasing lipolysis in the mature adipocytes (Campbell et al., 2011). 
 
Specifically, both direct and indirect effects of dexamethasone on lipid metabolism have been 
reported.  An early study demonstrated that 24h of dexamethasone treatment increased 
glycerol release from adipocytes (Slavin et al., 1994).  In agreement with these findings, 
another study demonstrated a dose-dependent lipolytic action occurring at a concentration 
of 1nM, which became more pronounced at 10-100nM (Xu et al., 2009).  Alterations in 
lipolysis are also affected by the length of treatment. Studies using short-term 
dexamethasone treatment of 6h or less observed only slight increases in lipolysis (Fain et al., 
1963 and 1965; Goodman, 1970).  Similar findings were found in the current study, as 
changes in lipid metabolism were more pronounced after 24h of treatment, and this effect 
has been observed elsewhere (Slavin et al., 1994; Xu et al., 2009).   
 
Proposed mechanisms for dexamethasone-induced lipolysis are similar to those of TNF-α / IL-
6 induced lipolysis, including increased intracellular cAMP leading to PKA activation (Miyoshi 
et al., 2006).  Other mechanisms include phosphorylation (Sztalryd et al., 2003; He et al., 
2006) or down-regulation of perilipin (Ren et al., 2006; Zu et al., 2008), and increased gene 
expression of HSL and ATGL (Fain and Saperstein, 1970; Slavin et al., 1994; Xu et al., 2009; 
Campbell et al., 2011).   
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6.5. EFFECT OF PRO- AND ANTI-INFLAMMATORY AGENTS ON EICOSANOID PRODUCTION BY 3T3-L1 
ADIPOCYTES 
An increase in the concentration of various eicosanoid species was observed in the current 
study after treatment with both the inflammatory mediators TNF-α and IL-6, and also the 
anti-inflammatory agent, dexamethasone. Eicosanoids are key mediators of inflammation; 
however, some species have anti-inflammatory properties, or have both pro- and anti-
inflammatory actions.  One example is PGE2, which is thought to be both pro-and anti-
inflammatory, which may explain why the concentration of this prostanoid (among others) 
increased with all of the treatments presented in this thesis.  Anti-inflammatory actions of 
PGE2 include inhibition of the production of pro-inflammatory cytokines (Miles et al., 2002), 
and also 5-lipoxygenase, which in turn decreases the production of series four leukotrienes 
(Levy et al., 2001).  This prostanoid also induces 15-lipoxygenase, leading to an increase in the 
formation of anti-inflammatory lipoxins (Levy et al., 2001; Vachier et al., 2002).   
 
6.6. IMPROVEMENTS TO THE WORK PRESENTED IN THE THESIS 
One limitation was the difficulty in confidently determining the FA composition of the 
phospholipid and DG/TG species identified, and it would be of interest to overcome thisThis 
could be achieved with the use of tandem mass spectrometry (MS/MS). By fragmenting an 
individual lipid, peaks representing its related FAs would be present in the spectrum, thereby 
allowing the FA composition to be determined.  Prior work would be necessary to optimise 
the collision energy to each lipid species for favourable fragmentation. 
 
During direct-infusion analyses, various phospholipid species were identified, although only a 
phosphatidylcholine internal standard was added.  Ideally, an internal standard would be 
useed for each group present in the samples, to allow for more accurate calculation of the 
concentration of sample lipids. 
 
Finally, changes in lipolysis were suggested in the adipocytes in response to the different 
treatments; however, this was only based on observations of changes in the concentration of 
selected TG species. More detailed investigations are required for confirmation.  One 
commonly used method is to determine the glycerol content of the medium (Bradley and 
Kaslow, 1989; Viswanadha and Londos, 2006).  Lipolysis is the process by which TG species 
are hydrolysed to yield FAs and glycerol, and so, in theory, a direct relationship would occur 
between the concentration of glycerol detected, and the rate of lipolysis.  
276 
 
6.7. FUTURE PERSPECTIVES 
 
The work presented in this thesis has provided a foundation for future studies, some of which 
have been described above, as they help to complete outlined experiments.  The effect of the 
inflammatory agents TNF-α and IL-6 were investigated (Chapter 4), and other mediators 
could be studied in the first instance, to provide a greater understanding of the effect of 
inflammation on the lipid metabolism processes occurring in 3T3-L1 adipocytes.  Some 
examples include other members of the interleukin family, such as IL-18, a pro-inflammatory 
cytokine, the concentration of which increases with obesity, and decreases after weight loss 
(Esposito et al., 2002).  Therefore, it is predicted that the profile of the gene expression of 
those investigated in the current study (leptin, adiponectin, TNF-α and IL-6) would be similar 
after treatment with other inflammatory agents, such as IL-18, than those seen after 
treatment with both TNF-α and IL-6 in the present work.  More specifically, it is predicted 
that the gene expression of leptin, TNF-α and IL-6 would increase, whereas that of 
adiponectin would decrease.  
 
The inflammatory environment present in the adipose tissue during obesity is associated with 
the infiltration of macrophages (Weisberg et al., 2003; Xu et al., 2003).  Macrophages are a 
potent source of the increased pro-inflammatory cytokines observed in obesity, and these 
proteins are able to induce an inflammatory response within the adipocyte, and cause insulin 
resistance (Suganami et al., 2005; Permana et al., 2006).  Therefore, it would be interesting to 
study the presence of macrophages, in terms of how they influence lipid metabolism of 3T3-
L1 adipocytes.  This could be achieved by co-culture of adipocytes and macrophages, either 
directly by growing both cell types in the same well, or indirectly by treating 3T3-L1 
adipocytes with medium previously used to feed the macrophage cell line.   
 
A recent example using direct co-culture of 3T3-L1 adipocytes and C2D or primary peritoneal 
mouse macrophages demonstrated that these two cell types communicate, and are involved 
in the onset of insulin resistance (Xie et al., 2010).  The presence of adipocytes increased the 
production of macrophage pro-inflammatory cytokines, which can induce insulin resistance in 
adipocytes by down-regulating the gene expression of glucose transport type 4 (GLUT4) and 
inhibiting adipocyte differentiation, with IL-6 having a key role in this process (Xie et al., 
2010). 
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In comparison, a recent indirect co-culture study with human pre-adipocytes investigated the 
effects of macrophage-derived factors on the gene expression and secretion of matrix 
metalloproteinases (MMP)s by these cells (Gao and Bing, 2011).  Adipocytes and adipose 
tissue express and secrete a number of MMPs, including MMP1 and MMP3 (Maquoi et al., 
2002; Chavey et al., 2003; Kawamura et al., 2008), both of which degrade extracellular matrix 
(ECM) proteins (Chavey et al., 2003), and ECM remodelling is known to occur as adipose 
tissue mass expands (Halberg et al., 2009; Khan et al., 2009).  Macrophage-derived factors 
induce the production of MMP1 and MMP3 by human pre-adipocytes, possibly suggesting a 
role in the ECM remodelling associated with obesity, as well as the gene expression of 
chemokines and pro-inflammatory cytokines, including IL-6 (Gao and Bing, 2011).  Both co-
culture experiments described here found increased gene expression and protein secretion of 
IL-6.  This was observed after treatment with pro-inflammatory mediators in the current 
study, and IL-6 treatment led to an increase in the concentration of various DG / TG species, 
suggesting that an increase in the rate of lipolysis had not occurred in these 3T3-L1 
adipocytes in the timeframe presented.  It would be interesting, therefore, to observe 
whether this result would be replicated in 3T3-L1 adipocytes co-cultured (either directly or 
indirectly) with a macrophage cell line.  It is likely that the inflammatory environment created 
by co-culture with macrophages would lead to increased rates of lipolysis. 
 
Another proposed cause of the inflammatory environment seen in the obese state is hypoxia.  
The original hypothesis suggested that the production of inflammation-related adipokines 
associated with obesity is a response to clusters of adipocytes becoming distant from 
vasculature, and therefore hypoxic.  The induced inflammatory response acts to stimulate 
angiogenesis and increase blood flow (Trayhurn and Wood, 2004).  A recent study found that 
hypoxia inhibited insulin action in 3T3-L1 adipocytes, leading to increased lipolysis and cell 
death (Yin et al., 2009).  Measuring the concentration of various individual DG/TG species in 
response to hypoxic conditions would, therefore, provide further information on the effect of 
hypoxia on adipocyte lipid metabolism.  Due to the inflammatory environment associated 
with hypoxia, it would also be of interest to investigate this condition on the effects of 
eicosanoid production from adipocytes, and an increase in the concentration of various pro-
inflammatory species such as the 2-series prostaglandins is likely. 
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The effect of the anti-inflammatory agent dexamethasone was also studied, and further work 
could incorporate the addition of other such agents to these cells’ environments, especially 
because glucocorticoids (and presumably other anti-inflammatory agents) cause different 
lipolytic and adipogenic actions depending on the dose and length of treatment, and the 
experimental model and agent used (Masuzaki et al., 2001; Kershaw et al., 2006; Xu et al., 
2009).  Of particular interest would be drugs used for the treatment of obesity and its 
associated co-morbidities, such as the thiazolidinediones (TZDs), especially pioglitazone. Both 
pioglitazone (Actos) and rosiglitazone (trade name Avandia, GlaxoSmithKline) came to market 
in the 1990s as anti-diabetic drugs; however, rosiglitazone has since been withdrawn due to 
its links with increased risk of myocardial infarction.  Chronic pioglitazone treatment 
increases FA and glycerol release and suppression of FA re-esterification, as seen in 
epididymal adipose tissue from hypertensive rats fed a high-sucrose diet (Pravenec et al., 
2008).  Replicating this study in cultured adipocytes would give a better understanding of the 
effect of this drug on lipid metabolism, and it is expected that an increase in the rate of 
lipolysis will be observed.  The increased concentration of FFAs associated with lipolysis is 
known to be involved in the development of insulin resistance (Reynisdottir et al., 1995; 
Large et al., 1999), and so the efficiency of this drug may be questioned, or other side effects 
may be discovered. 
 
Before pharmaceutical treatments, a calorie-controlled diet and exercise programme is often 
used first to treat obesity. A relatively new idea is the use of nutraceuticals, which are foods 
that provide health benefits.  In the case of obesity, treatment with omega 3-poly 
unsaturated fatty acids (PUFA) could be an option, as they have been shown to reduce body 
fat and reduce weight gain in rats, as well as decrease the concentration of circulating TGs 
(Belzung et al., 1993; Hainault et al., 1993; Ruzickova et al., 2004). More recently, two PUFAs 
with anti-inflammatory properties, namely eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) (Chapkin et al., 2009), have been shown to exhibit anti-obesity effects in mice 
(Ruzickova et al., 2004).  Both FAs prevent the development of obesity in rodents fed with 
high-fat (Storlien et al., 1987; Gonzalez-Periz et al., 2009) or high-sucrose (Ghafoorunissa et 
al., 2005) diets.  Similar effects were replicated in human studies; however, the FAs had no 
effect on insulin sensitivity in T2DM subjects (Rivellese et al., 1996; Kabir et al., 2007).  
Addition of these FAs to 3T3-L1 adipocytes could provide an insight into their effects on lipid 
metabolism, and possibly support their use as a preliminary treatment for obesity.  Attention 
should be drawn to their effect on the production of eicosanoid species from these cells, 
since both EPA and DHA are precursors of eicosanoid synthesis, and those produced are less 
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inflammatory than AA-derived species.  Increased EPA and DHA intake causes greater 
incorporation of these FAs into membrane phospholipids, rather than AA, and so it is 
predicted that the production of AA-derived eicosanoids would decrease in adipocytes 
treated with either EPA or DHA, as seen previously with PGE2 secretion from 3T3-L1 
adipocytes (Wortman et al., 2009). 
 
Possible links between eicosanoid production and lipid metabolism have been suggesting 
with some of the treatments used in the current study.  Investigating the effect of various 
PGs on the lipid metabolism of 3T3-L1 adipocytes, and vice-versa, would provide more 
information about these two pathways, and may help to confirm a link between them.  If 
established, a further step would be to repeat this work in the adipocyte / macrophage co-
culture system described above to explore whether the link between lipid metabolism and 
eicosanoid synthesis is affected by macrophages.  
 
One of the major findings presented in this thesis, is that treatment of 3T3-L1 adipocytes with 
selected pro- and anti-inflammatory agents effects the concentration of various DG, TG and 
FA species, suggesting alterations in the rates of lipolysis. This process may be of 
pharmacological interest, as increased rates lead to reduced TG accumulation, and eventually 
weight loss.  However, increased serum concentrations of FFAs also occur, leading to 
dyslipidemia and insulin resistance (Reynisdottir et al., 1995; Large et al., 1999), which would 
have to be addressed. 
 
6.8. CONCLUDING REMARKS 
In conclusion, the work presented in this thesis has revealed how adipocyte metabolism 
changes with the naturally occurring stages of adipogenesis, as well as treatment with pro- 
and anti-inflammatory agents. Associations were observed between adipokine gene 
expression, lipid metabolism and eicosanoid production; however, further work is required to 
confirm these links by identifying the underlying mechanisms involved.  
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